sign in sign up
<<
Home , Equine influenza, Flu season, Heterosubtypic immunity

APPENDIX 9 List of publications, and vaccine policy, 2010–2011

1. 2010. A call for mandatory flu vaccinations. OR.Manager. 26:5. 2. 2010. ACOG Committee Opinion No. 468: Influenza vaccination during pregnancy. Obstet.Gynecol. 116:1006–1007. doi:10.1097/AOG.0b013e3181fae845 [doi];00006250-201010000-00040 [pii]. 3. 2010. Antigenic and genetic characteristics of influenza A(H5N1)and influenza A(H9N2) and candidate vaccine viruses developed for potential use in human . Wkly.Epidemiol.Rec. 85:418–424. 4. 2010. European Medicines Agency updates on the review of and reports of narcolepsy. Euro.Surveill 15. 5. 2010. Flu vaccination challenge enters third season with room for more participants and better rates. Jt.Comm Perspect. 30:9, 11. 6. 2010. Future vaccines may face suspicion. Hum.Vaccin. 6:526. doi:12826 [pii]. 7. 2010. Global Advisory Committee on Vaccine Safety,3–4 December 2009. Wkly.Epidemiol.Rec. 85:29–33. 8. 2010. H1N1 and this . The pandemic may be over, but the is still around, and children, young adults, and pregnant women are susceptible. Harv.Health Lett. 36:1–2. 9. 2010. H1N1 vaccine in children – one dose seems to provide some protection . . . Child Health Alert. 28:1. 10. 2010. Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel – , August 2009–January 2010. MMWR Morb. Mortal.Wkly.Rep. 59:357–362. doi:mm5912a1 [pii]. 11. 2010. Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage – United States, October–December 2009. MMWR Morb.Mortal.Wkly.Rep. 59:44–48. doi:mm5902a4 [pii]. 12. 2010. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage – United States, October 2009–January 2010. MMWR Morb.Mortal.Wkly.Rep. 59:363–368. doi:mm5912a2 [pii]. 13. 2010. Licensure of a high-dose inactivated for persons aged >or=65 years (Fluzone High-Dose) and guidance for use – United States, 2010. MMWR Morb.Mortal.Wkly.Rep. 59:485–486. doi:mm5916a2 [pii]. 14. 2010. Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents – three states, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:74–77. doi:mm5903a3 [pii]. 15. 2010. Policy statement – recommendations for prevention and control of influenza in children, 2010–2011. Pediatrics 126:816–826. doi:peds.2010-2216 [pii];10.1542/peds.2010-2216 [doi]. 16. 2010. Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine – United States, 2009–2010. MMWR Morb.Mortal.Wkly.Rep. 59:657– 661. doi:mm5921a3 [pii].

59 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

17. 2010. Regional influenza A (H1N1) 2009 monovalent vaccination campaign – Skokie, Illinois, October 16–December 31, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:909–913. doi:mm5929a3 [pii]. 18. 2010. Seasonal flu vaccination for healthcare workers? Drug Ther.Bull. 48:122–125. doi:48/11/122 [pii];10.1136/dtb.2010.11.0055 [doi]. 19. 2010. Seasonal influenza and 2009 H1N1 influenza vaccination coverage among pregnant women – 10 states, 2009–10 influenza season. MMWR Morb.Mortal.Wkly.Rep. 59:1541–1545. doi:mm5947a1 [pii]. 20. 2010. Seasonal influenza vaccination coverage among children aged 6 months–18 years – eight immunization information system sentinel sites, United States, 2009–10 influenza season. MMWR Morb.Mortal.Wkly.Rep. 59:1266–1269. doi:mm5939a2 [pii]. 21. 2010. Seasonal trivalent influenza vaccine for 2010–2011. Med.Lett.Drugs Ther. 52:77–79. 22. 2010. Start of the influenza season 2010–11 in Europe dominated by 2009 pandemic influenza A(H1N1) virus. Euro.Surveill 15. 23. 2010. Update: influenza activity – United States, August 30, 2009–March 27, 2010, and composition of the 2010–11 influenza vaccine. MMWR Morb.Mortal.Wkly.Rep. 59:423–430. doi:mm5914a3 [pii]. 24. 2010. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010–11. MMWR Morb.Mortal.Wkly.Rep. 59:989–992. doi:mm5931a4 [pii]. 25. 2011. [Adherence to the H1N1 vaccination recommendation in patients with Crohn’s disease or ulcerative colitis]. Dtsch.Med.Wochenschr. 136:939–943. doi:10.1055/s-0031-1275829 [doi]. 26. 2011. Adjuvant-containing H1N1 influenza vaccine pandemrix: narcolepsy in children.. 20:154. 27. 2011. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness – February 2011. Wkly. Epidemiol.Rec. 86:93–100. 28. 2011. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Wkly.Epidemiol.Rec. 86:469–480. 29. 2011. Characteristics associated with seasonal influenza vaccination of preschool children – Oregon, 2006–2008. MMWR Morb.Mortal.Wkly.Rep. 60:981–984. doi:mm6029a2 [pii]. 30. 2011. Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study. BMJ Open. 1:e000167. doi:bmjopen-2011-000167 [pii];10.1136/bmjopen-2011-000167 [doi]. 31. 2011. Influenza A(H1N1) 2009 virus: current situation and post-pandemic recommendations. Wkly. Epidemiol.Rec. 86:61–65. 32. 2011. Influenza vaccination coverage among health-care personnel – United States, 2010–11 influenza season. MMWR Morb.Mortal.Wkly.Rep. 60:1073–1077. doi:mm6032a1 [pii]. 33. 2011. Influenza vaccination coverage among pregnant women – United States, 2010–11 influenza season. MMWR Morb.Mortal.Wkly.Rep. 60:1078–1082. doi:mm6032a2 [pii]. 34. 2011. Interim results: state-specific influenza vaccination coverage – United States, August 2010– February 2011. MMWR Morb.Mortal.Wkly.Rep. 60:737–743. doi:mm6022a3 [pii]. 35. 2011. Keeping up with your vaccinations. New guidelines include several changes. Harv.Womens Health Watch. 18:2–3. 36. 2011. Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1) – United States, April 2009–August 2010. MMWR Morb.Mortal.Wkly. Rep. 60:1193–1196. doi:mm6035a2 [pii].

60 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

37. 2011. National and state vaccination coverage among adolescents aged 13 through 17 years – United States, 2010. MMWR Morb.Mortal.Wkly.Rep. 60:1117–1123. doi:mm6033a1 [pii]. 38. 2011. Place of influenza vaccination among adults – United States, 2010–11 influenza season. MMWR Morb.Mortal.Wkly.Rep. 60:781–785. doi:mm6023a3 [pii]. 39. 2011. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb.Mortal.Wkly.Rep. 60:1128–1132. doi:mm6033a3 [pii]. 40. 2011. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. Am.J.Transplant. 11:2250–2255. doi:10.1111/j.1600- 6143.2011.03793.x [doi]. 41. 2011. Recommendations pertaining to the use of viral vaccines: influenza 2011. S.Afr.Med.J. 101:96. 42. 2011. Recommended composition of influenza vaccines for use in the 2012 influenza season. Wkly.Epidemiol.Rec. 86:457–468. 43. 2011. Recommended composition of influenza virus vaccines for use in the 2011–2012 influenza season. Wkly.Epidemiol.Rec. 86:86–90. 44. 2011. Seasonal influenza vaccination of the elderly. Prescrire.Int. 20:186–188. 45. 2011. Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy. Euro.Surveill 16. 46. 2011. TJC proposes 90% flu shot goal. Healthcare.Benchmarks.Qual.Improv. 18:70–71. 47. 2011. Update: influenza activity – United States, 2010–11 season, and composition of the 2011–12 influenza vaccine. MMWR Morb.Mortal.Wkly.Rep. 60:705–712. doi:mm6021a5 [pii]. 48. 2011. Update: influenza activity – United States, October 3, 2010–February 5, 2011. MMWR Morb. Mortal.Wkly.Rep. 60:175–181. doi:mm6006a4 [pii]. 49. Abbott, K. C., C. M. Yuan, and J. L. Lee. 2011. Nothing to sneeze at: efficacy and cost-effectiveness of the influenza vaccine in patients receiving long-term dialysis. Am.J.Kidney Dis. 57:651–653. doi:S0272-6386(11)00599-3 [pii];10.1053/j.ajkd.2011.02.380 [doi]. 50. Abdel-Haq, N. M. and B. I. Asmar. 2011. Novel swine – origin influenza A: the 2009 H1N1 influenza virus. Indian J.Pediatr. 78:74–80. doi:10.1007/s12098-010-0251-6 [doi]. 51. Abelin, A., T. Colegate, S. Gardner, N. Hehme, and A. Palache. 2011. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry’s perspective. Vaccine 29:1135–1138. doi:S0264-410X(10)01676-2 [pii];10.1016/j.vaccine.2010.11.042 [doi]. 52. Abramson, Z. H., O. Avni, O. Levi, and I. N. Miskin. 2010. Randomized trial of a program to increase staff influenza vaccination in primary care clinics. Ann.Fam.Med. 8:293–298. doi:8/4/293 [pii];10.1370/afm.1132 [doi]. 53. Abramson, Z. H., O. Avni, O. Levi, and I. N. Miskin. 2011. Is the influenza vaccination rate of elderly patients affected by raising the vaccination rate of the staff at their primary health care clinics? Isr. Med.Assoc.J. 13:325–328. 54. Abu-Gharbieh, E., S. Fahmy, B. A. Rasool, and S. Khan. 2010. Influenza vaccination: healthcare workers attitude in three Middle East countries. Int.J.Med.Sci. 7:319–325. 55. Adalja, A. A., P. S. Crooke, and J. R. Hotchkiss. 2010. Influenza Transmission in Preschools: Modulation by contact landscapes and interventions. Math.Model.Nat.Phenom. 5:3–14. doi:10.1051/ mmnp/20105301 [doi].

61 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

56. Adler-Moore, J., M. Munoz, H. Kim, J. Romero, T. Tumpey, H. Zeng, C. Petro, W. Ernst, S. Kosina, G. Jimenez, and G. Fujii. 2011. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 29:4460–4468. doi:S0264-410X(11)00585-8 [pii];10.1016/j.vaccine.2011.04.040 [doi]. 57. Aggarwal, K., F. Jing, L. Maranga, and J. Liu. 2011. Bioprocess optimization for cell culture based influenza vaccine production. Vaccine 29:3320–3328. doi:S0264-410X(11)00141-1 [pii];10.1016/j. vaccine.2011.01.081 [doi]. 58. Aguilar-Yanez, J. M., R. Portillo-Lara, G. I. Mendoza-Ochoa, S. A. Garcia-Echauri, F. Lopez-Pacheco, D. Bulnes-Abundis, J. Salgado-Gallegos, I. M. Lara-Mayorga, Y. Webb-Vargas, F. O. Leon-Angel, R. E. Rivero-Aranda, Y. Oropeza-Almazan, G. M. Ruiz-Palacios, M. I. Zertuche-Guerra, R. M. DuBois, S. W. White, S. Schultz-Cherry, C. J. Russell, and M. M. Alvarez. 2010. An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS.One. 5:e11694. doi:10.1371/journal. pone.0011694 [doi]. 59. Ahluwalia, I. B., D. J. Jamieson, S. A. Rasmussen, D. D’Angelo, D. Goodman, and H. Kim. 2010. Correlates of seasonal influenza vaccine coverage among pregnant women in Georgia and Rhode Island. Obstet.Gynecol. 116:949–955. doi:10.1097/AOG.0b013e3181f1039f [doi];00006250- 201010000-00022 [pii]. 60. Ahluwalia, I. B., J. A. Singleton, D. J. Jamieson, S. A. Rasmussen, and L. Harrison. 2011. Seasonal influenza vaccine coverage among pregnant women: pregnancy risk assessment monitoring system. J.Womens Health (Larchmt.) 20:649–651. doi:10.1089/jwh.2011.2794 [doi]. 61. Ahmed, F., V. Paine, F. Zhang, E. Gary, and M. C. Lindley. 2010. Evaluation of a legislatively mandated influenza vaccination program for adults in Rhode Island, USA. J.Public Health Manag.Pract. 16:E01– E08. doi:10.1097/PHH.0b013e3181c60ed4 [doi];00124784-201009000-00017 [pii]. 62. Ainai, A., M. Tashiro, and H. Hasegawa. 2011. Cross-protective immunity against influenza virus induced by intranasal vaccination together with a TLR3-mucosal adjuvant. Hum.Vaccin. 7 Suppl:174–182. doi:14584 [pii]. 63. Ainai, A., T. Ichinohe, S. Tamura, T. Kurata, T. Sata, M. Tashiro, and H. Hasegawa. 2010. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J.Med.Virol. 82:476–484. doi:10.1002/jmv.21694 [doi]. 64. Ajelli, M., S. Merler, A. Pugliese, and C. Rizzo. 2011. Model predictions and evaluation of possible control strategies for the 2009 A/H1N1v in Italy. Epidemiol.Infect. 139:68–79. doi:S0950268810001317 [pii];10.1017/S0950268810001317 [doi]. 65. Akarsu, H., K. Iwatsuki-Horimoto, T. Noda, E. Kawakami, H. Katsura, F. Baudin, T. Horimoto, and Y. Kawaoka. 2011. Structure-based design of NS2 mutants for attenuated vaccines. Virus Res. 155:240–248. doi:S0168-1702(10)00373-4 [pii];10.1016/j.virusres.2010.10.014 [doi]. 66. Akis, S., S. Velipasaoglu, A. D. Camurdan, U. Beyazova, and F. Sahn. 2011. Factors associated with parental acceptance and refusal of pandemic influenza A/H1N1 vaccine in Turkey. Eur.J.Pediatr. 170:1165–1172. doi:10.1007/s00431-011-1425-6 [doi]. 67. Akkad, W., B. Salem, J. W. Freeman, and M. K. Huntington. 2010. Longitudinally extensive transverse myelitis following vaccination with nasal attenuated novel influenza A(H1N1) vaccine. Arch.Neurol. 67:1018–1020. doi:67/8/1018 [pii];10.1001/archneurol.2010.167 [doi]. 68. Al Aklabi, M. M., J. G. Weinkauf, A. Humar, and N. Ghorpade. 2010. Successful bilateral lung transplantation in a patient with end-stage lung disease and positive novel influenza virus (H1N1). J.Heart Lung Transplant. 29:898–899. doi:S1053-2498(10)00274-3 [pii];10.1016/j. healun.2010.04.017 [doi].

62 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

69. Al, H. S. and K. McIntosh. 2010. The first influenza pandemic of the 21st century. Ann.Saudi.Med. 30:1–10. doi:AnnSaudiMed_2010_30_1_1_59365 [pii];10.4103/0256-4947.59365 [doi]. 70. Alam, S. and A. J. Sant. 2011. with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza. J.Virol. doi:JVI.05728-11 [pii];10.1128/JVI.05728-11 [doi]. 71. Alexander, J., P. Bilsel, M. F. del Guercio, A. Marinkovic-Petrovic, S. Southwood, S. Stewart, G. Ishioka, M. F. Kotturi, J. Botten, J. Sidney, M. Newman, and A. Sette. 2010. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Hum. Immunol. 71:468–474. doi:S0198-8859(10)00057-1 [pii];10.1016/j.humimm.2010.02.014 [doi]. 72. Alexander, J., P. Bilsel, M. F. del Guercio, S. Stewart, A. Marinkovic-Petrovic, S. Southwood, C. Crimi, L. Vang, L. Walker, G. Ishioka, V. Chitnis, A. Sette, E. Assarsson, D. Hannaman, J. Botten, and M. J. Newman. 2010. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine 28:664–672. doi:S0264- 410X(09)01652-1 [pii];10.1016/j.vaccine.2009.10.103 [doi]. 73. Alford, C. E., G. L. Chen, and A. Y. Armstrong. 2010. 2009 H1N1 influenza prevention and treatment: counseling infertility patients. Fertil.Steril. 94:1178–1180. doi:S0015-0282(10)00694-1 [pii];10.1016/j.fertnstert.2010.04.056 [doi]. 74. Alghisi, F., P. Palma, E. Montemitro, S. Bernardi, G. Pontrelli, P. Rossi, and V. Lucidi. 2011. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. Thorax 66:259–260. doi:thx.2010.156018 [pii];10.1136/thx.2010.156018 [doi]. 75. Alkuwari, M. G., N. A. Aziz, Z. A. Nazzal, and S. A. Al-Nuaimi. 2011. Pandemic influenza A/H1N1 vaccination uptake among health care workers in Qatar: motivators and barriers. Vaccine 29:2206– 2211. 76. Allison, M. A., M. Reyes, P. Young, L. Calame, X. Sheng, H. Y. Weng, and C. L. Byington. 2010. Parental attitudes about influenza immunization and school-based immunization for school-aged children. Pediatr.Infect.Dis.J. 29:751–755. doi:10.1097/INF.0b013e3181d8562c [doi]. 77. Allred, N. J., K. A. Poehling, P. G. Szilagyi, F. Zhang, K. M. Edwards, M. A. Staat, S. Donauer, M. M. Prill, and G. Fairbrother. 2011. The impact of missed opportunities on seasonal influenza vaccination coverage for healthy young children. J.Public Health Manag.Pract. 17:560–564. doi:10.1097/ PHH.0b013e31821831c3 [doi];00124784-201111000-00013 [pii]. 78. Allwinn, R. and H. W. Doerr. 2011. [Comparison of seasonal influenza vaccines: composition and properties]. Dtsch.Med.Wochenschr. 136:2315–2318. doi:10.1055/s-0031-1292046 [doi]. 79. Alsharifi, M. and A. Mullbacher. 2010. The gamma-irradiated influenza vaccine and the prospect of producing safe vaccines in general. Immunol.Cell Biol. 88:103–104. doi:icb200981 [pii];10.1038/ icb.2009.81 [doi]. 80. Altamirano-Diaz, L., L. West, A. Humar, L. Ely, S. Urschel, J. Gubbay, N. Crowcroft, and D. Kumar. 2011. Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients. Pediatr.Transplant. 15:172–175. doi:10.1111/j.1399-3046.2010.01433.x [doi]. 81. Althoff, K. N., K. Anastos, K. E. Nelson, D. D. Celentano, G. B. Sharp, R. M. Greenblatt, A. L. French, D. J. Diamond, S. Holman, M. Young, and S. J. Gange. 2010. Predictors of reported influenza vaccination in HIV-infected women in the United States, 2006–2007 and 2007–2008 seasons. Prev. Med. 50:223–229. doi:S0091-7435(10)00103-9 [pii];10.1016/j.ypmed.2010.03.007 [doi]. 82. Ambrose, C. S. 2011. Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults. Expert.Rev.Vaccines. 10:1127–1130. doi:10.1586/ erv.11.101 [doi].

63 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

83. Ambrose, C. S. and M. D. Rousculp . 2010. A valuable summary of various experiences with school-located influenza vaccination programs. J.Sch Nurs. 26:342–343. doi:26/5/342 [pii];10.1177/1059840510380210 [doi]. 84. Ambrose, C. S., B. Loop, and R. Miday. 2011. A case report of transverse myelitis following influenza vaccination. Arch.Neurol. 68:1085–1086. doi:68/8/1085 [pii];10.1001/archneurol.2011.172 [doi]. 85. Ambrose, C. S., M. J. Levin, and R. B. Belshe. 2011. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza.Other Respi.Viruses. 5:67–75. doi:10.1111/j.1750-2659.2010.00183.x [doi]. 86. Ambrose, C. S., X. Wu, and R. B. Belshe. 2010. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr.Infect.Dis.J. 29:806–811. doi:10.1097/INF.0b013e3181e2872f [doi]. 87. Amodio, E., G. Anastasi, M. G. Marsala, M. V. Torregrossa, N. Romano, and A. Firenze. 2011. Vaccination against the 2009 pandemic influenza A (H1N1) among healthcare workers in the major teaching hospital of Sicily (Italy). Vaccine 29:1408–1412. doi:S0264-410X(10)01814-1 [pii];10.1016/j.vaccine.2010.12.041 [doi]. 88. Amorij, J. P., W. L. Hinrichs, H. W. Frijlink, J. C. Wilschut, and A. Huckriede. 2010. Needle-free influenza vaccination. Lancet Infect.Dis. 10:699–711. doi:S1473-3099(10)70157-2 [pii];10.1016/ S1473-3099(10)70157-2 [doi]. 89. Ampofo, K., A. Herbener, A. J. Blaschke, C. Heyrend, M. Poritz, K. Korgenski, R. Rolfs, S. Jain, M. G. Carvalho, F. C. Pimenta, J. Daly, E. O. Mason, C. L. Byington, and A. T. Pavia. 2010. Association of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. Pediatr.Infect.Dis.J. 29:905–909. doi:10.1097/INF.0b013e3181df2c70 [doi]. 90. Ampofo, W. K., N. Baylor, S. Cobey, N. J. Cox, S. Daves, S. Edwards, N. Ferguson, G. Grohmann, A. Hay, J. Katz, K. Kullabutr, L. Lambert, R. Levandowski, A. C. Mishra, A. Monto, M. Siqueira, M. Tashiro, A. L. Waddell, N. Wairagkar, J. Wood, M. Zambon, and W. Zhang. 2011. Improving influenza vaccine virus selection Report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010. Influenza.Other Respi.Viruses. doi:10.1111/j.1750– 2659.2011.00277.x [doi]. 91. Anar, C., C. Bicmen, S. Yapicioglu, I. Unsal, H. Halilcolar, and U. Yilmaz. 2010. Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. New Microbiol. 33:117–127. 92. Andrade, A. L., C. M. Toscano, R. Minamisava, P. S. Costa, and J. G. Andrade. 2011. Pneumococcal disease manifestation in children before and after vaccination: what’s new? Vaccine 29 Suppl 3:C2–14. doi:S0264-410X(11)00990-X [pii];10.1016/j.vaccine.2011.06.096 [doi]. 93. Andrews, N. J., W. T. Walker, A. Finn, P. T. Heath, A. C. Collinson, A. J. Pollard, M. D. Snape, S. N. Faust, P. A. Waight, K. Hoschler, L. Sheasby, C. Waddington, S. Kerridge, J. Chalk, A. Reiner, T. John, M. Fletcher, R. Allen, N. Fineman, S. Wilkins, M. Casey, L. Michaelis, C. Oeser, I. Okike, S. Ladhani, and E. Miller. 2011. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine 29:7913– 7919. doi:S0264-410X(11)01335-1 [pii];10.1016/j.vaccine.2011.08.076 [doi]. 94. Andrews, N., J. Stowe, S. R. Al-Shahi, and E. Miller. 2011. Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the : self-controlled case series. Vaccine 29:7878–7882. doi:S0264-410X(11)01328-4 [pii];10.1016/j. vaccine.2011.08.069 [doi].

64 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

95. Andrews, N., P. Waight, C. F. Yung, and E. Miller. 2011. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J.Infect.Dis. 203:32–39. doi:jiq014 [pii];10.1093/infdis/jiq014 [doi]. 96. Andrianov, A. K., D. P. Decollibus, A. Marin, A. Webb, Y. Griffin, and R. J. Webby. 2010. PCPP- formulated H5N1 influenza vaccine displays improved stability and dose-sparing effect in lethal challenge studies. J.Pharm.Sci. doi:10.1002/jps.22367 [doi]. 97. Andrus, J. K., X. Aguilera, O. Oliva, and S. Aldighieri. 2010. Global health security and the International Health Regulations. BMC.Public Health 10 Suppl 1:S2. doi:1471-2458-10-S1-S2 [pii];10.1186/1471-2458-10-S1-S2 [doi]. 98. Ansaldi, F., M. Zancolli, P. Durando, E. Montomoli, L. Sticchi, G. G. Del, and G. Icardi. 2010. Antibody response against heterogeneous circulating influenza virus strains elicited by. Vaccine 28:4123– 4129. doi:S0264-410X(10)00536-0 [pii];10.1016/j.vaccine.2010.04.030 [doi]. 99. Ansaldi, F., P. Durando, and G. Icardi. 2011. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert.Opin.Biol.Ther. 11:415–427. doi:10.1517/1471259 8.2011.557658 [doi]. 100. Apinaniz, A., A. Lopez-Picado, E. Miranda-Serrano, A. Latorre, R. Cobos, N. Parraza-Diez, P. Amezua, M. Martinez-Cengotitabengoa, and F. Aizpuru. 2010. [Population-based cross sectional study about vaccine acceptability and perception of the severity of A/H1N1 influenza: opinion of the general population and health professionals]. Gac.Sanit. 24:314–320. doi:S0213-9111(10)00133-0 [pii];10.1016/j.gaceta.2010.03.009 [doi]. 101. Arad, U., S. Tzadok, S. Amir, M. Mandelboim, E. Mendelson, I. Wigler, H. Sarbagil-Maman, D. Paran, D. Caspi, and O. Elkayam. 2011. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 29:1643–1648. doi:S0264- 410X(10)01845-1 [pii];10.1016/j.vaccine.2010.12.072 [doi]. 102. Aranda-Romo, S., A. Comas-Garcia, C. A. Garcia-Sepulveda, A. E. Hernandez-Salinas, M. Pina- Ramirez, and D. E. Noyola. 2010. Effect of an immunization program on seasonal influenza hospitalizations in Mexican children. Vaccine 28:2550–2555. doi:S0264-410X(10)00066-6 [pii];10.1016/j.vaccine.2010.01.034 [doi]. 103. Araujo, P. R., G. A. Albertoni, S. R. Rizzo, F. O. Carvalho, and J. A. Barreto. 2011. H1N1 vaccination and false-positive test results for hepatitis B core antibody in health workers. Transfusion 51:1595– 1596. doi:10.1111/j.1537-2995.2011.03138.x [doi]. 104. Arcondo, M. F., A. Wachs, and M. Zylberman. 2011. [Transverse myelitis associated with anti- influenza A (H1N1) vaccination]. Medicina (B Aires) 71:161–164. 105. Arda, B., R. Durusoy, T. Yamazhan, O. R. Sipahi, M. Tasbakan, H. Pullukcu, E. Erdem, and S. Ulusoy. 2011. Did the pandemic have an impact on influenza vaccination attitude? A survey among health care workers. BMC.Infect.Dis. 11:87. doi:1471-2334-11-87 [pii];10.1186/1471-2334-11-87 [doi]. 106. Arguedas, A., C. Soley, A. Abdelnour, V. Sales, K. Lindert, C. G. Della, and R. Clemens. 2011. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum.Vaccin. 7:58–66. doi:13411 [pii]. 107. Arguedas, A., C. Soley, and K. Lindert. 2010. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N.Engl.J.Med. 362:370–372. doi:NEJMc0909988 [pii];10.1056/NEJMc0909988 [doi]. 108. Arnou, R., M. Frank, T. Hagel, and A. Prebet. 2011. Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany. Adv.Ther. 28:555–565. doi:10.1007/s12325-011-0035-z [doi].

65 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

109. Arnou, R., P. Eavis, J. R. Pardo, A. Ambrozaitis, M. P. Kazek, and F. Weber. 2010. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, phase III trial. Hum.Vaccin. 6:346–354. doi:10961 [pii]. 110. Arora, R., R. Chawla, R. Marwah, P. Arora, R. K. Sharma, V. Kaushik, R. Goel, A. Kaur, M. Silambarasan, R. P. Tripathi, and J. R. Bhardwaj. 2011. Potential of Complementary and Alternative Medicine in Preventive Management of Novel H1N1 Flu (Swine Flu) Pandemic: Thwarting Potential Disasters in the Bud. Evid.Based.Complement Alternat.Med. 2011:586506. doi:10.1155/2011/586506 [doi]. 111. Arslan, I., U. Beyazova, N. Aksakal, S. Polat, A. D. Camurdan, and F. Sahin. 2011. A NEW OPPORTUNITY FOR VACCINATING OLDER PEOPLE: WELL VISITS. Pediatr.Int. doi:10.1111/j.1442-200X.2011.03474.x [doi]. 112. Ashraf, S., W. Kong, S. Wang, J. Yang, and R. Curtiss, III. 2011. Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine. Vaccine 29:3990–4002. doi:S0264-410X(11)00448-8 [pii];10.1016/j.vaccine.2011.03.066 [doi]. 113. Ategbo, S., E. B. Ngoungou, J. Koko, Y. Vierin, C. E. Zang Ndong, and M. A. Moussavou. 2010. [Immunization coverage of children aged 0 to 5 years in Libreville (Gabon).]. Sante 20:215–219. doi:san.2010.0204 [pii];10.1684/san.2010.0204 [doi]. 114. At’kov, O. Y., A. V. Azarov, D. A. Zhukov, N. Nicoloyannis, and L. Durand. 2011. Influenza vaccination in healthy working adults in Russia: observational study of effectiveness and return on investment for the employer. Appl.Health Econ.Health Policy 9:89–99. doi:4 [pii];10.2165/11538680-000000000- 00000 [doi]. 115. Atmar, R. L., S. M. Patel, and W. A. Keitel. 2010. Intanza((R)): a new intradermal vaccine for seasonal influenza. Expert.Rev.Vaccines. 9:1399–1409. doi:10.1586/erv.10.134 [doi]. 116. Aubert, M., H. Aumaitre, J. Beytout, K. Bloch, D. Bouhour, P. Callamand, C. Chave, J. Cheymol, B. Combadiere, A. Dahlab, F. Denis, P. L. De, B. Dodet, M. A. Dommergues, V. Dufour, A. Gagneur, J. Gaillat, J. Gaudelus, G. Gavazzi, Y. Gillet, C. Gras-le-Guen, H. Haas, T. Hanslik, I. Hau-Rainsard, S. Larnaudie, O. Launay, M. Lorrot, P. Loulergue, D. Malvy, S. Marchand, G. Picherot, D. Pinquier, C. Pulcini, C. Rabaud, F. Regnier, P. Reinert, C. Sana, C. Savagner, B. Soubeyrand, J. L. Stephan, and C. Strady. 2011. [Current events in vaccination]. Arch.Pediatr. 18:1234–1246. doi:S0929- 693X(11)00330-7 [pii];10.1016/j.arcped.2011.07.025 [doi]. 117. Audouy, S. A., G. van der Schaaf, W. L. Hinrichs, H. W. Frijlink, J. Wilschut, and A. Huckriede. 2011. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine 29:4345–4352. doi:S0264-410X(11)00564-0 [pii];10.1016/j.vaccine.2011.04.029 [doi]. 118. Augustynowicz, E. 2010. [Selected problems of manufacturing influenza vaccines]. Przegl.Epidemiol. 64:373–380. 119. Auriel, E., A. Gadoth, K. Regev, and A. Karni. 2011. Seasonal and H1N1v influenza vaccines in MS: Safety and compliance. J.Neurol.Sci. doi:S0022-510X(11)00616-2 [pii];10.1016/j.jns.2011.10.013 [doi]. 120. Auriel, E., K. Regev, A. Dori, and A. Karni. 2011. Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle Nerve 43:893–894. doi:10.1002/ mus.22077 [doi]. 121. Baba, K., Y. Okuno, K. Tanaka-Taya, and N. Okabe. 2011. Immunization coverage and natural infection rates of vaccine-preventable diseases among children by questionnaire survey in 2005 in Japan. Vaccine 29:3089–3092. doi:S0264-410X(10)01332-0 [pii];10.1016/j.vaccine.2010.09.022 [doi].

66 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

122. Babcock, H. M., N. Gemeinhart, M. Jones, W. C. Dunagan, and K. F. Woeltje. 2010. Mandatory influenza vaccination of health care workers: translating policy to practice. Clin.Infect.Dis. 50:459– 464. doi:10.1086/650752 [doi]. 123. Babiuk, S., A. Masic, J. Graham, J. Neufeld, M. van der Loop, J. Copps, Y. Berhane, J. Pasick, A. Potter, L. A. Babiuk, H. Weingartl, and Y. Zhou. 2011. An elastase-dependent attenuated heterologous virus protects against pandemic H1N1 2009 influenza challenge in swine. Vaccine 29:3118–3123. doi:S0264-410X(11)00304-5 [pii];10.1016/j.vaccine.2011.02.069 [doi]. 124. Babouee, B., A. F. Widmer, and M. Battegay. 2011. [Vaccination against pneumococci and influenza. How good is the evidence?]. Internist (Berl) 52:265–276. doi:10.1007/s00108-010-2679-1 [doi]. 125. Baer, J., F. Santiago, H. Yang, H. Wu, J. Holden-Wiltse, J. Treanor, and D. J. Topham. 2010. B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. Vaccine 28:907– 915. doi:S0264-410X(09)01749-6 [pii];10.1016/j.vaccine.2009.11.002 [doi]. 126. Baguelin, M., A. J. Hoek, M. Jit, S. Flasche, P. J. White, and W. J. Edmunds. 2010. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 28:2370– 2384. doi:S0264-410X(10)00032-0 [pii];10.1016/j.vaccine.2010.01.002 [doi]. 127. Baldo, V., T. Baldovin, M. Pellegrini, G. Angiolelli, S. Majori, A. Floreani, M. C. Busana, C. Bertoncello, and R. Trivello. 2010. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin.Dev.Immunol. 2010:517198. doi:10.1155/2010/517198 [doi]. 128. Balicer, R. D., D. J. Barnett, C. B. Thompson, E. B. Hsu, C. L. Catlett, C. M. Watson, N. L. Semon, H. S. Gwon, and J. M. Links. 2010. Characterizing hospital workers’ willingness to report to duty in an influenza pandemic through threat- and efficacy-based assessment. BMC.Public Health 10:436. doi:1471-2458-10-436 [pii];10.1186/1471-2458-10-436 [doi]. 129. Balofsky, A., N. Agmon-Levin, and Y. Shoenfeld. 2010. The new H1N1 and HPV vaccines and old fears. Curr.Opin.Rheumatol. 22:431–436. doi:10.1097/BOR.0b013e32833a43c3 [doi]. 130. Banzhoff, A., S. Haertel, and M. Praus. 2011. Passive surveillance of adverse events of an MF59- adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum.Vaccin. 7:539–548. doi:14821 [pii]. 131. Baras, B., K. J. Stittelaar, T. Kuiken, V. Jacob, R. Bernhard, S. Giannini, W. L. de, A. G. van, J. H. Simon, A. D. Osterhaus, E. Hanon, and S. P. Mossman. 2011. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split in ferrets. Vaccine 29:2092–2099. doi:S0264-410X(11)00009-0 [pii];10.1016/j.vaccine.2010.12.128 [doi]. 132. Baras, B., W. L. de, K. J. Stittelaar, V. Jacob, S. Giannini, E. J. Kroeze, J. M. van den Brand, A. G. van, J. H. Simon, E. Hanon, S. P. Mossman, and A. D. Osterhaus. 2011. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naive ferrets. Vaccine 29:2120–2126. doi:S0264-410X(11)00006-5 [pii];10.1016/j.vaccine.2010.12.125 [doi]. 133. Bardenheier, B. H., A. M. Shefer, P. J. Lu, R. E. Remsburg, and J. A. Marsteller. 2010. Are standing order programs associated with influenza vaccination? – NNHS, 2004. J.Am.Med.Dir.Assoc. 11:654–661. doi:S1525-8610(09)00546-5 [pii];10.1016/j.jamda.2009.12.091 [doi]. 134. Bardenheier, B. H., P. Wortley, F. Ahmed, C. Hales, and A. Shefer. 2010. Influenza immunization coverage among residents of long-term care facilities certified by CMS, 2005–2006: the newest MDs quality indicator. J.Am.Med.Dir.Assoc. 11:59–69. doi:S1525-8610(09)00327-2 [pii];10.1016/j. jamda.2009.09.011 [doi].

67 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

135. Bardenheier, B., A. Shefer, F. Ahmed, R. Remsburg, C. J. Rowland Hogue, and S. Gravenstein. 2011. Do vaccination strategies implemented by nursing homes narrow the racial gap in receipt of influenza vaccination in the United States? J.Am.Geriatr.Soc. 59:687–693. doi:10.1111/j.1532- 5415.2011.03332.x [doi]. 136. Bardenheier, B., P. Wortley, F. Ahmed, S. Gravenstein, and C. J. Hogue. 2011. Racial inequities in receipt of influenza vaccination among long-term care residents within and between facilities in Michigan. Med.Care 49:371–377. doi:10.1097/MLR.0b013e3182054293 [doi]. 137. Barr, I. G., J. McCauley, N. Cox, R. Daniels, O. G. Engelhardt, K. Fukuda, G. Grohmann, A. Hay, A. Kelso, A. Klimov, T. Odagiri, D. Smith, C. Russell, M. Tashiro, R. Webby, J. Wood, Z. Ye, and W. Zhang. 2010. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season. Vaccine 28:1156–1167. doi:S0264-410X(09)01822-2 [pii];10.1016/j.vaccine.2009.11.043 [doi]. 138. Barrett, P. N. and H. J. Ehrlich. 2011. Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1). Lancet Infect.Dis. 11:496–497. doi:S1473-3099(11)70155-4 [pii];10.1016/S1473- 3099(11)70155-4 [doi]. 139. Barrett, P. N., D. Portsmouth, and H. J. Ehrlich. 2010. Developing cell culture-derived pandemic vaccines. Curr.Opin.Mol.Ther. 12:21–30. 140. Barrett, P. N., G. Berezuk, S. Fritsch, G. Aichinger, M. K. Hart, W. El-Amin, O. Kistner, and H. J. Ehrlich. 2011. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 377:751–759. doi:S0140-6736(10)62228-3 [pii];10.1016/S0140-6736(10)62228-3 [doi]. 141. Barriere, J., D. Vanjak, I. Kriegel, J. Otto, F. Peyrade, M. Esteve, and E. Chamorey. 2010. Acceptance of the 2009 A(H1N1) influenza vaccine among hospital workers in two French centers. Vaccine 28:7030–7034. doi:S0264-410X(10)01130-8 [pii];10.1016/j.vaccine.2010.08.021 [doi]. 142. Barros, S. M. and J. F. Carvalho. 2011. Shoenfeld’s syndrome after pandemic influenza A/H1N1 vaccination. Acta Reumatol.Port. 36:65–68. 143. Basha, S., S. Hazenfeld, R. C. Brady, and R. A. Subbramanian. 2011. Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum.Immunol. 72:463–469. doi:S0198-8859(11)00054-1 [pii];10.1016/j. humimm.2011.03.001 [doi]. 144. Bate, J., C. F. Yung, K. Hoschler, L. Sheasby, J. Morden, M. Taj, P. T. Heath, and E. Miller. 2010. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin.Infect.Dis. 51:e95–104. doi:10.1086/657403 [doi]. 145. Baxter, R., G. T. Ray, and B. H. Fireman. 2010. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine 28:7267–7272. doi:S0264-410X(10)01270-3 [pii];10.1016/j.vaccine.2010.08.088 [doi]. 146. Baxter, R., J. Lee, and B. Fireman. 2010. Evidence of bias in studies of influenza vaccine effectiveness in elderly patients. J.Infect.Dis. 201:186–189. doi:10.1086/649568 [doi]. 147. Baxter, R., P. A. Patriarca, K. Ensor, R. Izikson, K. L. Goldenthal, and M. M. Cox. 2011. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus- expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine 29:2272–2278. doi:S0264-410X(11)00078-8 [pii];10.1016/j. vaccine.2011.01.039 [doi].

68 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

148. Baxter, R., R. Jeanfreau, S. L. Block, M. Blatter, M. Pichichero, V. K. Jain, W. Dewe, and B. L. Innis. 2010. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr.Infect.Dis.J. 29:924–930. doi:10.1097/ INF.0b013e3181e075be [doi]. 149. Bayas Rodriguez, J. M., A. L. Garcia-Basteiro, and P. G. Mena. 2010. [Issues in vaccination against influenza A in Spain]. Arch.Bronconeumol. 46 Suppl 2:32–38. doi:S0300-2896(10)70018-1 [pii];10.1016/S0300-2896(10)70018-1 [doi]. 150. Beato, M. S., I. Monne, M. Mancin, E. Bertoli, and I. Capua. 2010. A proof-of-principle study to identify suitable vaccine seed candidates to combat introductions of Eurasian lineage H5 and H7 subtype viruses. Avian Pathol. 39:375–382. doi:928179599 [pii];10.1080/0307945 7.2010.513376 [doi]. 151. Bedard, M., V, R. L. Osorio Figueroa, and T. O. Vazquez. 2010. Guillain-Barre syndrome after influenza vaccine administration: two adult cases. Bol.Asoc.Med.P.R. 102:39–41. 152. Begue, P. 2010. [Consequences of opposition to vaccination in France and Europe. How to maintain effective vaccine coverage in 2010?]. Bull.Acad.Natl.Med. 194:719–732. 153. Begue, P. 2010. [Update on the H1N1 virus]. Bull.Acad.Natl.Med. 194:443–444. 154. Belmin, J., P. Bouree, D. Camus, N. Guiso, C. Jeandel, C. Trivalle, and P. Veyssier. 2010. Vaccination in older adults: development of an educational tool, Vaxisenior, in France. Expert.Rev.Vaccines. 9:15–20. doi:10.1586/erv.10.29 [doi]. 155. Belshe, R. B. 2010. The need for quadrivalent vaccine against seasonal influenza. Vaccine 28 Suppl 4:D45–D53. doi:S0264-410X(10)01137-0 [pii];10.1016/j.vaccine.2010.08.028 [doi]. 156. Belshe, R. B., K. Coelingh, C. S. Ambrose, J. C. Woo, and X. Wu. 2010. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28:2149-2156. doi:S0264-410X(09)01871-4 [pii];10.1016/j.vaccine.2009.11.068 [doi]. 157. Belshe, R. B., S. E. Frey, I. Graham, M. J. Mulligan, S. Edupuganti, L. A. Jackson, A. Wald, G. Poland, R. Jacobson, H. L. Keyserling, P. Spearman, H. Hill, and M. Wolff. 2011. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J.Infect.Dis. 203:666–673. doi:jiq093 [pii];10.1093/infdis/jiq093 [doi]. 158. Belshe, R. B., S. L. Toback, T. Yi, and C. S. Ambrose. 2010. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza.Other Respi.Viruses. 4:141–145. doi:IRV124 [pii];10.1111/j.1750-2659.2009.00124.x [doi]. 159. Benowitz, I., D. B. Esposito, K. D. Gracey, E. D. Shapiro, and M. Vazquez. 2010. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin.Infect.Dis. 51:1355–1361. doi:10.1086/657309 [doi]. 160. Ben-Shimol, S., R. Dagan, N. Givon-Lavi, Y. Bar-Ziv, and D. Greenberg. 2010. [Community acquired (CAP) in children younger than 5 years of age in southern Israel]. Harefuah 149:137–42, 196. 161. Ben-Yedidia, T. 2010. Multimeric-001: BiondVax’s universal flu vaccine. Interview by Duc Le. Expert. Rev.Vaccines. 9:241–242. doi:10.1586/erv.10.2 [doi]. 162. Ben-Yedidia, T. and W. Rudolph. 2011. A universal influenza vaccine: the BiondVax story. Expert.Rev. Vaccines. 10:1509–1512. doi:10.1586/erv.11.136 [doi]. 163. Beran, J., I. A. Abdel-Messih, J. Raupachova, L. Hobzova, and E. Fragapane. 2010. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin.Ther. 32:2186–2197. doi:S0149-2918(11)00024-5 [pii];10.1016/S0149- 2918(11)00024-5 [doi].

69 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

164. Bergeron, C., M. Valette, B. Lina, and M. Ottmann. 2010. Genetic content of Influenza H3N2 vaccine seeds. PLoS.Curr. 2:RRN1165. doi:k/-/-/29jjtx9ryltjb/3 [pii]. 165. Berman, P. P., W. A. Orenstein, A. R. Hinman, and J. Gazmararian. 2010. Stakeholder attitudes toward influenza in the United States. Health Promot.Pract. 11:807–816. doi:1524839909331552 [pii];10.1177/1524839909331552 [doi]. 166. Berthoud, T. K., M. Hamill, P. J. Lillie, L. Hwenda, K. A. Collins, K. J. Ewer, A. Milicic, H. C. Poyntz, T. Lambe, H. A. Fletcher, A. V. Hill, and S. C. Gilbert. 2011. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin.Infect.Dis. 52:1–7. doi:ciq015 [pii];10.1093/cid/ciq015 [doi]. 167. Bertram, U., M. C. Bernard, J. Haensler, P. Maincent, and R. Bodmeier. 2010. In situ gelling nasal inserts for influenza vaccine delivery. Drug Dev.Ind.Pharm. 36:581–593. doi:10.3109/03639040903382673 [doi]. 168. Beyer, W. E., J. J. Nauta, A. M. Palache, K. M. Giezeman, and A. D. Osterhaus. 2011. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 29:5785–5792. doi:S0264-410X(11)00760-2 [pii];10.1016/j. vaccine.2011.05.040 [doi]. 169. Bhatt, P., S. L. Block, S. L. Toback, and C. S. Ambrose. 2010. A prospective observational study of US in-office pediatric influenza vaccination during the 2007 to 2009 influenza seasons: use and factors associated with increased vaccination rates. Clin.Pediatr.(Phila) 49:954–963. doi:0009922810370868 [pii];10.1177/0009922810370868 [doi]. 170. Bhatt, P., S. L. Block, S. L. Toback, and C. S. Ambrose. 2011. Timing of the availability and administration of influenza vaccine through the vaccines for children program. Pediatr.Infect.Dis.J. 30:100–106. doi:10.1097/INF.0b013e3181efff54 [doi]. 171. Bhattacharyya, S. and C. T. Bauch. 2011. “Wait and see” vaccinating behaviour during a pandemic: a game theoretic analysis. Vaccine 29:5519–5525. doi:S0264-410X(11)00738-9 [pii];10.1016/j. vaccine.2011.05.028 [doi]. 172. Bhurayanontachai, R. 2010. Possible life-threatening adverse reaction to monovalent H1N1 vaccine. Crit Care 14:422. doi:cc9022 [pii];10.1186/cc9022 [doi]. 173. Bickel, M., H. N. von, I. Wieters, P. Khaykin, G. Nisius, A. Haberl, C. Stephan, E. Herrmann, H. W. Doerr, H. R. Brodt, and R. Allwinn. 2011. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin.Infect.Dis. 52:122– 127. doi:ciq003 [pii];10.1093/cid/ciq003 [doi]. 174. Bickel, M., I. Wieters, P. Khaykin, G. Nisius, A. Haberl, C. Stephan, H. N. Von, E. Herrmann, H. W. Doerr, H. R. Brodt, and R. Allwinn. 2010. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 24:F31–F35. doi:10.1097/QAD.0b013e3283398da1 [doi];00002030-201006010-00001 [pii]. 175. Bijl, D. 2011. Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects. Int.J.Risk Saf Med. 23:65–71. doi:P267TH7832P32713 [pii];10.3233/JRS-2011-0521 [doi]. 176. Bijl, D. and H. Schellekens. 2011. The sponsored pandemic of the Mexican flu? Int.J.Risk Saf Med. 23:73–79. doi:RT677PU758598084 [pii];10.3233/JRS-2011-0523 [doi]. 177. Bijl, M., N. Agmon-Levin, J. M. Dayer, E. Israeli, M. Gatto, and Y. Shoenfeld. 2011. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun.Rev. doi:S1568-9972(11)00235-7 [pii];10.1016/j.autrev.2011.10.015 [doi]. 178. Bird, S. M. 2011. Febrile convulsions after seasonal influenza immunisation in UK. Lancet 378:399– 400. doi:S0140-6736(11)61207-5 [pii];10.1016/S0140-6736(11)61207-5 [doi].

70 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

179. Birmingham, E., M. Catallozzi, S. E. Findley, D. K. Vawdrey, R. Kukafka, and M. S. Stockwell. 2011. FluAlert: a qualitative evaluation of providers’ desired characteristics and concerns regarding computerized influenza vaccination alerts. Prev.Med. 52:274–277. doi:S0091-7435(11)00034-X [pii];10.1016/j.ypmed.2011.01.008 [doi]. 180. Black, S., C. G. Della, A. Malfroot, P. Nacci, U. Nicolay, M. Pellegrini, E. Sokal, and A. Vertruyen. 2010. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 28:7331–7336. doi:S0264-410X(10)01245-4 [pii];10.1016/j.vaccine.2010.08.075 [doi]. 181. Black, S., U. Nicolay, T. Vesikari, M. Knuf, G. G. Del, C. G. Della, T. Tsai, R. Clemens, and R. Rappuoli. 2011. Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children. Pediatr.Infect.Dis.J. doi:10.1097/INF.0b013e3182367662 [doi]. 182. Blasi, F., P. Palange, G. Rohde, T. Severin, G. Cornaglia, and R. Finch. 2011. Healthcare workers and influenza vaccination: an ERS-ESCMID Web-based survey. Clin.Microbiol.Infect. 17:1223–1225. doi:10.1111/j.1469-0691.2011.03501.x [doi]. 183. Block, S. L., T. Heikkinen, S. L. Toback, W. Zheng, and C. S. Ambrose. 2011. The efficacy of live attenuated influenza vaccine against influenza-associated acute in children. Pediatr.Infect. Dis.J. 30:203–207. doi:10.1097/INF.0b013e3181faac7c [doi]. 184. Block, S. L., T. Yi, E. Sheldon, F. Dubovsky, and J. Falloon. 2011. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 29:9391– 9397. doi:S0264-410X(11)01551-9 [pii];10.1016/j.vaccine.2011.09.109 [doi]. 185. Blomberg, B. B. and D. Frasca. 2011. Quantity, not quality, of antibody response decreased in the elderly. J.Clin.Invest 121:2981–2983. doi:58406 [pii];10.1172/JCI58406 [doi]. 186. Blyth, C. C., T. Y. Markus, P. V. Effler, and P. C. Richmond. 2011. Ensuring safety of the 2011 trivalent influenza vaccine in young children. Med.J.Aust. 195:52. doi:letters_040711_fm-1 [pii]. 187. Boccia, A., T. D. Di, G. M. De, and T. G. La. 2011. Seasonal and pandemic influenza: the role of communication and preventive strategies. J.Prev.Med.Hyg. 52:124–126. 188. Bodewes, R., G. F. Rimmelzwaan, and A. D. Osterhaus. 2010. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert.Rev.Vaccines. 9:59–72. doi:10.1586/erv.09.148 [doi]. 189. Bodewes, R., J. H. Kreijtz, A. G. van, M. M. Geelhoed-Mieras, R. J. Verburgh, J. G. Heldens, J. Bedwell, J. M. van den Brand, T. Kuiken, C. A. van Baalen, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2010. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J.Virol. 84:7943–7952. doi:JVI.00549-10 [pii];10.1128/JVI.00549-10 [doi]. 190. Bodewes, R., J. H. Kreijtz, M. L. Hillaire, M. M. Geelhoed-Mieras, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2010. Vaccination with whole inactivated virus vaccine affects the induction of against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J.Gen.Virol. 91:1743–1753. doi:vir.0.020784-0 [pii];10.1099/ vir.0.020784-0 [doi]. 191. Bodewes, R., J. H. Kreijtz, M. M. Geelhoed-Mieras, A. G. van, R. J. Verburgh, S. E. van Trierum, T. Kuiken, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2011. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J.Virol. 85:2695–2702. doi:JVI.02371-10 [pii];10.1128/JVI.02371-10 [doi]. 192. Boehm, K. M. 2010. Seasonal and avian influenza knowledge base of attending physicians in a community-based hospital: a survey-based study. J.Am.Osteopath.Assoc. 110:285–289. doi:110/5/285 [pii].

71 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

193. Boehmer, L. M., S. N. Waqar, and R. Govindan. 2010. Influenza vaccination in patients with cancer: an overview. Oncology (Williston.Park) 24:1167–1170. 194. Boesteanu, A. C., N. S. Babu, M. Wheatley, E. S. Papazoglou, and P. D. Katsikis. 2010. Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus. Vaccine 29:314–322. doi:S0264-410X(10)01506-9 [pii];10.1016/j.vaccine.2010.10.036 [doi]. 195. Bohmer, M. M., D. Walter, S. Muters, G. Krause, and O. Wichmann. 2011. Seasonal influenza vaccine uptake in Germany 2007/2008 and 2008/2009: results from a national health update survey. Vaccine 29:4492–4498. doi:S0264-410X(11)00584-6 [pii];10.1016/j.vaccine.2011.04.039 [doi]. 196. Boltz, D. A., J. R. Aldridge, Jr., R. G. Webster, and E. A. Govorkova. 2010. Drugs in development for influenza. Drugs 70:1349–1362. doi:1 [pii];10.2165/11537960-000000000-00000 [doi]. 197. Bommakanti, G., M. P. Citron, R. W. Hepler, C. Callahan, G. J. Heidecker, T. A. Najar, X. Lu, J. G. Joyce, J. W. Shiver, D. R. Casimiro, M. J. ter, X. Liang, and R. Varadarajan. 2010. Design of an HA2- based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc.Natl.Acad.Sci.U.S.A 107:13701–13706. doi:1007465107 [pii];10.1073/pnas.1007465107 [doi]. 198. Bond, T. C., P. R. Patel, J. Krisher, L. Sauls, J. Deane, K. Strott, and W. McClellan. 2011. A group- randomized evaluation of a quality improvement intervention to improve influenza vaccination rates in dialysis centers. Am.J.Kidney Dis. 57:283–290. doi:S0272-6386(10)01441-1 [pii];10.1053/j. ajkd.2010.09.019 [doi]. 199. Bone, A., J. P. Guthmann, J. Nicolau, and D. Levy-Bruhl. 2010. Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009–2010: results of a national vaccination campaign. Vaccine 28:8157–8161. doi:S0264-410X(10)01438-6 [pii];10.1016/j.vaccine.2010.09.096 [doi]. 200. Bosch, B. J., R. Bodewes, R. P. de Vries, J. H. Kreijtz, W. Bartelink, A. G. van, G. F. Rimmelzwaan, C. A. de Haan, A. D. Osterhaus, and P. J. Rottier. 2010. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J.Virol. 84:10366–10374. doi:JVI.01035-10 [pii];10.1128/JVI.01035-10 [doi]. 201. Botsis, T. and R. Ball. 2011. Network analysis of possible anaphylaxis cases reported to the US vaccine adverse event reporting system after H1N1 influenza vaccine. Stud.Health Technol.Inform. 169:564–568. 202. Boulton, M. L., A. M. Grossman, R. Potter, P. A. Vranesich, and J. Clayton. 2011. Assessing the relationship between seasonal and H1N1 influenza vaccination status in Michigan children, 2009– 2010. Public Health Rep. 126 Suppl 2:70–77. 203. Bourgeois, N., C. Franke, S. A. O’Connor, H. Shaw, S. Hum, and S. Dunn. 2011. Preparing for an influenza pandemic: model of an immunization clinic in an urban family practice. Can.Fam.Physician 57:e367–e372. doi:57/10/e367 [pii]. 204. Bowman, C. S., J. Arino, and S. M. Moghadas. 2011. Evaluation of vaccination strategies during pandemic outbreaks. Math.Biosci.Eng 8:113–122. 205. Boyeau, C., M. Tanguy, S. Pean, A. Delhumeau, and S. Fanello. 2011. [Seasonal and pandemic A (H1N1) 2009 influenza vaccination coverage among health-care workers in a French university hospital]. Sante Publique 23:19–29. 206. Bragstad, K., C. J. Martel, J. S. Thomsen, K. L. Jensen, L. P. Nielsen, B. Aasted, and A. Fomsgaard. 2011. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades. Influenza.Other Respi.Viruses. 5:13–23. doi:10.1111/j.1750-2659.2010.00177.x [doi]. 207. Brahmakshatriya, V. R., B. Lupiani, and S. M. Reddy. 2010. Characterization and evaluation of avian influenza NS1 mutant virus as a potential live and killed DIVA (differentiating between infected and vaccinated animals) vaccine for chickens. Vaccine 28:2388–2396. doi:S0264-410X(10)00010-1 [pii];10.1016/j.vaccine.2009.12.074 [doi].

72 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

208. Brakemeier, S., B. Schweiger, N. Lachmann, P. Glander, C. Schonemann, F. Diekmann, H. H. Neumayer, and K. Budde. 2011. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(R)) in renal transplant recipients. Nephrol.Dial.Transplant. doi:gfr278 [pii];10.1093/ndt/ gfr278 [doi]. 209. Brantsaeter, A. B. 2011. [Did vaccines and hygiene recommendations affect the pandemic?]. Tidsskr. Nor Laegeforen. 131:662. doi:2089314 [pii];10.4045/tidsskr.11.0318 [doi]. 210. Braunack-Mayer, A. J., J. M. Street, W. A. Rogers, R. Givney, J. R. Moss, and J. E. Hiller. 2010. Including the public in pandemic planning: a deliberative approach. BMC.Public Health 10:501. doi:1471-2458-10-501 [pii];10.1186/1471-2458-10-501 [doi]. 211. Broderick, K. E., X. Shen, J. Soderholm, F. Lin, J. McCoy, A. S. Khan, J. Yan, M. P. Morrow, A. Patel, G. P. Kobinger, S. Kemmerrer, D. B. Weiner, and N. Y. Sardesai. 2011. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther. 18:258–265. doi:gt2010137 [pii];10.1038/gt.2010.137 [doi]. 212. Brodwall, K. 2011. [Vaccine against pandemic influenza A(H1N1) – effect and safety]. Tidsskr.Nor Laegeforen. 131:556. 213. Brooks, W. A., D. Goswami, M. Rahman, K. Nahar, A. M. Fry, A. Balish, N. Iftekharuddin, T. Azim, X. Xu, A. Klimov, J. Bresee, C. Bridges, and S. Luby. 2010. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr.Infect.Dis.J. 29:216–221. doi:10.1097/ INF.0b013e3181bc23fd [doi];00006454-201003000-00007 [pii]. 214. Broos, N., E. P. van Puijenbroek, and G. K. van. 2010. Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands. Drug Saf 33:1109–1115. doi:6 [pii];10.2165/11539280-000000000-00000 [doi]. 215. Brouqui, P., J. C. Lagier, N. Cassir, S. Badiaga, and H. Gadelius. 2010. H1N1 2009 pandemic flu vaccination campaign: The Homeless lesson. PLoS.Curr. 2:RRN1146. doi:k/-/-/qccicvnl16mc/2 [pii]. 216. Brown, D. M. 2010. Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell Immunol. 262:89–95. doi:S0008-8749(10)00038-9 [pii];10.1016/j.cellimm.2010.02.008 [doi]. 217. Brown, J. R., L. J. Goebel, S. M. Neitch, H. K. Tweel, and M. A. Mufson. 2011. Barriers to vaccinating the elderly with H1N1 vaccine. Am.J.Med.Sci. 342:24–26. doi:10.1097/MAJ.0b013e31820e782b [doi]. 218. Brown, K. F., J. S. Kroll, M. J. Hudson, M. Ramsay, J. Green, C. A. Vincent, G. Fraser, and N. Sevdalis. 2010. Omission bias and vaccine rejection by parents of healthy children: implications for the influenza A/H1N1 vaccination programme. Vaccine 28:4181–4185. doi:S0264- 410X(10)00505-0 [pii];10.1016/j.vaccine.2010.04.012 [doi]. 219. Brown, L. E. 2010. The role of adjuvants in vaccines for seasonal and pandemic influenza. Vaccine 28:8043–8045. doi:S0264-410X(10)01334-4 [pii];10.1016/j.vaccine.2010.09.024 [doi]. 220. Bruckhoff, B. 2011. [The production of influenza vaccines from MDCK cell cultures]. Pharm.Unserer Zeit 40:140–142. 221. Bryan, P. and S. Seabroke. 2011. No increased risk of febrile convulsions after seasonal influenza immunisation in UK. Lancet 377:904. doi:S0140-6736(11)60352-8 [pii];10.1016/S0140- 6736(11)60352-8 [doi]. 222. Bryan, P., S. Seabroke, and C. Davies. 2010. H1N1 vaccine safety: real-time surveillance in the UK. Lancet 376:417–418. doi:S0140-6736(10)61221-4 [pii];10.1016/S0140-6736(10)61221-4 [doi]. 223. Bryant, N. A., R. Paillot, A. S. Rash, E. Medcalf, F. Montesso, J. Ross, J. Watson, M. Jeggo, N. S. Lewis, J. R. Newton, and D. M. Elton. 2010. Comparison of two modern vaccines and previous influenza infection against challenge with an virus from the Australian 2007 outbreak. Vet.Res. 41:19. doi:10.1051/vetres/2009067 [doi];v09466 [pii].

73 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

224. Bucasas, K. L., L. M. Franco, C. A. Shaw, M. S. Bray, J. M. Wells, D. Nino, N. Arden, J. M. Quarles, R. B. Couch, and J. W. Belmont. 2011. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J.Infect.Dis. 203:921–929. doi:jiq156 [pii];10.1093/infdis/jiq156 [doi]. 225. Budimir, N., T. Meijerhof, J. Wilschut, A. Huckriede, and H. A. de. 2010. The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes. Vaccine 28:8280–8287. doi:S0264-410X(10)01467-2 [pii];10.1016/j. vaccine.2010.10.007 [doi]. 226. Bugarini, R., D. Casula, N. Groth, M. Lattanzi, S. Holmes, and A. Podda. 2010. Associations of the correlates of protection and implication on the statistical power for demonstrating non-inferiority: application of a re-sampling method on a large phase III influenza vaccine clinical trial. Vaccine 28:7401–7406. doi:S0264-410X(10)01292-2 [pii];10.1016/j.vaccine.2010.08.102 [doi]. 227. Bulifon, S., V. Tsatsaris, F. Goffinet, A. Mignon, F. Batteux, J. F. Delfraissy, and O. Launay. 2010. [Pandemic influenza A/H1N1v, pregnancy and vaccination]. Med.Mal Infect. 40:696–702. doi:S0399-077X(10)00208-8 [pii];10.1016/j.medmal.2010.07.010 [doi]. 228. Bults, M., D. J. Beaujean, Z. O. de, G. Kok, E. P. van, J. E. van Steenbergen, J. H. Richardus, and H. A. Voeten. 2010. [Mexican flu: risk perception in the general public, precautionary measures and trust in information provided by the government]. Ned.Tijdschr.Geneeskd. 154:A1686. 229. Burkardt, H. J. 2011. Pandemic H1N1 2009 (‘swine flu’): diagnostic and other challenges. Expert. Rev.Mol.Diagn. 11:35–40. doi:10.1586/erm.10.102 [doi]. 230. Burke, B. L., Jr., C. C. Nesmith, R. E. Ott, and M. L. Hedrick. 2010. Through with the flu: how free family and caregiver immunization protects sick neonates. Clin.Pediatr.(Phila) 49:20–23. doi:0009922809351962 [pii];10.1177/0009922809351962 [doi]. 231. Burt, D., C. Mallett, M. Plante, J. Zimmermann, K. Torossian, and L. Fries. 2011. Proteosome- adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert.Rev. Vaccines. 10:365–375. doi:10.1586/erv.10.172 [doi]. 232. Burwen, D. R., R. Ball, W. W. Bryan, H. S. Izurieta, V. L. La, N. A. Gibbs, R. Kliman, and M. M. Braun. 2010. Evaluation of Guillain-Barre Syndrome among recipients of influenza vaccine in 2000 and 2001. Am.J.Prev.Med. 39:296–304. doi:S0749-3797(10)00410-1 [pii];10.1016/j. amepre.2010.05.022 [doi]. 233. Bushnell, R. V., J. K. Tobin, J. Long, S. Schultz-Cherry, A. R. Chaudhuri, P. L. Nara, and G. J. Tobin. 2010. Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein. Virol.J. 7:200. doi:1743-422X-7-200 [pii];10.1186/1743-422X-7-200 [doi]. 234. Busse, W. W., S. P. Peters, M. J. Fenton, H. Mitchell, E. R. Bleecker, M. Castro, S. Wenzel, S. C. Erzurum, A. M. Fitzpatrick, W. G. Teague, N. Jarjour, W. C. Moore, K. Sumino, S. Simeone, S. Ratanamaneechat, M. Penugonda, B. Gaston, T. M. Ross, S. Sigelman, J. R. Schiepan, D. J. Zaccaro, C. J. Crevar, D. M. Carter, and A. Togias. 2011. Vaccination of patients with mild and severe with a 2009 pandemic H1N1 influenza virus vaccine. J.Allergy Clin.Immunol. 127:130–7, 137. doi:S0091-6749(10)01764-1 [pii];10.1016/j.jaci.2010.11.014 [doi]. 235. Butts, C., R. N. Murray, C. J. Smith, P. M. Ellis, K. Jasas, A. Maksymiuk, G. Goss, G. Ely, F. Beier, and D. Soulieres. 2010. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin.Lung Cancer 11:391–395. doi:S1525-7304(11)70044-4 [pii];10.3816/CLC.2010.n.101 [doi]. 236. Caban-Martinez, A. J., D. J. Lee, E. P. Davila, W. G. LeBlanc, K. L. Arheart, K. E. McCollister, S. L. Christ, T. Clarke, and L. E. Fleming. 2010. Sustained low influenza vaccination rates in US healthcare workers. Prev.Med. 50:210–212. doi:S0091-7435(10)00003-4 [pii];10.1016/j.ypmed.2010.01.001 [doi]. 74 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

237. Caillet, C., F. Piras, M. C. Bernard, M. A. de, F. Boudet, F. R. Vogel, A. Hoffenbach, C. Moste, and I. Kusters. 2010. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 28:3076–3079. doi:S0264-410X(10)00218-5 [pii];10.1016/j.vaccine.2010.02.050 [doi]. 238. Calcagnile, S. and G. V. Zuccotti . 2010. The virosomal adjuvanted influenza vaccine. Expert.Opin.Biol. Ther. 10:191–200. doi:10.1517/14712590903431014 [doi]. 239. Camilloni, B., M. Neri, E. Lepri, M. Basileo, N. Sigismondi, S. Puzelli, I. Donatelli, and A. M. Iorio. 2010. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine 28:7536–7541. doi:S0264-410X(10)01221-1 [pii];10.1016/j.vaccine.2010.08.064 [doi]. 240. Campbell, J. D., C. V. Chambers, R. C. Brady, M. C. Caldwell, N. L. Bennett, M. A. Fourneau, V. K. Jain, and B. L. Innis. 2011. Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults. Hum.Vaccin. 7:81–88. doi:13553 [pii]. 241. Campbell, J. P., K. M. Edwards, C. Ring, M. T. Drayson, J. A. Bosch, A. Inskip, J. E. Long, D. Pulsford, and V. E. Burns. 2010. The effects of vaccine timing on the efficacy of an acute eccentric exercise intervention on the immune response to an influenza vaccine in young adults. Brain Behav.Immun. 24:236–242. doi:S0889-1591(09)00465-6 [pii];10.1016/j.bbi.2009.10.001 [doi]. 242. Campitelli, M. A., L. C. Rosella, T. A. Stukel, and J. C. Kwong. 2010. Influenza vaccination and all- cause mortality in community-dwelling elderly in Ontario, Canada, a cohort study. Vaccine 29:240– 246. doi:S0264-410X(10)01550-1 [pii];10.1016/j.vaccine.2010.10.049 [doi]. 243. Campos-Outcalt, D. 2011. Ready for flu season? The 2011–2012 ACIP recommendations. J.Fam. Pract. 60:543–544. doi:jfp_6009f [pii]. 244. Canestri, A., A. Krivine, L. Assoumou, C. M. Le, F. Rozenberg, A. G. Marcelin, L. Schneider, A. Samri, G. Carcelain, B. Autran, C. Katlama, and A. Guihot. 2010. Maraviroc does not affect humoral response to the pandemic influenza A-H1N1v 2009 adjuvanted vaccine in HIV-1-infected patients. AIDS 24:2887–2889. doi:10.1097/QAD.0b013e3283402bc1 [doi]. 245. Cannava, P., D. Cicillini, M. Higgins, A. McGrath, and J. O’Leary. 2010. Response to H1N1 influenza outbreak in a pediatric children’s hospital: challenges faced and lessons learned. J.Pediatr.Nurs. 25:375–381. doi:S0882-5963(10)00104-1 [pii];10.1016/j.pedn.2010.03.001 [doi]. 246. Cao, W., J. H. Kim, T. Chirkova, A. J. Reber, R. Biber, D. K. Shay, and S. Sambhara. 2011. Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert.Rev.Vaccines. 10:1529– 1537. doi:10.1586/erv.11.137 [doi]. 247. Caplan, A. 2011. Time to mandate influenza vaccination in health-care workers. Lancet 378:310– 311. 248. Caplan, A. L. 2010. Duty to warn?-the ethics of disclosing information about possible risks associated with H1N1 vaccination. Sleep 33:1426–1427. 249. Carbo Malonda, R. M., M. F. Gonzalez, L. H. Vanaclocha, B. M. Martin-Sierra, R. S. Guiral, P. E. Perez, and M. T. Castellanos. 2010. [Pandemic influenza surveillance in the valencian community and seasonal influenza vaccines]. Rev.Esp.Salud Publica 84:623–633. doi:S1135-57272010000500013 [pii]. 250. Carcione, D., C. Giele, L. S. Goggin, K. S. Kwan, D. W. Smith, G. K. Dowse, D. B. Mak, and P. Effler. 2010. Association between 2009 seasonal influenza vaccine and influenza-like illness during the 2009 pandemic: preliminary results of a large household transmission study in Western . Euro.Surveill 15.

75 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

251. Carlson, S. J., D. N. Durrheim, and C. B. Dalton. 2010. Flutracking provides a measure of field influenza vaccine effectiveness, Australia, 2007–2009. Vaccine 28:6809–6810. doi:S0264- 410X(10)01196-5 [pii];10.1016/j.vaccine.2010.08.051 [doi]. 252. Carmona, A., F. Omenaca, J. C. Tejedor, J. M. Merino, T. Vaman, I. Dieussaert, P. Gillard, and J. Aristegui. 2010. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine 28:5837–5844. doi:S0264-410X(10)00887-X [pii];10.1016/j. vaccine.2010.06.065 [doi]. 253. Carney, P. J., A. S. Lipatov, A. S. Monto, R. O. Donis, and J. Stevens. 2010. Flexible label-free quantitative assay for antibodies to influenza virus hemagglutinins. Clin.Vaccine Immunol. 17:1407– 1416. doi:CVI.00509-09 [pii];10.1128/CVI.00509-09 [doi]. 254. Carr, S., K. J. Allison, L. A. Van De Velde, K. Zhang, E. Y. English, A. Iverson, N. C. Daw, S. C. Howard, F. Navid, C. Rodriguez-Galindo, J. Yang, E. E. Adderson, J. A. McCullers, and P. M. Flynn. 2011. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J.Infect.Dis. 204:1475–1482. doi:jir561 [pii];10.1093/infdis/jir561 [doi]. 255. Carrasco-Garrido, P., A. L. de Andres, V. Hernandez-Barrera, A. G. de Miguel, and R. Jimenez-Garcia. 2009. Patient’s perceptions and information provided by the public health service are predictors for influenza vaccine uptake. Hum.Vaccin. 5:839–842. doi:10042 [pii]. 256. Carroll, T. D., S. R. Matzinger, M. Barro, L. Fritts, M. B. McChesney, C. J. Miller, and R. E. Johnston. 2011. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone (R) in rhesus macaques. Vaccine 29:931–940. doi:S0264-410X(10)01633-6 [pii];10.1016/j. vaccine.2010.11.024 [doi]. 257. Carter, N. J. and M. P. Curran. 2011. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71:1591–1622. doi:7 [pii];10.2165/11206860-000000000-00000 [doi]. 258. Carvajal, A., P. G. Ortega, M. Sainz, V. Velasco, I. Salado, L. H. Arias, J. M. Eiros, A. P. Rubio, and J. Castrodeza. 2011. Adverse events associated with pandemic influenza vaccines: comparison of the results of a follow-up study with those coming from spontaneous reporting. Vaccine 29:519–522. doi:S0264-410X(10)01568-9 [pii];10.1016/j.vaccine.2010.10.067 [doi]. 259. Cassone, A. and R. Rappuoli. 2010. Universal vaccines: shifting to one for many. MBio. 1 . doi:10.1128/mBio.00042-10 [doi]. 260. Castilla, J., J. Moran, V. Martinez-Artola, G. Reina, I. Martinez-Baz, C. M. Garcia, N. Alvarez, F. Irisarri, M. Arriazu, F. Elia, and E. Salcedo. 2011. Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Euro.Surveill 16. 261. Cate, T. R., Y. Rayford, D. Nino, P. Winokur, R. Brady, R. Belshe, W. Chen, R. L. Atmar, and R. B. Couch. 2010. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 28:2076–2079. doi:S0264- 410X(09)01945-8 [pii];10.1016/j.vaccine.2009.12.041 [doi]. 262. Cavalcante, R. S., A. M. Jorge, and C. M. Fortaleza. 2010. Predictors of adherence to influenza vaccination for healthcare workers from a teaching hospital: a study in the prepandemic era. Rev.Soc. Bras.Med.Trop. 43:611–614. doi:S0037-86822010000600001 [pii]. 263. Cech, P. G., T. Aebi, M. S. Abdallah, M. Mpina, E. B. Machunda, N. Westerfeld, S. A. Stoffel, R. Zurbriggen, G. Pluschke, M. Tanner, C. Daubenberger, B. Genton, and S. Abdulla. 2011. Virosome- formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS.One. 6:e22273. doi:10.1371/journal. pone.0022273 [doi];PONE-D-11-02665 [pii].

76 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

264. Chaabane, A., K. Aouam, F. N. Ben, A. Toumi, D. Braham, A. Boughattas, and M. Chakroun. 2011. [H1N1 Influenza Vaccines in Tunisia: Efficiency and Safety]. Therapie 66:281–289. doi:10.2515/ therapie/2011028 [doi];th111933 [pii]. 265. Chambers, C. T., J. A. Buxton, and M. Koehoorn. 2010. Consultation with health care professionals and influenza immunization among women in contact with young children. Can.J.Public Health 101:15–19. 266. Chan, K. H., K. K. To, I. F. Hung, A. J. Zhang, J. F. Chan, V. C. Cheng, H. Tse, X. Y. Che, H. Chen, and K. Y. Yuen. 2011. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza. Clin.Vaccine Immunol. 18:867–873. doi:CVI.00555-10 [pii];10.1128/CVI.00555-10 [doi]. 267. Chan, T. C., C. K. Hsiao, C. C. Lee, P. H. Chiang, C. L. Kao, C. M. Liu, and C. C. King. 2010. The impact of matching vaccine strains and post-SARS public health efforts on reducing influenza- associated mortality among the elderly. PLoS.One. 5:e11317. doi:10.1371/journal.pone.0011317 [doi]. 268. Chang, H., C. Huang, J. Wu, F. Fang, W. Zhang, F. Wang, and Z. Chen. 2010. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. Virol.J. 7:197. doi:1743-422X-7-197 [pii];10.1186/1743-422X-7-197 [doi]. 269. Chang, H., X. Li, Y. Teng, Y. Liang, B. Peng, F. Fang, and Z. Chen. 2010. Comparison of adjuvant efficacy of chitosan and aluminum hydroxide for intraperitoneally administered inactivated influenza H5N1 vaccine. DNA Cell Biol. 29:563–568. doi:10.1089/dna.2009.0977 [doi]. 270. Chao, D. L., L. Matrajt, N. E. Basta, J. D. Sugimoto, B. Dean, D. A. Bagwell, B. Oiulfstad, M. E. Halloran, and I. M. Longini, Jr. 2011. Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States. Am.J.Epidemiol. 173:1121–1130. doi:kwq497 [pii];10.1093/ aje/kwq497 [doi]. 271. Chao, D. Y., K. F. Cheng, Y. H. Hsieh, T. C. Li, T. N. Wu, C. Y. Chen, C. A. Tsai, J. H. Chen, H. T. Chiu, J. J. Lu, M. C. Su, and Y. H. Liao. 2011. Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine. Vaccine 29:617–623. doi:S0264-410X(10)01622-1 [pii];10.1016/j.vaccine.2010.11.016 [doi]. 272. Charlier, C., O. Launay, H. Coignard-Biehler, M. Lecuit, and O. Lortholary. 2010. [Pregnancy: a high risk factor in influenza infection]. Med.Sci.(Paris) 26:100–104. doi:00/00/0E/E4/ [pii];10.1051/ medsci/2010261100 [doi]. 273. Chaudhary, V., R. K. Singh, V. K. Agrawal, A. Agarwal, R. Kumar, and M. Sharma. 2010. Awareness, perception and myths towards swine flu in school children of Bareilly, Uttar Pradesh. Indian J.Public Health 54:161–164. doi:IndianJPublicHealth_2010_54_3_161_75741 [pii];10.4103/0019- 557X.75741 [doi]. 274. Chaussee, M. S., H. R. Sandbulte, M. J. Schuneman, F. P. Depaula, L. A. Addengast, E. H. Schlenker, and V. C. Huber. 2011. Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections. Vaccine 29:3773–3781. doi:S0264- 410X(11)00383-5 [pii];10.1016/j.vaccine.2011.03.031 [doi]. 275. Chebykina, A. V. and M. P. Kostinov. 2011. [Postvaccination immunity against influenza in patients with chronic broncho-pulmonary pathology]. Zh.Mikrobiol.Epidemiol.Immunobiol.76–80. 276. Chen, A., S. L. Poh, C. Dietzsch, E. Roethl, M. L. Yan, and S. K. Ng. 2011. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells. BMC.Biotechnol. 11:81. doi:1472-6750-11-81 [pii];10.1186/1472-6750-11-81 [doi].

77 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

277. Chen, C. Y., H. J. Liu, C. P. Tsai, C. Y. Chung, Y. S. Shih, P. C. Chang, Y. T. Chiu, and Y. C. Hu. 2010. Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms. Vaccine 28:7644–7651. doi:S0264-410X(10)01358-7 [pii];10.1016/j. vaccine.2010.09.048 [doi]. 278. Chen, G. L., E. W. Lamirande, C. F. Yang, H. Jin, G. Kemble, and K. Subbarao. 2010. Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets. J.Virol. 84:7695–7702. doi:JVI.00511-10 [pii];10.1128/JVI.00511-10 [doi]. 279. Chen, G. L., E. W. Lamirande, H. Jin, G. Kemble, and K. Subbarao. 2010. Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets. Virology 398:109– 114. doi:S0042-6822(09)00788-0 [pii];10.1016/j.virol.2009.12.003 [doi]. 280. Chen, G. L., J. Y. Min, E. W. Lamirande, C. Santos, H. Jin, G. Kemble, and K. Subbarao. 2011. Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. J.Infect.Dis. 203:930–936. doi:jiq144 [pii];10.1093/infdis/jiq144 [doi]. 281. Chen, G. L., Y. F. Lau, E. W. Lamirande, A. W. McCall, and K. Subbarao. 2011. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc.Natl.Acad. Sci.U.S.A 108:1140–1145. doi:1009908108 [pii];10.1073/pnas.1009908108 [doi]. 282. Chen, J. F., C. P. Chiang, Y. F. Chen, and W. M. Wang. 2011. Pityriasis rosea following influenza (H1N1) vaccination. J.Chin Med.Assoc. 74:280–282. doi:S1726-4901(11)00125-0 [pii];10.1016/j. jcma.2011.04.010 [doi]. 283. Chen, J. R., C. Ma, and C. H. Wong. 2011. Vaccine design of hemagglutinin glycoprotein against influenza. Trends Biotechnol. 29:426–434. doi:S0167-7799(11)00073-4 [pii];10.1016/j. tibtech.2011.04.007 [doi]. 284. Chen, L. H., D. R. Hill, and A. Wilder-Smith. 2011. Vaccination of travelers: how far have we come and where are we going? Expert.Rev.Vaccines. 10:1609–1620. doi:10.1586/erv.11.138 [doi]. 285. Chen, M. W., H. Y. Liao, Y. Huang, J. T. Jan, C. C. Huang, C. T. Ren, C. Y. Wu, T. J. Cheng, D. D. Ho, and C. H. Wong. 2011. Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin. Proc.Natl.Acad.Sci.U.S.A 108:3510–3515. doi:1019744108 [pii];10.1073/pnas.1019744108 [doi]. 286. Chen, S. C. and C. M. Liao. 2010. Probabilistic indoor transmission modeling for influenza (sub)type viruses. J.Infect. 60:26–35. doi:S0163-4453(09)00276-X [pii];10.1016/j.jinf.2009.09.015 [doi]. 287. Chen, W. H., A. S. Cross, R. Edelman, M. B. Sztein, W. C. Blackwelder, and M. F. Pasetti. 2011. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 29:2865–2873. doi:S0264- 410X(11)00230-1 [pii];10.1016/j.vaccine.2011.02.017 [doi]. 288. Chen, X., G. J. Fernando, M. L. Crichton, C. Flaim, S. R. Yukiko, E. J. Fairmaid, H. J. Corbett, C. A. Primiero, A. B. Ansaldo, I. H. Frazer, L. E. Brown, and M. A. Kendall. 2011. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J.Control Release 152:349–355. doi:S0168-3659(11)00111-8 [pii];10.1016/j. jconrel.2011.02.026 [doi]. 289. Chen, Y., W. Luo, W. L. Wu, Z. Fang, L. Xia, X. Gui, Y. Chen, H. Chen, J. W. Shih, and N. Xia. 2010. Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1. Antiviral Res. 87:81–84. doi:S0166-3542(10)00598-X [pii];10.1016/j.antiviral.2010.04.012 [doi]. 290. Chen, Z., H. Zhou, and H. Jin. 2010. The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response. Vaccine 28:4079–4085. doi:S0264-410X(10)00478-0 [pii];10.1016/j.vaccine.2010.03.078 [doi].

78 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

291. Chen, Z., W. Wang, H. Zhou, A. L. Suguitan, Jr., C. Shambaugh, L. Kim, J. Zhao, G. Kemble, and H. Jin. 2010. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J.Virol. 84:44–51. doi:JVI.02106-09 [pii];10.1128/ JVI.02106-09 [doi]. 292. Cheng, A. C., T. Kotsimbos, H. A. Kelly, L. B. Irving, S. D. Bowler, S. G. Brown, M. Holmes, C. R. Jenkins, P. Thompson, G. Simpson, R. Wood-Baker, S. N. Senanayake, S. J. Brady, D. L. Paterson, P. A. Wark, J. W. Upham, T. M. Korman, D. E. Dwyer, G. W. Waterer, and P. M. Kelly. 2011. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study. Vaccine 29:7320–7325. doi:S0264-410X(11)01137-6 [pii];10.1016/j.vaccine.2011.07.087 [doi]. 293. Cheng, F. W., P. K. Chan, W. K. Leung, V. Lee, M. K. Shing, A. C. Yeung, and C. K. Li. 2011. Pandemic (H1N1) 2009 vaccine in paediatric oncology patients: one dose or two doses? Br.J.Haematol. 154:408–409. doi:10.1111/j.1365-2141.2010.08501.x [doi]. 294. Cheng, H. C., C. Y. Chang, F. I. Hsieh, J. J. Yeh, M. Y. Chien, R. N. Pan, M. C. Deng, and D. Z. Liu. 2011. Effects of tremella-alginate-liposome encapsulation on oral delivery of inactivated H5N3 vaccine. J.Microencapsul. 28:55–61. doi:10.3109/02652048.2010.523796 [doi]. 295. Cheng, X., Q. Xu, E. Song, C. F. Yang, G. Kemble, and H. Jin. 2010. The hemagglutinin protein of influenza A/Vietnam/1203/2004 (H5N1) contributes to hyperinduction of proinflammatory cytokines in human epithelial cells. Virology 406:28–36. doi:S0042-6822(10)00438-1 [pii];10.1016/j. virol.2010.06.048 [doi]. 296. Cheong, H. J., J. Y. Song, J. Y. Heo, J. Y. Noh, W. S. Choi, D. W. Park, S. H. Wie, and W. J. Kim. 2011. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin.Vaccine Immunol. 18:1358–1364. doi:CVI.05111-11 [pii];10.1128/CVI.05111-11 [doi]. 297. Cheong, H. J., J. Y. Song, J. Y. Heo, J. Y. Noh, W. S. Choi, D. W. Park, S. H. Wie, and W. J. Kim. 2011. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine 29:523–527. doi:S0264-410X(10)01561-6 [pii];10.1016/j.vaccine.2010.10.060 [doi]. 298. Cherdantsev, A. P., M. P. Kostinov, A. I. Kuselman, and N. V. Voznesenskaia. 2011. [Vaccination against influenza A (H1N1) in pregnancy]. Zh.Mikrobiol.Epidemiol.Immunobiol.46–50. 299. Chi, R. C., G. E. Reiber, B. A. Lipsky, E. J. Boyko, and K. M. Neuzil. 2010. Influenza vaccination rates of children in households with high-risk adults. Public Health Rep. 125:192–198. 300. Chi, R. C., M. T. Rock, and K. M. Neuzil. 2010. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin.Infect.Dis. 50:1331–1338. doi:10.1086/652144 [doi]. 301. Chiatti, C., P. Barbadoro, G. Lamura, L. Pennacchietti, S. F. Di, M. M. D’Errico, and E. Prospero. 2011. Influenza vaccine uptake among community-dwelling Italian elderly: results from a large cross- sectional study. BMC.Public Health 11:207. doi:1471-2458-11-207 [pii];10.1186/1471-2458-11-207 [doi]. 302. Chiatti, C., R. M. Di, P. Barbadoro, G. Lamura, S. F. Di, and E. Prospero. 2010. Socioeconomic determinants of influenza vaccination among older adults in Italy. Prev.Med. 51:332–333. doi:S0091-7435(10)00235-5 [pii];10.1016/j.ypmed.2010.06.008 [doi]. 303. Chien, Y. H. 2011. Message framing and color combination in the perception of medical information. Psychol.Rep. 108:667–672. 304. Chin-Yee, B. H., K. Monkman, Z. Hussain, and L. A. Minuk. 2011. Attitudes toward vaccination for pandemic H1N1 and seasonal influenza in patients with hematologic malignancies. J.Support.Oncol. 9:156–160.

79 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

305. Chioato, A., E. Noseda, S. D. Felix, M. Stevens, G. G. Del, S. Fitoussi, and A. Kleinschmidt. 2010. Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clin.Vaccine Immunol. 17:1952–1957. doi:CVI.00175-10 [pii];10.1128/CVI.00175-10 [doi]. 306. Chlibek, R. 2010. [New options of influenza vaccination]. Cas.Lek.Cesk. 149:111–114. 307. Chlibek, R., I. Anca, F. Andre, M. Bakir, I. Ivaskeviciene, A. Mangarov, Z. Meszner, P. Perenovska, R. Prymula, D. Richter, N. Salman, P. Simurka, E. Tamm, N. Toplak, and V. Usonis. 2010. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for 2009 pandemic influenza A(H1N1) vaccination. Vaccine 28:3758–3766. doi:S0264-410X(10)00472-X [pii];10.1016/j.vaccine.2010.03.072 [doi]. 308. Choe, Y. J., H. Cho, G. R. Bae, and J. K. Lee. 2011. Guillain-Barre syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition. Vaccine 29:2066–2070. doi:S0264-410X(11)00023-5 [pii];10.1016/j. vaccine.2011.01.007 [doi]. 309. Choe, Y. J., H. Cho, K. M. Song, J. H. Kim, O. P. Han, Y. H. Kwon, G. R. Bae, H. J. Lee, and J. K. Lee. 2011. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea. Jpn.J.Infect.Dis. 64:297–303. 310. Choo, A. Y., K. E. Broderick, J. J. Kim, and N. Y. Sardesai. 2010. DNA-based influenza vaccines: evaluating their potential to provide universal protection. IDrugs. 13:707–712. 311. Christensen, D., C. Foged, I. Rosenkrands, C. V. Lundberg, P. Andersen, E. M. Agger, and H. M. Nielsen. 2010. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int.J.Pharm. 390:19–24. doi:S0378-5173(09)00769-8 [pii];10.1016/j.ijpharm.2009.10.043 [doi]. 312. Chu, D. W., A. S. Kwong, W. W. Tsui, J. H. Wang, C. K. Ngai, P. K. Wan, G. Ong, H. W. Tang, F. Roman, M. Dram, and H. L. Bock. 2011. Cross-clade immunogenicity and safety of an AS03A- adjuvanted prepandemic H5N1 influenza vaccine in . Hong.Kong.Med.J. 17:39–46. 313. Chua, B. Y., D. Pejoski, S. J. Turner, W. Zeng, and D. C. Jackson. 2011. Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. J.Immunol. 187:1692–1701. doi:jimmunol.1100486 [pii];10.4049/jimmunol.1100486 [doi]. 314. Chua, J. V. and W. H. Chen. 2010. Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks. Crit Care 14:218. doi:cc8891 [pii];10.1186/cc8891 [doi]. 315. Chuaychoo, B., P. Wongsurakiat, A. Nana, U. Kositanont, and K. N. Maranetra. 2010. The immunogenicity of intradermal influenza vaccination in COPD patients. Vaccine 28:4045–4051. doi:S0264-410X(10)00499-8 [pii];10.1016/j.vaccine.2010.04.006 [doi]. 316. Chung, E. Y., L. Huang, and L. Schneider. 2010. Safety of influenza vaccine administration in egg- allergic patients. Pediatrics 125:e1024–e1030. doi:peds.2009-2512 [pii];10.1542/peds.2009-2512 [doi]. 317. Churchwell, A. L. and W. Schaffner. 2011. Facing down the triple threat of influenza and pneumococcal disease in African Americans: focusing on prevention. J.Natl.Med.Assoc. 103:278– 280. 318. Clark, N. M. and J. P. Lynch, III. 2011. Influenza: epidemiology, clinical features, therapy, and prevention. Semin.Respir.Crit Care Med. 32:373–392. doi:10.1055/s-0031-1283278 [doi]. 319. Clarke, A. J., P. Gulati, and S. M. Abraham. 2011. A cross-sectional audit of the uptake of seasonal and H1N1 influenza vaccination amongst patients with rheumatoid arthritis in a London hospital. Clin. Exp.Rheumatol. 29:596. doi:4469 [pii].

80 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

320. Clements, K. M., J. Chancellor, K. Nichol, K. DeLong, and D. Thompson. 2011. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value. Health 14:800–811. doi:S1098-3015(11)01402-1 [pii];10.1016/j.jval.2011.03.005 [doi]. 321. Cochran, L. W., S. Black, N. P. Klein, C. L. Dekker, E. Lewis, and A. L. Reingold. 2010. Vaccine effectiveness against laboratory-confirmed influenza in infants: A matched case control study. Hum. Vaccin. 6. doi:12470 [pii];10.4161/hv.6.9.12470 [doi]. 322. Cohen, A. D., J. Dreiher, M. Goldfracht, O. Yakovson, N. Lieberman, D. Weiss, C. Kay, S. Fleischmann, Y. Rosenbluth, H. Bitterman, and R. Balicer. 2011. [The effect of the introduction of pneumococcal vaccination for adults as a quality measure on vaccination rates in Clalit Health Services]. Harefuah 150:578–82, 617. 323. Cohen, S. A., K. K. Chui, and E. N. Naumova. 2011. Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002–2006. J.Am.Geriatr.Soc. 59:327–332. doi:10.1111/j.1532-5415.2010.03271.x [doi]. 324. Coleman, L. A., B. Kieke, S. Irving, D. K. Shay, M. Vandermause, S. Lindstrom, and E. A. Belongia. 2011. Comparison of influenza vaccine effectiveness using different methods of case detection: clinician-ordered rapid tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Vaccine 29:387–390. doi:S0264- 410X(10)01624-5 [pii];10.1016/j.vaccine.2010.10.082 [doi]. 325. Coler, R. N., S. L. Baldwin, N. Shaverdian, S. Bertholet, S. J. Reed, V. S. Raman, X. Lu, J. DeVos, K. Hancock, J. M. Katz, T. S. Vedvick, M. S. Duthie, C. H. Clegg, H. N. van, and S. G. Reed. 2010. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS.One. 5:e13677. doi:10.1371/journal.pone.0013677 [doi]. 326. Collignon, P. 2011. Influenza vaccination in young children. Lancet Infect.Dis. 11:657–658. doi:S1473-3099(11)70223-7 [pii];10.1016/S1473-3099(11)70223-7 [doi]. 327. Collin, N. and P. M. Dubois. 2011. The Vaccine Formulation Laboratory: a platform for access to adjuvants. Vaccine 29 Suppl 1:A37–A39. doi:S0264-410X(11)00691-8 [pii];10.1016/j. vaccine.2011.04.125 [doi]. 328. Combadiere, B., A. Vogt, B. Mahe, D. Costagliola, S. Hadam, O. Bonduelle, W. Sterry, S. Staszewski, H. Schaefer, S. van der Werf, C. Katlama, B. Autran, and U. Blume-Peytavi. 2010. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS.One. 5:e10818. doi:10.1371/journal.pone.0010818 [doi]. 329. Cooper, C., A. Thorne, M. Klein, B. Conway, G. Boivin, D. Haase, S. Shafran, W. Zubyk, J. Singer, S. Halperin, and S. Walmsley. 2011. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS.One. 6:e17758. doi:10.1371/journal.pone.0017758 [doi]. 330. Cooper, W. P., D. L. Baum, H. Ross, L. Falletta, and M. D. Reed. 2010. Cocooning: influenza vaccine for parents and caregivers in an urban, pediatric medical home. Clin.Pediatr.(Phila) 49:1123–1128. doi:0009922810374353 [pii];10.1177/0009922810374353 [doi]. 331. Cornforth, D. M., T. C. Reluga, E. Shim, C. T. Bauch, A. P. Galvani, and L. A. Meyers. 2011. Erratic flu vaccination emerges from short-sighted behavior in contact networks. PLoS.Comput.Biol. 7:e1001062. doi:10.1371/journal.pcbi.1001062 [doi]. 332. Cornwell, B. 2011. Unemployment and widespread influenza in America, 1999–2010. Influenza.Other Respi.Viruses. doi:10.1111/j.1750-2659.2011.00270.x [doi]. 333. Corti, D., A. L. Suguitan, Jr., D. Pinna, C. Silacci, B. M. Fernandez-Rodriguez, F. Vanzetta, C. Santos, C. J. Luke, F. J. Torres-Velez, N. J. Temperton, R. A. Weiss, F. Sallusto, K. Subbarao, and A.

81 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

Lanzavecchia. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J.Clin.Invest 120:1663–1673. doi:41902 [pii];10.1172/JCI41902 [doi]. 334. Coudeville, L., F. Bailleux, B. Riche, F. Megas, P. Andre, and R. Ecochard. 2010. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC.Med.Res.Methodol. 10:18. doi:1471-2288-10- 18 [pii];10.1186/1471-2288-10-18 [doi]. 335. Coudeville, L., P. Andre, F. Bailleux, F. Weber, and S. Plotkin. 2010. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. Hum.Vaccin. 6:841–848. doi:12636 [pii]. 336. Cowling, B. J., S. Ng, E. S. Ma, C. K. Cheng, W. Wai, V. J. Fang, K. H. Chan, D. K. Ip, S. S. Chiu, J. S. Peiris, and G. M. Leung. 2010. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin.Infect.Dis. 51:1370–1379. doi:10.1086/657311 [doi]. 337. Crawford, N. W., A. G. Catto-Smith, M. R. Oliver, D. J. Cameron, and J. P. Buttery. 2011. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC.Gastroenterol. 11:87. doi:1471-230X-11-87 [pii];10.1186/1471-230X-11-87 [doi]. 338. Crawford, N. W., J. E. Bines, J. Royle, and J. P. Buttery. 2011. Optimizing immunization in pediatric special risk groups. Expert.Rev.Vaccines. 10:175–186. doi:10.1586/erv.10.157 [doi]. 339. Crawford, V. L., A. O’Hanlon, and H. McGee. 2011. The effect of patient characteristics upon uptake of the influenza vaccination: a study comparing community-based older adults in two healthcare systems. Age Ageing 40:35–41. doi:afq152 [pii];10.1093/ageing/afq152 [doi]. 340. Creskey, M. C., D. G. Smith, and T. D. Cyr. 2010. Strain identification of commercial influenza vaccines by mass spectrometry. Anal.Biochem. 406:193–203. doi:S0003-2697(10)00462-8 [pii];10.1016/j.ab.2010.07.016 [doi]. 341. Cristiani, C., M. Tuccori, P. Pepe, A. Sarteschi, F. Maddalo, G. Simonini, P. Michi, V. Consigli, M. Fornai, L. Antonioli, and C. Blandizzi. 2011. Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. Vaccine 29:3443–3448. doi:S0264-410X(11)00303-3 [pii];10.1016/j.vaccine.2011.02.068 [doi]. 342. Crosby, J. B. 2010. Examining importance of adult immunization. J.Am.Osteopath.Assoc. 110:992. doi:110/2_suppl_1/992 [pii]. 343. Crovari, P., M. Alberti, and C. Alicino. 2011. History and evolution of influenza vaccines. J.Prev.Med. Hyg. 52:91–94. 344. Crowe, B. A., P. Bruhl, M. Gerencer, M. G. Schwendinger, A. Pilz, O. Kistner, K. Koelling-Schlebusch, G. Aichinger, J. Singer, M. Zeitlinger, M. Muller, H. Ehrlich, and P. N. Barrett. 2010. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 29:166–173. doi:S0264-410X(10)01566-5 [pii];10.1016/j.vaccine.2010.10.065 [doi]. 345. Crowe, S. R., J. T. Merrill, E. S. Vista, A. B. Dedeke, D. M. Thompson, S. Stewart, J. M. Guthridge, T. B. Niewold, B. S. Franek, G. M. Air, L. F. Thompson, and J. A. James. 2011. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum. 63:2396–2406. doi:10.1002/art.30388 [doi]. 346. Crowe, S., M. Utley, G. Walker, P. Grove, and C. Pagel. 2011. A model to evaluate mass vaccination against pneumococcus as a countermeasure against pandemic influenza. Vaccine 29:5065–5077. doi:S0264-410X(11)00579-2 [pii];10.1016/j.vaccine.2011.04.034 [doi].

82 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

347. Crucitti, A. and T. F. Tsai. 2011. Explorations of clinical trials and pharmacovigilance databases of MF59?-adjuvanted influenza vaccines for associated cases of narcolepsy: A six-month update. Scand.J.Infect.Dis. 43:993. doi:10.3109/00365548.2011.608714 [doi]. 348. Crum-Cianflone, N. F., E. Iverson, G. Defang, P. J. Blair, L. E. Eberly, J. Maguire, A. Ganesan, D. Faix, C. Duplessis, T. Lalani, T. Whitman, C. Brandt, G. Macalino, E. V. Millar, and T. Burgess. 2011. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 29:3183–3191. doi:S0264- 410X(11)00253-2 [pii];10.1016/j.vaccine.2011.02.040 [doi]. 349. Cruz-Aponte, M., E. C. McKiernan, and M. A. Herrera-Valdez. 2011. Mitigating effects of vaccination on influenza outbreaks given constraints in stockpile size and daily administration capacity. BMC. Infect.Dis. 11:207. doi:1471-2334-11-207 [pii];10.1186/1471-2334-11-207 [doi]. 350. Cullen, G., C. Bader, J. R. Korzenik, and B. E. Sands. 2011. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. doi:gutjnl-2011-300256 [pii];10.1136/gutjnl-2011-300256 [doi]. 351. Curran, M. P. and I. Leroux-Roels. 2010. Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs 70:1519– 1543. doi:4 [pii];10.2165/11205020-000000000-00000 [doi]. 352. Curtiss, R., III. 2011. The impact of vaccines and vaccinations: Challenges and opportunities for modelers. Math.Biosci.Eng 8:77–93. 353. Czarkowski, M. P., M. Romanowska, E. Staszewska, I. Stefanska, S. Donevski, and L. B. Brydak. 2011. [Influenza in Poland in 2009]. Przegl.Epidemiol. 65:199–203. 354. Czeizel, E. 2011. [Influenza vaccination of pregnant women and the experiences related to the pandemic influenza A-virus H1N1 infection in Hungary, 2009]. Lege.Artis.Med. 21:89–95. 355. Dabek, J., D. Gierek, G. Bonek-Wytrych, J. Koj, T. Lepich, and G. Bajor. 2011. [Vaccination against influenza – recommendations and reality in the assessments of patients of cardiology and family physician center]. Pol.Merkur Lekarski. 31:159–164. 356. D’Angio, C. T., R. J. Heyne, S. Duara, L. C. Holmes, T. M. O’Shea, H. Wang, D. Wang, P. J. Sanchez, R. C. Welliver, R. M. Ryan, K. C. Schnabel, and C. B. Hall. 2011. Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. Pediatr.Infect.Dis.J. 30:570– 574. doi:10.1097/INF.0b013e31820c1fdf [doi]. 357. Daniels, N. A., G. Gildengorin, T. T. Nguyen, Y. Liao, T. N. Luong, and S. J. McPhee. 2010. Influenza and pneumococcal vaccination rates among Vietnamese, Asian, and non-Hispanic white Americans. J.Immigr.Minor.Health 12:370–376. doi:10.1007/s10903-008-9195-6 [doi]. 358. D’Aoust, M. A., M. M. Couture, N. Charland, S. Trepanier, N. Landry, F. Ors, and L. P. Vezina. 2010. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol.J. 8:607–619. doi:PBI496 [pii];10.1111/j.1467- 7652.2009.00496.x [doi]. 359. Dauvilliers, Y., J. Montplaisir, V. Cochen, A. Desautels, M. Einen, L. Lin, M. Kawashima, S. Bayard, C. Monaca, M. Tiberge, D. Filipini, A. Tripathy, B. H. Nguyen, S. Kotagal, and E. Mignot. 2010. Post- H1N1 narcolepsy-cataplexy. Sleep 33:1428–1430. 360. David, S. A., D. V. Volokhov, Z. Ye, and V. Chizhikov. 2010. Evaluation of Mycoplasma inactivation during production of biologics: egg-based viral vaccines as a model. Appl.Environ.Microbiol. 76:2718–2728. doi:AEM.02776-09 [pii];10.1128/AEM.02776-09 [doi]. 361. Davidson, L. E., A. M. Fiorino, D. R. Snydman, and P. L. Hibberd. 2011. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur.J.Clin.Nutr. 65:501–507. doi:ejcn2010289 [pii];10.1038/ejcn.2010.289 [doi].

83 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

362. Davtyan, H., A. Ghochikyan, R. Cadagan, D. Zamarin, I. Petrushina, N. Movsesyan, L. Martinez- Sobrido, R. A. Albrecht, A. Garcia-Sastre, and M. G. Agadjanyan. 2011. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer’s disease. J.Transl.Med. 9:127. doi:1479-5876-9-127 [pii];10.1186/1479-5876-9-127 [doi]. 363. Dawood, F. S., A. M. Fry, C. Muangchana, W. Sanasuttipun, H. C. Baggett, S. Chunsuttiwat, S. A. Maloney, and J. M. Simmerman. 2011. A method for estimating vaccine-preventable pediatric influenza pneumonia hospitalizations in developing countries: Thailand as a case study. Vaccine 29:4416–4421. doi:S0264-410X(11)00492-0 [pii];10.1016/j.vaccine.2011.03.099 [doi]. 364. de Geus, E. D., D. A. van Haarlem, O. N. Poetri, J. J. de Wit, and L. Vervelde. 2011. A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia. Vet.Immunol.Immunopathol. 143:143–147. doi:S0165-2427(11)00172-3 [pii];10.1016/j. vetimm.2011.05.023 [doi]. 365. de Perio, M. A., D. M. Wiegand, and S. M. Evans. 2011. Low Influenza Vaccination Rates Among Child Care Workers in the United States: Assessing Knowledge, Attitudes, and Behaviors. J.Community Health. doi:10.1007/s10900-011-9478-z [doi]. 366. De, F. M., T. Ysenbaert, K. Roose, M. Schotsaert, S. Roels, E. Goossens, B. Schepens, W. Fiers, and X. Saelens. 2011. Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective. J.Gen.Virol. 92:301–306. doi:vir.0.027086-0 [pii];10.1099/vir.0.027086-0 [doi]. 367. de, L. H., P. Garland, T. Sekine, K. Hoschler, D. Marin, K. Stringaris, E. Loucaides, K. Howe, R. Szydlo, E. Kanfer, D. Macdonald, P. Kelleher, N. Cooper, A. Khoder, I. H. Gabriel, D. Milojkovic, J. Pavlu, J. M. Goldman, J. F. Apperley, and K. Rezvani. 2011. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 96:307–314. doi:haematol.2010.032664 [pii];10.3324/haematol.2010.032664 [doi]. 368. Dean, A. S., C. R. Moffatt, A. Rosewell, D. E. Dwyer, R. I. Lindley, R. Booy, and C. R. MacIntyre. 2010. Incompletely matched influenza vaccine still provides protection in frail elderly. Vaccine 28:864–867. doi:S0264-410X(09)00430-7 [pii];10.1016/j.vaccine.2009.03.024 [doi]. 369. Deans, G. D., H. G. Stiver, and J. E. McElhaney. 2010. Influenza vaccines provide diminished protection but are cost-saving in older adults. J.Intern.Med. 267:220–227. doi:JIM2201 [pii];10.1111/j.1365-2796.2009.02201.x [doi]. 370. Dedoukou, X., G. Nikolopoulos, A. Maragos, S. Giannoulidou, and H. C. Maltezou. 2010. Attitudes towards vaccination against seasonal influenza of health-care workers in primary health-care settings in Greece. Vaccine 28:5931–5933. doi:S0264-410X(10)00949-7 [pii];10.1016/j. vaccine.2010.06.108 [doi]. 371. Del Campo, M. T., V. J. Miguel, C. Susana, G. Ana, L. Gregoria, and M. F. Ignacio. 2011. 2009– 2010 seasonal and pandemic A (H1N1) influenza vaccination among healthcare workers. Vaccine 29:3703–3707. doi:S0264-410X(11)00373-2 [pii];10.1016/j.vaccine.2011.03.021 [doi]. 372. Della, C. G., T. Vesikari, E. Sokal, K. Lindert, and U. Nicolay. 2011. Trivalent and quadrivalent MF59((R))-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study. Vaccine 29:8696–8704. doi:S0264-410X(11)01388-0 [pii];10.1016/j.vaccine.2011.08.111 [doi]. 373. Denholm, J. T., A. Neal, B. Yan, S. Petty, J. Knox, C. French, and C. Marshall. 2010. Acute encephalomyelitis syndromes associated with H1N1 09 influenza vaccination. Neurology 75:2246– 2248. doi:75/24/2246 [pii];10.1212/WNL.0b013e3182020307 [doi]. 374. Derhovanessian, E. and G. Pawelec. 2011. Vaccination in the elderly. Microb.Biotechnol. doi:10.1111/ j.1751-7915.2011.00283.x [doi].

84 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

375. deSante, J. E., A. Caplan, F. Shofer, and A. J. Behrman. 2010. Physician attitudes towards influenza immunization and vaccine mandates. Vaccine 28:2517–2521. doi:S0264-410X(10)00074-5 [pii];10.1016/j.vaccine.2010.01.042 [doi]. 376. Desbat, B., E. Lancelot, T. Krell, M. C. Nicolai, F. Vogel, M. Chevalier, and F. Ronzon. 2011. Effect of the beta-Propiolactone Treatment on the Adsorption and Fusion of Influenza A/Brisbane/59/2007 and A/New Caledonia/20/1999 Virus H1N1 on a Dimyristoylphosphatidylcholine/Ganglioside GM3 Mixed Phospholipids Monolayer at the Air-Water Interface. Langmuir 27:13675–13683. doi:10.1021/ la2027175 [doi]. 377. Descatha, A. 2010. Unusual delayed reaction after H1N1 vaccine. Asian Pac.J.Allergy Immunol. 28:302–303. 378. DeStefano, F. and J. Tokars. 2010. H1N1 vaccine safety monitoring: beyond background rates. Lancet 375:1146–1147. doi:S0140-6736(09)61917-6 [pii];10.1016/S0140-6736(09)61917-6 [doi]. 379. Destefano, F., C. Vellozzi, L. B. Schonberger, and R. T. Chen. 2011. Safety of adjuvanted pandemic influenza A (H1N1) 2009 vaccines. BMJ 343:d4159. 380. Dhere, R., L. Yeolekar, P. Kulkarni, R. Menon, V. Vaidya, M. Ganguly, P. Tyagi, P. Barde, and S. Jadhav. 2011. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 29 Suppl 1:A16–A21. doi:S0264-410X(11)00685-2 [pii];10.1016/j.vaccine.2011.04.119 [doi]. 381. Di, B., X. Xu, T. Li, E. Lu, J. Wu, Y. Liu, Y. Chen, S. Pickerill, and M. Wang. 2010. Immunogenicity associated with the routine use of an influenza A H1N1 vaccine in health care personnel in Guangzhou, China. Clin.Vaccine Immunol. 17:1478–1480. doi:CVI.00137-10 [pii];10.1128/CVI.00137- 10 [doi]. 382. Diallo, I., A. J. Read, and P. D. Kirkland. 2011. Positive results in a real-time PCR for type A influenza associated with the use of an inactivated vaccine. Aust.Vet.J. 89 Suppl 1:145–146. doi:10.1111/ j.1751-0813.2011.00746.x [doi]. 383. Diamond, M. R. and A. O’Brien-Malone. 2011. Vaccination, consent and multidose vials. Med.J.Aust. 194:414–416. doi:dia10882_fm [pii]. 384. DiBiase, L. M., S. E. Davis, R. Rosselli, and J. Horney. 2011. Evaluation of the implementation of the H1N1 pandemic influenza vaccine in local health departments (LHDs) in North Carolina. Vaccine 29:3969–3976. doi:S0264-410X(11)00467-1 [pii];10.1016/j.vaccine.2011.03.085 [doi]. 385. Dieleman, J., S. Romio, K. Johansen, D. Weibel, J. Bonhoeffer, and M. Sturkenboom. 2011. Guillain- Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case- control study in Europe. BMJ 343:d3908. 386. Diez-Domingo, J., M. Garces-Sanchez, J. M. Baldo, M. V. Planelles, I. Ubeda, A. JuBert, J. Mares, P. Moris, P. Garcia-Corbeira, M. Drame, and P. Gillard. 2010. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr.Infect.Dis.J. 29:e35–e46. doi:10.1097/INF.0b013e3181daf921 [doi]. 387. Dikow, R., I. Eckerle, D. Ksoll-Rudek, H. Hampel, V. Schwenger, M. Zeier, P. Schnitzler, and C. Sommerer. 2011. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am.J.Kidney Dis. 57:716–723. doi:S0272-6386(11)00046-1 [pii];10.1053/j.ajkd.2010.11.031 [doi]. 388. DiNapoli, J. M., B. Nayak, L. Yang, B. W. Finneyfrock, A. Cook, H. Andersen, F. Torres-Velez, B. R. Murphy, S. K. Samal, P. L. Collins, and A. Bukreyev. 2010. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J.Virol. 84:1489–1503. doi:JVI.01946-09 [pii];10.1128/JVI.01946-09 [doi].

85 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

389. Ding, H., C. Tsai, F. Zhou, P. Buchy, V. Deubel, and P. Zhou. 2011. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus. PLoS.One. 6:e17821. doi:10.1371/journal.pone.0017821 [doi]. 390. Ding, H., C. Tsai, R. A. Gutierrez, F. Zhou, P. Buchy, V. Deubel, and P. Zhou. 2011. Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. PLoS.One. 6:e16563. doi:10.1371/journal. pone.0016563 [doi]. 391. Ding, H., T. A. Santibanez, D. J. Jamieson, C. M. Weinbaum, G. L. Euler, L. A. Grohskopf, P. J. Lu, and J. A. Singleton. 2011. Influenza vaccination coverage among pregnant women – National 2009 H1N1 Flu Survey (NHFS). Am.J.Obstet.Gynecol. 204:S96–106. doi:S0002-9378(11)00312-7 [pii];10.1016/j.ajog.2011.03.003 [doi]. 392. Dinges, D. F. 2010. Vaccination for H1N1 in influenza. Sleep 33:1425. 393. Dip, R. M. and M. A. Cabrera. 2010. Influenza vaccination in non-institutionalized elderly: a population-based study in a medium-sized city in Southern . Cad.Saude Publica 26:1035–1044. doi:S0102-311X2010000500025 [pii]. 394. Dixon, G. A., H. C. Moore, H. Kelly, P. Jacoby, D. Carcione, S. Williams, D. Smith, A. D. Keil, B. P. Van, and P. C. Richmond. 2010. Lessons from the first year of the WAIVE study investigating the protective effect of influenza vaccine against laboratory-confirmed influenza in hospitalised children aged 6–59 months. Influenza.Other Respi.Viruses. 4:231–234. doi:IRV141 [pii];10.1111/j.1750- 2659.2010.00141.x [doi]. 395. Dolgin, E. 2010. Prospects improve for long-lasting flu vaccine. Nat.Med. 16:1347. doi:nm1210-1347 [pii];10.1038/nm1210-1347 [doi]. 396. Dombu, C. Y., M. Kroubi, R. Zibouche, R. Matran, and D. Betbeder. 2010. Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells. Nanotechnology. 21:355102. doi:S0957-4484(10)59325-5 [pii];10.1088/0957-4484/21/35/355102 [doi]. 397. Donis, R. O. and N. J. Cox. 2011. Prospecting the influenza hemagglutinin to develop universal vaccines. Clin.Infect.Dis. 52:1010–1012. doi:cir129 [pii];10.1093/cid/cir129 [doi]. 398. Dormitzer, P. R., G. Galli, F. Castellino, H. Golding, S. Khurana, G. G. Del, and R. Rappuoli. 2011. Influenza vaccine immunology. Immunol.Rev. 239:167–177. doi:10.1111/j.1600-065X.2010.00974.x [doi]. 399. Doucet, J. D., M. A. Forget, C. Grange, R. N. Rouxel, N. Arbour, M. von, V, and R. Lapointe. 2011. Endogenously expressed matrix protein M1 and nucleoprotein of influenza A are efficiently presented by class I and class II major histocompatibility complexes. J.Gen.Virol. 92:1162–1171. doi:vir.0.029777-0 [pii];10.1099/vir.0.029777-0 [doi]. 400. Doukas, J., J. Morrow, D. Bellinger, T. Hilgert, T. Martin, D. Jones, R. Mahajan, D. Rusalov, S. Sullivan, and A. Rolland. 2011. Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin(R). Vaccine 29:5443– 5452. doi:S0264-410X(11)00780-8 [pii];10.1016/j.vaccine.2011.05.060 [doi]. 401. Douville, L. E., A. Myers, M. A. Jackson, and J. D. Lantos. 2010. Health care worker knowledge, attitudes, and beliefs regarding mandatory influenza vaccination. Arch.Pediatr.Adolesc.Med. 164:33– 37. doi:164/1/33 [pii];10.1001/archpediatrics.2009.252 [doi]. 402. Dower, J., M. Donald, N. Begum, S. Vlack, and I. Ozolins. 2011. Patterns and determinants of influenza and pneumococcal immunisation among adults with chronic disease living in Queensland, Australia. Vaccine 29:3031–3037. doi:S0264-410X(11)00189-7 [pii];10.1016/j.vaccine.2011.01.116 [doi].

86 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

403. Dresner, Y., E. Frank, T. Baevsky, E. Rotman, and S. Vinker. 2010. Screening practices of Israeli doctors’ and their patients. Prev.Med. 50:300–303. doi:S0091-7435(10)00060-5 [pii];10.1016/j. ypmed.2010.02.005 [doi]. 404. Drexler, S. K., J. Wales, E. Andreakos, P. Kong, A. Davis, C. Garlanda, A. Mantovani, T. Hussell, M. Feldmann, and B. M. Foxwell. 2010. Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR. Scand.J.Immunol. 71:393–402. doi:SJI2392 [pii];10.1111/j.1365- 3083.2010.02392.x [doi]. 405. Du, L., V. H. Leung, X. Zhang, J. Zhou, M. Chen, W. He, H. Y. Zhang, C. C. Chan, V. K. Poon, G. Zhao, S. Sun, L. Cai, Y. Zhou, B. J. Zheng, and S. Jiang. 2011. A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS.One. 6:e16555. doi:10.1371/journal.pone.0016555 [doi]. 406. Dube, E., D. Fannie, G. Vladimir, B. A. Julie, S. Chantal, L. France, B. D. Francois, M. Shelly, G. Ian, and B. Nicole. 2011. A(H1N1) pandemic influenza and its prevention by vaccination: paediatricians’ opinions before and after the beginning of the vaccination campaign. BMC.Public Health 11:128. doi:1471-2458-11-128 [pii];10.1186/1471-2458-11-128 [doi]. 407. Dube, E., V. Gilca, C. Sauvageau, N. Boulianne, F. D. Boucher, J. A. Bettinger, S. McNeil, I. Gemmill, F. Lavoie, and M. Ouakki. 2010. Canadian family physicians’ and paediatricians’ knowledge, attitudes and practices regarding A(H1N1) pandemic vaccine. BMC.Res.Notes 3:102. doi:1756-0500-3-102 [pii];10.1186/1756-0500-3-102 [doi]. 408. Dubnov, J., W. Kassabri, B. Bisharat, and S. Rishpon. 2010. Influenza vaccination coverage determinants among employees of the Nazareth Hospital in Israel. Isr.Med.Assoc.J. 12:338–341. 409. Ducatez, M. F., J. Bahl, Y. Griffin, E. Stigger-Rosser, J. Franks, S. Barman, D. Vijaykrishna, A. Webb, Y. Guan, R. G. Webster, G. J. Smith, and R. J. Webby. 2011. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc.Natl.Acad.Sci.U.S.A 108:349–354. doi:1012457108 [pii];10.1073/pnas.1012457108 [doi]. 410. Duggan, S. T. and G. L. Plosker. 2010. Intanza 15 microg intradermal seasonal influenza vaccine: in older adults (aged >or=60 years). Drugs Aging 27:597–605. doi:7 [pii];10.2165/11203880- 000000000-00000 [doi]. 411. Duggan, S. T. and G. L. Plosker. 2010. Intanza 15 mug intradermal seasonal influenza vaccine in older adults (aged >/= 60 years): profile report. BioDrugs. 24:407–409. doi:5 [pii];10.2165/11206780- 000000000-00000 [doi]. 412. Duong, M., S. Mahy, R. Binois, M. Buisson, L. Piroth, and P. Chavanet. 2011. [Vaccination coverage of healthcare professionals in an infectious diseases department]. Med.Mal Infect. 41:135–139. doi:S0399-077X(10)00335-5 [pii];10.1016/j.medmal.2010.11.018 [doi]. 413. Durando, P., G. Icardi, and F. Ansaldi. 2010. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert.Opin. Biol.Ther. 10:639–651. doi:10.1517/14712591003724662 [doi]. 414. Durando, P., L. Sticchi, M. Alberti, C. Alicino, R. Iudici, M. Martini, and G. Icardi. 2010. [Novel approaches for the prevention of influenza: the intradermal vaccination]. Ig Sanita Pubbl. 66:387– 400. 415. Durando, P., R. Iudici, C. Alicino, M. Alberti, F. D. de, F. Ansaldi, and G. Icardi. 2011. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum. Vaccin. 7 Suppl:29–40. doi:14560 [pii]. 416. Eames, K. T., E. Brooks-Pollock, D. Paolotti, M. Perosa, C. Gioannini, and W. J. Edmunds. 2011. Rapid assessment of influenza vaccine effectiveness: analysis of an internet-based cohort. Epidemiol. Infect.1–7. doi:S0950268811001804 [pii];10.1017/S0950268811001804 [doi].

87 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

417. Easterbrook, J. D., J. C. Kash, Z. M. Sheng, L. Qi, J. Gao, E. D. Kilbourne, M. C. Eichelberger, and J. K. Taubenberger. 2011. Immunization with 1976 swine. Influenza.Other Respi.Viruses. 5:198–205. doi:10.1111/j.1750-2659.2010.00191.x [doi]. 418. Easton, A. J., P. D. Scott, N. L. Edworthy, B. Meng, A. C. Marriott, and N. J. Dimmock. 2011. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine 29:2777–2784. doi:S0264- 410X(11)00174-5 [pii];10.1016/j.vaccine.2011.01.102 [doi]. 419. Eastwood, K., D. N. Durrheim, A. Jones, and M. Butler. 2010. Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public. Med.J.Aust. 192:33–36. doi:eas11124_fm [pii]. 420. Ebrahimi, S. M. and M. Tebianian . 2010. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein. Mol.Biol.Rep. 37:2877–2883. doi:10.1007/s11033-009- 9846-2 [doi]. 421. Ebrahimi, S. M. and M. Tebianian . 2011. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 42:1–8. doi:10.1007/s11262-010-0547-7 [doi]. 422. Ebrahimi, S. M., M. Tebianian, H. Toghyani, A. Memarnejadian, and H. R. Attaran. 2010. Cloning, expression and purification of the influenza A (H9N2) virus M2e antigen and truncated Mycobacterium tuberculosis HSP70 as a fusion protein in Pichia pastoris. Protein Expr.Purif. 70:7–12. doi:S1046-5928(09)00289-7 [pii];10.1016/j.pep.2009.11.001 [doi]. 423. Ebrahimi, S. M., M. Tebianian, K. Aghaiypour, H. Nili, and A. Mirjalili. 2010. Prokaryotic expression and characterization of avian influenza A virus M2 gene as a candidate for universal recombinant vaccine against influenza A subtypes; specially H5N1 and H9N2. Mol.Biol.Rep. 37:2909–2914. doi:10.1007/s11033-009-9851-5 [doi]. 424. Edwards, K. M., J. P. Campbell, C. Ring, M. T. Drayson, J. A. Bosch, C. Downes, J. E. Long, J. A. Lumb, A. Merry, N. J. Paine, and V. E. Burns. 2010. Exercise intensity does not influence the efficacy of eccentric exercise as a behavioural adjuvant to vaccination. Brain Behav.Immun. 24:623–630. doi:S0889-1591(10)00010-3 [pii];10.1016/j.bbi.2010.01.009 [doi]. 425. Edwards, N. M., N. L. Baumann-Blackmore, and T. N. Saari. 2011. Attitudes of Wisconsin pediatricians toward influenza immunization. WMJ. 110:63–67. 426. Edwards, S. M. and T. Rousseau-Pierre. 2010. Immunizations in adolescents – an update. Adolesc. Med.State Art.Rev. 21:173–86, vii. 427. Effler, P. V., C. Chu, H. He, K. Gaynor, S. Sakamoto, M. Nagao, L. Mendez, and S. Y. Park. 2010. Statewide school-located influenza vaccination program for children 5–13 years of age, Hawaii, USA. Emerg.Infect.Dis. 16:244–250. doi:10.3201/eid1602.091375 [doi]. 428. Eggert, D., C. Thomas, E. Spackman, N. Pritchard, F. Rojo, M. Bublot, and D. E. Swayne. 2010. Characterization and efficacy determination of commercially available Central American H5N2 avian influenza vaccines for poultry. Vaccine 28:4609–4615. doi:S0264-410X(10)00617-1 [pii];10.1016/j. vaccine.2010.04.081 [doi]. 429. Eggertson, L. 2010. Egg-allergic patients gain greater access to H1N1 vaccine after completion of clinical trial. CMAJ. 182:E99–100. doi:cmaj.109-3123 [pii];10.1503/cmaj.109-3123 [doi]. 430. Egorova, N. B., E. A. Kurbatova, N. K. Akhmatova, and I. B. Semenova. 2011. [Protective activity of Immunovac-VP-4 vaccine against avian influenza virus H5N2 administered by different methods]. Zh.Mikrobiol.Epidemiol.Immunobiol.49–53. 431. Ehrenstein, B. P., F. Hanses, S. Blaas, F. Mandraka, F. Audebert, and B. Salzberger. 2010. Perceived risks of adverse effects and influenza vaccination: a survey of hospital employees. Eur.J.Public Health 20:495–499. doi:ckp227 [pii];10.1093/eurpub/ckp227 [doi].

88 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

432. Eichelberger, M. C. and M. D. Green. 2011. Animal models to assess the toxicity, immunogenicity and effectiveness of candidate influenza vaccines. Expert.Opin.Drug Metab Toxicol. 7:1117–1127. doi:10.1 517/17425255.2011.602065 [doi]. 433. Eick, A. A., T. M. Uyeki, A. Klimov, H. Hall, R. Reid, M. Santosham, and K. L. O’Brien. 2011. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch.Pediatr.Adolesc. Med. 165:104–111. doi:archpediatrics.2010.192 [pii];10.1001/archpediatrics.2010.192 [doi]. 434. Eiselt, J., L. Kielberger, T. Sedlackova, J. Racek, and P. Pazdiora. 2010. High ferritin, but not hepcidin, is associated with a poor immune response to an influenza vaccine in hemodialysis patients. Nephron Clin.Pract. 115:c147–c153. doi:000312878 [pii];10.1159/000312878 [doi]. 435. Eisenberg, S. 2011. Would mandatory vaccines protect nurses and patients? ONS.Connect. 26:13. 436. Ekiert, D. C., R. H. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. Ophorst, F. Cox, H. J. Korse, B. Brandenburg, R. Vogels, J. P. Brakenhoff, R. Kompier, M. H. Koldijk, L. A. Cornelissen, L. L. Poon, M. Peiris, W. Koudstaal, I. A. Wilson, and J. Goudsmit. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:843–850. doi:science.1204839 [pii];10.1126/ science.1204839 [doi]. 437. Ekkelenkamp, M. B. and M. J. Bonten. 2011. Dual pneumococcal and influenza vaccination: severe concerns about the composition of the control groups. Clin.Infect.Dis. 52:557–558. doi:ciq185 [pii];10.1093/cid/ciq185 [doi]. 438. El, B. K., F. Descamps, F. M. De, A. Smet, E. Festjens, A. Birkett, R. N. Van, S. Verbeek, W. Fiers, and X. Saelens. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J.Immunol. 186:1022–1031. doi:jimmunol.0902147 [pii];10.4049/jimmunol.0902147 [doi]. 439. El, S. H. 2010. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert. Rev.Vaccines. 9:1135–1141. doi:10.1586/erv.10.111 [doi]. 440. Eladl, A. E., K. I. El-Azm, A. E. Ismail, A. Ali, Y. M. Saif, and C. W. Lee. 2011. Genetic characterization of highly pathogenic H5N1 avian influenza viruses isolated from poultry farms in Egypt. Virus Genes 43:272–280. doi:10.1007/s11262-011-0633-5 [doi]. 441. Eliasson, D. G., A. Helgeby, K. Schon, C. Nygren, K. El-Bakkouri, W. Fiers, X. Saelens, K. B. Lovgren, I. Nystrom, and N. Y. Lycke. 2011. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 29:3951–3961. doi:S0264- 410X(11)00483-X [pii];10.1016/j.vaccine.2011.03.090 [doi]. 442. Elkayam, O., A. Bashkin, M. Mandelboim, I. Litinsky, D. Comaheshter, D. Levartovsky, E. Mendelson, I. Wigler, D. Caspi, and D. Paran. 2010. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin.Arthritis Rheum. 39:442–447. doi:S0049-0172(08)00216-3 [pii];10.1016/j. semarthrit.2008.12.002 [doi]. 443. Elkayam, O., S. Amir, E. Mendelson, M. Schwaber, I. Grotto, J. Wollman, U. Arad, A. Brill, D. Paran, D. Levartovsky, I. Wigler, D. Caspi, and M. Mandelboim. 2011. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res. (Hoboken.) 63:1062–1067. doi:10.1002/acr.20465 [doi]. 444. Ellebedy, A. H., M. F. Ducatez, S. Duan, E. Stigger-Rosser, A. M. Rubrum, E. A. Govorkova, R. G. Webster, and R. J. Webby. 2011. Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine 29:3335–3339. doi:S0264- 410X(10)01236-3 [pii];10.1016/j.vaccine.2010.08.067 [doi].

89 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

445. Ellebedy, A. H., T. P. Fabrizio, G. Kayali, T. H. Oguin, III, S. A. Brown, J. Rehg, P. G. Thomas, and R. J. Webby. 2010. Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) Virus vaccination in ferrets. Clin.Vaccine Immunol. 17:1998–2006. doi:CVI.00247-10 [pii];10.1128/CVI.00247-10 [doi]. 446. Ellis, J., M. Galiano, R. Pebody, A. Lackenby, C. Thompson, A. Bermingham, E. McLean, H. Zhao, S. Bolotin, O. Dar, J. M. Watson, and M. Zambon. 2011. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11. Euro.Surveill 16. 447. Eng, N. F., S. Garlapati, V. Gerdts, L. A. Babiuk, and G. K. Mutwiri. 2010. PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus . J.Immune.Based.Ther.Vaccines. 8:4. doi:1476-8518-8-4 [pii];10.1186/1476-8518-8-4 [doi]. 448. Engelhard, D., Z. Zakay-Rones, M. Y. Shapira, I. Resnick, D. Averbuch, S. Grisariu, L. Dray, E. Djian, N. Strauss-Liviatan, I. Grotto, D. G. Wolf, and R. Or. 2011. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 29:1777–1782. doi:S0264- 410X(10)01900-6 [pii];10.1016/j.vaccine.2010.12.113 [doi]. 449. Englund, J. A., E. Walter, S. Black, M. Blatter, J. Nyberg, F. L. Ruben, and M. D. Decker. 2010. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr.Infect.Dis.J. 29:105–110. doi:10.1097/INF.0b013e3181b84c34 [doi]. 450. Enquselassie, F. 2010. Introducing vaccine against H1N1 influenza virus in schools. Ethiop.Med.J. 48:2p. 451. Epstein, S. L. and G. E. Price. 2010. Cross-protective immunity to influenza A viruses. Expert.Rev. Vaccines. 9:1325–1341. doi:10.1586/erv.10.123 [doi]. 452. Erdman, M. M., K. I. Kamrud, D. L. Harris, and J. Smith. 2010. Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept. Vaccine 28:594–596. doi:S0264-410X(09)01530-8 [pii];10.1016/j. vaccine.2009.10.015 [doi]. 453. Erofeeva, M. K., S. I. Mel’nikov, A. V. Semchenko, S. A. Korovkin, I. I. Nikonorov, V. L. Maksakova, E. M. Voitsekhovskaia, E. S. Erman, V. V. Gonchar, V. K. Pozdeev, and V. P. Drinevskii. 2010. [Clinical trial of safety and immunogenicity of new influenza vaccine Grifor in children]. Zh.Mikrobiol.Epidemiol. Immunobiol.55–59. 454. Ertek, M., R. Durmaz, D. Guldemir, A. B. Altas, N. Albayrak, and G. Korukluoglu. 2010. Epidemiological, demographic, and molecular characteristics of laboratory-confirmed pandemic influenza A (H1N1) virus infection in Turkey, May 15–November 30, 2009. Jpn.J.Infect.Dis. 63:239– 245. 455. Esposito, S. and N. Principi. 2011. Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. Vaccine 29:7535–7541. doi:S0264-410X(11)01221-7 [pii];10.1016/j.vaccine.2011.08.012 [doi]. 456. Esposito, S. and N. Principi. 2011. Influenza vaccination in young children. Lancet Infect.Dis. 11:656– 657. doi:S1473-3099(11)70222-5 [pii];10.1016/S1473-3099(11)70222-5 [doi]. 457. Esposito, S., E. D’Angelo, C. Daleno, F. Peia, A. Scala, D. Serra, N. Mirra, C. Galeone, and N. Principi. 2010. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/ H1N1 MF59-adjuvanted vaccine in patients with beta-thalassemia major. Vaccine 28:7825–7828. doi:S0264-410X(10)01379-4 [pii];10.1016/j.vaccine.2010.09.058 [doi].

90 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

458. Esposito, S., E. Meregalli, C. Daleno, L. Ghio, C. Tagliabue, A. Valzano, D. Serra, C. Galeone, A. Edefonti, and N. Principi. 2011. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol.Dial.Transplant. 26:2018–2024. doi:gfq657 [pii];10.1093/ndt/ gfq657 [doi]. 459. Esposito, S., L. Pugni, C. Daleno, A. Ronchi, A. Valzano, D. Serra, F. Mosca, and N. Principi. 2011. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 127:e1161–e1168. doi:peds.2010-1920 [pii];10.1542/peds.2010-1920 [doi]. 460. Esposito, S., L. Tagliaferri, C. Daleno, A. Valzano, I. Picciolli, F. Tel, G. Prunotto, D. Serra, C. Galeone, A. Plebani, and N. Principi. 2011. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 29:1677–1682. doi:S0264-410X(10)01820-7 [pii];10.1016/j.vaccine.2010.12.047 [doi]. 461. Esposito, S., P. Marchisio, F. Ansaldi, S. Bianchini, M. Pacei, E. Baggi, D. Trabattoni, G. Icardi, and N. Principi. 2010. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months. Vaccine 28:6137–6144. doi:S0264-410X(10)01036-4 [pii];10.1016/j.vaccine.2010.07.041 [doi]. 462. Even-Or, O., A. Joseph, N. Itskovitz-Cooper, S. Samira, E. Rochlin, H. Eliyahu, I. Goldwaser, S. Balasingam, A. J. Mann, R. Lambkin-Williams, E. Kedar, and Y. Barenholz. 2011. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine 29:2474–2486. doi:S0264- 410X(11)00037-5 [pii];10.1016/j.vaccine.2011.01.009 [doi]. 463. Even-Or, O., S. Samira, E. Rochlin, S. Balasingam, A. J. Mann, R. Lambkin-Williams, J. Spira, I. Goldwaser, R. Ellis, and Y. Barenholz. 2010. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 28:6527–6541. doi:S0264-410X(10)00504-9 [pii];10.1016/j.vaccine.2010.04.011 [doi]. 464. Ezoe, H., Y. Akeda, Z. Piao, T. Aoshi, S. Koyama, T. Tanimoto, K. J. Ishii, and K. Oishi. 2011. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice. Vaccine 29:1754–1761. doi:S0264-410X(10)01904-3 [pii];10.1016/j.vaccine.2010.12.117 [doi]. 465. Fabbiani, M., G. S. Di, M. Sali, S. Farina, P. Sansonetti, E. Tamburrini, L. Z. Dal Verme, G. Delogu, L. A. De, D. Kelvin, R. Cauda, and G. Fadda. 2011. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 29:2836–2839. doi:S0264- 410X(11)00233-7 [pii];10.1016/j.vaccine.2011.02.020 [doi]. 466. Fabry, P., A. Gagneur, and J. C. Pasquier. 2011. Determinants of A (H1N1) vaccination: cross- sectional study in a population of pregnant women in Quebec. Vaccine 29:1824–1829. doi:S0264- 410X(10)01896-7 [pii];10.1016/j.vaccine.2010.12.109 [doi]. 467. Fagone, P., D. J. Shedlock, H. Bao, O. U. Kawalekar, J. Yan, D. Gupta, M. P. Morrow, A. Patel, G. P. Kobinger, K. Muthumani, and D. B. Weiner. 2011. Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther. 18:1070–1077. doi:gt201159 [pii];10.1038/gt.2011.59 [doi]. 468. Fairbrother, G., A. Cassedy, I. R. Ortega-Sanchez, P. G. Szilagyi, K. M. Edwards, N. A. Molinari, S. Donauer, D. Henderson, S. Ambrose, D. Kent, K. Poehling, G. A. Weinberg, M. R. Griffin, C. B. Hall, L. Finelli, C. Bridges, and M. A. Staat. 2010. High costs of influenza: Direct medical costs of influenza disease in young children. Vaccine 28:4913–4919. doi:S0264-410X(10)00734-6 [pii];10.1016/j. vaccine.2010.05.036 [doi].

91 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

469. Falagas, M. E., N. V. Cholevas, A. M. Kapaskelis, E. K. Vouloumanou, A. Michalopoulos, and P. I. Rafailidis. 2010. Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the Northern Hemisphere. Eur.J.Clin.Microbiol.Infect.Dis. 29:1327–1347. doi:10.1007/s10096-010- 1002-3 [doi]. 470. Falato, R., S. Ricciardi, and G. Franco. 2011. [Influenza risk perception and vaccination attitude in medical and nursing students during the vaccination campaigns of 2007/2008 (seasonal influenza) and 2009/2010 (H1N1 influenza)]. Med.Lav. 102:208–215. 471. Falsey, A. R. 2010. New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine 28 Suppl 4:D24–D32. doi:S0264-410X(10)01135-7 [pii];10.1016/j. vaccine.2010.08.026 [doi]. 472. Fang, J., Z. Chen, X. Liu, H. Li, J. Wang, X. Shen, W. Chen, Y. Liu, Y. Wang, P. Zhao, and Z. Qi. 2011. Immunization with a low dose of hemagglutinin-encoding plasmid protects against 2009 H1N1 pandemic influenza virus in mice. J.Virol.Methods 173:314–319. doi:S0166-0934(11)00091-7 [pii];10.1016/j.jviromet.2011.03.001 [doi]. 473. Fang, Y., T. Rowe, A. J. Leon, D. Banner, A. Danesh, L. Xu, L. Ran, S. E. Bosinger, Y. Guan, H. Chen, C. C. Cameron, M. J. Cameron, and D. J. Kelvin. 2010. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. J.Virol. 84:8369–8388. doi:JVI.02305-09 [pii];10.1128/JVI.02305-09 [doi]. 474. Farez, M. F. and J. Correale. 2011. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J.Neurol. 258:1197–1206. doi:10.1007/s00415-011-5984-2 [doi]. 475. Farnsworth, A., T. D. Cyr, C. Li, J. Wang, and X. Li. 2011. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 29:1529–1533. doi:S0264-410X(10)01907-9 [pii];10.1016/j.vaccine.2010.12.120 [doi]. 476. Faruqui, F. and D. Mukundan. 2010. 2009 pandemic influenza: a review. Curr.Opin.Pediatr. 22:530– 535. doi:10.1097/MOP.0b013e32833bb81a [doi]. 477. Feemster, K. A., P. Prasad, M. J. Smith, C. Feudtner, A. Caplan, P. Offit, and S. E. Coffin. 2011. Employee designation and health care worker support of an influenza vaccine mandate at a large pediatric tertiary care hospital. Vaccine 29:1762–1769. doi:S0264-410X(10)01902-X [pii];10.1016/j. vaccine.2010.12.115 [doi]. 478. Feng, L., A. W. Mounts, Y. Feng, Y. Luo, P. Yang, Z. Feng, W. Yang, and H. Yu. 2010. Seasonal influenza vaccine supply and target vaccinated population in China, 2004–2009. Vaccine 28:6778– 6782. doi:S0264-410X(10)01075-3 [pii];10.1016/j.vaccine.2010.07.064 [doi]. 479. Feng, S. Z., P. R. Jiao, W. B. Qi, H. Y. Fan, and M. Liao. 2011. Development and strategies of cell- culture technology for influenza vaccine. Appl.Microbiol.Biotechnol. 89:893–902. doi:10.1007/ s00253-010-2973-9 [doi]. 480. Fenoglio, D., M. R. Zocchi, A. Parodi, P. Durando, G. Gabutitp, R. Gasparini, and A. Poggi. 2011. MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. J.Prev.Med.Hyg. 52:137–141. 481. Ferdinands, J. M., E. A. Belongia, C. Nwasike, and D. K. Shay. 2011. Influenza vaccination status is not associated with influenza testing among children: implications for observational studies of vaccine effectiveness. Vaccine 29:1935–1940. doi:S0264-410X(10)01885-2 [pii];10.1016/j. vaccine.2010.12.098 [doi]. 482. Ferguson, C. D., T. E. Ferguson, J. Golledge, and W. J. McBride. 2010. Pandemic influenza vaccination: will the health care system take its own medicine? Aust.J.Rural.Health 18:137–142. doi:AJR1148 [pii];10.1111/j.1440-1584.2010.01148.x [doi].

92 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

483. Fernando, G. J., X. Chen, T. W. Prow, M. L. Crichton, E. J. Fairmaid, M. S. Roberts, I. H. Frazer, L. E. Brown, and M. A. Kendall. 2010. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS.One. 5:e10266. doi:10.1371/journal. pone.0010266 [doi]. 484. Ferrante, G., S. Baldissera, P. F. Moghadam, G. Carrozzi, M. O. Trinito, and S. Salmaso. 2011. Surveillance of perceptions, knowledge, attitudes and behaviors of the Italian adult population (18–69 years) during the 2009–2010 A/H1N1 influenza pandemic. Eur.J.Epidemiol. 26:211–219. doi:10.1007/s10654-011-9576-3 [doi]. 485. Ferreira, O., I. Antunes, M. J. Cruz, A. Mota, H. Bettencourt, A. Canelhas, and F. Azevedo. 2011. Acute hemorrhagic edema of childhood after H1N1 immunization. Cutan.Ocul.Toxicol. 30:167–169. do i:10.3109/15569527.2010.536797 [doi]. 486. Ferroni, E. and T. Jefferson. 2011. Influenza. Clin.Evid.(Online.) 2011. doi:0911 [pii]. 487. Fielding, J. E., K. A. Grant, G. Papadakis, and H. A. Kelly. 2011. Estimation of type- and subtype- specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007–2008. BMC.Infect.Dis. 11:170. doi:1471-2334-11-170 [pii];10.1186/1471-2334-11- 170 [doi]. 488. Fielding, J. E., K. A. Grant, K. Garcia, and H. A. Kelly. 2011. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg.Infect.Dis. 17:1181–1187. doi:10.3201/eid1707.101959 [doi]. 489. Fierman, A. H. 2010. Voices from the field: controversies in vaccine mandates. Curr.Probl.Pediatr. Adolesc.Health Care 40:59. doi:S1538-5442(10)00003-9 [pii];10.1016/j.cppeds.2010.01.002 [doi]. 490. Finkelstein, E. A. and J. E. Segel. 2010. Does cost savings mean cost effective? Am.J.Prev.Med. 39:489–490. doi:S0749-3797(10)00471-X [pii];10.1016/j.amepre.2010.08.005 [doi]. 491. Finkelstein, S. N., K. J. Hedberg, J. A. Hopkins, S. Hashmi, and R. C. Larson. 2011. Vaccine availability in the United States during the 2009 H1N1 outbreak. Am.J.Disaster.Med. 6:23–30. 492. Fiore, A. E., T. M. Uyeki, K. Broder, L. Finelli, G. L. Euler, J. A. Singleton, J. K. Iskander, P. M. Wortley, D. K. Shay, J. S. Bresee, and N. J. Cox. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm.Rep. 59:1–62. doi:rr5908a1 [pii]. 493. Fisher, B. M., J. Scott, J. Hart, V. D. Winn, R. S. Gibbs, and A. M. Lynch. 2011. Behaviors and perceptions regarding seasonal and H1N1 influenza vaccination during pregnancy. Am.J.Obstet. Gynecol. 204:S107–S111. doi:S0002-9378(11)00231-6 [pii];10.1016/j.ajog.2011.02.041 [doi]. 494. Fisher, D., D. S. Hui, Z. Gao, C. Lee, M. D. Oh, B. Cao, T. T. Hien, K. Patlovich, and J. Farrar. 2011. Pandemic response lessons from influenza H1N1 2009 in Asia. Respirology. 16:876–882. doi:10.1111/j.1440-1843.2011.02003.x [doi]. 495. Fizzell, J., S. Campbell-Lloyd, A. J. Hallett, C. P. Lowbridge, D. Meijer, and S. E. Tyner. 2010. Pandemic (H1N1) 2009 influenza vaccine roll-out in NSW. N.S.W.Public Health Bull. 21:32–35. doi:NB09039 [pii];10.1071/NB09039 [doi]. 496. Fleming, J. D., A. J. Fogo, and D. J. Creamer. 2011. Stevens-Johnson syndrome triggered by seasonal influenza vaccination and flucloxacillin: a pathogenetic hypothesis. Eur.J.Dermatol. 21:434– 435. doi:ejd.2011.1314 [pii];10.1684/ejd.2011.1314 [doi]. 497. Flood, E. M., K. J. Ryan, M. D. Rousculp, K. M. Beusterien, S. L. Block, M. C. Hall, and P. J. Mahadevia. 2011. A survey of children’s preferences for influenza vaccine attributes. Vaccine 29:4334–4340. doi:S0264-410X(11)00528-7 [pii];10.1016/j.vaccine.2011.04.018 [doi].

93 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

498. Flood, E. M., K. J. Ryan, M. D. Rousculp, K. M. Beusterien, V. M. Divino, S. L. Block, M. C. Hall, and P. J. Mahadevia. 2011. Parent preferences for pediatric influenza vaccine attributes. Clin.Pediatr. (Phila) 50:338–347. doi:0009922810391247 [pii];10.1177/0009922810391247 [doi]. 499. Flood, E. M., M. D. Rousculp, K. J. Ryan, K. M. Beusterien, V. M. Divino, S. L. Toback, M. Sasane, S. L. Block, M. C. Hall, and P. J. Mahadevia. 2010. Parents’ decision-making regarding vaccinating their children against influenza: A web-based survey. Clin.Ther. 32:1448–1467. doi:S0149-2918(10)00225-0 [pii];10.1016/j.clinthera.2010.06.020 [doi]. 500. Flood, E. M., S. L. Block, M. C. Hall, M. D. Rousculp, V. M. Divino, S. L. Toback, and P. J. Mahadevia. 2011. Children’s perceptions of influenza illness and preferences for influenza vaccine. J.Pediatr. Health Care 25:171–179. doi:S0891-5245(10)00094-5 [pii];10.1016/j.pedhc.2010.04.007 [doi]. 501. Floret, D. 2010. [Pandemic vaccines]. Arch.Pediatr. 17:906–907. doi:S0929-693X(10)70172-X [pii];10.1016/S0929-693X(10)70172-X [doi]. 502. Floret, D. 2010. [Resistance to immunization]. Med.Sci.(Paris) 26:1087–1093. doi:00/00/10/1A/ [pii];10.1051/medsci/201026121087 [doi]. 503. Floyd, S. 2010. Administering the influenza vaccine. Nurs.N.Z. 16:20–21. 504. Folkenberg, M., T. Callreus, H. Svanstrom, P. Valentiner-Branth, and A. Hviid. 2011. Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009–March 2010. Vaccine 29:1180–1184. doi:S0264-410X(10)01746-9 [pii];10.1016/j. vaccine.2010.12.008 [doi]. 505. Forrest, B. D., A. D. Steele, L. Hiemstra, R. Rappaport, C. S. Ambrose, and W. C. Gruber. 2011. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 29:3633–3639. doi:S0264-410X(11)00381-1 [pii];10.1016/j.vaccine.2011.03.029 [doi]. 506. Foster, S. and C. E. Taylor. 2010. Influenza vaccination: Am I protected? J.Am.Pharm.Assoc.(2003.) 50:770–771. doi:C55147TP14075741 [pii];10.1331/JAPhA.2010.10541 [doi]. 507. Fouchier, R. A. and D. J. Smith. 2010. Use of antigenic cartography in vaccine seed strain selection. Avian Dis. 54:220–223. 508. Fox, C. B., S. L. Baldwin, M. S. Duthie, S. G. Reed, and T. S. Vedvick. 2011. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine. doi:S0264- 410X(11)01359-4 [pii];10.1016/j.vaccine.2011.08.089 [doi]. 509. Fox, K. A. and R. Theiler. 2011. Vaccination in pregnancy. Curr.Pharm.Biotechnol. 12:789–796. doi:BSP/CPB/E-Pub/00095-12-1 [pii]. 510. Fraaij, P. L., R. Bodewes, A. D. Osterhaus, and G. F. Rimmelzwaan. 2011. The ins and outs of universal childhood influenza vaccination. Future.Microbiol. 6:1171–1184. doi:10.2217/fmb.11.106 [doi]. 511. Fragapane, E., R. Gasparini, F. Schioppa, F. Laghi-Pasini, E. Montomoli, and A. Banzhoff. 2010. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin.Vaccine Immunol. 17:1817–1819. doi:CVI.00461-09 [pii];10.1128/CVI.00461-09 [doi]. 512. Francis, D. P. and G. Grohmann. 2011. WHO influenza vaccine technology transfer initiative: role and activities of the Technical Advisory Group. Vaccine 29 Suppl 1:A45–A47. doi:S0264- 410X(11)00326-4 [pii];10.1016/j.vaccine.2011.02.078 [doi]. 513. Francisci, D., R. Labianca, and F. Roila. 2010. Prevention and treatment of pandemic influenza in cancer patients. Ann.Oncol. 21:2301–2303. doi:mdq351 [pii];10.1093/annonc/mdq351 [doi].

94 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

514. Frasca, D., A. Diaz, M. Romero, A. M. Landin, M. Phillips, S. C. Lechner, J. G. Ryan, and B. B. Blomberg. 2010. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 28:8077–8084. doi:S0264-410X(10)01492-1 [pii];10.1016/j.vaccine.2010.10.023 [doi]. 515. Frenck, R. W., Jr., R. Belshe, R. C. Brady, P. L. Winokur, J. D. Campbell, J. Treanor, C. M. Hay, C. L. Dekker, E. B. Walter, Jr., T. R. Cate, K. M. Edwards, H. Hill, M. Wolff, T. Leduc, and N. Tornieporth. 2011. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults. Vaccine 29:5666–5674. doi:S0264-410X(11)00874-7 [pii];10.1016/j.vaccine.2011.06.010 [doi]. 516. Frew, P. M., B. Hixson, R. C. del, A. Esteves-Jaramillo, and S. B. Omer. 2011. Acceptance of pandemic 2009 influenza A (H1N1) vaccine in a minority population: determinants and potential points of intervention. Pediatrics 127 Suppl 1:S113–S119. doi:peds.2010-1722Q [pii];10.1542/ peds.2010-1722Q [doi]. 517. Frey, S., T. Vesikari, A. Szymczakiewicz-Multanowska, M. Lattanzi, A. Izu, N. Groth, and S. Holmes. 2010. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin.Infect.Dis. 51:997–1004. doi:10.1086/656578 [doi]. 518. Fridman, D., E. Steinberg, E. Azhar, J. Weedon, T. E. Wilson, and H. Minkoff. 2011. Predictors of H1N1 vaccination in pregnancy. Am.J.Obstet.Gynecol. 204:S124–S127. doi:S0002-9378(11)00457-1 [pii];10.1016/j.ajog.2011.04.011 [doi]. 519. Friede, M., L. Palkonyay, C. Alfonso, Y. Pervikov, G. Torelli, D. Wood, and M. P. Kieny. 2011. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 29 Suppl 1:A2–A7. doi:S0264-410X(11)00327-6 [pii];10.1016/j.vaccine.2011.02.079 [doi]. 520. Friedman, B. C. and R. D. Goldman. 2010. Influenza vaccination for children with asthma. Can.Fam. Physician 56:1137–1139. doi:56/11/1137 [pii]. 521. Fritz, S., E. Mossdorf, B. Durovic, G. Zenhaeusern, A. Conen, I. Steffen, M. Battegay, R. Nuesch, and C. Hess. 2010. Virosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy. AIDS 24:2287–2289. doi:10.1097/QAD.0b013e32833c6f92 [doi]. 522. Fu, C. 2010. Effectiveness of H1N1 vaccine against reported Influenza A (H1N1): Southern China, October 2009–February 2010. Hum.Vaccin. 6. doi:12638 [pii]. 523. Fu, C., J. Xu, H. Tan, and M. Wang. 2011. Serious adverse reactions should be further monitored after influenza A (H1N1) vaccination among children: postmarketing experience with 570,000 vaccinations between October 2009 and August 2010 in Guangzhou, China. Pediatr.Infect.Dis.J. 30:631–632. doi:10.1097/INF.0b013e31821f7da8 [doi];00006454-201107000-00030 [pii]. 524. Fu, Y. H., J. S. He, X. X. Zheng, X. B. Wang, C. Xie, C. X. Shi, M. Zhang, Q. Tang, W. Wei, J. G. Qu, and T. Hong. 2010. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice. Biochem.Biophys.Res.Commun. 391:857– 861. doi:S0006-291X(09)02348-1 [pii];10.1016/j.bbrc.2009.11.152 [doi]. 525. Fulvini, A. A., M. Ramanunninair, J. Le, B. A. Pokorny, J. M. Arroyo, J. Silverman, R. Devis, and D. Bucher. 2011. Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production. PLoS.One. 6:e20823. doi:10.1371/journal. pone.0020823 [doi];PONE-D-11-01114 [pii]. 526. Furuya, Y. 2011. Return of inactivated whole-virus vaccine for superior efficacy. Immunol.Cell Biol. doi:icb201170 [pii];10.1038/icb.2011.70 [doi].

95 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

527. Furuya, Y., J. Chan, E. C. Wan, A. Koskinen, K. R. Diener, J. D. Hayball, M. Regner, A. Mullbacher, and M. Alsharifi. 2011. Gamma-Irradiated Influenza Virus Uniquely Induces IFN-I Mediated Lymphocyte Activation Independent of the TLR7/MyD88 Pathway. PLoS.One. 6:e25765. doi:10.1371/ journal.pone.0025765 [doi];PONE-D-11-08201 [pii]. 528. Furuya, Y., M. Regner, M. Lobigs, A. Koskinen, A. Mullbacher, and M. Alsharifi. 2010. Effect of inactivation method on the cross-protective immunity induced by whole ‘killed’ influenza A viruses and commercial vaccine preparations. J.Gen.Virol. 91:1450–1460. doi:vir.0.018168-0 [pii];10.1099/ vir.0.018168-0 [doi]. 529. Gabay, C., M. Bel, C. Combescure, C. Ribi, S. Meier, K. Posfay-Barbe, S. Grillet, J. D. Seebach, L. Kaiser, W. Wunderli, P. A. Guerne, and C. A. Siegrist. 2011. Impact of synthetic and biologic disease- modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 63:1486– 1496. doi:10.1002/art.30325 [doi]. 530. Gagnon, R., M. N. Primeau, R. A. Des, C. Lemire, R. Kagan, S. Carr, M. Ouakki, M. Benoit, and S. G. De. 2010. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J.Allergy Clin.Immunol. 126:317–323. doi:S0091-6749(10)00894-8 [pii];10.1016/j. jaci.2010.05.037 [doi]. 531. Gambaryan, A. S., N. F. Lomakina, E. Y. Boravleva, E. A. Kropotkina, V. V. Mashin, I. V. Krasilnikov, A. I. Klimov, and L. G. Rudenko. 2011. Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine). Influenza.Other Respi.Viruses. doi:10.1111/j.1750-2659.2011.00291.x [doi]. 532. Gao, Q., A. C. Lowen, T. T. Wang, and P. Palese. 2010. A nine-segment influenza a virus carrying subtype H1 and H3 hemagglutinins. J.Virol. 84:8062–8071. doi:JVI.00722-10 [pii];10.1128/ JVI.00722-10 [doi]. 533. Garattini, L. and A. Padula. 2011. To model or not to model: lessons from two vaccinations. Eur.J.Health Econ. 12:189–191. doi:10.1007/s10198-011-0298-y [doi]. 534. Garattini, L. and D. Koleva. 2011. Influenza vaccine for healthy adult workers: an issue for health authorities or employers? Health Policy 102:89–95. doi:S0168-8510(10)00305-2 [pii];10.1016/j. healthpol.2010.10.011 [doi]. 535. Garattini, L., A. Padula, and G. Casadei. 2011. Management of vaccinations in Italy: a national survey after healthcare regionalization. J.Med.Econ. 14:527–541. doi:10.3111/13696998.2011.593603 [doi]. 536. Garcia, J. M., N. Lagarde, E. S. Ma, M. D. de Jong, and J. S. Peiris. 2010. Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay. J.Clin.Virol. 47:29–33. doi:S1386-6532(09)00499-5 [pii];10.1016/j.jcv.2009.10.009 [doi]. 537. Garcia-Basteiro, A. L., M. J. Alvarez-Pasquin, G. Mena, A. Llupia, M. Aldea, V. G. Sequera, S. Sanz, J. Tuells, J. A. Navarro-Alonso, A. J. de, and J. M. Bayas. 2011. A public-professional web- bridge for vaccines and vaccination: User concerns about vaccine safety. Vaccine. doi:S0264– 410X(11)01597-0 [pii];10.1016/j.vaccine.2011.10.003 [doi]. 538. Garcia-Canas, V., B. Lorbetskie, T. D. Cyr, M. A. Hefford, S. Smith, and M. Girard. 2010. Approach to the profiling and characterization of influenza vaccine constituents by the combined use of size- exclusion chromatography, gel electrophoresis and mass spectrometry. Biologicals 38:294–302. doi:S1045-1056(09)00187-0 [pii];10.1016/j.biologicals.2009.12.005 [doi]. 539. Garcia-Sastre, A. 2011. Induction and evasion of type I interferon responses by influenza viruses. Virus Res. doi:S0168–1702(11)00411-4 [pii];10.1016/j.virusres.2011.10.017 [doi].

96 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

540. Garcia-Sicilia, J., P. Gillard, A. Carmona, J. C. Tejedor, J. Aristegui, J. M. Merino, U. Behre, A. Caplanusi, T. Vaman, and I. Dieussaert. 2011. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 29:4353–4361. doi:S0264- 410X(11)00521-4 [pii];10.1016/j.vaccine.2011.04.011 [doi]. 541. Gargano, L. M., J. E. Painter, J. M. Sales, C. Morfaw, L. M. Jones, D. Murray, G. M. Wingood, R. J. DiClemente, and J. M. Hughes. 2011. Seasonal and 2009 H1N1 influenza vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination among secondary school teachers and staff. Hum.Vaccin. 7:89–95. doi:13460 [pii]. 542. Gargano, L. M., J. E. Painter, J. M. Sales, C. Morfaw, L. M. Jones, P. Weiss, D. Murray, R. J. DiClemente, and J. M. Hughes. 2011. Correlates of 2009 pandemic H1N1 influenza vaccine acceptance among middle and high school teachers in rural Georgia. J.Sch Health 81:297–303. doi:10.1111/j.1746-1561.2011.00594.x [doi]. 543. Garren, H. 2010. Gene Based Vaccines: Optimising Development and Delivery – A marcus evans Conference. IDrugs. 13:759–761. 544. Gasparini, R. and P. Lai. 2010. Utility of virosomal adjuvated influenza vaccines: a review of the literature. J.Prev.Med.Hyg. 51:1–6. 545. Gasparini, R., D. Amicizia, P. L. Lai, and D. Panatto. 2011. Live attenuated influenza vaccine – a review. J.Prev.Med.Hyg. 52:95–101. 546. Gasparini, R., F. Schioppa, M. Lattanzi, M. Barone, D. Casula, M. Pellegrini, K. Veitch, and N. Gaitatzis. 2010. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int.J.Clin.Pract. 64:432–438. doi:IJCP2309 [pii];10.1111/j.1742-1241.2009.02309.x [doi]. 547. Gavazzi, G. 2011. Influenza vaccination in long-term care facilities: more than standing order programs? J.Am.Med.Dir.Assoc. 12:315–316. doi:S1525-8610(10)00527-X [pii];10.1016/j. jamda.2010.12.096 [doi]. 548. Gavazzi, G., Y. Filali-Zegzouti, A. C. Guyon, W. B. De, B. Lejeune, J. L. Golmard, J. Belmin, F. Piette, and M. Rothan-Tondeur. 2011. French healthcare workers in geriatric healthcare settings staunchly opposed to influenza vaccination: the VESTA study. Vaccine 29:1611–1616. doi:S0264- 410X(10)01840-2 [pii];10.1016/j.vaccine.2010.12.067 [doi]. 549. Gavrilov, V., T. Orekov, C. Alabanza, U. Porika, H. Jiang, K. Connolly, and S. Pincus. 2011. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J.Virol.Methods 173:364–373. doi:S0166-0934(11)00101-7 [pii];10.1016/j.jviromet.2011.03.011 [doi]. 550. Gaygisiz, U., E. Gaygisiz, T. Ozkan, and T. Lajunen. 2010. Why were Turks unwilling to accept the A/ H1N1 influenza-pandemic vaccination? People’s beliefs and perceptions about the swine flu outbreak and vaccine in the later stage of the . Vaccine 29:329–333. doi:S0264-410X(10)01499-4 [pii];10.1016/j.vaccine.2010.10.030 [doi]. 551. Gazmararian, J. A., W. Orenstein, M. Prill, H. B. Hitzhusen, M. S. Coleman, K. Pazol, and N. V. Oster. 2010. Maternal knowledge and attitudes toward influenza vaccination: a focus group study in metropolitan Atlanta. Clin.Pediatr.(Phila) 49:1018–1025. doi:0009922810373946 [pii];10.1177/0009922810373946 [doi]. 552. Ge, J., G. Tian, X. Zeng, Y. Jiang, H. Chen, and Z. Bua. 2010. Generation and evaluation of a Newcastle disease virus-based H9 avian influenza live vaccine. Avian Dis. 54:294–296. 553. Geeraedts, F. and A. Huckriede. 2012. Influenza Vaccines: What Do We Want and How Can We Get It? Adv.Exp.Med.Biol. 780:161–174. doi:10.1007/978-1-4419-5632-3_13 [doi].

97 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

554. Geeraedts, F., V. Saluja, V. W. ter, J. P. Amorij, H. W. Frijlink, J. Wilschut, W. L. Hinrichs, and A. Huckriede . 2010. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS.J. 12:215–222. doi:10.1208/ s12248-010-9179-z [doi]. 555. Gendon, I. 2011. [Live cold-adapted influenza vaccine: state-of-the-art]. Vopr.Virusol. 56:4–17. 556. Gendon, I. and I. Vasiliev. 2011. [Problem of influenza prophylaxis by vaccines]. Zh.Mikrobiol. Epidemiol.Immunobiol.115–124. 557. George, M., M. Farooq, T. Dang, B. Cortes, J. Liu, and L. Maranga. 2010. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol.Bioeng. 106:906–917. doi:10.1002/bit.22753 [doi]. 558. Gerard, M. 2011. [From new vaccine to new target: revisiting influenza vaccination]. Rev.Med.Brux. 32:280–283. 559. Gerloff, N. A., J. R. Kremer, E. Charpentier, A. Sausy, C. M. Olinger, P. Weicherding, J. Schuh, R. K. Van, and C. P. Muller. 2011. Swine influenza virus antibodies in humans, western Europe, 2009. Emerg.Infect.Dis. 17:403–411. doi:10.3201/eid1703.100851 [doi]. 560. Gershon, R. R., L. A. Magda, A. N. Canton, H. E. Riley, F. Wiggins, W. Young, and M. F. Sherman. 2010. Pandemic-related ability and willingness in home healthcare workers. Am.J.Disaster.Med. 5:15–26. 561. Gesheva, V., K. Idakieva, N. Kerekov, K. Nikolova, N. Mihaylova, L. Doumanova, and A. Tchorbanov. 2011. Marine gastropod hemocyanins as adjuvants of non-conjugated bacterial and viral proteins. Fish.Shellfish.Immunol. 30:135–142. doi:S1050-4648(10)00305-0 [pii];10.1016/j.fsi.2010.09.018 [doi]. 562. Gijzen, K., W. M. Liu, I. Visontai, F. Oftung, S. van der Werf, G. E. Korsvold, I. Pronk, I. S. Aaberge, A. Tutto, I. Jankovics, M. Jankovics, B. Gentleman, J. E. McElhaney, and E. C. Soethout . 2010. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 28:3416–3422. doi:S0264-410X(10)00257-4 [pii];10.1016/j.vaccine.2010.02.076 [doi]. 563. Giles, B. M. and T. M. Ross. 2011. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29:3043– 3054. doi:S0264-410X(11)00172-1 [pii];10.1016/j.vaccine.2011.01.100 [doi]. 564. Gilles, I., A. Bangerter, A. Clemence, E. G. Green, F. Krings, C. Staerkle, and P. Wagner-Egger. 2011. Trust in medical organizations predicts pandemic (H1N1) 2009 vaccination behavior and perceived efficacy of protection measures in the Swiss public. Eur.J.Epidemiol. 26:203–210. doi:10.1007/ s10654-011-9577-2 [doi]. 565. Gilmour, H. and N. Hofmann. 2010. H1N1 vaccination. Health Rep. 21:63–69. 566. Girard, M. P., J. Katz, Y. Pervikov, L. Palkonyay, and M. P. Kieny. 2010. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17–18 February 2010. Vaccine 28:6811–6820. doi:S0264-410X(10)01029-7 [pii];10.1016/j.vaccine.2010.07.034 [doi]. 567. Girard, M. P., J. M. Katz, Y. Pervikov, J. Hombach, and J. S. Tam. 2011. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17–18 February 2011. Vaccine 29:7579–7586. doi:S0264-410X(11)01262-X [pii];10.1016/j. vaccine.2011.08.031 [doi]. 568. Girard, M. P., J. S. Tam, O. M. Assossou, and M. P. Kieny. 2010. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 28:4895–4902. doi:S0264-410X(10)00719-X [pii];10.1016/j. vaccine.2010.05.031 [doi].

98 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

569. Girgis, C. M., R. R. Russo, and K. Benson. 2010. Subacute thyroiditis following the H1N1 vaccine. J.Endocrinol.Invest 33:506. doi:7216 [pii]. 570. Glanz, J. M., S. R. Newcomer, S. J. Hambidge, M. F. Daley, K. J. Narwaney, S. Xu, G. M. Lee, J. Baggs, N. P. Klein, J. D. Nordin, A. L. Naleway, E. A. Belongia, and E. S. Weintraub. 2011. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch.Pediatr.Adolesc.Med. 165:749–755. doi:165/8/749 [pii];10.1001/archpediatrics.2011.112 [doi]. 571. Glaser, M. S., S. Chui, M. P. Webber, J. Gustave, R. Lee, M. T. McLaughlin, V. Ortiz, D. Prezant, and K. Kelly. 2011. Predictors of acceptance of H1N1 influenza vaccination by FDNY firefighters and EMS workers. Vaccine 29:5675–5680. doi:S0264-410X(11)00872-3 [pii];10.1016/j. vaccine.2011.06.008 [doi]. 572. Glasser, J., D. Taneri, Z. Feng, J. H. Chuang, P. Tull, W. Thompson, M. M. Mason, and J. Alexander. 2010. Evaluation of targeted influenza vaccination strategies via population modeling. PLoS.One. 5. doi:10.1371/journal.pone.0012777 [doi]. 573. Glezen, W. P. 2010. How did the 2008–2009 seasonal influenza vaccine affect the pandemic? Clin. Infect.Dis. 51:1380–1382. doi:10.1086/657312 [doi]. 574. Glezen, W. P. 2011. Cell-culture-derived influenza vaccine production. Lancet 377:698–700. doi:S0140-6736(11)60174-8 [pii];10.1016/S0140-6736(11)60174-8 [doi]. 575. Glezen, W. P., M. J. Gaglani, C. A. Kozinetz, and P. A. Piedra. 2010. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J.Infect.Dis. 202:1626–1633. doi:10.1086/657089 [doi]. 576. Goel, M. K., M. Goel, P. Khanna, and K. Mittal. 2011. Pandemic influenza A (H1N1) 2009 vaccine: an update. Indian J.Med.Microbiol. 29:13–18. doi:IndianJMedMicrobiol_2011_29_1_13_76517 [pii];10.4103/0255-0857.76517 [doi]. 577. Gold, M. S., P. Effler, H. Kelly, P. C. Richmond, and J. P. Buttery. 2010. Febrile convulsions after 2010 seasonal trivalent influenza vaccine: implications for vaccine safety surveillance in Australia. Med.J.Aust. 193:492–493. doi:gol10924_fm [pii]. 578. Goldfarb, I., B. Panda, B. Wylie, and L. Riley. 2011. Uptake of influenza vaccine in pregnant women during the 2009 H1N1 influenza pandemic. Am.J.Obstet.Gynecol. 204:S112–S115. doi:S0002-9378(11)00022-6 [pii];10.1016/j.ajog.2011.01.007 [doi]. 579. Goldschmidt, I., E. D. Pfister, M. Becker, S. Hackl, O. J. Bott, U. Baumann, and U. Baumann. 2011. Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients. J.Pediatr. 158:329–333. doi:S0022-3476(10)00925-X [pii];10.1016/j. jpeds.2010.10.034 [doi]. 580. Goldson, A. J., S. J. Fairweather-Tait, C. N. Armah, Y. Bao, M. R. Broadley, J. R. Dainty, C. Furniss, D. J. Hart, B. Teucher, and R. Hurst. 2011. Effects of selenium supplementation on selenoprotein gene expression and response to influenza vaccine challenge: a randomised controlled trial. PLoS.One. 6:e14771. doi:10.1371/journal.pone.0014771 [doi]. 581. Goldstein, E., A. Apolloni, B. Lewis, J. C. Miller, M. Macauley, S. Eubank, M. Lipsitch, and J. Wallinga. 2010. Distribution of vaccine/antivirals and the ‘least spread line’ in a stratified population. J.R.Soc. Interface 7:755–764. doi:rsif.2009.0393 [pii];10.1098/rsif.2009.0393 [doi]. 582. Gomez-Casado, E., S. Gomez-Sebastian, M. C. Nunez, R. Lasa-Covarrubias, S. Martinez-Pulgarin, and J. M. Escribano. 2011. Insect larvae biofactories as a platform for influenza vaccine production. Protein Expr.Purif. 79:35–43. doi:S1046-5928(11)00072-6 [pii];10.1016/j.pep.2011.03.007 [doi]. 583. Gonzalez, S. F., V. Lukacs-Kornek, M. P. Kuligowski, L. A. Pitcher, S. E. Degn, S. J. Turley, and M. C. Carroll. 2010. Complement-dependent transport of antigen into B cell follicles. J.Immunol. 185:2659–2664. doi:185/5/2659 [pii];10.4049/jimmunol.1000522 [doi].

99 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

584. Gorczyca-Michta, I. and B. Wozakowska-Kaplon. 2010. [Influenza and cardiovascular diseases]. Kardiol.Pol. 68:1168–1171. 585. Gosbell, I. B., T. Gottlieb, A. M. Kesson, J. J. Post, and D. E. Dwyer. 2010. Immunisation and multi-dose vials. Vaccine 28:6556–6561. doi:S0264-410X(10)01050-9 [pii];10.1016/j. vaccine.2010.07.052 [doi]. 586. Gotoh, K., Y. Ito, E. Suzuki, K. Kaneko, T. Kiuchi, H. Ando, and H. Kimura. 2011. Effectiveness and safety of inactivated influenza vaccination in pediatric liver transplant recipients over three influenza seasons. Pediatr.Transplant. 15:112–116. doi:10.1111/j.1399-3046.2010.01420.x [doi]. 587. Gracie, S., A. Metcalfe, S. M. Dolan, H. Kehler, J. Siever, and S. Tough. 2011. Utilization of the 2009 H1N1 vaccine by pregnant women in a pandemic year. J.Obstet.Gynaecol.Can. 33:127–133. 588. Grandea, A. G., III, O. A. Olsen, T. C. Cox, M. Renshaw, P. W. Hammond, P. Y. Chan-Hui, J. L. Mitcham, W. Cieplak, S. M. Stewart, M. L. Grantham, A. Pekosz, M. Kiso, K. Shinya, M. Hatta, Y. Kawaoka, and M. Moyle. 2010. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc.Natl.Acad.Sci.U.S.A 107:12658–12663. doi:0911806107 [pii];10.1073/pnas.0911806107 [doi]. 589. Granstrom, M. and A. C. Voordouw . 2011. Registration of influenza vaccines for children in Europe. Vaccine 29:7572–7575. doi:S0264-410X(11)01226-6 [pii];10.1016/j.vaccine.2011.08.017 [doi]. 590. Granwehr, B. 2010. ACP Journal Club. A 15-microg dose of unadjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in healthy adults within 21 days. Ann.Intern.Med. 152:JC1–JC8. doi:152/2/JC1-9 [pii];10.1059/0003-4819-152-2-201001190-02009 [doi]. 591. Granwehr, B. 2010. ACP Journal Club. One or two 7.5-microg doses of MF59-adjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in adults within 21 days. Ann.Intern.Med. 152:JC1–JC9. doi:152/2/JC1-8 [pii];10.1059/0003-4819-152-2-201001190-02008 [doi]. 592. Grau, S., S. Luque, J. Pi-Sunyer, J. P. Horcajada, R. Villar, N. Berenguer, O. Urbina, and C. Serra. 2011. [Low adherence to 2009 pandemic influenza A(H1N1) vaccination program among health care workers of a medical centre during the pandemic phase]. Enferm.Infecc.Microbiol.Clin. 29:269–275. doi:S0213-005X(10)00468-4 [pii];10.1016/j.eimc.2010.09.013 [doi]. 593. Gravel, C., C. Li, J. Wang, A. M. Hashem, B. Jaentschke, K. W. Xu, B. Lorbetskie, G. Gingras, Y. Aubin, D. G. Van, M. Girard, R. He, and X. Li. 2010. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 28:5774–5784. doi:S0264-410X(10)00903-5 [pii];10.1016/j. vaccine.2010.06.075 [doi]. 594. Gravenstein, S., A. Pop-Vicas, and A. Ambrozaitis. 2010. The 2009 A/H1N1 pandemic influenza and the nursing home. Med.Health R.I. 93:382–384. 595. Green, T. 2010. Beginning the school year with novel H1N1: where are we now? NASN.Sch Nurse 25:56–57. 596. Greene, S. K., M. Kulldorff, E. M. Lewis, R. Li, R. Yin, E. S. Weintraub, B. H. Fireman, T. A. Lieu, J. D. Nordin, J. M. Glanz, R. Baxter, S. J. Jacobsen, K. R. Broder, and G. M. Lee. 2010. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am.J.Epidemiol. 171:177–188. doi:kwp345 [pii];10.1093/aje/kwp345 [doi]. 597. Greene, S. K., M. Kulldorff, R. Yin, W. K. Yih, T. A. Lieu, E. S. Weintraub, and G. M. Lee. 2011. Near real-time vaccine safety surveillance with partially accrued data. Pharmacoepidemiol.Drug Saf 20:583–590. doi:10.1002/pds.2133 [doi]. 598. Greenhawt, M. J., A. S. Chernin, L. Howe, J. T. Li, and G. Sanders. 2010. The safety of the H1N1 influenza A vaccine in egg allergic individuals. Ann.Allergy Asthma Immunol. 105:387–393. doi:S1081-1206(10)00781-7 [pii];10.1016/j.anai.2010.08.015 [doi].

100 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

599. Greenhawt, M. J., J. T. Li, D. I. Bernstein, J. Blessing-Moore, L. Cox, D. Khan, D. M. Lang, R. A. Nicklas, J. Oppenheimer, J. M. Portnoy, C. Randolph, D. E. Schuller, S. L. Spector, S. A. Tilles, and D. Wallace. 2011. Administering influenza vaccine to egg allergic recipients: a focused practice parameter update. Ann.Allergy Asthma Immunol. 106:11–16. doi:S1081-1206(10)01075-6 [pii];10.1016/j.anai.2010.11.015 [doi]. 600. Greer, A. L., A. Tuite, and D. N. Fisman. 2010. Age, influenza and disease dynamics. Epidemiol.Infect. 138:1542–1549. doi:S0950268810000579 [pii];10.1017/S0950268810000579 [doi]. 601. Gregersen, J. P., H. J. Schmitt, H. Trusheim, and M. Broker. 2011. Safety of MDCK cell culture-based influenza vaccines. Future.Microbiol. 6:143–152. doi:10.2217/fmb.10.161 [doi]. 602. Griffin, M. R., A. S. Monto, E. A. Belongia, J. J. Treanor, Q. Chen, J. Chen, H. K. Talbot, S. E. Ohmit, L. A. Coleman, G. Lofthus, J. G. Petrie, J. K. Meece, C. B. Hall, J. V. Williams, P. Gargiullo, L. Berman, and D. K. Shay. 2011. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS.One. 6:e23085. doi:10.1371/journal.pone.0023085 [doi];PONE-D-11-09174 [pii]. 603. Griffiths, P. D. 2011. Editorial: which influenza subtype should be added to the next vaccine? Rev. Med.Virol. 21:203–204. doi:10.1002/rmv.701 [doi]. 604. Grijalva, C. G., Y. Zhu, L. Simonsen, and M. R. Griffin. 2010. Establishing the baseline burden of influenza in preparation for the evaluation of a countywide school-based influenza vaccination campaign. Vaccine 29:123–129. doi:S0264-410X(10)01242-9 [pii];10.1016/j.vaccine.2010.08.072 [doi]. 605. Grijalva, C. G., Y. Zhu, L. Simonsen, E. Mitchel, and M. R. Griffin. 2010. The population impact of a large school-based influenza vaccination campaign. PLoS.One. 5:e15097. doi:10.1371/journal. pone.0015097 [doi]. 606. Grimaldi-Bensouda, L., A. Alperovitch, G. Besson, C. Vial, J. M. Cuisset, C. Papeix, O. Lyon-Caen, J. Benichou, and M. Rossignol. 2011. Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am.J.Epidemiol. 174:326– 335. doi:kwr072 [pii];10.1093/aje/kwr072 [doi]. 607. Grimprel, E. 2011. [Follow-up vaccination of children from 3 to 12 years]. Rev.Prat. 61:513–515. 608. Grotto, I. and D. Engelhard. 2009. [The safety and immunogenicity of the vaccines against pandemic (H1N1) 2009 influenza]. Harefuah 148:799–803, 857. 609. Gruenberg, D. A. and M. S. Shaker. 2011. An update on influenza vaccination in patients with egg allergy. Curr.Opin.Pediatr. 23:566–572. doi:10.1097/MOP.0b013e32834ac7a3 [doi]. 610. Grund, S., O. Adams, S. Wahlisch, and B. Schweiger. 2011. Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus. J.Virol.Methods 171:369– 373. doi:S0166-0934(10)00423-4 [pii];10.1016/j.jviromet.2010.11.024 [doi]. 611. Gui, L., K. Chen, and Y. Zhang. 2011. Acute transverse myelitis following vaccination against H1N1 influenza: a case report. Int.J.Clin.Exp.Pathol. 4:312–314. 612. Guo, J., L. Yao, A. Chen, X. Liu, J. Fu, P. Xu, and Z. Zhang. 2011. Evaluation of the immune response to recombinant DNA vaccine and adenoviral vaccine co-expressing the M1 and HA genes of H5N1 influenza virus in mice. Sheng Wu Gong.Cheng Xue.Bao. 27:876–883. 613. Guo, J., L. Yao, A. Chen, Y. Xu, X. Liu, Y. Shu, and Z. Zhang. 2010. [Immunological evaluation of vector-expressed M2 and HA genes of H5N1 influenza virus in mice]. Sheng Wu Gong.Cheng Xue. Bao. 26:649–656.

101 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

614. Guo, L., M. Zheng, Y. Ding, D. Li, Z. Yang, H. Wang, Q. Chen, Z. Sui, F. Fang, and Z. Chen. 2010. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch.Virol. 155:1765–1775. doi:10.1007/s00705-010-0756-3 [doi]. 615. Gupta, S. K., M. Srivastava, B. A. Akhoon, S. Smita, U. Schmitz, O. Wolkenhauer, J. Vera, and S. K. Gupta. 2011. Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase. Infect.Genet.Evol. 11:308–319. doi:S1567-1348(10)00294-7 [pii];10.1016/j.meegid.2010.10.013 [doi]. 616. Gustin, K. M., T. R. Maines, J. A. Belser, H. N. van, X. Lu, L. Dong, I. Isakova-Sivak, L. M. Chen, J. T. Voeten, J. G. Heldens, H. van den Bosch, N. J. Cox, T. M. Tumpey, A. I. Klimov, L. Rudenko, R. O. Donis, and J. M. Katz. 2011. Comparative Immunogenicity and Cross-Clade Protective Efficacy of Mammalian Cell-Grown Inactivated and Live Attenuated H5N1 Reassortant Vaccines in Ferrets. J.Infect.Dis. 204:1491–1499. doi:jir596 [pii];10.1093/infdis/jir596 [doi]. 617. Gutierrez, G., R. Perez-Cuevas, S. Levy, H. Reyes, B. Acosta, S. F. Canton, and O. Munoz. 2010. Strengthening preventive care programs: a permanent challenge for healthcare systems; lessons from PREVENIMSS Mexico. BMC.Public Health 10:417. doi:1471-2458-10-417 [pii];10.1186/1471-2458- 10-417 [doi]. 618. Gwini, S. M., C. A. Coupland, and A. N. Siriwardena. 2011. The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. Vaccine 29:1145–1149. doi:S0264- 410X(10)01755-X [pii];10.1016/j.vaccine.2010.12.017 [doi]. 619. Haaheim, L. R. and J. M. Katz. 2011. Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1–3, 2010. Influenza.Other Respi.Viruses. 5:288–295. doi:10.1111/j.1750-2659.2011.00242.x [doi]. 620. Haber, P., J. Iskander, K. Walton, S. R. Campbell, and K. S. Kohl. 2011. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety. Pediatrics 127 Suppl 1:S39–S44. doi:peds.2010-1722G [pii];10.1542/peds.2010- 1722G [doi]. 621. Haddock, R. L., Y. S. Damian, L. A. Duguies, and Y. C. Paulino. 2010. Guam’s influenza epidemic(s) of 2009. Hawaii Med.J. 69:50–51. 622. Hagenaars, N., M. Mania, J. P. de, I. Que, R. Nieuwland, B. Slutter, H. Glansbeek, J. Heldens, H. van den Bosch, C. Lowik, E. Kaijzel, E. Mastrobattista, and W. Jiskoot. 2010. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J.Control Release 144:17–24. doi:S0168-3659(10)00057-X [pii];10.1016/j. jconrel.2010.01.027 [doi]. 623. Hai, R., A. Garcia-Sastre, D. E. Swayne, and P. Palese. 2011. A -incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains. J.Virol. 85:6832– 6843. doi:JVI.00609-11 [pii];10.1128/JVI.00609-11 [doi]. 624. Hajiabdolbaghi, M., S. Jam, S. SeyedAlinaghi, S. Jafari, B. M. Badie, and D. Sabzvari. 2010. Adverse reactions of trivalent influenza vaccine in HIV-infected individuals. Acta Med.Iran 48:95–100. 625. Hak, E. 2011. Influenza vaccination in young children. Lancet Infect.Dis. 11:656–658. doi:S1473-3099(11)70221-3 [pii];10.1016/S1473-3099(11)70221-3 [doi]. 626. Hak, E., L. M. Knol, J. C. Wilschut, and M. J. Postma. 2010. [Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance]. Ned.Tijdschr.Geneeskd. 154:A1188. 627. Hakim, H., A. H. Gaur, and J. A. McCullers. 2011. Motivating factors for high rates of influenza vaccination among healthcare workers. Vaccine 29:5963–5969. doi:S0264-410X(11)00905-4 [pii];10.1016/j.vaccine.2011.06.041 [doi].

102 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

628. Halasa, N. B. 2011. Make new friends, but keep the old: influenza vaccines in children with cancer. J.Infect.Dis. 204:1471–1474. doi:jir563 [pii];10.1093/infdis/jir563 [doi]. 629. Halasa, N., J. A. Englund, S. Nachman, G. A. Weinberg, V. C. Huber, K. Allison, F. Dubovsky, T. Yi, J. A. McCullers, and P. M. Flynn. 2011. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 29:4110–4115. doi:S0264-410X(11)00490-7 [pii];10.1016/j.vaccine.2011.03.097 [doi]. 630. Hall, S. J., L. Klotz, A. J. Pantuck, D. J. George, J. B. Whitmore, M. W. Frohlich, and R. B. Sims. 2011. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J.Urol. 186:877–881. doi:S0022-5347(11)03851-1 [pii];10.1016/j.juro.2011.04.070 [doi]. 631. Halliley, J. L., S. Kyu, J. J. Kobie, E. E. Walsh, A. R. Falsey, T. D. Randall, J. Treanor, C. Feng, I. Sanz, and F. E. Lee. 2010. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine 28:3582–3587. doi:S0264- 410X(10)00280-X [pii];10.1016/j.vaccine.2010.02.088 [doi]. 632. Hamad, M. 2011. Universal vaccines: shifting to one for many or shooting too high too soon! APMIS 119:565–573. doi:10.1111/j.1600-0463.2011.02776.x [doi]. 633. Hambleton, S. 2011. Editorial commentary: a better grip: T cells strengthen our hand against influenza. Clin.Infect.Dis. 52:8–9. doi:ciq018 [pii];10.1093/cid/ciq018 [doi]. 634. Hamouda, T., A. Chepurnov, N. Mank, J. Knowlton, T. Chepurnova, A. Myc, J. Sutcliffe, and J. R. Baker. 2010. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum.Vaccin. 6:585–594. doi:11818 [pii]. 635. Hamouda, T., J. A. Sutcliffe, S. Ciotti, and J. R. Baker, Jr. 2011. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clin. Vaccine Immunol. 18:1167–1175. doi:CVI.00035-11 [pii];10.1128/CVI.00035-11 [doi]. 636. Han, F., L. Lin, S. C. Warby, J. Faraco, J. Li, S. X. Dong, P. An, L. Zhao, L. H. Wang, Q. Y. Li, H. Yan, Z. C. Gao, Y. Yuan, K. P. Strohl, and E. Mignot. 2011. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann.Neurol. 70:410–417. doi:10.1002/ana.22587 [doi]. 637. Handel, A., I. M. Longini, Jr., and R. Antia. 2009. Intervention strategies for an influenza pandemic taking into account secondary bacterial infections. . 1:185–195. doi:10.1016/j. epidem.2009.09.001 [doi]. 638. Hanna, M. and A. Poullis. 2011. Sub-optimal H1N1 vaccine uptake by immunocompromised inflammatory bowel disease patients. Clin.Med. 11:301. 639. Hara, M., K. Tanaka, T. Kase, A. Maeda, and Y. Hirota. 2010. Evaluation of seasonal influenza vaccination effectiveness based on antibody efficacy among the institutionalized elderly in Japan. Vaccine 28:5664–5668. doi:S0264-410X(10)00883-2 [pii];10.1016/j.vaccine.2010.06.061 [doi]. 640. Harada, Y. and S. Itamura. 2011. [The latest trend and prospects of development of influenza vaccine]. Nihon Rinsho 69:1567–1570. 641. Harada, Y., A. Ninomiya-Mori, Y. Takahashi, M. Shirakura, N. Kishida, T. Kageyama, Y. Tada, M. Tashiro, and T. Odagiri. 2011. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre- pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine 29:8330–8337. doi:S0264- 410X(11)01361-2 [pii];10.1016/j.vaccine.2011.08.091 [doi]. 642. Hardelid, P., D. M. Fleming, J. McMenamin, N. Andrews, C. Robertson, P. Sebastianpillai, J. Ellis, W. Carman, T. Wreghitt, J. M. Watson, and R. G. Pebody. 2011. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009–2010. Euro.Surveill 16.

103 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

643. Harmark, L., H. F. van, E. Hak, and G. K. van. 2011. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring. Vaccine 29:1941–1947. doi:S0264-410X(11)00004-1 [pii];10.1016/j.vaccine.2010.12.123 [doi]. 644. Haroon, M., F. Adeeb, A. Eltahir, and S. Harney. 2011. The uptake of influenza and pneumococcal vaccination among immunocompromised patients attending rheumatology outpatient clinics. Joint Bone Spine 78:374–377. doi:S1297-319X(10)00288-5 [pii];10.1016/j.jbspin.2010.10.012 [doi]. 645. Harris, K. M., J. Maurer, and A. L. Kellermann. 2010. Influenza vaccine – safe, effective, and mistrusted. N.Engl.J.Med. 363:2183–2185. doi:10.1056/NEJMp1012333 [doi]. 646. Harris, K., J. Maurer, C. Black, G. Euler, and S. Kadiyala. 2011. Workplace efforts to promote influenza vaccination among healthcare personnel and their association with uptake during the 2009 pandemic influenza A (H1N1). Vaccine 29:2978–2985. doi:S0264-410X(11)00184-8 [pii];10.1016/j. vaccine.2011.01.112 [doi]. 647. Hartgroves, L. C., W. Koudstaal, C. McLeod, O. Moncorge, C. I. Thompson, J. Ellis, C. Bull, M. J. Havenga, J. Goudsmit, and W. S. Barclay. 2010. Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. Vaccine 28:2973–2979. doi:S0264-410X(10)00180-5 [pii];10.1016/j.vaccine.2010.02.012 [doi]. 648. Harvey, R., C. Nicolson, R. E. Johnson, K. A. Guilfoyle, D. L. Major, J. S. Robertson, and O. G. Engelhardt. 2010. Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules. Vaccine 28:8008–8014. doi:S0264-410X(10)01314-9 [pii];10.1016/j.vaccine.2010.09.006 [doi]. 649. Harvey, R., K. A. Guilfoyle, S. Roseby, J. S. Robertson, and O. G. Engelhardt. 2011. Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules. J.Virol. 85:6086–6090. doi:JVI.00096-11 [pii];10.1128/JVI.00096-11 [doi]. 650. Hashem, A. M., D. G. Van, C. Li, J. Wang, Y. M. She, T. D. Cyr, J. Sui, R. He, W. A. Marasco, and X. Li. 2010. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem.Biophys.Res.Commun. 403:247–251. doi:S0006- 291X(10)02078-4 [pii];10.1016/j.bbrc.2010.11.030 [doi]. 651. Hashim, A. B., T. McKeever, S. J. Kelly, and J. S. Nguyen-Van-Tam. 2010. Evaluation of inter- pandemic influenza vaccine effectiveness during eight consecutive winter seasons in England and Wales in patients with cardiovascular risk factors. J.Infect.Public Health 3:159–165. doi:S1876-0341(10)00077-8 [pii];10.1016/j.jiph.2010.09.007 [doi]. 652. Hassantoufighi, A., H. Zhang, M. Sandbulte, J. Gao, J. Manischewitz, L. King, H. Golding, T. M. Straight, and M. C. Eichelberger. 2010. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 28:790–797. doi:S0264-410X(09)01596-5 [pii];10.1016/j.vaccine.2009.10.066 [doi]. 653. Hatta, Y., M. Hatta, P. Bilsel, G. Neumann, and Y. Kawaoka. 2011. An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus. Vaccine 29:2308– 2312. doi:S0264-410X(11)00051-X [pii];10.1016/j.vaccine.2011.01.023 [doi]. 654. Haviland, A. M., M. N. Elliott, K. Hambarsoomian, and N. Lurie. 2011. Immunization disparities by Hispanic ethnicity and language preference. Arch.Intern.Med. 171:158–165. doi:171/2/158 [pii];10.1001/archinternmed.2010.499 [doi]. 655. Hayward, A. C. and J. Watson. 2011. Effectiveness of influenza vaccination of staff on morbidity, and mortality of residents of long term care facilities for the elderly. Vaccine 29:2357–2358. doi:S0264- 410X(11)00048-X [pii];10.1016/j.vaccine.2011.01.020 [doi]. 656. He, C., Z. Yang, and K. Tong. 2011. Downstream processing of Vero cell-derived human influenza A virus (H1N1) grown in serum-free medium. J.Chromatogr.A 1218:5279–5285. doi:S0021-9673(11)00858-2 [pii];10.1016/j.chroma.2011.06.043 [doi].

104 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

657. He, X. S., S. Sasaki, C. F. Narvaez, C. Zhang, H. Liu, J. C. Woo, G. W. Kemble, C. L. Dekker, M. M. Davis, and H. B. Greenberg. 2011. Plasmablast-derived polyclonal antibody response after influenza vaccination. J.Immunol.Methods 365:67–75. doi:S0022-1759(10)00373-X [pii];10.1016/j. jim.2010.12.008 [doi]. 658. Hearty, S., P. J. Conroy, B. V. Ayyar, B. Byrne, and R. O’Kennedy. 2010. Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Expert.Rev.Vaccines. 9:645–664. doi:10.1586/erv.10.52 [doi]. 659. Hebert, K., G. Marzouka, L. Arcement, E. Julian, F. Cortazar, A. Dias, and L. Tamariz. 2010. Prevalence of vaccination rates in systolic heart failure: a prospective study of 549 patients by age, race, ethnicity, and sex in a heart failure disease management program. Congest.Heart Fail. 16:278– 283. doi:10.1111/j.1751-7133.2010.00190.x [doi]. 660. Heijmans, S., M. M. De, P. Reynders, D. Giet, E. Demanet, P. Y. Devresse, G. Icardi, M. Drame, F. Roman, and P. Gillard. 2011. Immunogenicity profile of a 3.75-mug hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J.Infect.Dis. 203:1054– 1062. doi:jiq174 [pii];10.1093/infdis/jiq174 [doi]. 661. Heijstek, M. W., L. M. Ott de Bruin, M. Bijl, R. Borrow, F. van der Klis, I. Kone-Paut, A. Fasth, K. Minden, A. Ravelli, M. Abinun, G. S. Pileggi, M. Borte, and N. M. Wulffraat. 2011. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann.Rheum.Dis. 70:1704–1712. doi:ard.2011.150193 [pii];10.1136/ard.2011.150193 [doi]. 662. Heikkinen, T. and S. Heinonen. 2011. Effectiveness and safety of influenza vaccination in children: European perspective. Vaccine 29:7529–7534. doi:S0264-410X(11)01220-5 [pii];10.1016/j. vaccine.2011.08.011 [doi]. 663. Heinonen, S., H. Silvennoinen, P. Lehtinen, R. Vainionpaa, T. Ziegler, and T. Heikkinen. 2011. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect.Dis. 11:23–29. doi:S1473-3099(10)70255-3 [pii];10.1016/S1473- 3099(10)70255-3 [doi]. 664. Helfenberger, S., A. Tschopp, L. Robyn, C. Hatz, and P. Schlagenhauf. 2010. Knowledge, attitudes, and practices of business travelers regarding influenza and the use of antiviral medication. J.Travel. Med. 17:367–373. doi:10.1111/j.1708-8305.2010.00467.x [doi]. 665. Helms, C., J. Leask, S. C. Robbins, M. Y. Chow, and P. McIntyre. 2011. Implementation of mandatory immunisation of healthcare workers: observations from New South Wales, Australia. Vaccine 29:2895–2901. doi:S0264-410X(11)00212-X [pii];10.1016/j.vaccine.2011.02.011 [doi]. 666. Helms, C., P. Polgreen, L. Polgreen, T. Evans, L. L. Roberts, G. Clabaugh, and P. Quinlisk. 2011. Voluntary reporting of employee influenza vaccination rates by acute care hospitals in Iowa: the impact of a four year provider-based statewide performance improvement project. Vaccine 29:3483– 3488. doi:S0264-410X(11)00291-X [pii];10.1016/j.vaccine.2011.02.056 [doi]. 667. Henderson, D. A. 2010. Universal influenza vaccination: an optimal goal – but how and when? Biosecur.Bioterror. 8:219–221. doi:10.1089/bsp.2010.0816 [doi]. 668. Hendriks, J., M. Holleman, B. O. de, J. P. de, and W. Luytjes. 2011. An international technology platform for influenza vaccines. Vaccine 29 Suppl 1:A8–11. doi:S0264-410X(11)00690-6 [pii];10.1016/j.vaccine.2011.04.124 [doi]. 669. Hermann, R., A. Pfeil, M. Busch, C. Kettner, D. Kretzschmar, A. Hansch, R. P. La, and G. Wolf. 2010. [Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination]. Med.Klin.(Munich) 105:663–668. doi:10.1007/s00063-010-1107-6 [doi]. 670. Hernandez-Garcia, I. 2011. [Acceptability of A/H1N1 vaccination among hospitalized patients]. Med. Clin.(Barc.) 136:694–695. doi:S0025-7753(10)00138-7 [pii];10.1016/j.medcli.2009.12.018 [doi].

105 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

671. Hernandez-Garcia, I., A. M. Haro-Perez, R. Gonzalez-Celador, and M. C. Saenz-Gonzalez. 2011. [Adverse events after administration of A/H1N1 vaccine to patients]. Med.Clin.(Barc.) 137:136–137. doi:S0025-7753(10)00100-4 [pii];10.1016/j.medcli.2010.01.004 [doi]. 672. Hernandez-Garcia, I., J. Sanchez-Paya, R. Camargo, J. Barrenengoa, H. Martinez, and A. Gonzalez-Torga. 2010. [Frequency of adverse reactions after influenza vaccination in health care personnel of a university hospital in Spain]. Enferm.Infecc.Microbiol.Clin. 28:435–438. doi:S0213- 005X(10)00073-X [pii];10.1016/j.eimc.2009.11.010 [doi]. 673. Hessel, A., M. Schwendinger, D. Fritz, S. Coulibaly, G. W. Holzer, N. Sabarth, O. Kistner, W. Wodal, A. Kerschbaum, H. Savidis-Dacho, B. A. Crowe, T. R. Kreil, P. N. Barrett, and F. G. Falkner . 2010. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS.One. 5:e12217. doi:10.1371/journal. pone.0012217 [doi]. 674. Hessel, A., M. Schwendinger, G. W. Holzer, K. K. Orlinger, S. Coulibaly, H. Savidis-Dacho, M. L. Zips, B. A. Crowe, T. R. Kreil, H. J. Ehrlich, P. N. Barrett, and F. G. Falkner. 2011. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS.One. 6:e16247. doi:10.1371/journal.pone.0016247 [doi]. 675. Hidiroglu, S., P. Ay, A. Topuzoglu, C. Kalafat, and M. Karavus. 2010. Resistance to vaccination: the attitudes and practices of primary healthcare workers confronting the H1N1 pandemic. Vaccine 28:8120–8124. doi:S0264-410X(10)01446-5 [pii];10.1016/j.vaccine.2010.09.104 [doi]. 676. Hilgendorf, I., M. Freund, W. Jilg, H. Einsele, J. Gea-Banacloche, H. Greinix, J. Halter, A. Lawitschka, D. Wolff, and R. Meisel. 2011. Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. Vaccine 29:2825–2833. doi:S0264-410X(11)00231-3 [pii];10.1016/j.vaccine.2011.02.018 [doi]. 677. Hillaire, M. L., A. D. Osterhaus, and G. F. Rimmelzwaan. 2011. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J.Biomed. Biotechnol. 2011:939860. doi:10.1155/2011/939860 [doi]. 678. Hillaire, M. L., S. E. van Trierum, J. H. Kreijtz, R. Bodewes, M. M. Geelhoed-Mieras, N. J. Nieuwkoop, R. A. Fouchier, T. Kuiken, A. D. Osterhaus, and G. F. Rimmelzwaan. 2011. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J.Gen.Virol. 92:2339–2349. doi:vir.0.033076-0 [pii];10.1099/vir.0.033076-0 [doi]. 679. Hilton, S. and E. Smith. 2010. Public views of the UK media and government reaction to the . BMC.Public Health 10:697. doi:1471-2458-10-697 [pii];10.1186/1471-2458- 10-697 [doi]. 680. Hinshaw, D. and A. U. Chandran. 2011. Evaluation of a geriatric inpatient influenza immunization program. Am.J.Infect.Control 39:342–344. doi:S0196-6553(11)00107-6 [pii];10.1016/j. ajic.2010.12.006 [doi]. 681. Hirsch, P., M. Hodgson, and V. Davey. 2011. Seasonal influenza vaccination of healthcare employees: results of a 4-year campaign. Infect.Control Hosp.Epidemiol. 32:444–448. doi:10.1086/659764 [doi]. 682. Ho, J., S. Moir, W. Wang, J. G. Posada, W. Gu, M. T. Rehman, R. Dewar, C. Kovacs, M. C. Sneller, T. W. Chun, D. A. Follmann, and A. S. Fauci. 2011. Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS 25:295– 302. doi:10.1097/QAD.0b013e328342328b [doi]. 683. Ho, T. S., S. M. Wang, and C. C. Liu. 2010. Historical review of pandemic influenza A in Taiwan, 2009. Pediatr.Neonatol. 51:83–88. doi:S1875-9572(10)60016-2 [pii];10.1016/S1875- 9572(10)60016-2 [doi].

106 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

684. Hoa, L. K., L. V. Hiep, and L. V. Be. 2011. Development of pandemic influenza vaccine production capacity in Viet Nam. Vaccine 29 Suppl 1:A34–A36. doi:S0264-410X(11)00684-0 [pii];10.1016/j. vaccine.2011.04.118 [doi]. 685. Hoen, A. G., D. L. Buckeridge, K. M. Charland, K. D. Mandl, C. Quach, and J. S. Brownstein. 2011. Effect of expanded US recommendations for seasonal influenza vaccination: comparison of two pediatric emergency departments in the United States and Canada. CMAJ. 183:E1025–E1032. doi:cmaj.110241 [pii];10.1503/cmaj.110241 [doi]. 686. Hoffman, D. E. 2011. Going viral: the Pentagon takes on a new enemy: swine flu. New Yorker.26–32. 687. Hoft, D. F., E. Babusis, S. Worku, C. T. Spencer, K. Lottenbach, S. M. Truscott, G. Abate, I. G. Sakala, K. M. Edwards, C. B. Creech, M. A. Gerber, D. I. Bernstein, F. Newman, I. Graham, E. L. Anderson, and R. B. Belshe. 2011. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J.Infect.Dis. 204:845–853. doi:jir436 [pii];10.1093/infdis/jir436 [doi]. 688. Hojsak, I., Y. Avitzur, E. Mor, R. Shamir, Y. Haimi-Cohen, Z. Zakay-Rones, D. Wolf, and R. Shapiro. 2011. Antibody response to influenza vaccine in pediatric liver transplant recipients. Pediatr.Infect. Dis.J. 30:491–494. doi:10.1097/INF.0b013e31820b7c22 [doi]. 689. Holvast, A., H. A. de, A. S. van, C. A. Stegeman, M. G. Huitema, A. Huckriede, C. A. Benne, J. Westra, A. Palache, J. Wilschut, C. G. Kallenberg, and M. Bijl. 2010. Cell-mediated immune responses to influenza vaccination in Wegener’s granulomatosis. Ann.Rheum.Dis. 69:924–927. doi:ard.2009.112813 [pii];10.1136/ard.2009.112813 [doi]. 690. Hong, D. K., S. Chang, C. M. Botham, T. D. Giffon, J. Fairman, and D. B. Lewis. 2010. Cationic lipid/ DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J.Virol. 84:12691–12702. doi:JVI.00769-10 [pii];10.1128/JVI.00769-10 [doi]. 691. Hong, S. H., Y. H. Byun, C. T. Nguyen, S. Y. Kim, B. L. Seong, S. Park, G. J. Woo, Y. Yoon, J. T. Koh, K. Fujihashi, J. H. Rhee, and S. E. Lee. 2011. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine. doi:S0264-410X(11)01695-1 [pii];10.1016/j.vaccine.2011.10.058 [doi]. 692. Hopman, C. E., J. Riphagen-Dalhuisen, I. Looijmans-van den Akker, G. Frijstein, Van der Geest- Blankert AD, M. B. Danhof-Pont, H. J. De Jager, A. A. Bos, E. Smeets, M. J. De Vries, P. M. Gallee, A. F. Lenderink, and E. Hak. 2011. Determination of factors required to increase uptake of influenza vaccination among hospital-based healthcare workers. J.Hosp.Infect. 77:327–331. doi:S0195-6701(10)00463-9 [pii];10.1016/j.jhin.2010.10.009 [doi]. 693. Hoppe, K. K. and L. O. Eckert. 2011. Achieving high coverage of H1N1 influenza vaccine in an ethnically diverse obstetric population: success of a multifaceted approach. Infect.Dis.Obstet.Gynecol. 2011:746214. doi:10.1155/2011/746214 [doi]. 694. Horney, J. A., Z. Moore, M. Davis, and P. D. MacDonald. 2010. Intent to receive pandemic influenza A (H1N1) vaccine, compliance with and sources of information in NC, 2009. PLoS. One. 5:e11226. doi:10.1371/journal.pone.0011226 [doi]. 695. Horster, S., R. P. Laubender, L. Lehmeyer, D. P. Ankerst, J. Eberle, R. Reinert, M. Imohl, M. van der Linden, B. Schweiger, and J. R. Bogner. 2010. Influence of antiretroviral therapy on immunogenicity of simultaneous vaccinations against influenza, pneumococcal disease and hepatitis A and B in human immunodeficiency virus positive individuals. J.Infect. 61:484–491. doi:S0163-4453(10)00292-6 [pii];10.1016/j.jinf.2010.09.030 [doi]. 696. Howe, L. E., A. S. Conlon, M. J. Greenhawt, and G. M. Sanders. 2011. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. Ann.Allergy Asthma Immunol. 106:446–447. doi:S1081-1206(11)00087-1 [pii];10.1016/j.anai.2011.01.024 [doi].

107 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

697. Hu, A. Y., Y. F. Tseng, T. C. Weng, C. C. Liao, J. Wu, A. H. Chou, H. J. Chao, A. Gu, J. Chen, S. C. Lin, C. H. Hsiao, S. C. Wu, and P. Chong. 2011. Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS.One. 6 :e14578. doi:10.1371/journal.pone.0014578 [doi]. 698. Hu, X., W. Meng, Z. Dong, W. Pan, C. Sun, and L. Chen. 2011. Comparative immunogenicity of recombinant adenovirus-vectored vaccines expressing different forms of hemagglutinin (HA) proteins from the H5 serotype of influenza A viruses in mice. Virus Res. 155:156–162. doi:S0168-1702(10)00350-3 [pii];10.1016/j.virusres.2010.09.014 [doi]. 699. Huang, B. Y., L. Ruan, and W. L. Wang. 2011. [Research and development of M2- and M2e-based broad-spectrum influenza A vaccines]. Bing.Du Xue.Bao. 27:176–183. 700. Huang, B. Y., X. P. Wang, W. J. Tang, W. L. Wang, and L. Ruan. 2011. [The 50% effective dose (ED50a) of seasonal spilt influenza vaccine in mice]. Zhonghua Shi Yan.He.Lin.Chuang.Bing.Du Xue. Za Zhi. 25:92–95. 701. Huang, D. T., P. L. Shao, K. C. Huang, C. Y. Lu, J. R. Wang, S. R. Shih, H. Chi, M. R. Lai, C. Y. Lee, L. Y. Chang, and L. M. Huang. 2011. Serologic status for pandemic (H1N1) 2009 virus, Taiwan. Emerg. Infect.Dis. 17:76–78. doi:10.3201/eid1701.100014 [doi]. 702. Huang, M. H., S. C. Lin, C. H. Hsiao, H. J. Chao, H. R. Yang, C. C. Liao, P. W. Chuang, H. P. Wu, C. Y. Huang, C. H. Leng, S. J. Liu, H. W. Chen, A. H. Chou, A. Y. Hu, and P. Chong. 2010. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS.One. 5:e12279. doi:10.1371/journal. pone.0012279 [doi]. 703. Huang, W. T., C. C. Hsu, P. I. Lee, and J. H. Chuang. 2010. Mass psychogenic illness in nationwide in-school vaccination for pandemic influenza A(H1N1) 2009, Taiwan, November 2009–January 2010. Euro.Surveill 15:19575. 704. Huang, W. T., J. H. Chuang, and S. H. Kuo. 2010. Monitoring the safety of pandemic H1N1 vaccine. Lancet 375:1164. doi:S0140-6736(10)60515-6 [pii];10.1016/S0140-6736(10)60515-6 [doi]. 705. Huang, W. T., W. W. Chen, H. W. Yang, W. C. Chen, Y. N. Chao, Y. W. Huang, J. H. Chuang, and H. S. Kuo. 2010. Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan. Vaccine 28:7161–7166. doi:S0264-410X(10)01238-7 [pii];10.1016/j.vaccine.2010.08.069 [doi]. 706. Hubble, M. W., T. L. Zontek, and M. E. Richards. 2011. Predictors of influenza vaccination among emergency medical services personnel. Prehosp.Emerg.Care 15:175–183. doi:10.3109/10903127.2 010.541982 [doi]. 707. Huber, V. C., V. Peltola, A. R. Iverson, and J. A. McCullers. 2010. Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J.Virol. 84:4105–4108. doi:JVI.02621-09 [pii];10.1128/JVI.02621-09 [doi]. 708. Hughes, R., J. P. Lacour, B. Baldin, M. Reverte, J. P. Ortonne, and T. Passeron. 2010. Urticarial vasculitis secondary to H1N1 vaccination. Acta Derm.Venereol. 90:651–652. doi:10.2340/00015555-0950 [doi]. 709. Hull, B., A. Dey, S. Campbell-Lloyd, R. I. Menzies, and P. B. McIntyre. 2011. NSW Annual Immunisation Coverage Report, 2010. N.S.W.Public Health Bull. 22:179–195. doi:NB11021 [pii];10.1071/NB11021 [doi]. 710. Hull, H. F. and C. S. Ambrose. 2011. Current experience with school-located influenza vaccination programs in the United States: a review of the medical literature. Hum.Vaccin. 7:153–160. doi:13668 [pii]. 711. Hull, H. F. and C. S. Ambrose. 2011. The impact of school-located influenza vaccination programs on student absenteeism: a review of the U.S. literature. J.Sch Nurs. 27 :34–42. doi:1059840510389182 [pii];10.1177/1059840510389182 [doi].

108 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

712. Hull, H. F. and H. O’Connor. 2010. Optimizing protection against influenza in children eligible for the vaccine for children program. Pediatr.Infect.Dis.J. 29:910–914. doi:10.1097/INF.0b013e3181e05579 [doi]. 713. Humiston, S. G., N. M. Bennett, C. Long, S. Eberly, L. Arvelo, J. Stankaitis, and P. G. Szilagyi. 2011. Increasing inner-city adult influenza vaccination rates: a randomized controlled trial. Public Health Rep. 126 Suppl 2:39–47. 714. Hung, I. F., A. Y. Leung, D. W. Chu, D. Leung, T. Cheung, C. K. Chan, C. L. Lam, S. H. Liu, C. M. Chu, P. L. Ho, S. Chan, T. H. Lam, R. Liang, and K. Y. Yuen. 2010. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin.Infect.Dis. 51:1007–1016. doi:10.1086/656587 [doi]. 715. Hurst, F. P., J. J. Lee, R. M. Jindal, L. Y. Agodoa, and K. C. Abbott. 2011. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin.J.Am.Soc.Nephrol. 6:1192– 1197. doi:CJN.05430610 [pii];10.2215/CJN.05430610 [doi]. 716. Hussain, A. I., M. Cordeiro, E. Sevilla, and J. Liu. 2010. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 28:3848–3855. doi:S0264-410X(10)00341-5 [pii];10.1016/j.vaccine.2010.03.005 [doi]. 717. Hwang, S. M., K. W. Choe, S. H. Cho, S. J. Yoon, D. E. Park, J. S. Kang, M. J. Kim, B. C. Chun, and S. M. Lee. 2011. The adverse events of influenza A (H1N1) vaccination and its risk factors in healthcare personnel in 18 military healthcare units in Korea. Jpn.J.Infect.Dis. 64:183–189. 718. Iannazzo, S. 2011. Pharmacoeconomic evaluation of the MF59 – adjuvanted influenza vaccine in the elderly population in Italy. J.Prev.Med.Hyg. 52:1–8. 719. Ichihashi, T., R. Yoshida, C. Sugimoto, A. Takada, and K. Kajino. 2011. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS.One. 6:e24626. doi:10.1371/journal.pone.0024626 [doi];PONE-D-11-09066 [pii]. 720. Ichinohe, T. 2010. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design. Expert.Rev.Vaccines. 9:1315–1324. doi:10.1586/erv.10.118 [doi]. 721. Ichinohe, T., A. Ainai, Y. Ami, N. Nagata, N. Iwata, A. Kawaguchi, Y. Suzaki, T. Odagiri, M. Tashiro, H. Takahashi, D. R. Strayer, W. A. Carter, J. Chiba, S. Tamura, T. Sata, T. Kurata, and H. Hasegawa. 2010. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J.Med.Virol. 82:1754–1761. doi:10.1002/jmv.21824 [doi]. 722. Igari, H., A. Watanabe, H. Chiba, K. Shoji, S. Segawa, Y. Nakamura, M. Watanabe, K. Suzuki, and T. Sato. 2011. Effectiveness and safety of pandemic influenza A (H1N1) 2009 vaccine in healthcare workers at a university hospital in Japan. Jpn.J.Infect.Dis. 64:177–182. 723. Igari, H., S. Segawa, A. Watanabe, A. Suzuki, M. Watanabe, T. Sakurai, F. Kuroda, M. Watanabe, K. Tatsumi, M. Nakayama, T. Nakayama, K. Suzuki, and T. Sato. 2010. Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health-care workers of a university hospital in Japan. Microbiol.Immunol. 54:618–624. doi:10.1111/j.1348-0421.2010.00254.x [doi]. 724. Ignat’eva, A. V., I. A. Rudneva, T. A. Timofeeva, A. A. Shilov, A. D. Zaberezhnyi, T. I. Aliper, N. V. Kaverin, and D. K. L’vov. 2011. [High-yield reassortant virus containing hemagglutinin and neuraminidase genes of pandemic influenza A/Moscowl/01/2009 (H1N1) virus]. Vopr.Virusol. 56:9–14. 725. Ihara, T. 2010. [Evaluation of alum-adjuvanted whole virus influenza vaccine and future aspects of influenza A (H1N1) 2009 vaccine]. Uirusu 60:69–78.

109 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

726. Ihara, T. 2010. [Influenza vaccination: recommendations and remarks]. Nihon Rinsho 68:1690–1694. 727. Ikematsu, H., H. Nagai, M. Kawashima, Y. Kawakami, K. Tenjinbaru, A. Maeda, P. Li, P. Gillard, and F. Roman. 2010. Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum.Vaccin. 6:888–893. doi:12851 [pii]. 728. Ikeno, D., K. Kimachi, K. Ibaragi, Y. Kudo, S. Goto, K. Odoh, S. Itamura, T. Odagiri, M. Tashiro, and Y. Kino. 2011. Differences in the priming effect of various clades/subclades of inactivated H5N1 vaccine for booster injection with heterologous clades of vaccine strains. Vaccine 29:4156–4161. doi:S0264- 410X(11)00466-X [pii];10.1016/j.vaccine.2011.03.084 [doi]. 729. Ikeno, D., K. Kimachi, Y. Kino, S. Harada, K. Yoshida, S. Tochihara, S. Itamura, T. Odagiri, M. Tashiro, K. Okada, C. Miyazaki, and K. Ueda. 2010. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol.Immunol. 54:81–88. doi:MIM191 [pii];10.1111/j.1348-0421.2009.00191.x [doi]. 730. Imamura, T. and H. Oshitani. 2011. Mucosal immunity against influenza induced by attenuated recombinant Sendai virus. Expert.Rev.Vaccines. 10:1393–1395. doi:10.1586/erv.11.123 [doi]. 731. Imamura, T., R. Sakamoto, T. Sasaki, N. Kokumai, T. Ohgitani, A. Sawata, Z. Lin, and M. Sakaguchi. 2010. Safety test and field study of an inactivated oil-adjuvanted H5N1 avian influenza vaccine. J.Vet. Med.Sci. 72:1455–1463. doi:JST.JSTAGE/jvms/10-0091 [pii]. 732. Iorio, A., M. Basileo, M. Marcucci, F. Guercini, B. Camilloni, E. Paccamiccio, M. Vecchioli, and A. M. Iorio. 2010. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. Arch.Intern.Med. 170:609–616. doi:170/7/609 [pii];10.1001/archinternmed.2010.49 [doi]. 733. Isakova-Sivak, I., L. M. Chen, Y. Matsuoka, J. T. Voeten, I. Kiseleva, J. G. Heldens, B. H. den, A. Klimov, L. Rudenko, N. J. Cox, and R. O. Donis. 2011. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology 412:297–305. doi:S0042-6822(11)00009-2 [pii];10.1016/j.virol.2011.01.004 [doi]. 734. Issa, N. C., F. M. Marty, L. S. Gagne, S. Koo, K. A. Verrill, E. P. Alyea, C. S. Cutler, J. Koreth, P. Armand, V. T. Ho, J. H. Antin, R. J. Soiffer, and L. R. Baden. 2011. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol.Blood Marrow Transplant. 17:434–438. doi:S1083-8791(10)00436-2 [pii];10.1016/j. bbmt.2010.10.002 [doi]. 735. Itoh, Y., H. Ozaki, H. Ishigaki, Y. Sakoda, T. Nagata, K. Soda, N. Isoda, T. Miyake, H. Ishida, K. Okamoto, M. Nakayama, H. Tsuchiya, R. Torii, H. Kida, and K. Ogasawara. 2010. Subcutaneous inoculation of a whole virus particle vaccine prepared from a non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic avian influenza virus in cynomolgus macaques. Vaccine 28:780–789. doi:S0264-410X(09)01597-7 [pii];10.1016/j.vaccine.2009.10.067 [doi]. 736. Jackson, L. A., M. J. Gaglani, H. L. Keyserling, J. Balser, N. Bouveret, L. Fries, and J. J. Treanor. 2010. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC.Infect.Dis. 10:71. doi:1471- 2334-10-71 [pii];10.1186/1471-2334-10-71 [doi]. 737. Jackson, L. A., S. M. Patel, G. K. Swamy, S. E. Frey, C. B. Creech, F. M. Munoz, R. Artal, W. A. Keitel, D. L. Noah, C. R. Petrie, M. Wolff, and K. M. Edwards. 2011. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J.Infect.Dis. 204:854–863. doi:jir440 [pii];10.1093/infdis/jir440 [doi]. 738. Jacquet, A., S. Ouaret, C. Kreft-Jais, and A. Castot. 2010. [Post-licensure safety surveillance for influenza A(H1N1) pandemic vaccines: first results]. Rev.Prat. 60:1392–1394.

110 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

739. Jalilian, B., A. R. Omar, M. H. Bejo, N. B. Alitheen, M. Rasoli, and S. Matsumoto. 2010. Development of avian influenza virus H5 DNA vaccine and MDP-1 gene of Mycobacterium bovis as genetic adjuvant. Genet.Vaccines.Ther. 8:4. doi:1479-0556-8-4 [pii];10.1186/1479-0556-8-4 [doi]. 740. Jamali, A., F. Sabahi, T. Bamdad, H. Hashemi, F. Mahboudi, and M. T. Kheiri. 2010. A DNA vaccine- encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model. Clin.Vaccine Immunol. 17:683–687. doi:CVI.00445-09 [pii];10.1128/CVI.00445-09 [doi]. 741. Janjua, N. Z., D. M. Skowronski, T. S. Hottes, S. G. De, N. S. Crowcroft, and L. C. Rosella. 2010. Seasonal vaccine effectiveness against pandemic A/H1N1. Lancet 375:801–802. doi:S0140-6736(10)60338-8 [pii];10.1016/S0140-6736(10)60338-8 [doi]. 742. Janjua, N. Z., D. M. Skowronski, T. S. Hottes, W. Osei, E. Adams, M. Petric, S. Sabaiduc, T. Chan, A. Mak, M. Lem, P. Tang, D. M. Patrick, S. G. De, and D. Bowering. 2010. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clin.Infect.Dis. 51:1017–1027. doi:10.1086/656586 [doi]. 743. Javelle, E., B. Soulier, C. Brosset, S. Lorcy, and F. Simon. 2011. Delayed focal lipoatrophy after AS03- adjuvanted influenza A (H1N1) 2009 vaccine. Vaccine 29:1123–1125. doi:S0264-410X(10)01756-1 [pii];10.1016/j.vaccine.2010.12.018 [doi]. 744. Jefferies, S., D. Earl, N. Berry, T. Blackmore, S. Rooker, N. Raymond, A. Pritchard, M. Weatherall, R. Beasley, and K. Perrin. 2011. Effectiveness of the 2009 seasonal influenza vaccine against pandemic influenza A(H1N1)2009 in healthcare workers in New Zealand, June–August 2009. Euro.Surveill 16. 745. Jefferson, T., P. C. Di, A. Rivetti, G. A. Bawazeer, L. A. Al-Ansary, and E. Ferroni. 2010. Vaccines for preventing influenza in healthy adults. Cochrane.Database.Syst.Rev.CD001269. doi:10.1002/14651858.CD001269.pub4 [doi]. 746. Jefferson, T., P. C. Di, L. A. Al-Ansary, E. Ferroni, S. Thorning, and R. E. Thomas. 2010. Vaccines for preventing influenza in the elderly. Cochrane.Database.Syst.Rev.CD004876. doi:10.1002/14651858. CD004876.pub3 [doi]. 747. Jenlink, C. H., P. Kuehnert, and D. Mazyck. 2010. Key components of a school-located vaccination clinic: lessons learned from fall 2009. J.Sch Nurs. 26:14S–26S. doi:1059840510372345 [pii];10.1177/1059840510372345 [doi]. 748. Jennings, L. C. 2011. We should give the influenza vaccine to elderly patients in rest homes who are suffering from severe dementia: Yes. J.Prim.Health Care 3:58–59. 749. Ji, W. Y., L. Lu, M. Lu, L. Miao, T. Gao, R. G. Huang, L. D. Suo, D. L. Liu, R. Ma, R. Yu, J. Z. Zhangzhu, W. X. Liu, Y. Zeng, X. M. Li, and J. Wu. 2010. [Safety and epidemiological effects of the first China-made mass A (H1N1) influenza vaccination.]. Zhonghua Liu Xing.Bing.Xue.Za Zhi. 31:481–484. 750. Jick, H. and K. W. Hagberg. 2010. Effectiveness of influenza vaccination in the United kingdom, 1996–2007. Pharmacotherapy 30:1199–1206. doi:10.1592/phco.30.12.1199 [doi];10.1592/ phco.30.12.1199 [pii]. 751. Jick, H., D. P. Chamberlin, and K. W. Hagberg. 2010. Vaccine policy and incidence of influenza. Epidemiology 21:270–271. doi:10.1097/EDE.0b013e3181cc95f8 [doi];00001648-201003000- 00018 [pii]. 752. Jimenez-Garcia, R., C. Rodriguez-Rieiro, V. Hernandez-Barrera, A. A. Lopez de, C. A. Rivero, L. A. Rodriguez, and P. Carrasco-Garrido. 2011. Effectiveness of age-based strategies to increase influenza vaccination coverage among high risk subjects in Madrid (Spain). Vaccine 29:2840–2845. doi:S0264-410X(11)00205-2 [pii];10.1016/j.vaccine.2011.02.004 [doi].

111 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

753. Jimenez-Garcia, R., V. Hernandez-Barrera, A. L. de Andres, I. Jimenez-Trujillo, J. Esteban-Hernandez, and P. Carrasco-Garrido. 2010. Gender influence in influenza vaccine uptake in Spain: time trends analysis (1995–2006). Vaccine 28:6169–6175. doi:S0264-410X(10)01024-8 [pii];10.1016/j. vaccine.2010.07.029 [doi]. 754. Jimenez-Garcia, R., V. Hernandez-Barrera, A. L. de Andres, I. Jimenez-Trujillo, J. Esteban, A. Gil, and P. Carrasco-Garrido. 2010. Predictors of influenza vaccination uptake among adults with a history of heart attack. Hum.Vaccin. 6:566–571. doi:11884 [pii]. 755. Jimenez-Garcia, R., V. Hernandez-Barrera, P. Carrasco-Garrido, A. L. de Andres, D. J. de Miguel, and A. G. de Miguel. 2010. Coverage and predictors of adherence to influenza vaccination among Spanish children and adults with asthma. Infection 38:52–57. doi:10.1007/s15010-009-9069-4 [doi]. 756. Jit, M., D. Cromer, M. Baguelin, J. Stowe, N. Andrews, and E. Miller. 2010. The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine 29:115–122. doi:S0264-410X(10)01248-X [pii];10.1016/j.vaccine.2010.08.078 [doi]. a. Johns, M. C., A. A. Eick, D. L. Blazes, S. E. Lee, C. L. Perdue, R. Lipnick, K. G. Vest, K. L. Russell, R. F. DeFraites, and J. L. Sanchez. 2010. Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel. PLoS.One. 5:e10722. doi:10.1371/ journal.pone.0010722 [doi]. 757. Johnson, J. G. and T. R. Talbot. 2011. New approaches for influenza vaccination of healthcare workers. Curr.Opin.Infect.Dis. 24:363–369. doi:10.1097/QCO.0b013e328347b0e7 [doi]. 758. Johnson, P. V., B. M. Blair, S. Zeller, C. N. Kotton, and E. L. Hohmann. 2011. Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers. Microbiol.Immunol. 55:304–317. doi:10.1111/j.1348-0421.2011.00322.x [doi]. 759. Jones, F. R., E. S. Gabitzsch, Y. Xu, J. P. Balint, V. Borisevich, J. Smith, J. Smith, B. H. Peng, A. Walker, M. Salazar, and S. Paessler. 2011. Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29:7020–7026. doi:S0264-410X(11)01119-4 [pii];10.1016/j.vaccine.2011.07.073 [doi]. 760. Jones, J. C., E. W. Settles, C. R. Brandt, and S. Schultz-Cherry. 2011. Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine. Vaccine 29:7696–7703. doi:S0264- 410X(11)01202-3 [pii];10.1016/j.vaccine.2011.07.133 [doi]. 761. Jones, T. F., M. McMillian, E. Boothe, S. Hanna, and L. A. Ingram. 2010. Hospital discharge data for Guillain-Barre syndrome and influenza A (H1N1) vaccine adverse events. Emerg.Infect.Dis. 16:1500– 1501. doi:10.3201/eid1609.091837 [doi]. 762. Joshi, A. Y., R. S. Abraham, M. R. Snyder, and T. G. Boyce. 2011. Immune evaluation and vaccine responses in Down syndrome: evidence of immunodeficiency? Vaccine 29:5040–5046. doi:S0264- 410X(11)00605-0 [pii];10.1016/j.vaccine.2011.04.060 [doi]. 763. Judge, E. P., M. M. Hannan, J. F. McCarthy, and J. J. Egan. 2011. Delayed diagnosis of novel H1N1 influenza pneumonitis in a vaccinated heart transplant recipient. J.Heart Lung Transplant. 30:357– 358. doi:S1053-2498(10)00679-0 [pii];10.1016/j.healun.2010.10.010 [doi]. 764. Jung, E. J., K. H. Lee, and B. L. Seong. 2010. Reverse genetic platform for inactivated and live- attenuated influenza vaccine. Exp.Mol.Med. 42:116–121. doi:10.3858/emm.2010.42.2.013 [doi]. 765. Kaboli, F., G. Astrakianakis, G. Li, J. Guzman, T. Donovan, and M. Naus. 2010. Influenza vaccination and intention to receive the pandemic H1N1 influenza vaccine among healthcare workers of British Columbia, Canada: a cross-sectional study. Infect.Control Hosp.Epidemiol. 31:1017–1024. doi:10.1086/655465 [doi].

112 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

766. Kaczmarek, M., R. Owen, and I. G. Barr. 2010. Annual report of the National Influenza Surveillance Scheme, 2008. Commun.Dis.Intell. 34:8–22. 767. Kajaste-Rudnitski, A., L. Galli, S. Nozza, G. Tambussi, P. A. Di, G. Pellicciotta, A. Monti, P. Mascagni, M. Moro, and E. Vicenzi. 2011. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 25:177–183. doi:10.1097/ QAD.0b013e328341afa8 [doi]. 768. Kanemitsu, Y., H. Kita, Y. Fuseya, K. Tanimura, Y. Katayama, W. Chiba, and M. Suga. 2010. [Interstitial pneumonitis caused by seasonal influenza vaccine]. Nihon Kokyuki.Gakkai Zasshi 48:739–742. 769. Kang, S. M., D. G. Yoo, M. C. Kim, J. M. Song, M. K. Park, O E, F. S. Quan, S. Akira, and R. W. Compans. 2011. MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J.Virol. 85 :11391–11400. doi:JVI.00080-11 [pii];10.1128/ JVI.00080-11 [doi]. 770. Kang, S. M., J. M. Song, and R. W. Compans. 2011. Novel vaccines against influenza viruses. Virus Res. doi:S0168-1702(11)00390-X [pii];10.1016/j.virusres.2011.09.037 [doi]. 771. Kao, T. M., S. M. Hsieh, H. C. Kung, Y. C. Lee, K. C. Huang, L. M. Huang, F. Y. Chang, N. C. Wang, Y. C. Liu, W. S. Lee, H. E. Liu, C. I. Chen, and C. H. Chen. 2010. Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine 28:6159– 6163. doi:S0264-410X(10)01021-2 [pii];10.1016/j.vaccine.2010.07.026 [doi]. 772. Kappes, M. A., M. R. Sandbulte, R. Platt, C. Wang, K. M. Lager, J. N. Henningson, A. Lorusso, A. L. Vincent, C. L. Loving, J. A. Roth, and M. E. Kehrli, Jr. 2011. Vaccination with NS1-truncated H3N2 swine influenza virus primes T cells and confers cross-protection against an H1N1 heterosubtypic challenge in pigs. Vaccine. doi:S0264-410X(11)01748-8 [pii];10.1016/j.vaccine.2011.10.098 [doi]. 773. Kash, J. C., L. Qi, V. G. Dugan, B. W. Jagger, R. J. Hrabal, M. J. Memoli, D. M. Morens, and J. K. Taubenberger. 2010. Prior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus. Influenza.Other Respi.Viruses. 4:121–127. doi:IRV132 [pii];10.1111/j.1750-2659.2010.00132.x [doi]. 774. Kassianos, G. 2010. Vaccination for tomorrow: the need to improve immunisation rates. J.Fam.Health Care 20:13–16. 775. Katayose, M., M. Hosoya, T. Haneda, H. Yamaguchi, Y. Kawasaki, M. Sato, and P. F. Wright. 2011. The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. Vaccine 29:1844–1849. doi:S0264-410X(10)01822-0 [pii];10.1016/j.vaccine.2010.12.049 [doi]. 776. Katerinis, I., K. Hadaya, R. Duquesnoy, S. Ferrari-Lacraz, S. Meier, D. C. van, P. Y. Martin, C. A. Siegrist, and J. Villard. 2011. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am.J.Transplant. 11:1727–1733. doi:10.1111/j.1600- 6143.2011.03604.x [doi]. 777. Kaufmann, A. M., R. Schmidt-Ott, and A. Prechtl. 2011. [Novel adjuvants in vaccine development]. MMW.Fortschr.Med. 152 Suppl 4:115–118. 778. Kaur, K., M. Sullivan, and P. C. Wilson. 2011. Targeting B cell responses in universal influenza vaccine design. Trends Immunol. 32:524–531. doi:S1471-4906(11)00148-7 [pii];10.1016/j.it.2011.08.007 [doi]. 779. Kawabuchi, K. 2011. Crisis of novel infectious diseases: why don’t Japan have enough vaccines? Jpn. Hosp.53–59. 780. Kawai, S., S. Nanri, E. Ban, M. Inokuchi, T. Tanaka, M. Tokumura, K. Kimura, and N. Sugaya. 2011. Influenza vaccination of schoolchildren and influenza outbreaks in a school. Clin.Infect.Dis. 53:130– 136. doi:cir336 [pii];10.1093/cid/cir336 [doi].

113 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

781. Kawakami, K., Y. Ohkusa, R. Kuroki, T. Tanaka, K. Koyama, Y. Harada, K. Iwanaga, T. Yamaryo, and K. Oishi. 2010. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28:7063–7069. doi:S0264-410X(10)01119-9 [pii];10.1016/j.vaccine.2010.08.010 [doi]. 782. Kayamuro, H., Y. Yoshioka, Y. Abe, H. Kamada, S. Tsunoda, and Y. Tsutsumi. 2010. [Application of bioactive mutant TNF alpha to a mucosal vaccine adjuvant]. Yakugaku Zasshi 130:55–61. doi:JST. JSTAGE/yakushi/130.55 [pii]. 783. Kayamuro, H., Y. Yoshioka, Y. Abe, S. Arita, K. Katayama, T. Nomura, T. Yoshikawa, R. Kubota- Koketsu, K. Ikuta, S. Okamoto, Y. Mori, J. Kunisawa, H. Kiyono, N. Itoh, K. Nagano, H. Kamada, Y. Tsutsumi, and S. Tsunoda. 2010. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J.Virol. 84:12703–12712. doi:JVI.01182-10 [pii];10.1128/JVI.01182-10 [doi]. 784. Keeling, M. J. and P. J. White. 2011. Targeting vaccination against novel infections: risk, age and spatial structure for pandemic influenza in Great Britain. J.R.Soc.Interface 8:661–670. doi:rsif.2010.0474 [pii];10.1098/rsif.2010.0474 [doi]. 785. Keeton, V. F. and A. K. Chen. 2010. Immunization updates and challenges. Curr.Opin.Pediatr. 22:234–240. doi:10.1097/MOP.0b013e328337685b [doi]. 786. Keitel, W., N. Groth, M. Lattanzi, M. Praus, A. K. Hilbert, A. Borkowski, and T. F. Tsai. 2010. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28:840–848. doi:S0264-410X(09)01534-5 [pii];10.1016/j. vaccine.2009.10.019 [doi]. 787. Kelen, K., D. Ferenczi, I. Jankovics, M. Varga, M. Z. Molnar, P. Sallay, G. Reusz, R. M. Langer, K. Pasti, Z. Gerlei, and A. J. Szabo. 2011. H1N1 vaccination in pediatric renal transplant patients. Transplant.Proc. 43:1244–1246. doi:S0041-1345(11)00587-2 [pii];10.1016/j. transproceed.2011.03.072 [doi]. 788. Kelley, N. S., M. T. Osterholm, and E. A. Belongia. 2011. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N.Engl.J.Med. 364:1181–1182. doi:10.1056/NEJMc1100442#SA1 [doi]. 789. Kelly, H. A., D. M. Skowronski, S. G. De, and P. V. Effler. 2011. Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Med.J.Aust. 195:318–320. doi:kel10941_fm [pii]. 790. Kelly, H. and M. Valenciano. 2011. Estimating the effect of influenza vaccines. Lancet Infect.Dis. doi:S1473-3099(11)70289-4 [pii];10.1016/S1473-3099(11)70289-4 [doi]. 791. Kelly, H., D. Carcione, G. Dowse, and P. Effler. 2010. Quantifying benefits and risks of vaccinating Australian children aged six months to four years with trivalent inactivated seasonal influenza vaccine in 2010. Euro.Surveill 15. 792. Kelly, H., P. Jacoby, G. A. Dixon, D. Carcione, S. Williams, H. C. Moore, D. W. Smith, A. D. Keil, B. P. Van, and P. C. Richmond. 2011. Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children: A Case-Control Study. Pediatr.Infect.Dis.J. 30:107–111. doi:10.1097/ INF.0b013e318201811c [doi]. 793. Kelly, H., S. Barry, K. Laurie, and G. Mercer. 2010. Seasonal influenza vaccination and the risk of infection with pandemic influenza: a possible illustration of non-specific temporary immunity following infection. Euro.Surveill 15. 794. Kelso, J. M. 2010. Administration of influenza vaccines to patients with egg allergy: Update for the 2010–2011 season. J.Allergy Clin.Immunol. 126:1302–1304. doi:S0091-6749(10)01582-4 [pii];10.1016/j.jaci.2010.10.015 [doi]. 795. Kendal, A. P. and N. E. MacDonald. 2010. Influenza pandemic planning and performance in Canada, 2009. Can.J.Public Health 101:447–453.

114 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

796. Kendall, P. R. 2011. The 2009 Provincial decision to de-emphasize seasonal influenza vaccine in Canada: real-time risk-benefit analysis. Clin.Infect.Dis. 52:829–830. doi:cir037 [pii];10.1093/cid/ cir037 [doi]. 797. Kent, J. N., C. S. Lea, X. Fang, L. F. Novick, and J. Morgan. 2010. Seasonal influenza vaccination coverage among local health department personnel in North Carolina, 2007–2008. Am.J.Prev.Med. 39:74–77. doi:S0749-3797(10)00256-4 [pii];10.1016/j.amepre.2010.03.007 [doi]. 798. Keynan, Y., C. M. Card, B. T. Ball, Y. Li, F. A. Plummer, and K. R. Fowke. 2010. Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains. Clin.Microbiol.Infect. 16:1179–1186. doi:CLM3142 [pii];10.1111/j.1469- 0691.2010.03142.x [doi]. 799. Khan, K., Z. A. Memish, A. Chabbra, J. Liauw, W. Hu, D. A. Janes, J. Sears, J. Arino, M. Macdonald, F. Calderon, P. Raposo, C. Heidebrecht, J. Wang, A. Chan, J. Brownstein, and M. Gardam. 2010. Global public health implications of a mass gathering in Mecca, Saudi Arabia during the midst of an influenza pandemic. J.Travel.Med. 17:75–81. doi:JTM397 [pii];10.1111/j.1708-8305.2010.00397.x [doi]. 800. Kharbanda, E. O., C. Y. Vargas, P. M. Castano, M. Lara, R. Andres, and M. S. Stockwell. 2011. Exploring pregnant women’s views on influenza vaccination and educational text messages. Prev.Med. 52:75–77. doi:S0091-7435(10)00429-9 [pii];10.1016/j.ypmed.2010.10.009 [doi]. 801. Khurana, S., C. Larkin, S. Verma, M. B. Joshi, J. Fontana, A. C. Steven, L. R. King, J. Manischewitz, W. McCormick, R. K. Gupta, and H. Golding. 2011. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 29:5657–5665. doi:S0264-410X(11)00878-4 [pii];10.1016/j. vaccine.2011.06.014 [doi]. 802. Khurana, S., J. Wu, N. Verma, S. Verma, R. Raghunandan, J. Manischewitz, L. R. King, E. Kpamegan, S. Pincus, G. Smith, G. Glenn, and H. Golding. 2011. H5N1 virus-like particle vaccine elicits cross- reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J.Virol. 85:10945–10954. doi:JVI.05406-11 [pii];10.1128/JVI.05406-11 [doi]. 803. Khurana, S., N. Verma, J. W. Yewdell, A. K. Hilbert, F. Castellino, M. Lattanzi, G. G. Del, R. Rappuoli, and H. Golding. 2011. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci.Transl.Med. 3:85ra48. doi:3/85/85ra48 [pii];10.1126/ scitranslmed.3002336 [doi]. 804. Khurana, S., S. Verma, N. Verma, C. J. Crevar, D. M. Carter, J. Manischewitz, L. R. King, T. M. Ross, and H. Golding. 2010. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS.One. 5:e11548. doi:10.1371/journal.pone.0011548 [doi]. 805. Khurana, S., S. Verma, N. Verma, C. J. Crevar, D. M. Carter, J. Manischewitz, L. R. King, T. M. Ross, and H. Golding. 2011. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J.Virol. 85:1246–1256. doi:JVI.02107-10 [pii];10.1128/JVI.02107-10 [doi]. 806. Khurana, S., W. Chearwae, F. Castellino, J. Manischewitz, L. R. King, A. Honorkiewicz, M. T. Rock, K. M. Edwards, G. G. Del, R. Rappuoli, and H. Golding. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci.Transl.Med. 2:15ra5. doi:2/15/15ra5 [pii];10.1126/scitranslmed.3000624 [doi]. 807. Kiertiburanakul, S., K. Malathum, S. P. Watcharananan, P. Bunupuradah, P. Piebpien, U. Rujiraviroj, W. Likitsinsipon, S. Apivanich, P. Kehachindawat, R. Burakitcharoen, S. Leelaudomlipi,

115 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

and W. Wananukul. 2011. High coverage and safety of influenza A (H1N1) 2009 monovalent vaccination among health care personnel in Thailand. Am.J.Infect.Control 39:525–528. doi:S0196-6553(10)00980-6 [pii];10.1016/j.ajic.2010.09.011 [doi]. 808. Kilany, W. H., A. Arafa, A. M. Erfan, M. S. Ahmed, A. A. Nawar, A. A. Selim, S. G. Khoulosy, M. K. Hassan, M. M. Aly, H. M. Hafez, and E. M. Abdelwhab. 2010. Isolation of highly pathogenic avian influenza H5N1 from table eggs after vaccinal break in commercial layer flock. Avian Dis. 54:1115– 1119. 809. Killingley, B., J. Enstone, R. Booy, A. Hayward, J. Oxford, N. Ferguson, and J. N. Van-Tam. 2011. Potential role of human challenge studies for investigation of influenza transmission. Lancet Infect.Dis. 11:879–886. doi:S1473-3099(11)70142-6 [pii];10.1016/S1473-3099(11)70142-6 [doi]. 810. Kim, D., S. Kwon, J. W. Rhee, K. D. Kim, Y. E. Kim, C. S. Park, M. J. Choi, J. G. Suh, D. S. Kim, Y. Lee, and H. J. Kwon. 2011. Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC.Immunol. 12:29. doi:1471-2172-12-29 [pii];10.1186/1471-2172-12-29 [doi]. 811. Kim, J. E., E. K. Kim, D. H. Lee, S. W. Kim, C. Suh, and J. S. Lee. 2011. False-positive hypermetabolic lesions on post-treatment PET-CT after influenza vaccination. Korean J.Intern.Med. 26:210–212. doi:10.3904/kjim.2011.26.2.210 [doi]. 812. Kim, J. N., S. H. Byun, S. Y. Kang, and I. P. Mo. 2010. Evaluation of neuraminidase antigen based competitive enzyme-linked immunosorbent assay in chickens vaccinated with avian influenza inactivated vaccine. Avian Dis. 54:682–685. 813. Kim, N., G. Choi, C. Y. Lim, J. W. Lee, K. H. Kim, and H. J. Lee. 2010. An open-label, single-arm, phase I study to evaluate the safety and immunogenicity of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, in healthy adult volunteers. Arch.Pharm.Res. 33:919–924. doi:10.1007/s12272-010-0615-5 [doi]. 814. Kim, T. H., J. Johnstone, and M. Loeb. 2011. Vaccine herd effect. Scand.J.Infect.Dis. 43 :683–689. doi:10.3109/00365548.2011.582247 [doi]. 815. Kim, Y. C., C. Jarrahian, D. Zehrung, S. Mitragotri, and M. R. Prausnitz. 2012. Delivery systems for intradermal vaccination. Curr.Top.Microbiol.Immunol. 351:77–112. doi:10.1007/82_2011_123 [doi]. 816. Kim, Y. C., F. S. Quan, D. G. Yoo, R. W. Compans, S. M. Kang, and M. R. Prausnitz. 2010. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J.Infect.Dis. 201:190–198. doi:10.1086/649228 [doi]. 817. Kim, Y. C., F. S. Quan, J. M. Song, A. Vunnava, D. G. Yoo, K. M. Park, R. W. Compans, S. M. Kang, and M. R. Prausnitz. 2010. Influenza immunization with trehalose-stabilized virus-like particle vaccine using microneedles. Procedia.Vaccinol. 2:15–19. doi:10.1016/j.provac.2010.03.004 [doi]. 818. Kim, Y. C., F. S. Quan, R. W. Compans, S. M. Kang, and M. R. Prausnitz. 2010. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J.Control Release 142:187–195. doi:S0168-3659(09)00708-1 [pii];10.1016/j. jconrel.2009.10.013 [doi]. 819. Kim, Y. C., F. S. Quan, R. W. Compans, S. M. Kang, and M. R. Prausnitz. 2010. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS.PharmSciTech. 11:1193–1201. doi:10.1208/s12249-010-9471-3 [doi]. 820. Kim, Y. C., F. S. Quan, R. W. Compans, S. M. Kang, and M. R. Prausnitz. 2011. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm.Res. 28:135–144. doi:10.1007/s11095-010-0134-6 [doi]. 821. King, J. C., Jr., R. Lichenstein, G. E. Cummings, and L. S. Magder. 2010. Impact of influenza vaccination of schoolchildren on medical outcomes among all residents of Maryland. Vaccine 28:7737–7742. doi:S0264-410X(10)01385-X [pii];10.1016/j.vaccine.2010.09.064 [doi].

116 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

822. Kiseleva, I. V., J. T. Voeten, L. C. Teley, N. V. Larionova, Drieszen-van der Cruijsen SK, S. M. Basten, J. G. Heldens, H. van den Bosch, and L. G. Rudenko. 2010. PB2 and PA genes control the expression of the temperature-sensitive phenotype of cold-adapted B/USSR/60/69 influenza master donor virus. J.Gen.Virol. 91:931–937. doi:vir.0.017996-0 [pii];10.1099/vir.0.017996-0 [doi]. 823. Kiseleva, I. V., N. V. Larionova, J. T. Voeten, L. C. Teley, Drieszen-van der Cruijsen SK, J. G. Heldens, J. F. van den Bosch, and L. G. Rudenko. 2010. [Leading role of genes coding polymerase complex in attenuation of domestic donor viruses for A and B live influenza vaccine]. Zh.Mikrobiol.Epidemiol. Immunobiol.41– 47. 824. Kiseleva, I. V., N. V. Larionova, L. C. Teley, and L. G. Rudenko. 2011. [Restriction analysis of genome composition of live influenza vaccine]. Vopr.Virusol. 56:28–32. 825. Kiseleva, I., N. Larionova, V. Kuznetsov, and L. Rudenko. 2010. Phenotypic characteristics of novel swine-origin influenza A/California/07/2009 (H1N1) virus. Influenza.Other Respi.Viruses. 4:1–5. doi:IRV118 [pii];10.1111/j.1750-2659.2009.00118.x [doi]. 826. Kissling, E. and M. Valenciano. 2011. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Euro.Surveill 16. 827. Kissmann, J., S. B. Joshi, J. R. Haynes, L. Dokken, C. Richardson, and C. R. Middaugh. 2011. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers. J.Pharm. Sci. 100:634–645. doi:10.1002/jps.22304 [doi]. 828. Kistner, O., B. A. Crowe, W. Wodal, A. Kerschbaum, H. Savidis-Dacho, N. Sabarth, F. G. Falkner, I. Mayerhofer, W. Mundt, M. Reiter, L. Grillberger, C. Tauer, M. Graninger, A. Sachslehner, M. Schwendinger, P. Bruhl, T. R. Kreil, H. J. Ehrlich, and P. N. Barrett. 2010. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS.One. 5:e9349. doi:10.1371/journal.pone.0009349 [doi]. 829. Kitano, M., Y. Itoh, M. Kodama, H. Ishigaki, M. Nakayama, T. Nagata, H. Ishida, H. Tsuchiya, R. Torii, K. Baba, R. Yoshida, A. Sato, and K. Ogasawara. 2010. Establishment of a cynomolgus macaque model of infection. Virology 407:178–184. doi:S0042-6822(10)00523-4 [pii];10.1016/j.virol.2010.08.006 [doi]. 830. Klein, N. P., W. M. Weston, S. Kuriyakose, D. Kolhe, B. Howe, L. R. Friedland, and O. Van Der Meeren. 2011. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine. doi:S0264-410X(11)01702-6 [pii];10.1016/j.vaccine.2011.10.065 [doi]. 831. Klimova, R. R., O. V. Masalova, E. I. Burtseva, E. V. Chichev, E. I. Lesnova, T. A. Oskerko, E. A. Mukasheva, I. A. Rudneva, D. K. Lvov, and A. A. Kushch. 2011. [Monoclonal antibodies with high virus-neutralizing activity against pandemic influenza virus A/llV-Moscow/01/2009 (H1N1)swl]. Vopr. Virusol. 56:15–20. 832. Klugman, K. P. 2011. Contribution of vaccines to our understanding of pneumococcal disease. Philos. Trans.R.Soc.Lond B Biol.Sci. 366:2790–2798. doi:366/1579/2790 [pii];10.1098/rstb.2011.0032 [doi]. 833. Kmietowicz, Z. 2011. H1N1 vaccine is released in UK to meet demand for protection against flu. BMJ 342:d111. 834. Knuf, M., H. J. Schmitt, J. M. Jacquet, A. Collard, D. Kieninger, C. U. Meyer, C. A. Siegrist, and F. Zepp. 2010. Booster vaccination after neonatal priming with acellular pertussis vaccine. J.Pediatr. 156:675–678. doi:S0022-3476(09)01248-7 [pii];10.1016/j.jpeds.2009.12.019 [doi]. 835. Kobayashi, M., M. Takechi, K. Kondo, S. Ohfuji, W. Fukushima, A. Maeda, and Y. Hirota. 2010. [Literature review on the association between inactivated influenza vaccines and the Guillain-Barre syndrome]. Nihon Koshu Eisei Zasshi 57:605–611.

117 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

836. Kobinger, G. P., I. Meunier, A. Patel, S. Pillet, J. Gren, S. Stebner, A. Leung, J. L. Neufeld, D. Kobasa, and M. von, V. 2010. Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus. J.Infect.Dis. 201:1000–1006. doi:10.1086/651171 [doi]. 837. Konishi, M., S. Koarada, K. Yamaguchi, S. Tashiro, S. Soejima, R. Suematsu, H. Inoue, Y. Tada, A. Ohta, and K. Nagasawa. 2011. [Case of microscopic polyangiitis and giant cell arteritis after influenza vaccination]. Nihon Rinsho Meneki.Gakkai Kaishi 34:154–161. doi:JST.JSTAGE/jsci/34.154 [pii]. 838. Korn-Lubetzki, I., M. Dano, and D. Raveh. 2011. H1N1 vaccine-related acute transverse myelitis. Isr. Med.Assoc.J. 13:249–250. 839. Kosalaraksa, P., U. Srirompotong, R. W. Newman, P. Lumbiganon, and J. M. Wood. 2011. Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status. Vaccine 29:3055–3060. doi:S0264-410X(11)00163-0 [pii];10.1016/j.vaccine.2011.01.091 [doi]. 840. Kositanont, U., P. Wongsurakiat, P. Pooruk, N. Maranetra, and P. Puthavathana. 2010. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients. Viral Immunol. 23:329–334. doi:10.1089/vim.2009.0082 [doi]. 841. Koutsonanos, D. G., M. M. del Pilar, V. G. Zarnitsyn, J. Jacob, M. R. Prausnitz, R. W. Compans, and I. Skountzou . 2011. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J.Infect.Dis. 204:582–591. doi:jir094 [pii];10.1093/infdis/jir094 [doi]. 842. Koyama, S., T. Aoshi, T. Tanimoto, Y. Kumagai, K. Kobiyama, T. Tougan, K. Sakurai, C. Coban, T. Horii, S. Akira, and K. J. Ishii. 2010. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci.Transl.Med. 2:25ra24. doi:2/25/25ra24 [pii];10.1126/scitranslmed.3000759 [doi]. 843. Krammer, F. and R. Grabherr. 2010. Alternative influenza vaccines made by insect cells. Trends Mol. Med. 16:313–320. doi:S1471-4914(10)00071-7 [pii];10.1016/j.molmed.2010.05.002 [doi]. 844. Krammer, F., T. Schinko, D. Palmberger, C. Tauer, P. Messner, and R. Grabherr. 2010. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol.Biotechnol. 45:226–234. doi:10.1007/s12033-010-9268-3 [doi]. 845. Krasil’nikov, I. V., A. S. Gambarian, V. V. Mashin, and A. K. Lobastova. 2010. [The immunogenic and protective properties of inactivated and live candidate vaccines against highly pathogenic avian influenza H5N1 virus]. Vopr.Virusol. 55:16–19. 846. Krause, J. C., T. Tsibane, T. M. Tumpey, C. J. Huffman, C. F. Basler, and J. E. Crowe, Jr. 2011. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J.Virol. 85:10905–10908. doi:JVI.00700-11 [pii];10.1128/JVI.00700-11 [doi]. 847. Kreijtz, J. H., R. A. Fouchier, and G. F. Rimmelzwaan. 2011. Immune responses to influenza virus infection. Virus Res. doi:S0168-1702(11)00375-3 [pii];10.1016/j.virusres.2011.09.022 [doi]. 848. Kreijtz, J. H., Y. Suzer, R. Bodewes, A. Schwantes, A. G. van, R. J. Verburgh, M. G. de, J. van den Brand, S. E. van Trierum, T. Kuiken, R. A. Fouchier, A. D. Osterhaus, G. Sutter, and G. F. Rimmelzwaan. 2010. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J.Gen.Virol. 91:2745–2752. doi:vir.0.024885-0 [pii];10.1099/vir.0.024885-0 [doi]. 849. Kryscio, K. E. 2010. Cost analysis of influenza vaccine administration in Fayette County, Kentucky, 2005–2007. Public Health Rep. 125:358–363. 850. Kuehn, B. M. 2011. Influenza vaccine makers seek ways to speed production, boost effectiveness. JAMA 305:1079–1080. doi:305/11/1079 [pii];10.1001/jama.2011.283 [doi].

118 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

851. Kuehnert, P. 2010. Now more than ever: building and sustaining capacity for school- located vaccination initiatives. J.Sch Nurs. 26:27S–29S. doi:1059840510368525 [pii];10.1177/1059840510368525 [doi]. 852. Kuether, G., B. Dietrich, T. Smith, C. Peter, and S. Gruessner. 2011. Atraumatic osteonecrosis of the humeral head after influenza A-(H1N1) v-2009 vaccination. Vaccine 29:6830–6833. doi:S0264- 410X(11)01097-8 [pii];10.1016/j.vaccine.2011.07.052 [doi]. 853. Kumar, D., E. A. Blumberg, L. Danziger-Isakov, C. N. Kotton, N. B. Halasa, M. G. Ison, R. K. Avery, M. Green, U. D. Allen, K. M. Edwards, G. Miller, and M. G. Michaels. 2011. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am.J.Transplant. 11:2020–2030. doi:10.1111/j.1600-6143.2011.03753.x [doi]. 854. Kung, H. C., K. C. Huang, T. M. Kao, Y. C. Lee, F. Y. Chang, N. C. Wang, Y. C. Liu, W. S. Lee, H. J. Liu, C. I. Chen, C. H. Chen, L. M. Huang, and S. M. Hsieh. 2010. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low- level epidemics of pandemic influenza. Vaccine 28:7337–7343. doi:S0264-410X(10)01243-0 [pii];10.1016/j.vaccine.2010.08.073 [doi]. 855. Kunisaki, K. M. 2011. Influenza vaccines in patients with IBD: ready for primetime? Gut 60:433–434. doi:gut.2010.236679 [pii];10.1136/gut.2010.236679 [doi]. 856. Kurz, X., F. Domergue, J. Slattery, A. Segec, A. Szmigiel, and A. Hidalgo-Simon. 2011. Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. Vaccine 29:4378–4387. doi:S0264-410X(11)00515-9 [pii];10.1016/j.vaccine.2011.04.005 [doi]. 857. Kutzler, M. A., K. A. Kraynyak, S. J. Nagle, R. M. Parkinson, D. Zharikova, M. Chattergoon, H. Maguire, K. Muthumani, K. Ugen, and D. B. Weiner. 2010. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Ther. 17:72–82. doi:gt2009112 [pii];10.1038/gt.2009.112 [doi]. 858. Kwok, R. 2011. Vaccines: The real issues in vaccine safety. Nature 473:436–438. doi:473436a [pii];10.1038/473436a [doi]. 859. Kwon, Y., H. Y. Cho, Y. K. Lee, G. R. Bae, and S. G. Lee. 2010. Relationship between intention of novel influenza A (H1N1) vaccination and vaccination coverage rate. Vaccine 29:161–165. doi:S0264- 410X(10)01564-1 [pii];10.1016/j.vaccine.2010.10.063 [doi]. 860. Kwong, E. W., S. M. Pang, P. P. Choi, and T. K. Wong. 2010. Influenza vaccine preference and uptake among older people in nine countries. J.Adv.Nurs. 66:2297–2308. doi:JAN5397 [pii];10.1111/ j.1365-2648.2010.05397.x [doi]. 861. Kwong, J. C., H. Ge, L. C. Rosella, J. Guan, S. Maaten, K. Moran, H. Johansen, and A. Guttmann. 2010. School-based influenza vaccine delivery, vaccination rates, and healthcare use in the context of a universal influenza immunization program: an ecological study. Vaccine 28:2722–2729. doi:S0264-410X(10)00056-3 [pii];10.1016/j.vaccine.2010.01.024 [doi]. 862. Kyriakis, C. S., M. R. Gramer, F. Barbe, D. J. Van, and R. K. Van. 2010. Efficacy of commercial swine influenza vaccines against challenge with a recent European H1N1 field isolate. Vet.Microbiol. 144:67–74. doi:S0378-1135(10)00011-8 [pii];10.1016/j.vetmic.2009.12.039 [doi]. 863. La, T. G., G. Iarocci, C. Cadeddu, and A. Boccia. 2010. Influence of sociodemographic inequalities and chronic conditions on influenza vaccination coverage in Italy: results from a survey in the general population. Public Health 124:690–697. doi:S0033-3506(10)00235-0 [pii];10.1016/j. puhe.2010.06.006 [doi]. 864. Labadie, J. 2011. Vaccine safety. Int.J.Risk Saf Med. 23:113–115. doi:A848P17U951407U4 [pii];10.3233/JRS-2011-0524 [doi].

119 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

865. Labriola, L., A. Hombrouck, C. Marechal, G. S. Van, B. Brochier, I. Thomas, M. Jadoul, and P. Goubau. 2011. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol.Dial.Transplant. 26:1424–1428. doi:gfq782 [pii];10.1093/ndt/ gfq782 [doi]. 866. Labro, M. T. and J. Etiemble. 2010. [The strategy against influenza]. Rev.Prat. 60:81–92. 867. Lachenal, F., C. Sebban, M. Duruisseaux, P. Biron, J. Y. Blay, and H. Ghesquieres. 2010. Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center. Bull.Cancer 97:E33-E36. doi:bdc.2010.1079 [pii];10.1684/bdc.2010.1079 [doi]. 868. Lacroix, I., C. Damase-Michel, C. Kreft-Jais, A. Castot, and J. L. Montastruc. 2011. 2009 H1N1 influenza vaccines in pregnant women: the French Pharmacovigilance survey. Vaccine 29:1357– 1358. doi:S0264-410X(10)01749-4 [pii];10.1016/j.vaccine.2010.12.011 [doi]. 869. Laffon-Pioger, M., F. Rocher, M. Cohen, S. Chanalet, P. Thomas, and C. Lebrun. 2010. [Bilateral optic neuropathy with loss of vision after an influenza vaccination in a patient suffering from mixed connective tissue disease]. Rev.Neurol.(Paris) 166 :1024–1027. doi:S0035-3787(10)00408-X [pii];10.1016/j.neurol.2010.07.037 [doi]. 870. LaForce, F. M. 2011. Technology transfer to developing country vaccine manufacturers to improve global influenza vaccine production: a success story and a window into the future. Vaccine 29 Suppl 1:A1. doi:S0264-410X(11)00325-2 [pii];10.1016/j.vaccine.2011.02.077 [doi]. 871. Lahad, A. 2011. Low influenza vaccination rate over the age of 65: should we increase the pressure on medical teams? Isr.Med.Assoc.J. 13:366–367. 872. Lai, J., K. E. Fay, and J. A. Bocchini. 2011. Update on childhood and adolescent immunizations: selected review of US recommendations and literature: part 2. Curr.Opin.Pediatr. 23:470–481. doi:10.1097/MOP.0b013e3283488160 [doi]. 873. Lamere, M. W., A. Moquin, F. E. Lee, R. S. Misra, P. J. Blair, L. Haynes, T. D. Randall, F. E. Lund, and D. A. Kaminski. 2011. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J.Virol. 85:5027–5035. doi:JVI.00150-11 [pii];10.1128/JVI.00150-11 [doi]. 874. Lamere, M. W., H. T. Lam, A. Moquin, L. Haynes, F. E. Lund, T. D. Randall, and D. A. Kaminski. 2011. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J.Immunol. 186:4331–4339. doi:jimmunol.1003057 [pii];10.4049/jimmunol.1003057 [doi]. 875. Landry, N., B. J. Ward, S. Trepanier, E. Montomoli, M. Dargis, G. Lapini, and L. P. Vezina. 2010. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS.One. 5:e15559. doi:10.1371/journal.pone.0015559 [doi]. 876. Lang, D. P. 2011. Inactivated influenza vaccines:: pre-vaccination haemagglutinin-antibody titres influence the vaccine response but not necessarily the vaccine effectiveness. Drugs Aging 28:505. doi:7 [pii];10.2165/11592350-000000000-00000 [doi]. 877. Lang, P. O. 2011. [Adverse effects of the herd immunity or when childhood vaccination becomes deleterious for the epidemiology of infectious diseases in adults]. Geriatr.Psychol.Neuropsychiatr.Vieil. 9:11–19. doi:pnv.2011.0260 [pii];10.1684/pnv.2011.0260 [doi]. 878. Lang, P. O. and J. P. Michel. 2010. [Vaccination: a programme for the whole life]. Rev.Med.Suisse 6:2118–2124. 879. Lang, P. O., S. Govind, W. A. Mitchell, C. A. Siegrist, and R. Aspinall. 2011. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res.Rev. 10:389–395. doi:S1568-1637(10)00080-2 [pii];10.1016/j.arr.2010.09.005 [doi].

120 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

880. Langley, J. M., F. Aoki, B. J. Ward, A. McGeer, J. B. Angel, G. Stiver, I. Gorfinkel, D. Shu, L. White, B. Lasko, P. Dzongowski, K. Papp, M. Alexander, G. Boivin, and L. Fries. 2011. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine 29:1921–1928. doi:S0264- 410X(10)01887-6 [pii];10.1016/j.vaccine.2010.12.100 [doi]. 881. Langley, J. M., G. Risi, M. Caldwell, L. Gilderman, B. Berwald, C. Fogarty, T. Poling, D. Riff, M. Baron, L. Frenette, E. Sheldon, H. Collins, M. Shepard, M. Dionne, D. Brune, L. Ferguson, D. Vaughn, P. Li, and L. Fries. 2011. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J.Infect.Dis. 203:1729– 1738. doi:jir172 [pii];10.1093/infdis/jir172 [doi]. 882. Langley, J. M., L. Dodds, D. Fell, and G. R. Langley. 2010. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990–2002. BMC.Infect.Dis. 10:219. doi:1471-2334-10-219 [pii];10.1186/1471-2334-10-219 [doi]. 883. Langley, J. M., L. Frenette, L. Ferguson, D. Riff, E. Sheldon, G. Risi, C. Johnson, P. Li, R. Kenney, B. Innis, and L. Fries. 2010. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J.Infect.Dis. 201:1644–1653. doi:10.1086/652701 [doi]. 884. Langley, W. A., K. C. Bradley, Z. N. Li, G. R. Talekar, S. E. Galloway, and D. A. Steinhauer. 2010. The effects of preexisting immunity to influenza on responses to influenza vectors in mice. Vaccine 28:6305–6313. doi:S0264-410X(10)00953-9 [pii];10.1016/j.vaccine.2010.06.112 [doi]. 885. Lanthier, P. A., G. E. Huston, A. Moquin, S. M. Eaton, F. M. Szaba, L. W. Kummer, M. P. Tighe, J. E. Kohlmeier, P. J. Blair, M. Broderick, S. T. Smiley, and L. Haynes. 2011. Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine 29:7849–7856. doi:S0264- 410X(11)01143-1 [pii];10.1016/j.vaccine.2011.07.093 [doi]. 886. Lantos, J. D., M. A. Jackson, D. J. Opel, E. K. Marcuse, A. L. Myers, and B. L. Connelly. 2010. Controversies in vaccine mandates. Curr.Probl.Pediatr.Adolesc.Health Care 40:38–58. doi:S1538-5442(10)00004-0 [pii];10.1016/j.cppeds.2010.01.003 [doi]. 887. Lanza, G. A., L. Barone, G. Scalone, D. Pitocco, G. A. Sgueglia, R. Mollo, R. Nerla, F. Zaccardi, G. Ghirlanda, and F. Crea. 2011. Inflammation-related effects of adjuvant influenza A vaccination on platelet activation and cardiac autonomic function. J.Intern.Med. 269:118–125. doi:10.1111/j.1365- 2796.2010.02285.x [doi]. 888. Lapphra, K., L. Huh, and D. W. Scheifele. 2011. Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination. Pediatr.Infect.Dis.J. 30:84- 86. doi:10.1097/INF.0b013e3181f11126 [doi]. 889. Lapphra, K., S. Dobson, and J. A. Bettinger. 2010. Acceptability of Internet adverse event self- reporting for pandemic and seasonal influenza immunization among health care workers. Vaccine 28:6199–6202. doi:S0264-410X(10)01002-9 [pii];10.1016/j.vaccine.2010.07.019 [doi]. 890. Larrauri, A., C. Savulescu, S. Jimenez-Jorge, P. Perez-Brena, F. Pozo, I. Casas, J. Ledesma, and M. S. de. 2011. Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008–9 trivalent vaccine against pandemic influenza in Spain. Gac.Sanit. 25:23–28. doi:S0213-9111(10)00288-8 [pii];10.1016/j.gaceta.2010.06.010 [doi]. 891. Larson, H. J., L. Z. Cooper, J. Eskola, S. L. Katz, and S. Ratzan. 2011. Addressing the vaccine confidence gap. Lancet 378:526–535. doi:S0140-6736(11)60678-8 [pii];10.1016/S0140- 6736(11)60678-8 [doi]. 892. LaRussa, P. 2011. Pandemic novel 2009 H1N1 influenza: what have we learned? Semin.Respir.Crit Care Med. 32:393–399. doi:10.1055/s-0031-1283279 [doi].

121 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

893. Lau, J. T., N. C. Yeung, K. C. Choi, M. Y. Cheng, H. Y. Tsui, and S. Griffiths. 2010. Factors in association with acceptability of A/H1N1 vaccination during the influenza A/H1N1 pandemic phase in the Hong Kong general population. Vaccine 28:4632–4637. doi:S0264-410X(10)00612-2 [pii];10.1016/j.vaccine.2010.04.076 [doi]. 894. Lau, J. T., S. Griffiths, K. C. Choi, and C. Lin. 2010. Prevalence of preventive behaviors and associated factors during early phase of the H1N1 influenza epidemic. Am.J.Infect.Control 38:374– 380. doi:S0196-6553(10)00186-0 [pii];10.1016/j.ajic.2010.03.002 [doi]. 895. Lau, J. T., Y. Cai, H. Y. Tsui, and K. C. Choi. 2010. Prevalence of influenza vaccination and associated factors among pregnant women in Hong Kong. Vaccine 28:5389–5397. doi:S0264- 410X(10)00792-9 [pii];10.1016/j.vaccine.2010.05.071 [doi]. 896. Lau, Y. F., C. Santos, F. J. Torres-Velez, and K. Subbarao. 2011. The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines. J.Virol. 85:76–85. doi:JVI.01564-10 [pii];10.1128/JVI.01564-10 [doi]. 897. Lau, Y. F., L. H. Tang, A. W. McCall, E. E. Ooi, and K. Subbarao. 2010. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J.Virol. 84:8639–8649. doi:JVI.00596-10 [pii];10.1128/JVI.00596-10 [doi]. 898. Launay, O., C. Desaint, C. Durier, P. Loulergue, X. Duval, C. Jacomet, G. Pialoux, J. Ghosn, F. Raffi, D. Rey, F. Ajana, d. Colin, V, J. Reynes, V. Foubert, F. Roman, J. M. Devaster, J. F. Delfraissy, and J. P. Aboulker. 2011. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J.Infect. Dis. 204:124–134. doi:jir211 [pii];10.1093/infdis/jir211 [doi]. 899. Layton, R. C., A. Gigliotti, P. Armijo, L. Myers, J. Knight, N. Donart, J. Pyles, S. Vaughan, J. Plourde, N. Fomukong, K. S. Harrod, P. Gao, and F. Koster. 2011. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS.One. 6:e20641. doi:10.1371/journal.pone.0020641 [doi];PONE-D-10-05020 [pii]. 900. Le, R. A., D. Jacob, J. Transfiguracion, S. Ansorge, O. Henry, and A. A. Kamen. 2010. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 28:3661– 3671. doi:S0264-410X(10)00376-2 [pii];10.1016/j.vaccine.2010.03.029 [doi]. 901. Leask, J., C. M. Helms, M. Y. Chow, S. C. Robbins, and P. B. McIntyre. 2010. Making influenza vaccination mandatory for health care workers: the views of NSW Health administrators and clinical leaders. N.S.W.Public Health Bull. 21:243–247. doi:NB10042 [pii];10.1071/NB10042 [doi]. 902. Ledgerwood, J. E., C. J. Wei, Z. Hu, I. J. Gordon, M. E. Enama, C. S. Hendel, P. M. McTamney, M. B. Pearce, H. M. Yassine, J. C. Boyington, R. Bailer, T. M. Tumpey, R. A. Koup, J. R. Mascola, G. J. Nabel, and B. S. Graham. 2011. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect.Dis. doi:S1473-3099(11)70240-7 [pii];10.1016/ S1473-3099(11)70240-7 [doi]. 903. Lee, B. Y., J. H. Tai, R. R. Bailey, K. J. Smith, and A. J. Nowalk. 2010. Economics of influenza vaccine administration timing for children. Am.J.Manag.Care 16:e75–e85. doi:12583 [pii]. 904. Lee, B. Y., K. M. Bacon, J. M. Donohue, A. E. Wiringa, R. R. Bailey, and R. K. Zimmerman. 2011. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine 29:2149–2158. doi:S0264-410X(10)01851-7 [pii];10.1016/j.vaccine.2010.12.078 [doi]. 905. Lee, B. Y., R. M. Stalter, K. M. Bacon, J. H. Tai, R. R. Bailey, S. M. Zimmer, and M. M. Wagner. 2011. Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients. Am.J.Kidney Dis. 57:724–732. doi:S0272-6386(11)00047-3 [pii];10.1053/j. ajkd.2010.12.016 [doi].

122 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

906. Lee, B. Y., S. T. Brown, G. W. Korch, P. C. Cooley, R. K. Zimmerman, W. D. Wheaton, S. M. Zimmer, J. J. Grefenstette, R. R. Bailey, T. M. Assi, and D. S. Burke. 2010. A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 28:4875– 4879. doi:S0264-410X(10)00664-X [pii];10.1016/j.vaccine.2010.05.002 [doi]. 907. Lee, B. Y., S. T. Brown, P. C. Cooley, R. K. Zimmerman, W. D. Wheaton, S. M. Zimmer, J. J. Grefenstette, T. M. Assi, T. J. Furphy, D. K. Wagener, and D. S. Burke. 2010. A computer simulation of employee vaccination to mitigate an influenza epidemic. Am.J.Prev.Med. 38:247–257. doi:S0749-3797(09)00847-2 [pii];10.1016/j.amepre.2009.11.009 [doi]. 908. Lee, B. Y., S. T. Brown, P. Cooley, J. J. Grefenstette, R. K. Zimmerman, S. M. Zimmer, M. A. Potter, R. Rosenfeld, W. D. Wheaton, A. E. Wiringa, K. M. Bacon, and D. S. Burke. 2010. Vaccination deep into a pandemic wave potential mechanisms for a “third wave” and the impact of vaccination. Am.J.Prev. Med. 39:e21–e29. doi:S0749-3797(10)00443-5 [pii];10.1016/j.amepre.2010.07.014 [doi]. 909. Lee, B. Y., S. T. Brown, R. R. Bailey, R. K. Zimmerman, M. A. Potter, S. M. McGlone, P. C. Cooley, J. J. Grefenstette, S. M. Zimmer, W. D. Wheaton, S. C. Quinn, R. E. Voorhees, and D. S. Burke . 2011. The benefits to all of ensuring equal and timely access to influenza vaccines in poor communities. Health Aff.(Millwood.) 30:1141–1150. doi:30/6/1141 [pii];10.1377/hlthaff.2010.0778 [doi]. 910. Lee, C. K. 2010. Influenza A (H1N1) 2009 pandemic virus: learning from the first wave, preparing for the second. Med.J.Malaysia 65:1–2. 911. Lee, G. M., S. K. Greene, E. S. Weintraub, J. Baggs, M. Kulldorff, B. H. Fireman, R. Baxter, S. J. Jacobsen, S. Irving, M. F. Daley, R. Yin, A. Naleway, J. D. Nordin, L. Li, N. McCarthy, C. Vellozzi, F. Destefano, and T. A. Lieu. 2011. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am.J.Prev.Med. 41:121–128. doi:S0749-3797(11)00260-1 [pii];10.1016/j. amepre.2011.04.004 [doi]. 912. Lee, S., R. Morales, and C. Castillo-Chavez. 2011. A note on the use of influenza vaccination strategies when supply is limited. Math.Biosci.Eng 8:171–182. 913. Lee, T. 2010. Ask the doctor. Now that the fuss over H1N1 swine flu has died down, do I need to get vaccinated this year? Harv.Heart Lett. 21:8. 914. Lee, V. J., J. K. Tay, M. I. Chen, M. C. Phoon, M. L. Xie, Y. Wu, C. X. Lee, J. Yap, K. R. Sakharkar, M. K. Sakharkar, R. T. Lin, L. Cui, P. M. Kelly, Y. S. Leo, Y. J. Tan, and V. T. Chow. 2010. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine 28:6852–6857. doi:S0264- 410X(10)01176-X [pii];10.1016/j.vaccine.2010.08.031 [doi]. 915. Lee, Y. S., K. A. Lee, J. Y. Lee, M. H. Kang, Y. C. Song, D. J. Baek, S. Kim, and C. Y. Kang. 2011. An alpha-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine. Vaccine 29:417–425. doi:S0264-410X(10)01599-9 [pii];10.1016/j. vaccine.2010.11.005 [doi]. 916. Lees, W. D., D. S. Moss, and A. J. Shepherd. 2010. A computational analysis of the antigenic properties of haemagglutinin in influenza A H3N2. Bioinformatics. 26:1403–1408. doi:btq160 [pii];10.1093/bioinformatics/btq160 [doi]. 917. Legutki, J. B., D. M. Magee, P. Stafford, and S. A. Johnston. 2010. A general method for characterization of humoral immunity induced by a vaccine or infection. Vaccine 28:4529–4537. doi:S0264-410X(10)00585-2 [pii];10.1016/j.vaccine.2010.04.061 [doi]. 918. Lehmann, H. C., H. P. Hartung, B. C. Kieseier, and R. A. Hughes. 2010. Guillain-Barre syndrome after exposure to influenza virus. Lancet Infect.Dis. 10:643–651. doi:S1473-3099(10)70140-7 [pii];10.1016/S1473-3099(10)70140-7 [doi].

123 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

919. Lei, H., Y. Xu, J. Chen, X. Wei, and D. M. Lam. 2010. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 407:319–324. doi:S0042-6822(10)00524-6 [pii];10.1016/j.virol.2010.08.007 [doi]. 920. Lei, H., Z. Sheng, Q. Ding, J. Chen, X. Wei, D. M. Lam, and Y. Xu. 2011. Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clin.Vaccine Immunol. 18:1046– 1051. doi:CVI.00050-11 [pii];10.1128/CVI.00050-11 [doi]. 921. Leng, J., H. W. Stout-Delgado, U. Kavita, A. Jacobs, J. Tang, W. Du, L. Tussey, and D. R. Goldstein. 2011. Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. Vaccine 29:8147–8155. doi:S0264-410X(11)01256-4 [pii];10.1016/j. vaccine.2011.08.027 [doi]. 922. Leroux-Roels, G. and I. Leroux-Roels. 2011. Head-to-head comparison of pandemic influenza vaccines. Lancet Infect.Dis. 11:74–75. doi:S1473-3099(10)70298-X [pii];10.1016/S1473- 3099(10)70298-X [doi]. 923. Leroux-Roels, I., F. Roman, S. Forgus, C. Maes, B. F. De, M. Drame, P. Gillard, R. van der Most, M. M. Van, E. Hanon, and G. Leroux-Roels. 2010. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28:849–857. doi:S0264-410X(09)01532-1 [pii];10.1016/j.vaccine.2009.10.017 [doi]. 924. Leung, G. M. and A. Nicoll. 2010. Reflections on pandemic (H1N1) 2009 and the international response. PLoS.Med. 7. doi:10.1371/journal.pmed.1000346 [doi]. 925. Levine, B., T. Wilcosky, D. Wagener, and P. Cooley. 2010. Mass commuting and influenza vaccination prevalence in new york city: protection in a mixing environment. Epidemics. 2:183–188. doi:10.1016/j.epidem.2010.07.002 [doi]. 926. Levine, H., R. D. Balicer, D. Laor, and I. Grotto. 2011. Challenges and opportunities in the Israeli 2009 Pandemic Influenza Vaccination Program. Hum.Vaccin. 7. doi:17627 [pii]. 927. Li, C., M. Shao, X. Cui, Y. Song, J. Li, L. Yuan, H. Fang, Z. Liang, T. D. Cyr, F. Li, X. Li, and J. Wang. 2010. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Biologicals 38:284–289. doi:S1045-1056(09)00186-9 [pii];10.1016/j. biologicals.2009.12.004 [doi]. 928. Li, K. L., W. D. Wu, and D. W. Liu. 2010. [Review of the sudden and death following immunization of influenza vaccine]. Zhongguo Yi.Miao.He.Mian.Yi. 16:270–274. 929. Li, N., Y. Qi, F. Y. Zhang, X. H. Yu, Y. G. Wu, Y. Chen, C. L. Jiang, and W. Kong. 2011. Overexpression of alpha-2,6 sialyltransferase stimulates propagation of human influenza viruses in Vero cells. Acta Virol. 55:147–153. 930. Li, R., A. Lim, S. T. Ow, M. C. Phoon, C. Locht, V. T. Chow, and S. Alonso. 2011. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine 29:5502–5511. doi:S0264-410X(11)00772-9 [pii];10.1016/j.vaccine.2011.05.052 [doi]. 931. Li, Y. C. 2010. Absence of influenza vaccination among high-risk older adults in Taiwan. BMC.Public Health 10:603. doi:1471-2458-10-603 [pii];10.1186/1471-2458-10-603 [doi]. 932. Liang, X. F., H. Q. Wang, J. Z. Wang, H. H. Fang, J. Wu, F. C. Zhu, R. C. Li, S. L. Xia, Y. L. Zhao, F. J. Li, S. H. Yan, W. D. Yin, K. An, D. J. Feng, X. L. Cui, F. C. Qi, C. J. Ju, Y. H. Zhang, Z. J. Guo, P. Y. Chen, Z. Chen, K. M. Yan, and Y. Wang. 2010. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375:56–66. doi:S0140-6736(09)62003-1 [pii];10.1016/S0140-6736(09)62003-1 [doi].

124 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

933. Liang, X. F., L. Li, D. W. Liu, K. L. Li, W. D. Wu, B. P. Zhu, H. Q. Wang, H. M. Luo, L. S. Cao, J. S. Zheng, D. P. Yin, L. Cao, B. B. Wu, H. H. Bao, D. S. Xu, W. Z. Yang, and Y. Wang. 2011. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N.Engl.J.Med. 364:638–647. doi:10.1056/NEJMoa1008553 [doi]. 934. Liao, Q., B. J. Cowling, W. W. Lam, and R. Fielding. 2011. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong Kong: a longitudinal study. PLoS.One. 6:e17713. doi:10.1371/journal.pone.0017713 [doi]. 935. Lim, S. H., J. H. Lee, B. C. Kim, S. U. Jung, Y. B. Park, and C. S. Lee. 2010. Adverse reaction of influenza A (H1N1) 2009 virus vaccination in pregnant women and its effect on newborns. Vaccine 28:7455–7456. doi:S0264-410X(10)01269-7 [pii];10.1016/j.vaccine.2010.08.087 [doi]. 936. Lin, C. J., M. P. Nowalk, S. L. Toback, M. D. Rousculp, M. Raymund, C. S. Ambrose, and R. K. Zimmerman. 2010. Importance of vaccination habit and vaccine choice on influenza vaccination among healthy working adults. Vaccine 28:7706–7712. doi:S0264-410X(10)00992-8 [pii];10.1016/j.vaccine.2010.07.009 [doi]. 937. Lin, F., X. Shen, J. R. McCoy, J. M. Mendoza, J. Yan, S. V. Kemmerrer, A. S. Khan, D. B. Weiner, K. E. Broderick, and N. Y. Sardesai. 2011. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 29:6771–6780. doi:S0264- 410X(10)01830-X [pii];10.1016/j.vaccine.2010.12.057 [doi]. 938. Lin, H. H., K. L. Hsu, W. W. Ko, Y. C. Yang, Y. W. Chang, M. C. Yu, and K. T. Chen. 2010. Cost- effectiveness of influenza immunization in adult cancer patients in Taiwan. Clin.Microbiol.Infect. 16:663–670. doi:CLM2937 [pii];10.1111/j.1469-0691.2009.02937.x [doi]. 939. Lin, J., S. Somanathan, S. Roy, R. Calcedo, and J. M. Wilson. 2010. Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza. Vaccine 28:5669–5675. doi:S0264-410X(10)00864-9 [pii];10.1016/j.vaccine.2010.06.053 [doi]. 940. Lin, S. C., M. H. Huang, P. C. Tsou, L. M. Huang, P. Chong, and S. C. Wu. 2011. Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS.One. 6:e20052. doi:10.1371/journal.pone.0020052 [doi];PONE-D-11-04213 [pii]. 941. Lin, W., H. Fan, X. Cheng, Y. Ye, X. Chen, T. Ren, W. Qi, and M. Liao. 2011. A baculovirus dual expression system-based vaccine confers complete protection against lethal challenge with H9N2 avian influenza virus in mice. Virol.J. 8:273. doi:1743-422X-8-273 [pii];10.1186/1743-422X-8-273 [doi]. 942. Lindley, M. C., S. A. Lorick, J. R. Spinner, A. R. Krull, G. T. Mootrey, F. Ahmed, R. Myers, G. P. Bednash, T. C. Cymet, R. Maeshiro, C. F. Raines, S. C. Shannon, H. M. Sondheimer, and R. A. Strikas. 2011. Student vaccination requirements of U.S. health professional schools: a survey. Ann. Intern.Med. 154:391–400. doi:154/6/391 [pii];10.1059/0003-4819-154-6-201103150-00004 [doi]. 943. Linn, S. T., J. M. Guralnik, and K. V. Patel. 2010. Disparities in influenza vaccine coverage in the United States, 2008. J.Am.Geriatr.Soc. 58:1333–1340. doi:JGS2904 [pii];10.1111/j.1532- 5415.2010.02904.x [doi]. 944. Lippi, G., G. Targher, and M. Franchini. 2010. Vaccination, squalene and anti-squalene antibodies: facts or fiction? Eur.J.Intern.Med. 21:70–73. doi:S0953-6205(09)00244-1 [pii];10.1016/j. ejim.2009.12.001 [doi]. 945. Lisotti, A., G. Roda, S. Brillanti, and E. Roda. 2010. Reactivation of Crohn’s disease after pandemic aH1N1 and seasonal flu vaccinations. Dig.Liver Dis. 42:909–910. doi:S1590-8658(10)00105-2 [pii];10.1016/j.dld.2010.03.014 [doi].

125 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

946. Litchfield, S. M. 2010. Preparing for the 2010–2011 influenza season. AAOHN.J. 58:453–456. doi:10.3928/08910162-20101027-03 [doi]. 947. Liu, C. G., M. Liu, F. Liu, d. F. Liu, Y. Zhang, W. Q. Pan, H. Chen, C. H. Wan, E. C. Sun, H. T. Li, and W. H. Xiang. 2011. Evaluation of several adjuvants in avian influenza vaccine to chickens and ducks. Virol.J. 8:321. doi:1743-422X-8-321 [pii];10.1186/1743-422X-8-321 [doi]. 948. Liu, G., B. Tarbet, L. Song, L. Reiserova, B. Weaver, Y. Chen, H. Li, F. Hou, X. Liu, J. Parent, S. Umlauf, A. Shaw, and L. Tussey. 2011. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS.One. 6:e20928. doi:10.1371/ journal.pone.0020928 [doi];PONE-D-11-03279 [pii]. 949. Liu, H., L. Bungener, V. W. ter, B. A. Coller, J. Wilschut, and A. Huckriede. 2011. Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine 29:2037–2043. doi:S0264-410X(11)00040-5 [pii];10.1016/j. vaccine.2011.01.012 [doi]. 950. Liu, J., S. Mani, R. Schwartz, L. Richman, and D. E. Tabor. 2010. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 28:1285–1293. doi:S0264-410X(09)01786-1 [pii];10.1016/j. vaccine.2009.11.023 [doi]. 951. Liu, L. J., X. A. Zhang, M. T. Wei, C. He, L. Zhang, H. Yang, W. Liu, W. C. Cao, D. S. Xin, P. Y. Zhao, C. He, and L. Zhang. 2010. The role of seasonal influenza vaccination in preventing pandemic 2009 influenza (H1N1) during a school outbreak. J.Clin.Virol. 49:225–226. doi:S1386-6532(10)00318-5 [pii];10.1016/j.jcv.2010.07.021 [doi]. 952. Liu, P. Y., Z. Y. Shi, and C. H. Lee. 2010. Cutaneous vasculitis following influenza vaccination. Intern. Med. 49:2187–2188. doi:JST.JSTAGE/internalmedicine/49.4113 [pii]. 953. Liu, W. M., B. A. van der Zeijst, C. J. Boog, and E. C. Soethout. 2011. Aging and impaired immunity to influenza viruses: implications for vaccine development. Hum.Vaccin. 7 Suppl:94–98. doi:14568 [pii]. 954. Liu, W., S. J. de Vlas, F. Tang, M. J. Ma, M. T. Wei, L. J. Liu, Z. D. Li, L. Zhang, Z. T. Xin, Y. G. Tong, T. Jiang, X. A. Zhang, C. He, C. Li, X. N. Xu, H. Yang, J. H. Richardus, and W. C. Cao. 2010. Clinical and immunological characteristics of patients with 2009 pandemic influenza A (H1N1) virus infection after vaccination. Clin.Infect.Dis. 51:1028–1032. doi:10.1086/656588 [doi]. 955. Liu, Y. Z., W. H. Wang, F. C. Li, H. Yang, H. Zhang, Z. H. Deng, Y. Wang, C. Chen, W. C. Li, H. J. Zhang, F. Q. Liu, S. Y. Zhang, and S. X. Hu. 2011. [Serological survey of pandemic influenza A (H1N1) virus infection among population in Hunan Province]. Zhonghua Shi Yan.He.Lin.Chuang.Bing.Du Xue. Za Zhi. 25:17–19. 956. Liu, Y., X. Liu, J. Fang, X. Shen, W. Chen, X. Lin, H. Li, W. Tan, Y. Wang, P. Zhao, and Z. Qi. 2010. Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses. Vaccine 29:183–190. doi:S0264-410X(10)01560-4 [pii];10.1016/j. vaccine.2010.10.059 [doi]. 957. Liu, Z., W. D. Li, M. B. Sun, L. Ma, Z. Q. Guo, S. D. Jiang, G. Y. Liao, J. S. Yang, and C. G. Li. 2010. Screening of a high growth influenza B virus strain in Vero cells. Virol.Sin. 25:65–70. doi:10.1007/ s12250-010-3066-8 [doi]. 958. Lloyd, S. J. 2010. Immunization via the anal mucosa and adjacent skin to protect against respiratory virus infections and allergic rhinitis: a hypothesis. Med.Hypotheses 74:542–546. doi:S0306-9877(09)00665-3 [pii];10.1016/j.mehy.2009.09.046 [doi]. 959. Loeb, M. 2010. Community-acquired pneumonia. Clin.Evid.(Online.) 2010. doi:1503 [pii].

126 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

960. Loeb, M., M. L. Russell, L. Moss, K. Fonseca, J. Fox, D. J. Earn, F. Aoki, G. Horsman, C. P. Van, K. Chokani, M. Vooght, L. Babiuk, R. Webby, and S. D. Walter. 2010. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 303:943–950. doi:303/10/943 [pii];10.1001/jama.2010.250 [doi]. 961. Loebermann, M., G. Anders, G. Brestrich, C. Fritzsche, S. Klammt, D. Borso, S. Frimmel, D. Riebold, and E. C. Reisinger. 2011. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open- label single-arm study. Vaccine 29 :1228–1234. doi:S0264-410X(10)01738-X [pii];10.1016/j. vaccine.2010.11.092 [doi]. 962. Loeffen, W. L., N. Stockhofe, E. Weesendorp, D. van Zoelen-Bos, R. Heutink, S. Quak, D. Goovaerts, J. G. Heldens, R. Maas, R. J. Moormann, and G. Koch. 2011. Efficacy of a pandemic (H1N1) 2009 virus vaccine in pigs against the pandemic influenza virus is superior to commercially available swine influenza vaccines. Vet.Microbiol. 152:304–314. doi:S0378-1135(11)00305-1 [pii];10.1016/j. vetmic.2011.05.027 [doi]. 963. Loeffen, W. L., R. P. de Vries, N. Stockhofe, D. van Zoelen-Bos, R. Maas, G. Koch, R. J. Moormann, P. J. Rottier, and C. A. de Haan. 2011. Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus. Vaccine 29:1545– 1550. doi:S0264-410X(10)01880-3 [pii];10.1016/j.vaccine.2010.12.096 [doi]. 964. Logue, E., P. Dudley, T. Imhoff, W. Smucker, J. Stapin, J. DiSabato, and C. Schueller. 2011. An opt-out influenza vaccination policy improves immunization rates in primary care. J.Health Care Poor Underserved 22:232–242. doi:S1548686911100169 [pii];10.1353/hpu.2011.0009 [doi]. 965. Lohiya, G. S., L. Tan-Figueroa, and V. Krishna. 2010. Serious pH1N1 influenza illness and pneumonia despite inactivated vaccine: success of prompt diagnosis and treatment. J.Natl.Med.Assoc. 102:950–952. 966. Lohr, V., Y. Genzel, I. Behrendt, K. Scharfenberg, and U. Reichl. 2010. A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 28:6256–6264. doi:S0264-410X(10)00987-4 [pii];10.1016/j.vaccine.2010.07.004 [doi]. 967. Long, C. B., I. Ramos, D. Rastogi, D. Manwani, G. Janow, R. M. Del, M. Mayers, B. C. Herold, A. Fernandez-Sesma, and R. P. Madan. 2011. Humoral and Cell-Mediated Immune Responses to Monovalent 2009 Influenza A/H1N1 and Seasonal Trivalent Influenza Vaccines in High-Risk Children. J.Pediatr. doi:S0022-3476(11)00672-X [pii];10.1016/j.jpeds.2011.06.045 [doi]. 968. Looijmans-van den Akker, I., J. J. van Delden, T. J. Verheij, M. A. van der Sande, G. A. van Essen, J. Riphagen-Dalhuisen, M. E. Hulscher, and E. Hak. 2010. Effects of a multi-faceted program to increase influenza vaccine uptake among health care workers in nursing homes: A cluster randomised controlled trial. Vaccine 28:5086–5092. doi:S0264-410X(10)00665-1 [pii];10.1016/j. vaccine.2010.05.003 [doi]. 969. Lopert, R. 2010. Benefit and risks of trivalent 2010 seasonal influenza vaccine in Australian children. Euro.Surveill 15. 970. Lopez, N. M., G. J. Gomez, P. A. Losa, and M. G. Aguila. 2010. [Guillain-Barre syndrome secondary to H1N1 influenza vaccine]. Rev.Clin.Esp. 210:485–486. doi:S0014-2565(10)00303-6 [pii];10.1016/j.rce.2010.05.003 [doi]. 971. Lopez, P., Y. Caicedo, A. Sierra, S. Tilman, A. Banzhoff, and R. Clemens. 2011. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J.Infect.Dis. 203:1719–1728. doi:jir191 [pii];10.1093/infdis/jir191 [doi].

127 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

972. Lorbetskie, B., J. Wang, C. Gravel, C. Allen, M. Walsh, A. Rinfret, X. Li, and M. Girard. 2011. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 29:3377– 3389. doi:S0264-410X(11)00338-0 [pii];10.1016/j.vaccine.2011.02.090 [doi]. 973. Loudon, P. T., E. J. Yager, D. T. Lynch, A. Narendran, C. Stagnar, A. M. Franchini, J. T. Fuller, P. A. White, J. Nyuandi, C. A. Wiley, M. Murphey-Corb, and D. H. Fuller. 2010. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS.One. 5:e11021. doi:10.1371/journal.pone.0011021 [doi]. 974. Louie, J. K., D. A. Wadford, A. Norman, and D. J. Jamieson. 2011. 2009 pandemic influenza A (H1N1) and vaccine failure in pregnancy. Obstet.Gynecol. 117:470–472. doi:10.1097/ AOG.0b013e3181fd2e38 [doi];00006250-201102001-00017 [pii]. 975. Loulergue, P., J. Alexandre, I. Iurisci, S. Grabar, J. Medioni, S. Ropert, V. Dieras, C. F. Le, S. Oudard, F. Goldwasser, P. Lebon, and O. Launay. 2011. Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. Br.J.Cancer 104:1670–1674. doi:bjc2011142 [pii];10.1038/bjc.2011.142 [doi]. 976. Loureiro, S., J. Ren, P. Phapugrangkul, C. A. Colaco, C. R. Bailey, H. Shelton, E. Molesti, N. J. Temperton, W. S. Barclay, and I. M. Jones. 2011. Adjuvant-free immunization with hemagglutinin- Fc fusion proteins as an approach to influenza vaccines. J.Virol. 85:3010–3014. doi:JVI.01241-10 [pii];10.1128/JVI.01241-10 [doi]. 977. Lower, J. 2010. [Pandemic influenza vaccines. How should they be designed?]. Bundesgesundheitsblatt.Gesundheitsforschung.Gesundheitsschutz. 53:1238–1241. doi:10.1007/ s00103-010-1159-z [doi]. 978. Lozano-Dubernard, B., E. Soto-Priante, D. Sarfati-Mizrahi, F. Castro-Peralta, R. Flores-Castro, E. Loza-Rubio, and M. Gay-Gutierrez. 2010. Protection and differentiation of infected from vaccinated animals by an inactivated recombinant Newcastle disease virus/avian influenza H5 vaccine. Avian Dis. 54:242–245. 979. Lu, C. C., Y. C. Wang, J. H. Lai, T. S. Lee, H. T. Lin, and D. M. Chang. 2011. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 29:444– 450. doi:S0264-410X(10)01594-X [pii];10.1016/j.vaccine.2010.10.081 [doi]. 980. Lu, C. Y., P. L. Shao, L. Y. Chang, Y. C. Huang, C. H. Chiu, Y. C. Hsieh, T. Y. Lin, and L. M. Huang. 2010. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 28:5864–5870. doi:S0264-410X(10)00881-9 [pii];10.1016/j.vaccine.2010.06.059 [doi]. 981. Lu, P. J. and G. L. Euler. 2011. Influenza, hepatitis B, and tetanus vaccination coverage among health care personnel in the United States. Am.J.Infect.Control 39:488–494. doi:S0196-6553(10)00944-2 [pii];10.1016/j.ajic.2010.10.009 [doi]. 982. Lu, W. and P. A. Tambyah. 2010. Safety and immunogenicity of influenza A H1N1 vaccines. Expert. Rev.Vaccines. 9:365–369. doi:10.1586/erv.10.23 [doi]. 983. Luke, J. M., A. E. Carnes, P. Sun, C. P. Hodgson, D. S. Waugh, and J. A. Williams. 2011. Thermostable tag (TST) protein expression system: engineering thermotolerant recombinant proteins and vaccines. J.Biotechnol. 151:242–250. doi:S0168-1656(10)02062-6 [pii];10.1016/j. jbiotec.2010.12.011 [doi]. 984. Luke, J. M., G. G. Simon, J. Soderholm, J. S. Errett, J. T. August, M. Gale, Jr., C. P. Hodgson, and J. A. Williams. 2011. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J.Virol. 85:1370–1383. doi:JVI.01250-10 [pii];10.1128/JVI.01250-10 [doi].

128 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

985. Luke, T. C., A. Casadevall, S. J. Watowich, S. L. Hoffman, J. H. Beigel, and T. H. Burgess. 2010. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 38:e66–e73. doi:10.1097/CCM.0b013e3181d44c1e [doi]. 986. Lum, L. C., C. F. Borja-Tabora, R. F. Breiman, T. Vesikari, B. P. Sablan, O. M. Chay, T. Tantracheewathorn, H. J. Schmitt, Y. L. Lau, P. Bowonkiratikachorn, J. S. Tam, B. W. Lee, K. K. Tan, J. Pejcz, S. Cha, M. Gutierrez-Brito, P. Kaltenis, A. Vertruyen, H. Czajka, J. Bojarskas, W. A. Brooks, S. M. Cheng, R. Rappaport, S. Baker, W. C. Gruber, and B. D. Forrest. 2010. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 28:1566–1574. doi:S0264-410X(09)01857-X [pii];10.1016/j.vaccine.2009.11.054 [doi]. 987. Luteijn, J. M., H. Dolk, and G. J. Marnoch. 2011. Differences in pandemic influenza vaccination policies for pregnant women in Europe. BMC.Public Health 11:819. doi:1471-2458-11-819 [pii];10.1186/1471-2458-11-819 [doi]. 988. Lynch, G. W., P. Selleck, W. B. Church, and J. S. Sullivan. 2011. Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans. Immunol.Cell Biol. doi:icb201138 [pii];10.1038/icb.2011.38 [doi]. 989. Lynch, J. R., E. Frankovich, C. A. Tetrick, and A. D. Howard. 2010. Improving influenza vaccination in dialysis facilities. Am.J.Med.Qual. 25:416–428. doi:1062860610367957 [pii];10.1177/1062860610367957 [doi]. 990. Lynch, M. M., E. W. Mitchell, J. L. Williams, K. Brumbaugh, M. Jones-Bell, D. E. Pinkney, C. M. Layton, P. W. Mersereau, J. S. Kendrick, P. E. Medina, and L. R. Smith. 2011. Pregnant and Recently Pregnant Women’s Perceptions about Influenza A Pandemic (H1N1) 2009: Implications for Public Health and Provider Communication. Matern.Child Health J. doi:10.1007/s10995-011-0865-y [doi]. 991. Ma, W. and J. A. Richt. 2010. Swine influenza vaccines: current status and future perspectives. Anim Health Res.Rev. 11:81–96. doi:S146625231000006X [pii];10.1017/S146625231000006X [doi]. 992. Machowicz, R., T. Wyszomirski, J. Ciechanska, N. Mahboobi, E. Wnekowicz, M. Obrowski, K. Zycinska, and T. M. Zielonka. 2010. Knowledge, attitudes, and influenza vaccination of medical students in Warsaw, Strasbourg, and Teheran. Eur.J.Med.Res. 15 Suppl 2:235–240. 993. Mackay, H. J., J. McGee, D. Villa, J. B. Gubbay, L. M. Tinker, L. Shi, J. Kuruvilla, L. Wang, K. MacAlpine, and A. M. Oza. 2011. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J.Clin.Virol. 50:212– 216. doi:S1386-6532(10)00464-6 [pii];10.1016/j.jcv.2010.11.013 [doi]. 994. MacLeod, M. K., A. S. McKee, A. David, J. Wang, R. Mason, J. W. Kappler, and P. Marrack. 2011. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc.Natl.Acad.Sci.U.S.A 108:7914–7919. doi:1104588108 [pii];10.1073/pnas.1104588108 [doi]. 995. Madhi, S. A., M. Maskew, A. Koen, L. Kuwanda, T. G. Besselaar, D. Naidoo, C. Cohen, M. Valette, C. L. Cutland, and I. Sanne. 2011. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin.Infect.Dis. 52:128–137. doi:ciq004 [pii];10.1093/cid/ciq004 [doi]. 996. Madhun, A. S., L. R. Haaheim, J. K. Nostbakken, T. Ebensen, J. Chichester, V. Yusibov, C. A. Guzman, and R. J. Cox. 2011. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine 29:4973–4982. doi:S0264-410X(11)00649-9 [pii];10.1016/j.vaccine.2011.04.094 [doi].

129 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

997. Madhun, A. S., P. E. Akselsen, H. Sjursen, G. Pedersen, S. Svindland, J. K. Nostbakken, M. Nilsen, K. Mohn, A. Jul-Larsen, I. Smith, D. Major, J. Wood, and R. J. Cox. 2010. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 29:266–273. doi:S0264-410X(10)01508-2 [pii];10.1016/j.vaccine.2010.10.038 [doi]. 998. Maggi, S. 2010. Vaccination and healthy aging. Expert.Rev.Vaccines. 9:3–6. doi:10.1586/erv.10.26 [doi]. 999. Mahajan, D., I. Roomiani, M. S. Gold, G. L. Lawrence, P. B. McIntyre, and R. I. Menzies. 2010. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun.Dis.Intell. 34:259–276. 1000. Mahajan, D., S. Campbell-Lloyd, J. Cook, and R. I. Menzies. 2011. NSW Annual Report Describing Adverse Events Following Immunisation, 2010. N.S.W.Public Health Bull. 22 :196–208. doi:NB11024 [pii];10.1071/NB11024 [doi]. 1001. Mahmud, S., G. Hammond, L. Elliott, T. Hilderman, C. Kurbis, P. Caetano, C. P. Van, J. Kettner, and M. Dawood. 2011. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine 29:7975–7981. doi:S0264- 410X(11)01327-2 [pii];10.1016/j.vaccine.2011.08.068 [doi]. 1002. Mahnke, Y. D., A. Saqr, S. Hazenfeld, R. C. Brady, M. Roederer, and R. A. Subbramanian. 2011. Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses. Vaccine 29:8606–8614. doi:S0264-410X(11)01425-3 [pii];10.1016/j. vaccine.2011.09.019 [doi]. 1003. Mahut, B., L. Refabert, V. Marchac, J. L. Iniguez, G. Aubertin, A. Tamalet, M. N. Lebras, C. Troadec, G. Chatellier, and C. Delclaux. 2011. Influenza-like illness responsible for severe exacerbations in asthmatic children during H1N1 pandemic: a survey before vaccination. J.Asthma 48:224–227. doi:1 0.3109/02770903.2011.555032 [doi]. 1004. Mallick, A. I., P. Parvizi, L. R. Read, E. Nagy, S. Behboudi, and S. Sharif. 2011. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine 29:1657–1665. doi:S0264-410X(10)01819-0 [pii];10.1016/j.vaccine.2010.12.046 [doi]. 1005. Mallory, R. M., E. Malkin, C. S. Ambrose, T. Bellamy, L. Shi, T. Yi, T. Jones, G. Kemble, and F. Dubovsky. 2010. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS.One. 5:e13755. doi:10.1371/journal.pone.0013755 [doi]. 1006. Mallory, R. M., T. Yi, and C. S. Ambrose. 2011. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6–59 months of age. Vaccine 29:4322–4327. doi:S0264- 410X(11)00534-2 [pii];10.1016/j.vaccine.2011.04.022 [doi]. 1007. Maltezou, H. C., S. Wicker, M. Borg, U. Heininger, V. Puro, M. Theodoridou, and G. A. Poland. 2011. Vaccination policies for health-care workers in acute health-care facilities in Europe. Vaccine. doi:S0264-410X(11)01495-2 [pii];10.1016/j.vaccine.2011.09.076 [doi]. 1008. Maltezou, H. C., X. Dedoukou, S. Patrinos, A. Maragos, S. Poufta, P. Gargalianos, and M. Lazanas. 2010. Determinants of intention to get vaccinated against novel (pandemic) influenza A H1N1 among health-care workers in a nationwide survey. J.Infect. 61:252–258. doi:S0163-4453(10)00171-4 [pii];10.1016/j.jinf.2010.06.004 [doi]. 1009. Mandusic, N. T., K. M. Pipic, and S. Tomic. 2010. Quality control of seasonal influenza vaccines. Arh. Hig.Rada Toksikol. 61:437–443. doi:H687401647672304 [pii];10.2478/10004-1254-61-2010- 2033 [doi].

130 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1010. Mantadakis, E., E. Farmaki, S. Thomaidis, A. Tsalkidis, and A. Chatzimichael. 2010. A case of immune thrombocytopenic purpura after influenza vaccination: consequence or coincidence? J.Pediatr.Hematol.Oncol. 32:e227–e229. doi:10.1097/MPH.0b013e3181e33fe0 [doi]. 1011. Manuel, O., A. Humar, C. Berutto, L. Ely, S. Giulieri, D. Lien, P. R. Meylan, J. Weinkauf, M. Pascual, R. Nador, J. D. Aubert, and D. Kumar. 2011. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J.Heart Lung Transplant. 30:679–684. doi:S1053-2498(11)00736-4 [pii];10.1016/j.healun.2011.01.705 [doi]. 1012. Manuel, O., M. Pascual, K. Hoschler, S. Giulieri, D. Alves, K. Ellefsen, P. A. Bart, J. P. Venetz, T. Calandra, and M. Cavassini. 2011. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin.Infect.Dis. 52:248–256. doi:ciq104 [pii];10.1093/cid/ciq104 [doi]. 1013. Manz, B., V. Gotz, K. Wunderlich, J. Eisel, J. Kirchmair, J. Stech, O. Stech, G. Chase, R. Frank, and M. Schwemmle. 2011. Disruption of the viral polymerase complex assembly as a novel approach to attenuate influenza A virus. J.Biol.Chem. 286:8414–8424. doi:M110.205534 [pii];10.1074/jbc. M110.205534 [doi]. 1014. Manzoli, L., V. C. De, G. Salanti, M. D’Addario, P. Villari, and J. P. Ioannidis. 2011. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS.One. 6:e24384. doi:10.1371/journal.pone.0024384 [doi];PONE1D-11-11001 [pii]. 1015. Manzur, A., C. Izquierdo, L. Ruiz, D. Sousa, J. M. Bayas, J. M. Celorrio, W. Varona, M. Nebot, L. Salleras, A. Dominguez, and J. Carratala. 2011. Influence of Prior Pneumococcal and Influenza Vaccination on Outcomes of Older Adults with Community-Acquired Pneumonia. J.Am.Geriatr.Soc. doi:10.1111/j.1532–5415.2011.03541.x [doi]. 1016. Marcelin, G., R. Dubois, A. Rubrum, C. J. Russell, J. E. McElhaney, and R. J. Webby. 2011. A Contributing Role for Anti-Neuraminidase Antibodies on Immunity to Pandemic H1N1 2009 Influenza A Virus. PLoS.One. 6:e26335. doi:10.1371/journal.pone.0026335 [doi];PONE-D-11-08355 [pii]. 1017. Marcus, P. I., J. M. Ngunjiri, M. J. Sekellick, L. Wang, and C. W. Lee. 2010. In vitro analysis of virus particle subpopulations in candidate live-attenuated influenza vaccines distinguishes effective from ineffective vaccines. J.Virol. 84:10974–10981. doi:JVI.00502-10 [pii];10.1128/JVI.00502-10 [doi]. 1018. Mares, B. J., A. D. van Esso, D. Moreno-Perez, M. M. Merino, F. J. Alvarez Garcia, M. J. Cilleruelo Ortega, F. J. Aristegui, C. L. Ortigosa del, J. Ruiz-Contreras, C. F. Barrio, and J. Gonzalez-Hachero. 2011. [Vaccination schedule of the Spanish Association of Paediatrics: recommendations 2011]. An.Pediatr.(Barc.) 74:132. doi:S1695-4033(10)00493-5 [pii];10.1016/j.anpedi.2010.10.004 [doi]. 1019. Marin, L. F., A. Abrahao, F. A. Carvalho, W. A. Santos, C. C. Dallalba, L. B. Barcelos, G. S. Silva, and A. S. Oliveira. 2010. Guillain-Barre syndrome associated with H1N1 vaccination. Arq Neuropsiquiatr. 68:974–975. doi:S0004-282X2010000600029 [pii]. 1020. Markushin, S. G., I. Gendon, G. G. Krivtsov, I. I. Akopova, A. S. Sukhno, and A. D. Pereverzev. 2010. [Increase of immunogenicity of cold-adapted influenza vaccine by using adjuvant]. Zh.Mikrobiol. Epidemiol.Immunobiol.29–34. 1021. Marshall, R. J., L. M. Tetu-Mouradjian, and J. P. Fulton. 2010. Increasing annual influenza vaccinations among healthcare workers in Rhode Island: a social marketing approach. Med.Health R.I. 93:271–278. 1022. Martel, C. J., E. M. Agger, J. J. Poulsen, J. T. Hammer, L. Andresen, D. Christensen, L. P. Nielsen, M. Blixenkrone-Moller, P. Andersen, and B. Aasted. 2011. CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. PLoS.One. 6:e22891. doi:10.1371/journal. pone.0022891 [doi];PONE-D-11-04727 [pii].

131 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1023. Martin Martinez, M. A., A. R. Carmona, and S. A. Sarria. 2010. [Improvement of the anti-flu vaccine coverage in people older than 65 years, but whom do we vaccinate?]. Med.Clin.(Barc.) 134:708– 709. doi:S0025-7753(09)00731-3 [pii];10.1016/j.medcli.2009.03.018 [doi]. 1024. Martin, M. P., S. Seth, D. G. Koutsonanos, J. Jacob, R. W. Compans, and I. Skountzou. 2010. Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. PLoS.One. 5:e10897. doi:10.1371/journal.pone.0010897 [doi]. 1025. Martina, B. E., P. van den Doel, P. Koraka, A. G. van, G. Spohn, B. L. Haagmans, L. B. Provacia, A. D. Osterhaus, and G. F. Rimmelzwaan. 2011. A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS. One. 6:e18995. doi:10.1371/journal.pone.0018995 [doi]. 1026. Martinon-Torres, F. and G. J. Pena. 2010. [Flu pandemic consequences in Spain might be minimized with conjugate anti-pneumococcal vaccine]. Arch.Bronconeumol. 46:335–336. doi:S0300- 2896(09)00461-X [pii];10.1016/j.arbres.2009.11.011 [doi]. 1027. Martins, W. A., M. D. Ribeiro, L. B. Oliveira, L. S. Barros, A. C. Jorge, C. M. Santos, D. P. Almeida, I. F. Cabral, R. T. Souza, and T. A. Furquim. 2011. Influenza and pneumococcal vaccination in heart failure: a little applied recommendation. Arq Bras.Cardiol. 96:240–245. doi:S0066- 782X2011005000010 [pii]. 1028. Mastelic, B., S. Ahmed, W. M. Egan, G. G. Del, H. Golding, I. Gust, P. Neels, S. G. Reed, R. L. Sheets, C. A. Siegrist, and P. H. Lambert. 2010. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 38:594–601. doi:S1045-1056(10)00120-X [pii];10.1016/j. biologicals.2010.06.002 [doi]. 1029. Mato, C. G., L. A. Mariano, P. F. Alcudia, and B. C. Verdejo. 2011. [Flu vaccination in the elderly]. Rev.Esp.Geriatr.Gerontol. 46:89–95. doi:S0211-139X(10)00248-9 [pii];10.1016/j.regg.2010.10.003 [doi]. 1030. Matrajt, L., Jr. and I. M. Longini. 2010. Optimizing vaccine allocation at different points in time during an epidemic. PLoS.One. 5:e13767. doi:10.1371/journal.pone.0013767 [doi]. 1031. Matsui, D., M. Shigeta, K. Ozasa, N. Kuriyama, I. Watanabe, and Y. Watanabe. 2011. Factors associated with influenza vaccination status of residents of a rural community in Japan. BMC.Public Health 11:149. doi:1471-2458-11-149 [pii];10.1186/1471-2458-11-149 [doi]. 1032. Matsui, M., S. Kohyama, T. Suda, S. Yokoyama, M. Mori, A. Kobayashi, M. Taneichi, and T. Uchida. 2010. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Biochem.Biophys.Res.Commun. 391:1494–1499. doi:S0006-291X(09)02473-5 [pii];10.1016/j.bbrc.2009.12.100 [doi]. 1033. Maurer, J. and K. M. Harris. 2011. Contact and communication with healthcare providers regarding influenza vaccination during the 2009–2010 H1N1 pandemic. Prev.Med. 52:459–464. doi:S0091-7435(11)00126-5 [pii];10.1016/j.ypmed.2011.03.016 [doi]. 1034. Maurer, J., L. Uscher-Pines, and K. M. Harris. 2010. Perceived seriousness of seasonal and A(H1N1) , attitudes toward vaccination, and vaccine uptake among U.S. adults: does the source of information matter? Prev.Med. 51:185–187. doi:S0091-7435(10)00183-0 [pii];10.1016/j. ypmed.2010.05.008 [doi]. 1035. Mavros, M. N., P. K. Mitsikostas, I. G. Kontopidis, D. N. Moris, G. Dimopoulos, and M. E. Falagas. 2011. H1N1v influenza vaccine in Greek medical students. Eur.J.Public Health 21:329–332. doi:ckq109 [pii];10.1093/eurpub/ckq109 [doi].

132 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1036. Mayet, A., C. Ligier, K. Gache, G. Manet, P. Nivoix, A. Dia, R. Haus-Cheymol, C. Verret, S. Duron, N. Faure, M. Piarroux, L. F. De, F. Simon, C. Decam, H. Chaudet, J. B. Meynard, C. Rapp, X. Deparis, and R. Migliani. 2011. Adverse events following pandemic influenza vaccine Pandemrix(R) reported in the French military forces – 2009–2010. Vaccine 29:2576–2581. doi:S0264-410X(11)00107-1 [pii];10.1016/j.vaccine.2011.01.056 [doi]. 1037. Mayor, S. 2010. Department of Health agrees deal with GSK to cancel part of swine flu vaccine order. BMJ 340:c1946. 1038. Mazurkova, N. A., I. Desheva, L. N. Shishkina, E. A. Stavskii, and L. G. Rudenko. 2011. [Immunogenicity of influenza virus H5N2 vaccine strain samples produced by roller cultivation in media with plant derived components]. Zh.Mikrobiol.Epidemiol.Immunobiol.48–52. 1039. Mazurkova, N. A., N. N. Ryndiuk, L. N. Shishkina, V. A. Ternovoi, I. Tumanov, L. E. Bulychev, M. O. Skarnovich, A. S. Kabanov, S. G. Panchenko, R. P. Aleinikov, T. N. Il’ina, V. I. Kuzubov, S. I. Mel’nikov, A. N. Mironov, S. A. Korovkin, A. N. Sergeev, and I. G. Drozdov. 2010. [Results of clinical trials on reactogenicity, safety, and immunogenicity of influenza allantoic intranasal live vaccine “Ultragrivac” (type A/H5N2)]. Vestn.Ross.Akad.Med.Nauk15–20. 1040. Mazurkova, N. A., Troshkova, L. N. Shishkina, E. A. Stavskii, and I. G. Drozdov. 2011. [Development of new nutrient medium for MDCK and Vero cells based on soy hydrolysate obtained using bromeline and assessment of growth characteristics of influenza virus vaccine strains cultivated on them]. Zh.Mikrobiol.Epidemiol.Immunobiol.86–90. 1041. McCarthy, A. E., C. Lafleur, J. Sutherland, P. P. Lam, V. Roth, A. M. O’Connor, and L. W. Chambers. 2010. Helping healthcare workers decide: evaluation of an influenza immunization decision tool. Can.J.Infect.Control 25:21–24. 1042. McCarthy, E. M., B. E. de, C. Bergin, G. Cunnane, and M. Doran. 2011. Influenza and pneumococcal vaccination and varicella status in inflammatory arthritis patients. Ir.Med.J. 104:208–211. 1043. McCarthy, N. L., J. Gee, E. Weintraub, J. G. Donahue, J. D. Nordin, M. F. Daley, A. Naleway, M. Henninger, R. Baxter, B. Crane, L. Aukes, N. Wagner, S. Fisher, S. J. Jacobsen, L. Sy, and J. Baggs. 2011. Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza. Vaccine 29:4891–4896. doi:S0264-410X(11)00696-7 [pii];10.1016/j. vaccine.2011.05.003 [doi]. 1044. McCullers, J. A., L. A. Van De Velde, K. J. Allison, K. C. Branum, R. J. Webby, and P. M. Flynn. 2010. Recipients of vaccine against the 1976 “swine flu” have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin.Infect.Dis. 50:1487–1492. doi:10.1086/652441 [doi]. 1045. McElhaney, J. E. 2011. Influenza vaccine responses in older adults. Ageing Res.Rev. 10:379–388. doi:S1568-1637(10)00109-1 [pii];10.1016/j.arr.2010.10.008 [doi]. 1046. McElligott, J. T. and P. M. Darden. 2010. Are patient-held vaccination records associated with improved vaccination coverage rates? Pediatrics 125:e467–e472. doi:peds.2009-0835 [pii];10.1542/peds.2009-0835 [doi]. 1047. McGill, J., R. N. Van, and K. L. Legge. 2010. IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. J.Exp.Med. 207:521–534. doi:jem.20091711 [pii];10.1084/jem.20091711 [doi]. 1048. McGuire-Wolfe, C. 2011. Impact of organizational structure on vaccination of first responders: a case study. Am.J.Disaster.Med. 6:71–72. 1049. McKinney, K. K., L. Webb, M. Petersen, M. Nelson, and S. Laubach. 2011. Ovalbumin content of 2010–2011 influenza vaccines. J.Allergy Clin.Immunol. 127:1629–1632. doi:S0091-6749(11)00259-4 [pii];10.1016/j.jaci.2011.02.003 [doi].

133 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1050. McKinstry, K. K., T. M. Strutt, and S. L. Swain. 2011. Hallmarks of CD4 T cell immunity against influenza. J.Intern.Med. 269:507–518. doi:10.1111/j.1365-2796.2011.02367.x [doi]. 1051. McLennan, S. and S. Wicker. 2010. Reflections on the influenza vaccination of healthcare workers. Vaccine 28:8061–8064. doi:S0264-410X(10)01488-X [pii];10.1016/j.vaccine.2010.10.019 [doi]. 1052. McNeil, M. M., K. R. Broder, C. Vellozzi, and F. DeStefano. 2010. Risk of fatal adverse events after H1N1 influenza vaccine: limitations of passive surveillance data. Clin.Infect.Dis. 51:871–872. doi:10.1086/656295 [doi]. 1053. McVernon, J. and T. Nolan. 2011. Panvax((R)): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009. Expert.Rev.Vaccines. 10:35–43. doi:10.1586/erv.10.143 [doi]. 1054. McVernon, J., K. Laurie, I. Barr, A. Kelso, M. Skeljo, and T. Nolan. 2011. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months–9 years: a prospective study. Influenza.Other Respi.Viruses. 5:7–11. doi:10.1111/j.1750-2659.2010.00172.x [doi]. 1055. Medina, R. A., B. Manicassamy, S. Stertz, C. W. Seibert, R. Hai, R. B. Belshe, S. E. Frey, C. F. Basler, P. Palese, and A. Garcia-Sastre. 2010. Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat.Commun. 1:28. doi:ncomms1026 [pii];10.1038/ncomms1026 [doi]. 1056. Meier, S., M. Bel, A. L’huillier, P. A. Crisinel, C. Combescure, L. Kaiser, S. Grillet, K. Posfay-Barbe, and C. A. Siegrist. 2011. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 29:3548–3557. doi:S0264-410X(11)00342-2 [pii];10.1016/j.vaccine.2011.02.094 [doi]. 1057. Melendi, G. A., D. Bridget, A. C. Monsalvo, F. F. Laham, P. Acosta, M. F. Delgado, F. P. Polack, and P. M. Irusta. 2011. Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses. Virus Genes 42:46–54. doi:10.1007/s11262-010-0545-9 [doi]. 1058. Melgar, M., R. E. De-Leon, M. Geronimo, M. Ramirez, E. J. Asturias, F. Antillon-Klussmann, D. Guimera, and M. A. Caniza. 2011. How we optimized prevention and control of pandemic 2009 influenza A (H1N1) in a resource-limited nation’s pediatric oncology unit. Am.J.Infect.Control 39:534–535. doi:S0196-6553(10)00989-2 [pii];10.1016/j.ajic.2010.10.012 [doi]. 1059. Mendelson, M. 2010. The scramble for influenza vaccine in 2010. S.Afr.Med.J. 100:428–430. 1060. Mendrinos, E. and E. Baglivo. 2010. Acute posterior multifocal placoid pigment epitheliopathy following influenza vaccination. Eye (Lond) 24:180–181. doi:eye200968 [pii];10.1038/eye.2009.68 [doi]. 1061. Menzies, R. and R. Andrews. 2011. Immunisation issues for Indigenous Australian children. J.Paediatr.Child Health. doi:10.1111/j.1440-1754.2011.02079.x [doi]. 1062. Mercer, G. and H. Kelly. 2011. Seasonal influenza vaccination and the 2009 pandemic. Clin.Infect.Dis. 52:828–829. doi:cir035 [pii];10.1093/cid/cir035 [doi]. 1063. Mereckiene, J., S. Cotter, F. D’Ancona, C. Giambi, A. Nicoll, D. Levy-Bruhl, P. L. Lopalco, J. T. Weber, K. Johansen, L. Dematte, S. Salmaso, P. Stefanoff, D. Greco, F. Dorleans, A. Polkowska, and D. O’Flanagan. 2010. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008–2009. Euro.Surveill 15. 1064. Meyer, S., M. Adam, B. Schweiger, C. Ilchmann, C. Eulenburg, E. Sattinger, H. Runte, M. Schluter, T. Deuse, H. Reichenspurner, and A. Costard-Jackle. 2011. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 91:1031–1035. doi:10.1097/TP.0b013e3182115be0 [doi].

134 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1065. Miao, L., L. Lu, J. Wu, L. D. Suo, D. L. Liu, M. P. Sun, X. H. Pang, Y. Deng, and X. L. Wang. 2010. [Analysis of adverse events following 2009 influenza A (H1N1) vaccinoprophylaxis in Beijing]. Zhonghua Yu Fang Yi.Xue.Za Zhi. 44:884–887. 1066. Michel, J. P. 2010. Updated vaccine guidelines for aging and aged citizens of Europe. Expert.Rev. Vaccines. 9:7–10. doi:10.1586/erv.10.27 [doi]. 1067. Michiels, B., F. Govaerts, R. Remmen, E. Vermeire, and S. Coenen. 2011. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 29:9159–9170. doi:S0264-410X(11)01217-5 [pii];10.1016/j.vaccine.2011.08.008 [doi]. 1068. Middelberg, A. P., T. Rivera-Hernandez, N. Wibowo, L. H. Lua, Y. Fan, G. Magor, C. Chang, Y. P. Chuan, M. F. Good, and M. R. Batzloff. 2011. A microbial platform for rapid and low-cost virus- like particle and capsomere vaccines. Vaccine 29:7154–7162. doi:S0264-410X(11)00822-X [pii];10.1016/j.vaccine.2011.05.075 [doi]. 1069. Middleman, A. B. and J. S. Tung. 2010. Urban middle school parent perspectives: the vaccines they are willing to have their children receive using school-based immunization programs. J.Adolesc.Health 47:249–253. doi:S1054-139X(10)00032-7 [pii];10.1016/j.jadohealth.2010.01.009 [doi]. 1070. Milkman, K. L., J. Beshears, J. J. Choi, D. Laibson, and B. C. Madrian. 2011. Using implementation intentions prompts to enhance influenza vaccination rates. Proc.Natl.Acad.Sci.U.S.A 108:10415– 10420. doi:1103170108 [pii];10.1073/pnas.1103170108 [doi]. 1071. Miller, D. S., J. Finnie, T. R. Bowden, A. C. Scholz, S. Oh, T. Kok, C. J. Burrell, L. Trinidad, D. B. Boyle, and P. Li. 2011. Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine. J.Gen.Virol. 92:1152–1161. doi:vir.0.028985-0 [pii];10.1099/ vir.0.028985-0 [doi]. 1072. Miller, E. K., L. Dumitrescu, C. Cupp, S. Dorris, S. Taylor, R. Sparks, D. Fawkes, V. Frontiero, A. M. Rezendes, C. Marchant, K. M. Edwards, and D. C. Crawford. 2011. Atopy history and the genomics of wheezing after influenza vaccination in children 6–59 months of age. Vaccine 29:3431–3437. doi:S0264-410X(11)00306-9 [pii];10.1016/j.vaccine.2011.02.071 [doi]. 1073. Millner, V. S., B. H. Eichold, R. D. Franks, and G. D. Johnson. 2010. Influenza vaccination acceptance and refusal rates among health care personnel. South.Med.J. 103:993–998. doi:10.1097/ SMJ.0b013e3181eda3d5 [doi]. 1074. Milunic, S. L., J. F. Quilty, D. M. Super, and G. H. Noritz. 2010. Patterns of influenza vaccination among medical students. Infect.Control Hosp.Epidemiol. 31:85–88. doi:10.1086/649219 [doi]. 1075. Min, J. Y., G. L. Chen, C. Santos, E. W. Lamirande, Y. Matsuoka, and K. Subbarao. 2010. Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. Virology 408:128–133. doi:S0042-6822(10)00584-2 [pii];10.1016/j.virol.2010.09.009 [doi]. 1076. Min, J. Y., L. Vogel, Y. Matsuoka, B. Lu, D. Swayne, H. Jin, G. Kemble, and K. Subbarao. 2010. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J.Virol. 84:11950–11960. doi:JVI.01305-10 [pii];10.1128/ JVI.01305-10 [doi]. 1077. Minor, D. S., J. T. Eubanks, K. R. Butler, Jr., M. R. Wofford, A. D. Penman, and W. H. Replogle. 2010. Improving influenza vaccination rates by targeting individuals not seeking early seasonal vaccination. Am.J.Med. 123:1031–1035. doi:S0002-9343(10)00577-2 [pii];10.1016/j.amjmed.2010.06.017 [doi]. 1078. Minor, P. D. 2010. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin.Infect.Dis. 50:560–565. doi:10.1086/650171 [doi].

135 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1079. Mirdamadi, K. and A. Einarson. 2011. H1N1 and influenza viruses: why pregnant women might be hesitant to be vaccinated. Can.Fam.Physician 57:1003–1004. doi:57/9/1003 [pii]. 1080. Mironov, A. N., A. A. Romanova, N. V. Dyldina, D. S. Bushmenkov, A. A. Tsaan, M. M. Alsynbaev, N. V. Zagidullin, and S. E. Kolbasov. 2010. [Results of preclinical study of inactivated subunit adsorbed monovalent influenza vaccine “PANDEFLU”]. Zh.Mikrobiol.Epidemiol.Immunobiol.27–32. 1081. Mironov, A. N., D. S. Bushmenkov, N. V. Dyldina, A. A. Romanova, A. A. Tsaan, S. I. Bryzgalova, O. V. Nikitina, and S. E. Kolbasov. 2010. [Results of preclinical studies of live monovalent influenza vaccine Influvir]. Zh.Mikrobiol.Epidemiol.Immunobiol.35–39. 1082. Mironov, A. N., D. S. Bushmenkov, N. V. Dyldina, A. A. Romanova, A. A. Tsaan, O. I. Kiselev, M. K. Erofeeva, and M. A. Stukova. 2010. [Study of tolerability and reactogenicity of pandemic vaccines against influenza type A/H1N1]. Zh.Mikrobiol.Epidemiol.Immunobiol.32–35. 1083. Miyaki, C., M. Meros, A. R. Precioso, and I. Raw. 2011. Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer. Vaccine 29 Suppl 1:A12– A15. doi:S0264-410X(11)00693-1 [pii];10.1016/j.vaccine.2011.04.127 [doi]. 1084. Miyaki, C., W. Quintilio, E. N. Miyaji, V. F. Botosso, F. S. Kubrusly, F. L. Santos, D. Iourtov, H. G. Higashi, and I. Raw. 2010. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine 28:2505–2509. doi:S0264-410X(10)00076-9 [pii];10.1016/j.vaccine.2010.01.044 [doi]. 1085. Miyakis, S., V. Giannakaki, E. Moustakidis, A. Trelopoulou, C. Trakatelli, V. Kotsis, and M. Sion. 2011. Vaccination against 2009 pandemic H1N1 influenza among healthcare workers in a tertiary hospital: rates, reasoning, beliefs. J.Hosp.Infect. 78:75–76. doi:S0195-6701(11)00015-6 [pii];10.1016/j. jhin.2010.12.014 [doi]. 1086. Mizuno, D., T. Kimoto, T. Takei, A. Fukuta, W. Shinahara, E. Takahashi, M. Yano, and H. Kido. 2011. Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity. Vaccine 29:5368–5378. doi:S0264-410X(11)00847-4 [pii];10.1016/j.vaccine.2011.05.090 [doi]. 1087. Mogasale, V. and J. Barendregt. 2011. Cost-effectiveness of influenza vaccination of people aged 50–64 years in Australia: results are inconclusive. Aust.N.Z.J.Public Health 35:180–186. doi:10.1111/j.1753-6405.2010.00639.x [doi]. 1088. Mohseni-Zadeh, M., D. Rey, M. L. Batard, W. G. Beck, M. L. Partisani, J. M. Lang, Y. Hansmann, D. Christmann, and M. Martinot. 2010. [Inadequate vaccination coverage in a French cohort of HIV positive patients]. Med.Mal Infect. 40:683–690. doi:S0399-077X(10)00154-X [pii];10.1016/j. medmal.2010.06.005 [doi]. 1089. Mohty, B., M. Bel, M. Vukicevic, M. Nagy, E. Levrat, S. Meier, S. Grillet, C. Combescure, L. Kaiser, Y. Chalandon, J. Passweg, C. A. Siegrist, and E. Roosnek. 2011. Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica 96:896–904. doi:haematol.2011.040386 [pii];10.3324/haematol.2011.040386 [doi]. 1090. Molnar, T., K. Farkas, I. Jankovics, M. Melles, F. Nagy, Z. Szepes, and T. Wittmann. 2011. Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy. Am.J.Gastroenterol. 106:370–372. doi:ajg2010395 [pii];10.1038/ajg.2010.395 [doi]. 1091. Montagnani, S., M. Tuccori, G. Lombardo, A. Testi, S. Mantarro, E. Ruggiero, and C. Blandizzi. 2011. Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. Ann.Pharmacother. 45:e8. doi:aph.1P480 [pii];10.1345/aph.1P480 [doi].

136 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1092. Montaner, A. D., A. Denichilo, J. M. Rodriguez, J. Flo, R. A. Lopez, A. Pontoriero, V. Savy, E. Baumeister, R. Frank, J. Zorzopulos, and F. Elias. 2011. Addition of the immunostimulatory oligonucleotide IMT504 to a seasonal flu vaccine increases hemagglutinin antibody titers in young adult and elder rats, and expands the anti-hemagglutinin antibody repertoire. Nucleic Acid Ther. 21:265–274. doi:10.1089/nat.2011.0284 [doi]. 1093. Montastruc, J. L., G. Durrieu, and O. Rascol. 2011. Pandemrix degrees , (H1N1)v influenza and reported cases of narcolepsy. Vaccine 29:2010. doi:S0264-410X(10)01865-7 [pii];10.1016/j. vaccine.2010.12.092 [doi]. 1094. Monto, A. S. 2010. Seasonal influenza and vaccination coverage. Vaccine 28 Suppl 4:D33–D44. doi:S0264-410X(10)01136-9 [pii];10.1016/j.vaccine.2010.08.027 [doi]. 1095. Monto, A. S. 2010. Seasonal influenza vaccinations: specialized products for different target groups. Vaccine 28 Suppl 4:D14–D23. doi:S0264-410X(10)01134-5 [pii];10.1016/j.vaccine.2010.08.025 [doi]. 1096. Morabia, A. and M. C. Costanza. 2010. Influenza vaccine coverage: resistance and alternatives. Prev. Med. 50:221–222. doi:S0091-7435(10)00119-2 [pii];10.1016/j.ypmed.2010.04.006 [doi]. 1097. Morabia, A. and M. C. Costanza. 2011. Influenza epidemics: do we really want more protection? Prev. Med. 52:411–412. doi:S0091-7435(11)00178-2 [pii];10.1016/j.ypmed.2011.05.007 [doi]. 1098. Moraes, T. J., G. H. Lin, T. Wen, and T. H. Watts. 2011. Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease. Vaccine 29:6301– 6312. doi:S0264-410X(11)00886-3 [pii];10.1016/j.vaccine.2011.06.022 [doi]. 1099. Morel, S., A. Didierlaurent, P. Bourguignon, S. Delhaye, B. Baras, V. Jacob, C. Planty, A. Elouahabi, P. Harvengt, H. Carlsen, A. Kielland, P. Chomez, N. Garcon, and M. M. Van. 2011. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461–2473. doi:S0264-410X(11)00039-9 [pii];10.1016/j. vaccine.2011.01.011 [doi]. 1100. Morelon, E., N. C. Pouteil, S. Daoud, R. Cahen, C. Goujon-Henry, F. Weber, P. E. Laurent, D. Kaiserlian, and J. F. Nicolas. 2010. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 28:6885–6890. doi:S0264-410X(10)01124-2 [pii];10.1016/j.vaccine.2010.08.015 [doi]. 1101. Morihara, K., Y. Arakawa, H. Takenaka, T. Morihara, and N. Katoh. 2011. Systemic lupus erythematosus following vaccination against 2009 influenza A (H1N1). Lupus 20:775–776. doi:0961203310389485 [pii];10.1177/0961203310389485 [doi]. 1102. Morikane, K. 2010. [Changing management of pandemic influenza]. Rinsho Byori 58:254–262. 1103. Moris, P., R. van der Most, I. Leroux-Roels, F. Clement, M. Drame, E. Hanon, G. G. Leroux-Roels, and M. M. Van. 2011. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T–cell responses. J.Clin.Immunol. 31:443–454. doi:10.1007/s10875-010-9490- 6 [doi]. 1104. Moro, P. L., K. Broder, Y. Zheteyeva, K. Walton, P. Rohan, A. Sutherland, A. Guh, P. Haber, F. Destefano, and C. Vellozzi. 2011. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990–2009. Am.J.Obstet.Gynecol. 204:146–147. doi:S0002-9378(10)01105-1 [pii];10.1016/j.ajog.2010.08.050 [doi]. 1105. Moro, P. L., K. Broder, Y. Zheteyeva, N. Revzina, N. Tepper, D. Kissin, F. Barash, J. Arana, M. D. Brantley, H. Ding, J. A. Singleton, K. Walton, P. Haber, P. Lewis, X. Yue, F. Destefano, and C. Vellozzi. 2011. Adverse events following administration to pregnant women of influenza A (H1N1) 2009

137 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am.J.Obstet.Gynecol. 205:473–479. doi:S0002-9378(11)00775-7 [pii];10.1016/j.ajog.2011.06.047 [doi]. 1106. Morton, M. J., E. B. Hsu, S. H. Shah, Y. H. Hsieh, and T. D. Kirsch. 2011. Pandemic influenza and major disease outbreak preparedness in US emergency departments: a selected survey of emergency health professionals. Am.J.Disaster.Med. 6:187–195. 1107. Mosby, L. G., S. R. Ellington, S. E. Forhan, L. F. Yeung, M. Perez, M. M. Shah, K. MacFarlane, S. K. Laird, L. D. House, and D. J. Jamieson. 2011. The Centers for Disease Control and Prevention’s maternal health response to 2009 H1N1 influenza. Am.J.Obstet.Gynecol. 204:S7–12. doi:S0002- 9378(11)00247-X [pii];10.1016/j.ajog.2011.02.057 [doi]. 1108. Moser, C., M. Amacker, and R. Zurbriggen. 2011. Influenza virosomes as a vaccine adjuvant and carrier system. Expert.Rev.Vaccines. 10:437–446. doi:10.1586/erv.11.15 [doi]. 1109. Mu, X. D. 2011. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N.Engl.J.Med. 364:1181–1182. doi:10.1056/NEJMc1100442#SA2 [doi]. 1110. Mueller, S., J. R. Coleman, D. Papamichail, C. B. Ward, A. Nimnual, B. Futcher, S. Skiena, and E. Wimmer. 2010. Live attenuated influenza virus vaccines by computer-aided rational design. Nat. Biotechnol. 28:723–726. doi:nbt.1636 [pii];10.1038/nbt.1636 [doi]. 1111. Muhammad, H. S. and B. Hayes. 2010. Factors determining uptake of influenza vaccine among healthcare workers in a hospital setting. J.Hosp.Infect. 76:90–91. doi:S0195-6701(10)00240-9 [pii];10.1016/j.jhin.2010.05.008 [doi]. 1112. Muhammad, R. D., P. Haber, K. R. Broder, Z. Leroy, R. Ball, M. M. Braun, R. L. Davis, and A. W. McMahon. 2010. Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System. Pediatr.Infect.Dis.J. doi:10.1097/ INF.0b013e3181ff9795 [doi]. 1113. Mukhopadhyay, T. K. 2010. Vaccines Europe 2009. Expert.Rev.Vaccines. 9:125–128. doi:10.1586/ erv.09.162 [doi]. 1114. Mulder, S. F., J. F. Jacobs, M. A. Olde Nordkamp, J. M. Galama, I. M. Desar, R. Torensma, S. Teerenstra, P. F. Mulders, K. C. Vissers, C. J. Punt, I. J. de Vries, and C. M. van Herpen. 2011. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin.Cancer Res. 17:4541–4549. doi:1078-0432.CCR-11-0253 [pii];10.1158/1078-0432.CCR-11-0253 [doi]. 1115. Mullins, R. J. and M. S. Gold. 2011. Influenza vaccination of the egg-allergic individual. Med.J.Aust. 195:52–53. doi:letters_040711_fm-2 [pii]. 1116. Munoz, M. P., N. Soldevila, A. Martinez, G. Carmona, J. Batalla, L. M. Acosta, and A. Dominguez. 2011. Influenza vaccine coverage, influenza-associated morbidity and all-cause mortality in Catalonia (Spain). Vaccine 29:5047–5052. doi:S0264-410X(11)00612-8 [pii];10.1016/j.vaccine.2011.04.067 [doi]. 1117. Murata, H., J. Macauley, A. M. Lewis, Jr., and K. Peden. 2011. Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds. Vaccine 29:3155–3161. doi:S0264-410X(11)00254-4 [pii];10.1016/j.vaccine.2011.02.041 [doi]. 1118. Myers, A. L., J. Lantos, L. Douville, and M. A. Jackson. 2010. Healthcare worker knowledge and attitudes regarding influenza immunization and childhood vaccination. Infect.Control Hosp.Epidemiol. 31:643–646. doi:10.1086/652777 [doi]. 1119. Myers, C. A., D. J. Faix, and P. J. Blair. 2011. Possible reduced effectiveness of the 2009 H1N1 component of live, attenuated influenza vaccine. Clin.Infect.Dis. 53:207–208. doi:cir282 [pii];10.1093/cid/cir282 [doi].

138 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1120. Myers, E. R., D. A. Misurski, and G. K. Swamy. 2011. Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy. Am.J.Obstet.Gynecol. 204:S128– S140. doi:S0002-9378(11)00455-8 [pii];10.1016/j.ajog.2011.04.009 [doi]. 1121. Myers, L. B. and R. Goodwin. 2011. Determinants of adults’ intention to vaccinate against pandemic swine flu. BMC.Public Health 11:15. doi:1471-2458-11-15 [pii];10.1186/1471-2458-11-15 [doi]. 1122. Nabel, G. J. and A. S. Fauci. 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat.Med. 16:1389–1391. doi:nm1210-1389 [pii];10.1038/ nm1210-1389 [doi]. 1123. Nabel, G. J., C. J. Wei, and J. E. Ledgerwood. 2011. Vaccinate for the next H2N2 pandemic now. Nature 471:157–158. doi:471157a [pii];10.1038/471157a [doi]. 1124. Nagai, H., H. Ikematsu, K. Tenjinbaru, A. Maeda, M. Drame, and F. P. Roman. 2010. A phase II, open- label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. BMC.Infect.Dis. 10:338. doi:1471-2334-10- 338 [pii];10.1186/1471-2334-10-338 [doi]. 1125. Nagai, T., Y. Shimizu, T. Shirahata, T. Sunazuka, H. Kiyohara, S. Omura, and H. Yamada. 2010. Oral adjuvant activity for nasal influenza vaccines caused by combination of two trihydroxy fatty acid stereoisomers from the tuber of Pinellia ternata. Int.Immunopharmacol. 10:655–661. doi:S1567-5769(10)00077-9 [pii];10.1016/j.intimp.2010.03.004 [doi]. 1126. Nailescu, C., X. Xu, H. Zhou, H. Hall, A. C. Wilson, J. D. Leiser, D. H. Chand, R. P. Valentini, D. Hebert, and J. D. Mahan. 2011. Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study. Pediatr.Nephrol. 26:459–467. doi:10.1007/s00467-010-1729-1 [doi]. 1127. Nakada, H., N. Murashige, T. Matsumura, Y. Kodama, and M. Kami. 2010. Informal network of communication tools played an important role in sharing safety information on H1N1 influenza vaccine. Clin.Infect.Dis. 51:873–874. doi:10.1086/656297 [doi]. 1128. Nakaya, H. I., J. Wrammert, E. K. Lee, L. Racioppi, S. Marie-Kunze, W. N. Haining, A. R. Means, S. P. Kasturi, N. Khan, G. M. Li, M. McCausland, V. Kanchan, K. E. Kokko, S. Li, R. Elbein, A. K. Mehta, A. Aderem, K. Subbarao, R. Ahmed, and B. Pulendran. 2011. Systems biology of vaccination for seasonal influenza in humans. Nat.Immunol. 12:786–795. doi:ni.2067 [pii];10.1038/ni.2067 [doi]. 1129. Nakowitsch, S., M. Wolschek, A. Morokutti, T. Ruthsatz, B. M. Krenn, B. Ferko, N. Ferstl, A. Triendl, T. Muster, A. Egorov, and J. Romanova. 2011. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine 29:3517–3524. doi:S0264-410X(11)00348-3 [pii];10.1016/j. vaccine.2011.02.100 [doi]. 1130. Nam, J. S., A. R. Kim, J. C. Yoon, Y. Byun, S. A. Kim, K. R. Kim, S. Cho, B. L. Seong, C. W. Ahn, and J. M. Lee. 2011. The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 mellitus in Korea. Diabet.Med. 28:815–817. doi:10.1111/j.1464-5491.2011.03255.x [doi]. 1131. Nara, P. L., G. J. Tobin, A. R. Chaudhuri, J. D. Trujillo, G. Lin, M. W. Cho, S. A. Levin, W. Ndifon, and N. S. Wingreen. 2010. How can vaccines against influenza and other viral diseases be made more effective? PLoS.Biol. 8:e1000571. doi:10.1371/journal.pbio.1000571 [doi]. 1132. Narula, N., D. L. Yamamura, and J. K. Marshall. 2010. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? Can.J.Gastroenterol. 24:121–125. 1133. Nativ, T., A. Paz, I. Peterfreund, and I. Potasman. 2010. [Influence of knowledge and attitude on the uptake of influenza vaccine by healthcare workers]. Harefuah 149:626–9, 685.

139 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1134. Nayak, B., S. Kumar, J. M. DiNapoli, A. Paldurai, D. R. Perez, P. L. Collins, and S. K. Samal. 2010. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J.Virol. 84:2408–2420. doi:JVI.02135-09 [pii];10.1128/JVI.02135-09 [doi]. 1135. Nayak, J. L., K. A. Richards, F. A. Chaves, and A. J. Sant. 2010. Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins. Viral Immunol. 23:169–180. doi:10.1089/ vim.2009.0099 [doi]. 1136. Nelson, C. A., E. K. France, S. M. Shetterly, and J. M. Glanz. 2011. Seasonal influenza vaccination status among children with laboratory evidence of pandemic H1N1 infection. Pediatr.Infect.Dis.J. 30:562–565. doi:10.1097/INF.0b013e31820bb482 [doi]. 1137. Nelson, M. R. 2011. A no-fault compensation scheme for serious adverse events attributed to vaccination. Med.J.Aust. 195:263. doi:letters_fm-2 [pii]. 1138. Nembrini, C., A. Stano, K. Y. Dane, M. Ballester, A. J. van der Vlies, B. J. Marsland, M. A. Swartz, and J. A. Hubbell. 2011. From the Cover: Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc.Natl.Acad.Sci.U.S.A 108:E989–E997. doi:1104264108 [pii];10.1073/pnas.1104264108 [doi]. 1139. Neumann, G. and Y. Kawaoka. 2011. The first influenza pandemic of the new millennium. Influenza. Other Respi.Viruses. 5:157–166. doi:10.1111/j.1750-2659.2011.00231.x [doi]. 1140. Neumeier, E. 2011. [Flu vaccine production in hens’s eggs]. Pharm.Unserer Zeit 40:136–139. 1141. Newall, A. T., J. G. Wood, N. Oudin, and C. R. MacIntyre. 2010. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies. Emerg.Infect.Dis. 16:224–230. doi:10.3201/eid1602.090571 [doi]. 1142. Newman, A. B., C. M. Bayles, C. N. Milas, K. McTigue, K. Williams, J. F. Robare, C. A. Taylor, S. M. Albert, and L. H. Kuller. 2010. The 10 keys to healthy aging: findings from an innovative prevention program in the community. J.Aging Health 22:547–566. doi:0898264310363772 [pii];10.1177/0898264310363772 [doi]. 1143. Ng, S., P. Wu, H. Nishiura, D. K. Ip, E. S. Lee, and B. J. Cowling. 2011. An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009–10 and 2010–11. BMC.Infect.Dis. 11:230. doi:1471-2334-11-230 [pii];10.1186/1471-2334- 11-230 [doi]. 1144. Nguyen, T., A. Rashford, and C. R. Penn. 2011. Influenza in the 21st century: a call for papers. Bull. World Health Organ 89:318. doi:10.2471/BLT.11.088476 [doi]. 1145. Nguyen-Van-Tam, J. S., P. J. Openshaw, A. Hashim, E. M. Gadd, W. S. Lim, M. G. Semple, R. C. Read, B. L. Taylor, S. J. Brett, J. McMenamin, J. E. Enstone, C. Armstrong, and K. G. Nicholson. 2010. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May–September 2009). Thorax 65:645–651. doi:65/7/645 [pii];10.1136/ thx.2010.135210 [doi]. 1146. Nichol, K. L., K. Tummers, A. Hoyer-Leitzel, J. Marsh, M. Moynihan, and S. McKelvey. 2010. Modeling seasonal influenza outbreak in a closed college campus: impact of pre-season vaccination, in-season vaccination and holidays/breaks. PLoS.One. 5:e9548. doi:10.1371/journal.pone.0009548 [doi]. 1147. Nicholson, K. G., K. R. Abrams, S. Batham, T. W. Clark, K. Hoschler, W. S. Lim, M. Medina, J. S. Nguyen-Van-Tam, R. C. Read, F. C. Warren, and M. Zambon. 2010. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. Health Technol.Assess. 14:193–334. doi:10.3310/hta14550-04 [doi].

140 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1148. Nicholson, K. G., K. R. Abrams, S. Batham, T. W. Clark, K. Hoschler, W. S. Lim, M. J. Medina, J. S. Nguyen-Van-Tam, R. C. Read, F. C. Warren, and M. Zambon. 2011. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect.Dis. 11:91–101. doi:S1473-3099(10)70296-6 [pii];10.1016/S1473-3099(10)70296-6 [doi]. 1149. Nicoll, A. 2010. Pandemic risk prevention in European countries: role of the ECDC in preparing for pandemics. Development and experience with a national self-assessment procedure, 2005–2008. Bundesgesundheitsblatt.Gesundheitsforschung.Gesundheitsschutz. 53:1267–1275. doi:10.1007/ s00103-010-1163-3 [doi]. 1150. Nicoll, A., A. Ammon, G. A. Amato, B. Ciancio, P. Zucs, I. Devaux, F. Plata, A. Mazick, K. Molbak, T. Asikainen, and P. Kramarz. 2010. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Public Health 124:14–23. doi:S0033-3506(09)00367-9 [pii];10.1016/j. puhe.2009.12.001 [doi]. 1151. Niculescu, C. and J. M. Balloul. 2010. A key for successful development of flu vaccines: public-private collaboration – the Barcelona Vaccine Forum, Phacilitate, the Fira Palace Barcelona Spain, 21–23 June, 2010, the meeting report. Hum.Vaccin. 6:966–969. doi:13353 [pii];10.4161/hv.6.12.13353 [doi]. 1152. Nielsen, J. S., D. A. Wick, E. Tran, B. H. Nelson, and J. R. Webb. 2010. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. J.Immunol.Methods 360:149–156. doi:S0022-1759(10)00199-7 [pii];10.1016/j.jim.2010.07.003 [doi]. 1153. Nikolakopoulou, N. M. 2010. H1N1 vaccine acceptance among parents in Greece. Int.J.Adolesc.Med. Health 22:339–340. 1154. Nishiura, H. and H. Oshitani. 2011. Effects of vaccination against pandemic (H1N1) 2009 among Japanese children. Emerg.Infect.Dis. 17:746–747. doi:10.3201/eid1706.100525 [doi]. 1155. Nitsch-Osuch, A., E. Kuchar, K. Zycinska, A. Topczewska-Cabanek, E. Gyrczuk, and K. Wardyn. 2010. Influenza vaccine coverage among children under the age of 5 years in Poland during 2004–2008. Eur.J.Med.Res. 15 Suppl 2:102–104. 1156. Nolan, T., J. McVernon, M. Skeljo, P. Richmond, U. Wadia, S. Lambert, M. Nissen, H. Marshall, R. Booy, L. Heron, G. Hartel, M. Lai, R. Basser, C. Gittleson, and M. Greenberg. 2010. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303:37–46. doi:2009.1911 [pii];10.1001/jama.2009.1911 [doi]. 1157. Nougairede, A., J. C. Lagier, L. Ninove, C. Sartor, S. Badiaga, E. Botelho, P. Brouqui, C. Zandotti, L. De, X, S. B. La, M. Drancourt, E. A. Gould, R. N. Charrel, and D. Raoult. 2010. Likely correlation between sources of information and acceptability of A/H1N1 swine-origin influenza virus vaccine in Marseille, France. PLoS.One. 5:e11292. doi:10.1371/journal.pone.0011292 [doi]. 1158. Nowalk, M. P., C. J. Lin, R. K. Zimmerman, D. E. Fox, M. Raymund, M. D. Tanis, and J. D. Harper. 2010. Establish the habit: influenza vaccination for health care personnel. J.Healthc.Qual. 32:35–42. 1159. Nowalk, M. P., C. J. Lin, S. L. Toback, M. D. Rousculp, C. Eby, M. Raymund, and R. K. Zimmerman. 2010. Improving influenza vaccination rates in the workplace: a randomized trial. Am.J.Prev.Med. 38:237–246. doi:S0749-3797(09)00852-6 [pii];10.1016/j.amepre.2009.11.011 [doi]. 1160. Ogimi, C., R. Tanaka, A. Saitoh, and T. Oh-Ishi. 2011. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr.Infect.Dis.J. 30:208– 211. doi:10.1097/INF.0b013e3181f7ce44 [doi].

141 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1161. Oh, C. E., J. Lee, J. H. Kang, Y. J. Hong, Y. K. Kim, H. J. Cheong, Y. J. Ahn, S. H. Kim, and H. J. Lee. 2010. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 28:5857–5863. doi:S0264-410X(10)00882-0 [pii];10.1016/j.vaccine.2010.06.060 [doi]. 1162. O’Hagan, D. T., R. Rappuoli, G. E. De, T. Tsai, and G. G. Del. 2011. MF59 adjuvant: the best insurance against influenza strain diversity. Expert.Rev.Vaccines. 10:447–462. doi:10.1586/erv.11.23 [doi]. 1163. Ohara, M., M. Tsubokura, H. Naoto, M. Kami, and T. Mochizuki. 2011. H1N1 influenza A outbreak among young medical staff members who received single dose of non-adjuvanted split-virion 2009 H1N1 vaccine. Hum.Vaccin. 7:56–57. doi:13459 [pii]. 1164. Ohara, Y. 2010. [Communication between health care professionals and patients]. Rinsho Byori 58:595–605. 1165. Ohfuji, S., W. Fukushima, M. Deguchi, K. Kawabata, H. Yoshida, H. Hatayama, A. Maeda, and Y. Hirota. 2011. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J.Infect.Dis. 203:1301–1308. doi:jir026 [pii];10.1093/infdis/jir026 [doi]. 1166. Ohmit, S. E., J. G. Petrie, R. T. Cross, E. Johnson, and A. S. Monto. 2011. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J.Infect.Dis. 204:1879–1885. doi:jir661 [pii];10.1093/infdis/jir661 [doi]. 1167. Ohshima, N., H. Ariga, M. Shindo, and H. Nagai. 2010. [Safety of simultaneous H1N1 and seasonal influenza vaccination in Japan]. Kansenshogaku Zasshi 84:744–745. 1168. O’Leary, S. T., J. C. Barrow, L. McQuillan, M. F. Daley, L. A. Crane, B. L. Beaty, C. I. Babbel, L. M. Dickinson, and A. Kempe. 2011. Influenza vaccine delivery delays from the perspective of primary care physicians. Am.J.Prev.Med. 40:620–624. doi:S0749-3797(11)00138-3 [pii];10.1016/j. amepre.2011.02.021 [doi]. 1169. Omer, S. B., D. Goodman, M. C. Steinhoff, R. Rochat, K. P. Klugman, B. J. Stoll, and U. Ramakrishnan. 2011. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS.Med. 8:e1000441. doi:10.1371/ journal.pmed.1000441 [doi];10-PLME-RA-5455R3 [pii]. 1170. Omon, E., C. Damase-Michel, C. Hurault-Delarue, I. Lacroix, J. L. Montastruc, S. Oustric, and B. Escourrou. 2011. Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: The results of a French prospective descriptive study. Vaccine. doi:S0264-410X(11)01641-0 [pii];10.1016/j. vaccine.2011.10.034 [doi]. 1171. O’Neill, A. M., E. J. Livant, and S. J. Ewald. 2010. Interferon alpha-induced inhibition of infectious bursal disease virus in chicken embryo fibroblast cultures differing in Mx genotype. Avian Dis. 54:802–806. 1172. Ong, R., A. L. Kwa, and W. Lee. 2011. Dual pneumococcal and influenza vaccination in elderly patients with chronic illnesses: protective benefits overestimated? Clin.Infect.Dis. 52:558–559. doi:ciq187 [pii];10.1093/cid/ciq187 [doi]. 1173. Openshaw, P. J. and J. Dunning. 2010. Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak. Mucosal.Immunol. 3:422–424. doi:mi201034 [pii];10.1038/ mi.2010.34 [doi]. 1174. Opstelten, W., G. A. van Essen, M. L. Heijnen, M. J. Ballieux, and A. N. Goudswaard. 2010. High vaccination rates for seasonal and pandemic (A/H1N1) influenza among healthcare workers in Dutch general practice. Vaccine 28:6164–6168. doi:S0264-410X(10)01026-1 [pii];10.1016/j. vaccine.2010.07.031 [doi].

142 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1175. Orellano, P. W., J. I. Reynoso, O. Carlino, and O. Uez. 2010. Protection of trivalent inactivated influenza vaccine against hospitalizations among pandemic influenza A (H1N1) cases in . Vaccine 28:5288–5291. doi:S0264-410X(10)00749-8 [pii];10.1016/j.vaccine.2010.05.051 [doi]. 1176. Oria, P. A., W. Matini, I. Nelligan, G. Emukule, M. Scherzer, B. Oyier, H. N. Ochieng, L. Hooper, A. Kanyuga, P. Muthoka, K. F. Morales, C. Nzioka, R. F. Breiman, and M. A. Katz. 2011. Are Kenyan healthcare workers willing to receive the pandemic influenza vaccine? Results from a cross-sectional survey of healthcare workers in Kenya about knowledge, attitudes and practices concerning infection with and vaccination against 2009 pandemic influenza A (H1N1), 2010. Vaccine 29:3617–3622. doi:S0264-410X(11)00123-X [pii];10.1016/j.vaccine.2011.01.063 [doi]. 1177. Orlando, G., E. Pariani, F. Mazza, E. Tanzi, P. Meraviglia, E. Gianelli, B. Argenteri, A. Amendola, M. Galli, G. Rizzardini, and A. Zanetti. 2010. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS 24:2142–2143. doi:10.1097/QAD.0b013e32833cfcb0 [doi];00002030-201008240-00027 [pii]. 1178. Ortiz, J. R. and K. M. Neuzil. 2011. The promise of maternal vaccination to prevent influenza in young infants. Arch.Pediatr.Adolesc.Med. 165:179–180. doi:archpediatrics.2010.193 [pii];10.1001/ archpediatrics.2010.193 [doi]. 1179. Ortiz, J. R., J. A. Englund, and K. M. Neuzil. 2011. Influenza vaccine for pregnant women in resource- constrained countries: a review of the evidence to inform policy decisions. Vaccine 29:4439–4452. doi:S0264-410X(11)00593-7 [pii];10.1016/j.vaccine.2011.04.048 [doi]. 1180. Ortiz, J. R., K. M. Neuzil, J. C. Victor, M. L. Aitken, and C. H. Goss. 2010. Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007. Chest 138:1448– 1455. doi:chest.10-0356 [pii];10.1378/chest.10-0356 [doi]. 1181. Ortqvist, A., I. Berggren, M. Insulander, J. B. de, and B. Svenungsson. 2011. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin.Infect.Dis. 52:1203–1211. doi:cir182 [pii];10.1093/cid/cir182 [doi]. 1182. Oster, G., D. Weycker, J. Edelsberg, K. L. Nichol, J. O. Klein, and R. B. Belshe. 2010. Benefits and risks of live attenuated influenza vaccine in young children. Am.J.Manag.Care 16:e235–e244. 1183. Osterhaus, A., R. Fouchier, and G. Rimmelzwaan. 2011. Towards universal influenza vaccines? Philos. Trans.R.Soc.Lond B Biol.Sci. 366:2766–2773. doi:366/1579/2766 [pii];10.1098/rstb.2011.0102 [doi]. 1184. Osterholm, M. T., N. S. Kelley, A. Sommer, and E. A. Belongia. 2011. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect.Dis. doi:S1473- 3099(11)70295-X [pii];10.1016/S1473-3099(11)70295-X [doi]. 1185. Ottenberg, A. L., J. T. Wu, G. A. Poland, R. M. Jacobson, B. A. Koenig, and J. C. Tilburt. 2011. Vaccinating health care workers against influenza: the ethical and legal rationale for a mandate. Am.J.Public Health 101:212–216. doi:101/2/212 [pii];10.2105/AJPH.2009.190751 [doi]. 1186. Oveissi, S., A. R. Omar, K. Yusoff, F. Jahanshiri, and S. S. Hassan. 2010. DNA vaccine encoding avian influenza virus H5 and Esat-6 of Mycobacterium tuberculosis improved antibody responses against AIV in chickens. Comp Immunol.Microbiol.Infect.Dis. 33:491–503. doi:S0147-9571(09)00046-0 [pii];10.1016/j.cimid.2009.08.004 [doi]. 1187. Owens, G. and A. MacGinnitie. 2011. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J.Allergy Clin.Immunol. 127:264–265. doi:S0091-6749(10)01564-2 [pii];10.1016/j.jaci.2010.10.005 [doi]. 1188. Ozawa, M. and Y. Kawaoka. 2011. Taming influenza viruses. Virus Res. doi:S0168-1702(11)00388-1 [pii];10.1016/j.virusres.2011.09.035 [doi].

143 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1189. Ozer, A., D. C. Arikan, E. Kirecci, and H. C. Ekerbicer. 2010. Status of pandemic influenza vaccination and factors affecting it in pregnant women in Kahramanmaras, an eastern Mediterranean city of Turkey. PLoS.One. 5:e14177. doi:10.1371/journal.pone.0014177 [doi]. 1190. Ozturk, S. 2010. Swine flu vaccine adjuvants and multiple sclerosis – Is there potential for harmful effect? Med.Hypotheses 75:50–52. doi:S0306-9877(10)00030-7 [pii];10.1016/j. mehy.2010.01.026 [doi]. 1191. Pabst, L. J., A. E. Fiore, and K. A. Cullen. 2011. Completion of the 2-dose influenza vaccine series among children aged 6 to 59 months: immunization information system sentinel sites, 2007–2008 influenza season. Clin.Pediatr.(Phila) 50:1068–1070. doi:0009922810385928 [pii];10.1177/0009922810385928 [doi]. 1192. Pada, S. and P. A. Tambyah. 2011. Overview/reflections on the 2009 H1N1 pandemic. Microbes. Infect. 13:470–478. doi:S1286-4579(11)00039-6 [pii];10.1016/j.micinf.2011.01.009 [doi]. 1193. Padela, A. I. 2010. Public health measures & individualized decision-making: The confluence of the H1N1 vaccine and Islamic bioethics. Hum.Vaccin. 6. doi:12015 [pii]. 1194. Paget, W. J., C. Balderston, I. Casas, G. Donker, L. Edelman, D. Fleming, A. Larrauri, A. Meijer, S. Puzelli, C. Rizzo, and L. Simonsen. 2010. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur.J.Pediatr. 169:997–1008. doi:10.1007/ s00431-010-1164-0 [doi]. 1195. Paillet, C., G. Forno, N. Soldano, R. Kratje, and M. Etcheverrigaray. 2011. Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero). Vaccine 29:7212– 7217. doi:S0264-410X(11)01037-1 [pii];10.1016/j.vaccine.2011.07.016 [doi]. 1196. Paillot, R., L. Prowse, C. Donald, E. Medcalf, F. Montesso, N. Bryant, J. Watson, M. Jeggo, D. Elton, R. Newton, P. Trail, and H. Barnes. 2010. Efficacy of a whole inactivated EI vaccine against a recent EIV outbreak isolate and comparative detection of virus shedding. Vet.Immunol.Immunopathol. 136:272–283. doi:S0165-2427(10)00091-7 [pii];10.1016/j.vetimm.2010.03.019 [doi]. 1197. Painter, J. E., J. M. Sales, K. Pazol, G. M. Wingood, M. Windle, W. A. Orenstein, and R. J. DiClemente. 2010. Psychosocial correlates of intention to receive an influenza vaccination among rural adolescents. Health Educ.Res. 25:853–864. doi:cyq037 [pii];10.1093/her/cyq037 [doi]. 1198. Painter, J. E., J. M. Sales, K. Pazol, G. M. Wingood, M. Windle, W. A. Orenstein, and R. J. DiClemente. 2011. Adolescent attitudes toward influenza vaccination and vaccine uptake in a school-based influenza vaccination intervention: a mediation analysis. J.Sch Health 81:304–312. doi:10.1111/j.1746-1561.2011.00595.x [doi]. 1199. Painter, J. E., J. M. Sales, K. Pazol, T. Grimes, G. M. Wingood, and R. J. DiClemente. 2010. Development, theoretical framework, and lessons learned from implementation of a school- based influenza vaccination intervention. Health Promot.Pract. 11:42S–52S. doi:11/3_suppl/42S [pii];10.1177/1524839909360171 [doi]. 1200. Pallikkuth, S., K. S. Pilakka, S. Y. Silva, M. Fischl, R. Pahwa, and S. Pahwa. 2011. Upregulation of IL-21 receptor on B cells and IL-21 secretion distinguishes novel 2009 H1N1 vaccine responders from nonresponders among HIV-infected persons on combination antiretroviral therapy. J.Immunol. 186:6173–6181. doi:jimmunol.1100264 [pii];10.4049/jimmunol.1100264 [doi]. 1201. Palmer, R. 2010. Amidst growing vaccine concerns, NIH sets up engine for answers. Nat.Med. 16:940. doi:nm0910-940a [pii];10.1038/nm0910-940a [doi]. 1202. Panatto, D., D. Amicizia, P. L. Lai, R. Camerini, R. A. De, and R. Gasparini. 2011. Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review. J.Prev.Med.Hyg. 52:111–115.

144 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1203. Panda, A., F. Qian, S. Mohanty, D. D. van, F. K. Newman, L. Zhang, S. Chen, V. Towle, R. B. Belshe, E. Fikrig, H. G. Allore, R. R. Montgomery, and A. C. Shaw. 2010. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J.Immunol. 184:2518– 2527. doi:jimmunol.0901022 [pii];10.4049/jimmunol.0901022 [doi]. 1204. Panda, B., R. Stiller, and A. Panda. 2011. Influenza vaccination during pregnancy and factors for lacking compliance with current CDC guidelines. J.Matern.Fetal Neonatal Med. 24:402–406. doi:10. 3109/14767058.2010.497882 [doi]. 1205. Pandolfi, E., E. Carloni, M. G. Marino, M. L. Ciofi Degli Atti, F. Gesualdo, M. Romano, A. Giannattasio, A. Guarino, R. Carloni, P. Borgia, E. Volpe, F. Perrelli, R. Pizzuti, and A. E. Tozzi. 2011. Immunization coverage and timeliness of vaccination in Italian children with chronic diseases. Vaccine. doi:S0264- 410X(11)00347-1 [pii];10.1016/j.vaccine.2011.02.099 [doi]. 1206. Paolini, V. and M. Trapani. 2010. A/H1N1: effectiveness of prevention in childhood. Ann.Ig 22:273– 275. 1207. Paredes-Solis, S., J. Legorreta-Soberanis, C. Leyva-Alvarado, H. Vargas-Millan, M. Flores-Moreno, and N. Andersson. 2010. [Vaccination coverage against seasonal influenza in workers from four hospitals of Guerrero, Mexico]. Gac.Med.Mex. 146:318–325. 1208. Pariani, E., A. Boschini, A. Amendola, R. Poletti, G. Anselmi, M. Begnini, A. Ranghiero, G. Cecconi, and A. R. Zanetti. 2011. Response to 2009 pandemic and seasonal influenza vaccines co- administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine 29:9209–9213. doi:S0264-410X(11)01545-3 [pii];10.1016/j.vaccine.2011.09.103 [doi]. 1209. Parikh, F. S. 2011. Experience from influenza A (H1N1) pandemic 2009 – is prevention better than cure? J.Assoc.Physicians India 59:11–12. 1210. Park, K. S., Y. B. Seo, J. Y. Lee, S. J. Im, S. H. Seo, M. S. Song, Y. K. Choi, and Y. C. Sung. 2011. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine 29:5481–5487. doi:S0264-410X(11)00782-1 [pii];10.1016/j. vaccine.2011.05.062 [doi]. 1211. Park, S. W., J. H. Lee, E. S. Kim, Y. G. Kwak, C. S. Moon, J. S. Yeom, J. H. Lee, and C. S. Lee. 2011. Adverse events associated with the 2009 H1N1 influenza vaccination and the vaccination coverage rate in health care workers. Am.J.Infect.Control 39:69–71. doi:S0196-6553(10)00816-3 [pii];10.1016/j.ajic.2010.08.007 [doi]. 1212. Parodi, V., F. D. de, M. Martini, and F. Ansaldi. 2011. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 28:93–106. doi:1 [pii];10.2165/11586770- 000000000-00000 [doi]. 1213. Parretta, E., B. Ianniello, F. Ferrazin, F. Rossi, and A. Capuano. 2011. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. Vaccine 29:3708– 3713. doi:S0264-410X(11)00345-8 [pii];10.1016/j.vaccine.2011.02.097 [doi]. 1214. Parry, H. M., S. Damery, A. Fergusson, H. Draper, J. Bion, and A. E. Low. 2011. Pandemic influenza A (H1N1) 2009 in a critical care and theatre setting: beliefs and attitudes towards staff vaccination. J.Hosp.Infect. 78:302–307. doi:S0195-6701(11)00100-9 [pii];10.1016/j.jhin.2011.02.009 [doi]. 1215. Partridge, J. and M. P. Kieny. 2010. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets. Vaccine 28:4709–4712. doi:S0264-410X(10)00619-5 [pii];10.1016/j.vaccine.2010.04.083 [doi]. 1216. Parveen, S., S. Kaur, S. A. David, J. L. Kenney, W. M. McCormick, and R. K. Gupta. 2011. Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products. Vaccine 29:8012–8023. doi:S0264-410X(11)01296-5 [pii];10.1016/j. vaccine.2011.08.055 [doi].

145 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1217. Patel, J. A., S. Nair, E. E. Ochoa, R. Huda, N. J. Roberts, and T. Chonmaitree. 2010. Interleukin-6(1) and tumor necrosis factor alpha(3) polymorphisms enhance cytokine production by human macrophages exposed to respiratory viruses. J.Interferon Cytokine Res. 30:917–921. doi:10.1089/ jir.2010.0033 [doi]. 1218. Patel, S. M., R. L. Atmar, H. M. El Sahly, T. R. Cate, and W. A. Keitel. 2010. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine 28:3025–3029. doi:S0264-410X(09)01735-6 [pii];10.1016/j.vaccine.2009.10.152 [doi]. 1219. Patois, E., M. A. Capelle, R. Gurny, and T. Arvinte. 2011. Stability of seasonal influenza vaccines investigated by spectroscopy and microscopy methods. Vaccine 29:7404–7413. doi:S0264- 410X(11)01112-1 [pii];10.1016/j.vaccine.2011.07.067 [doi]. 1220. Patterson, J. E., J. Cadena, T. Prigmore, J. Bowling, B. A. Ayala, L. Kirkman, A. Parekh, and T. Scepanski. 2011. Improving health care workers for seasonal influenza vaccination at university health system: a paradigm for closing the quality chasm. Trans.Am.Clin.Climatol.Assoc. 122:166–173. 1221. Pauwels, C., C. B. Livideanu, A. Maza, L. Lamant, and C. Paul. 2011. Cytophagic histiocytic panniculitis after H1N1 vaccination: a case report and review of the cutaneous side effects of influenza vaccines. Dermatology 222:217–220. doi:000326912 [pii];10.1159/000326912 [doi]. 1222. Payaprom, Y., P. Bennett, E. Alabaster, and H. Tantipong. 2011. Using the Health Action Process Approach and implementation intentions to increase flu vaccine uptake in high risk Thai individuals: a controlled before-after trial. Health Psychol. 30 :492–500. doi:2011-08731-001 [pii];10.1037/ a0023580 [doi]. 1223. Payaprom, Y., P. Bennett, P. Burnard, E. Alabaster, and H. Tantipong. 2010. Understandings of influenza and influenza vaccination among high-risk urban dwelling Thai adults: a qualitative study. J.Public Health (Oxf) 32:26–31. doi:fdp086 [pii];10.1093/pubmed/fdp086 [doi]. 1224. Pearce, M. B., J. A. Belser, K. V. Houser, J. M. Katz, and T. M. Tumpey. 2011. Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets. Vaccine 29:2887–2894. doi:S0264-410X(11)00215-5 [pii];10.1016/j. vaccine.2011.02.014 [doi]. 1225. Pearton, M., S. M. Kang, J. M. Song, A. V. Anstey, M. Ivory, R. W. Compans, and J. C. Birchall. 2010. Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines. PLoS.One. 5:e12410. doi:10.1371/journal.pone.0012410 [doi]. 1226. Pearton, M., S. M. Kang, J. M. Song, Y. C. Kim, F. S. Quan, A. Anstey, M. Ivory, M. R. Prausnitz, R. W. Compans, and J. C. Birchall. 2010. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine 28:6104–6113. doi:S0264- 410X(10)00764-4 [pii];10.1016/j.vaccine.2010.05.055 [doi]. 1227. Pebody, R., N. Andrews, P. Waight, R. Malkani, C. McCartney, J. Ellis, and E. Miller. 2011. No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in England. Vaccine 29:2613–2618. doi:S0264–410X(11)00085–5 [pii];10.1016/j. vaccine.2011.01.046 [doi]. 1228. Pebody, R., P. Hardelid, D. Fleming, J. McMenamin, N. Andrews, C. Robertson, D. Thomas, P. Sebastianpillai, J. Ellis, W. Carman, T. Wreghitt, M. Zambon, and J. Watson. 2011. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid–season analysis 2010/11. Euro.Surveill 16. 1229. Pedersen, G. K., T. Ebensen, I. H. Gjeraker, S. Svindland, G. Bredholt, C. A. Guzman, and R. J. Cox. 2011. Evaluation of the Sublingual Route for Administration of Influenza H5N1 Virosomes in Combination with the Bacterial Second Messenger c–di–GMP. PLoS.One. 6:e26973. doi:10.1371/ journal.pone.0026973 [doi];PONE–D–11–13512 [pii].

146 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1230. Pedersen, G., A. Halstensen, H. Sjursen, A. Naess, E. K. Kristoffersen, and R. J. Cox. 2011. Pandemic influenza vaccination elicits influenza–specific CD4+ Th1–cell responses in hypogammaglobulinaemic patients: four case reports. Scand.J.Immunol. 74:210–218. doi:10.1111/j.1365-3083.2011.02561.x [doi]. 1231. Pedersen, G., D. Major, S. Roseby, J. Wood, A. S. Madhun, and R. J. Cox. 2011. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza. Other Respi.Viruses. 5:426–437. doi:10.1111/j.1750-2659.2011.00256.x [doi]. 1232. Pejoski, D., W. Zeng, S. Rockman, L. E. Brown, and D. C. Jackson. 2010. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol.Cell Biol. 88:605– 611. doi:icb201015 [pii];10.1038/icb.2010.15 [doi]. 1233. Pelat, C., A. Falchi, F. Carrat, A. Mosnier, I. Bonmarin, C. Turbelin, S. Vaux, S. van der Werf, J. M. Cohen, B. Lina, T. Blanchon, and T. Hanslik. 2011. Field effectiveness of pandemic and 2009–2010 seasonal vaccines against 2009–2010 A(H1N1) influenza: estimations from surveillance data in France. PLoS.One. 6:e19621. doi:10.1371/journal.pone.0019621 [doi];PONE-D-10-05586 [pii]. 1234. Pelly, L. P., D. M. Pierrynowski Macdougall, B. A. Halperin, R. A. Strang, S. K. Bowles, D. M. Baxendale, and S. A. McNeil. 2010. THE VAXED PROJECT: an assessment of immunization education in Canadian health professional programs. BMC.Med.Educ. 10:86. doi:1472-6920-10-86 [pii];10.1186/1472-6920-10-86 [doi]. 1235. Peltola, V., O. Ruuskanen, and T. Heikkinen. 2011. Targeting influenza vaccinations of children. CMAJ. 183:1464–1465. doi:cmaj.111055 [pii];10.1503/cmaj.111055 [doi]. 1236. Pena, L., A. L. Vincent, J. Ye, J. R. Ciacci-Zanella, M. Angel, A. Lorusso, P. C. Gauger, B. H. Janke, C. L. Loving, and D. R. Perez. 2011. Modifications in the polymerase genes of a swine-like triple- reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses. J.Virol. 85:456–469. doi:JVI.01503-10 [pii];10.1128/JVI.01503-10 [doi]. 1237. Penfold, R. B., D. Rusinak, T. A. Lieu, A. Shefer, M. Messonnier, and G. M. Lee. 2011. Financing and systems barriers to seasonal influenza vaccine delivery in community settings. Vaccine. doi:S0264- 410X(11)01661-6 [pii];10.1016/j.vaccine.2011.10.041 [doi]. 1238. Perdue, M. L. and R. A. Bright. 2011. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Vaccine 29 Suppl 1:A48–A50. doi:S0264-410X(11)00328-8 [pii];10.1016/j.vaccine.2011.02.080 [doi]. 1239. Perdue, M. L., F. Arnold, S. Li, A. Donabedian, V. Cioce, T. Warf, and R. Huebner. 2011. The future of cell culture-based influenza vaccine production. Expert.Rev.Vaccines. 10:1183–1194. doi:10.1586/ erv.11.82 [doi]. 1240. Pereira, C. C. and D. Bishai. 2010. Vaccine presentation in the USA: economics of prefilled syringes versus multidose vials for influenza vaccination. Expert.Rev.Vaccines. 9:1343–1349. doi:10.1586/ erv.10.129 [doi]. 1241. Pereira, C. C., M. Mulligan, J. F. Bridges, and D. Bishai. 2011. Determinants of influenza vaccine purchasing decision in the US: a conjoint analysis. Vaccine 29:1443–1447. doi:S0264- 410X(10)01765-2 [pii];10.1016/j.vaccine.2010.12.027 [doi]. 1242. Pereira, T. S., A. T. Freire, A. D. Braga, G. W. Pereira, C. R. Blatt, and A. A. Borges. 2011. [Study on the adverse effects and protective effects of influenza vaccine among elderly individuals vaccinated through the public system in the municipality of Tubarao, State of Santa Catarina]. Rev.Soc.Bras.Med. Trop. 44:48–52. doi:S0037-86822011000100012 [pii]. 1243. Perez-Rubio, A., J. M. Eiros Bouza, and J. J. Castrodeza Sanz. 2010. [Evaluation of the influenza a H1N1 vaccination in Castilla and Leon regions, Spain]. Med.Clin.(Barc.) 135:543–545. doi:S0025-7753(10)00698-6 [pii];10.1016/j.medcli.2010.05.016 [doi].

147 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1244. Peterson, C. 2011. [Smoke screens on adverse effect of Pandemrix]. Lakartidningen 108:1062. 1245. Petiot, E., D. Jacob, S. Lanthier, V. Lohr, S. Ansorge, and A. A. Kamen. 2011. Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC.Biotechnol. 11:84. doi:1472- 6750-11-84 [pii];10.1186/1472-6750-11-84 [doi]. 1246. Petousis-Harris, H., T. Poole, R. Booy, and N. Turner. 2011. Fever following administration of two inactivated influenza vaccines – a survey of parents of New Zealand infants and children 5 years of age and under. Vaccine 29:2933–2937. doi:S0264-410X(11)00213-1 [pii];10.1016/j. vaccine.2011.02.012 [doi]. 1247. Petrie, J. G., S. E. Ohmit, E. Johnson, R. T. Cross, and A. S. Monto. 2011. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J.Infect.Dis. 203:1309–1315. doi:jir015 [pii];10.1093/infdis/jir015 [doi]. 1248. Petrovic, V., Z. Seguljev, S. Medic, M. Ristic, S. Tomic, and G. Cvetic. 2011. [Analysis of suspected adverse reactions following immunization against pandemic influenza]. Med.Pregl. 64:305–309. 1249. Petrovsky, N. and D. Sajkov. 2011. Pediatric influenza immunization. Expert.Rev.Vaccines. 10:567– 570. doi:10.1586/erv.11.53 [doi]. 1250. Petrovsky, N. and T. M. Ross. 2011. Challenges in improving influenza vaccine protection in the elderly. Expert.Rev.Vaccines. 10:7–11. doi:10.1586/erv.10.153 [doi]. 1251. Petruccelli, B., J. L. Otto, M. C. Johns, and R. J. Lipnick. 2010. U.S. military public health surveillance and response to pandemic influenza A (H1N1). Am.J.Prev.Med. 39:483–486. doi:S0749-3797(10)00429-0 [pii];10.1016/j.amepre.2010.07.006 [doi]. 1252. Petukhova, G., D. Korenkov, T. Chirkova, S. Donina, L. Rudenko, and A. Naykhin. 2011. B- and T-cell memory elicited by a seasonal live attenuated reassortant influenza vaccine: assessment of local antibody avidity and virus-specific memory T-cells using trogocytosis-based method. Influenza.Other Respi.Viruses. doi:10.1111/j.1750-2659.2011.00279.x [doi]. 1253. Pfeil, A., M. Mutsch, C. Hatz, and T. D. Szucs. 2010. A cross-sectional survey to evaluate knowledge, attitudes and practices (KAP) regarding seasonal influenza vaccination among European travellers to resource-limited destinations. BMC.Public Health 10:402. doi:1471-2458-10-402 [pii];10.1186/1471-2458-10-402 [doi]. 1254. Pfleiderer, M. 2010. [Pandemic influenza vaccines. Concepts, European mock-up licenses, and acceptance criteria]. Bundesgesundheitsblatt.Gesundheitsforschung.Gesundheitsschutz. 53:1242– 1249. doi:10.1007/s00103-010-1161-5 [doi]. 1255. Pfleiderer, M. 2011. [Flu vaccines]. Pharm.Unserer Zeit 40:126–134. 1256. Pham, H., S. A. Geraci, and M. J. Burton. 2011. Adult immunizations: update on recommendations. Am.J.Med. 124:698–701. doi:S0002-9343(11)00314-7 [pii];10.1016/j.amjmed.2010.07.032 [doi]. 1257. Phillips, M., R. N. Cataneo, A. Chaturvedi, P. J. Danaher, A. Devadiga, D. A. Legendre, K. L. Nail, P. Schmitt, and J. Wai. 2010. Effect of influenza vaccination on oxidative stress products in breath. J.Breath.Res. 4:026001. doi:S1752-7155(10)34354-0 [pii];10.1088/1752-7155/4/2/026001 [doi]. 1258. Pielak, K. L., C. C. McIntyre, A. W. Tu, V. P. Remple, B. Halperin, and J. A. Buxton. 2010. Identifying attitudes, beliefs and reported practices of nurses and doctors as immunization providers. J.Adv.Nurs. 66:1602–1611. doi:JAN5326 [pii];10.1111/j.1365-2648.2010.05326.x [doi]. 1259. Pien, G. C., K. S. LeBenger, D. R. Carotenuto, M. Difilippi, D. Scolpino, J. M. Simmons, C. Barrett, and R. W. Brenner. 2010. Coordination of multidisciplinary resources for vaccination of egg-allergic individuals during an H1N1 (novel) influenza pandemic. Allergy Asthma Proc. 31:507–510. doi:3396 [pii];10.2500/aap.2010.31.3396 [doi].

148 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1260. Pierce, C. L., T. L. Williams, H. Moura, J. L. Pirkle, N. J. Cox, J. Stevens, R. O. Donis, and J. R. Barr. 2011. Quantification of immunoreactive viral influenza proteins by immunoaffinity capture and isotope-dilution liquid chromatography-tandem mass spectrometry. Anal.Chem. 83:4729–4737. doi:10.1021/ac2006526 [doi]. 1261. Pilisuk, T., J. Goad, and H. Backer. 2010. Vaccination delivery by chain pharmacies in California: Results of a 2007 survey. J.Am.Pharm.Assoc.(2003.) 50:134–139. doi:W81462U4Q52N3766 [pii];10.1331/JAPhA.2010.09168 [doi]. 1262. Pillot, C., J. B. Chevaux, N. Petitpain, and L. Peyrin-Biroulet. 2011. Acute hepatic cytolysis following H1N1 vaccination in a patient with Crohn’s disease on infliximab. Inflamm.Bowel.Dis. 17:679. doi:10.1002/ibd.21321 [doi]. 1263. Placidi, D., G. Franco, M. Bacis, L. Belotti, N. Biggi, P. Carrer, L. Cologni, V. Gattini, V. Lodi, N. Magnavita, G. Micheloni, C. Negro, R. Polato, V. Puro, F. Tonelli, and S. Porru. 2010. [Focus on coverage and promotion of anti influenza vaccine in health workers: results and perspectives of a multicenter working group]. G.Ital.Med.Lav.Ergon. 32:286–291. 1264. Plennevaux, E., E. Sheldon, M. Blatter, M. K. Reeves-Hoche, and M. Denis. 2010. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 375:41–48. doi:S0140-6736(09)62026-2 [pii];10.1016/S0140-6736(09)62026-2 [doi]. 1265. Plennevaux, E., M. Blatter, M. J. Cornish, K. Go, D. Kirby, M. Wali, M. K. Reeves-Hoche, and M. Denis. 2011. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. Vaccine 29:1569–1575. doi:S0264-410X(10)01903-1 [pii];10.1016/j.vaccine.2010.12.116 [doi]. 1266. Poehling, K. A., G. Fairbrother, Y. Zhu, S. Donauer, S. Ambrose, K. M. Edwards, M. A. Staat, M. M. Prill, L. Finelli, N. J. Allred, B. Bardenheier, and P. G. Szilagyi. 2010. Practice and child characteristics associated with influenza vaccine uptake in young children. Pediatrics 126:665–673. doi:peds.2009-2620 [pii];10.1542/peds.2009-2620 [doi]. 1267. Poehling, K. A., L. Vannoy, L. S. Light, C. K. Suerken, B. M. Snively, A. Guitierrez, and T. R. Peters. 2011. Assessment of Parental Report for 2009–2010 Seasonal and Monovalent H1N1 Influenza Vaccines among Children in the or Hospital. Acad.Pediatr. doi:S1876-2859(11)00229-4 [pii];10.1016/j.acap.2011.08.006 [doi]. 1268. Poehling, K. A., P. G. Szilagyi, M. A. Staat, B. M. Snively, D. C. Payne, C. B. Bridges, S. Y. Chu, L. S. Light, M. M. Prill, L. Finelli, M. R. Griffin, and K. M. Edwards. 2011. Impact of maternal immunization on influenza hospitalizations in infants. Am.J.Obstet.Gynecol. 204:S141–S148. doi:S0002-9378(11)00232-8 [pii];10.1016/j.ajog.2011.02.042 [doi]. 1269. Poland, G. A. 2010. Putting the puzzle pieces together: the dynamic landscape of influenza vaccine and policy. Vaccine 28 Suppl 4:D1–D2. doi:S0264-410X(10)01138-2 [pii];10.1016/j. vaccine.2010.08.029 [doi]. 1270. Poland, G. A. 2010. The 2009–2010 influenza pandemic: effects on pandemic and seasonal vaccine uptake and lessons learned for seasonal vaccination campaigns. Vaccine 28 Suppl 4:D3–13. doi:S0264-410X(10)01133-3 [pii];10.1016/j.vaccine.2010.08.024 [doi]. 1271. Poland, G. A. 2011. Pandemic 2009–2010 influenza vaccine: six lessons learned and the way forward (Allegro not Adagio). Vaccine 29:613–614. doi:S0264-410X(10)01730-5 [pii];10.1016/j. vaccine.2010.11.086 [doi]. 1272. Poland, G. A. 2011. Sophiology, vaccinology, and the healing professions – a warning from ancient Greece? Vaccine 29:4535–4536. doi:S0264-410X(11)00783-3 [pii];10.1016/j.vaccine.2011.05.063 [doi].

149 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1273. Poletti, P., M. Ajelli, and S. Merler. 2011. The effect of risk perception on the 2009 H1N1 pandemic influenza dynamics. PLoS.One. 6:e16460. doi:10.1371/journal.pone.0016460 [doi]. 1274. Polgreen, P. M., E. Septimus, T. R. Talbot, S. E. Beekmann, and C. Helms. 2010. Results of a national survey of infectious diseases specialists regarding influenza vaccination programs for healthcare workers. Infect.Control Hosp.Epidemiol. 31:1063–1065. doi:10.1086/656382 [doi]. 1275. Polgreen, P. M., T. L. Tassier, S. V. Pemmaraju, and A. M. Segre. 2010. Prioritizing healthcare worker vaccinations on the basis of social network analysis. Infect.Control Hosp.Epidemiol. 31:893–900. doi:10.1086/655466 [doi]. 1276. Pollyea, D. A., J. M. Brown, and S. J. Horning. 2010. Utility of influenza vaccination for oncology patients. J.Clin.Oncol. 28:2481–2490. doi:JCO.2009.26.6908 [pii];10.1200/JCO.2009.26.6908 [doi]. 1277. Ponce-de-Leon, S., R. Velazquez-Fernandez, J. Bugarin-Gonzalez, P. Garcia-Banuelos, A. Lopez- Sotelo, M. E. Jimenez-Corona, F. Padilla-Catalan, and R. Cervantes-Rosales. 2011. Domestic influenza vaccine production in Mexico: a state-owned and a multinational company working together for public health. Vaccine 29 Suppl 1:A26–A28. doi:S0264-410X(11)00687-6 [pii];10.1016/j. vaccine.2011.04.121 [doi]. 1278. Popa, C., P. C. Wever, and M. Moviat. 2011. H1N1 vaccination: expect the unexpected. Neth.J.Med. 69:223, 246. 1279. Potter, M. B., J. M. Walsh, T. M. Yu, G. Gildengorin, L. W. Green, and S. J. McPhee. 2011. The effectiveness of the FLU-FOBT program in primary care a randomized trial. Am.J.Prev.Med. 41:9–16. doi:S0749-3797(11)00223-6 [pii];10.1016/j.amepre.2011.03.011 [doi]. 1280. Prabakaran, M., F. He, T. Meng, S. Madhan, T. Yunrui, Q. Jia, and J. Kwang. 2010. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J.Virol. 84:11822–11830. doi:JVI.00891-10 [pii];10.1128/JVI.00891-10 [doi]. 1281. Prabakaran, M., S. Madhan, N. Prabhu, G. Y. Geng, R. New, and J. Kwang. 2010. Reverse micelle- encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res. 86:180–187. doi:S0166-3542(10)00344-X [pii];10.1016/j.antiviral.2010.02.315 [doi]. 1282. Prabakaran, M., S. Madhan, N. Prabhu, J. Qiang, and J. Kwang. 2010. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J.Virol. 84:3201–3209. doi:JVI.02175-09 [pii];10.1128/JVI.02175-09 [doi]. 1283. Precioso, A. R., J. L. Miraglia, L. M. Campos, A. C. Goulart, M. C. Timenetsky, M. R. Cardoso, E. Luna, G. Mondini, J. S. Guedes, and I. Raw. 2011. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. Vaccine 29:8974–8981. doi:S0264-410X(11)01446-0 [pii];10.1016/j.vaccine.2011.09.040 [doi]. 1284. Price, G. E., M. R. Soboleski, C. Y. Lo, J. A. Misplon, M. R. Quirion, K. V. Houser, M. B. Pearce, C. Pappas, T. M. Tumpey, and S. L. Epstein. 2010. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS.One. 5:e13162. doi:10.1371/journal.pone.0013162 [doi]. 1285. Principi, N. and S. Esposito. 2011. Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. Hum.Vaccin. 7:905–912. doi:15986 [pii];10.4161/ hv.7.9.15986 [ doi ] . 1286. Principi, N., S. Esposito, and P. Marchisio. 2011. Present and future of influenza prevention in pediatrics. Expert.Opin.Biol.Ther. 11:641–653. doi:10.1517/14712598.2011.562495 [doi]. 1287. Prior, L., M. R. Evans, and H. Prout. 2011. Talking about colds and flu: the lay diagnosis of two common illnesses among older British people. Soc.Sci.Med. 73:922–928. doi:S0277-9536(10)00798-7 [pii];10.1016/j.socscimed.2010.09.054 [doi].

150 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1288. Prosser, L. A., M. I. Meltzer, A. Fiore, S. Epperson, C. B. Bridges, V. Hinrichsen, and T. A. Lieu. 2011. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch.Pediatr.Adolesc.Med. 165:112–118. doi:archpediatrics.2010.182 [pii];10.1001/archpediatrics.2010.182 [doi]. 1289. Protasov, A. D., A. V. Zhestkov, N. E. Lavrenteva, M. P. Kostinov, and A. A. Ryzhkov. 2011. [Effect of complex vaccination against pneumococcal, Haemophilus type b infections and influenza in patients with chronic obstructive pulmonary disease]. Zh.Mikrobiol.Epidemiol.Immunobiol.80–84. 1290. Puig-Barbera, J. 2011. 2010–2011 influenza seasonal vaccine, preliminary mid-season effectiveness estimates: reason for concern, confounding or are we following the right track? Euro.Surveill 16. 1291. Puig-Barbera, J., A. Arnedo-Pena, F. Pardo-Serrano, M. D. Tirado-Balaguer, S. Perez-Vilar, E. Silvestre-Silvestre, C. Calvo-Mas, L. Safont-Adsuara, and M. Ruiz-Garcia. 2010. Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital- based, case-control study. Vaccine 28:7460–7467. doi:S0264-410X(10)01352-6 [pii];10.1016/j. vaccine.2010.09.042 [doi]. 1292. Puig-Barbera, J., S. Perez-Vilar, and J. Diez-Domingo. 2011. MF59-adjuvanted seasonal influenza vaccine in young children. Expert.Rev.Vaccines. 10:1519–1528. doi:10.1586/erv.11.131 [doi]. 1293. Puleston, R. L., G. Bugg, K. Hoschler, J. Konje, J. Thornton, I. Stephenson, P. Myles, J. Enstone, G. Augustine, Y. Davis, M. Zambon, K. G. Nicholson, and J. S. Nguyen-Van-Tam. 2010. Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy. Health Technol.Assess. 14:1–82. doi:10.3310/hta14550-01 [doi]. 1294. Puliyel, J. M. 2010. GAVI (Global Alliance for Vaccines and Immunisation) and WHO. Demanding accountability. BMJ 341:c4081. 1295. Pushko, P., M. B. Pearce, A. Ahmad, I. Tretyakova, G. Smith, J. A. Belser, and T. M. Tumpey. 2011. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29:5911–5918. doi:S0264-410X(11)00932-7 [pii];10.1016/j.vaccine.2011.06.068 [doi]. 1296. Pushko, P., T. Kort, M. Nathan, M. B. Pearce, G. Smith, and T. M. Tumpey. 2010. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 28:4771–4776. doi:S0264-410X(10)00631-6 [pii];10.1016/j. vaccine.2010.04.093 [doi]. 1297. Puthillath, A., D. L. Trump, C. Andrews, A. Bir, K. Romano, M. Wisniewski, and M. G. Fakih. 2011. Serological immune responses to influenza vaccine in patients with colorectal cancer. Cancer Chemother.Pharmacol. 67:111–115. doi:10.1007/s00280-010-1292-2 [doi]. 1298. Quach, S., J. S. Hamid, J. A. Pereira, C. L. Heidebrecht, J. Foisy, J. A. Bettinger, L. Rosella, N. S. Crowcroft, S. L. Deeks, S. D. Quan, M. Finkelstein, M. Guay, D. L. Buckeridge, C. A. Sikora, and J. C. Kwong. 2011. Time and motion study to compare electronic and hybrid data collection systems during the pandemic (H1N1) 2009 influenza vaccination campaign. Vaccine 29:1997–2003. doi:S0264- 410X(10)01325-3 [pii];10.1016/j.vaccine.2010.09.016 [doi]. 1299. Quan, F. S., A. Vunnava, R. W. Compans, and S. M. Kang. 2010. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS.One. 5:e9161. doi:10.1371/journal. pone.0009161 [doi]. 1300. Quan, F. S., Y. C. Kim, A. Vunnava, D. G. Yoo, J. M. Song, M. R. Prausnitz, R. W. Compans, and S. M. Kang. 2010. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J.Virol. 84:7760–7769. doi:JVI.01849-09 [pii];10.1128/JVI.01849-09 [doi].

151 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1301. Quan, F. S., Y. C. Kim, R. W. Compans, M. R. Prausnitz, and S. M. Kang. 2010. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J.Control Release 147:326–332. doi:S0168-3659(10)00652-8 [pii];10.1016/j.jconrel.2010.07.125 [doi]. 1302. Quan, F. S., Y. Kim, S. Lee, H. Yi, S. M. Kang, J. Bozja, M. L. Moore, and R. W. Compans. 2011. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J.Infect.Dis. 204:987–995. doi:jir474 [pii];10.1093/infdis/jir474 [doi]. 1303. Quan, F. S., Z. N. Li, M. C. Kim, D. Yang, R. W. Compans, D. A. Steinhauer, and S. M. Kang. 2011. Immunogenicity of low-pH treated whole viral influenza vaccine. Virology 417:196–202. doi:S0042-6822(11)00249-2 [pii];10.1016/j.virol.2011.05.014 [doi]. 1304. Querci, M., M. E. Stryjewski, F. Herrera, E. Temporiti, W. Alcala, N. Chavez, L. Figueras, F. Barberis, M. Echavarria, C. Videla, A. Martinez, G. Carballal, and P. Bonvehi. 2011. Healthcare personnel infected with novel influenza A H1N1 virus in university hospitals in Buenos Aires, Argentina. Scand.J.Infect.Dis. 43:70–74. doi:10.3109/00365548.2010.515244 [doi]. 1305. Rachiotis, G., V. A. Mouchtouri, J. Kremastinou, K. Gourgoulianis, and C. Hadjichristodoulou. 2010. Low acceptance of vaccination against the 2009 pandemic influenza A(H1N1) among healthcare workers in Greece. Euro.Surveill 15. 1306. Rage, A. and T. Hassan. 2011. Improving influenza vaccination rates by targeting individuals not seeking early seasonal vaccination. Am.J.Med. 124:e9. doi:S0002-9343(11)00244-0 [pii];10.1016/j. amjmed.2011.02.018 [doi]. 1307. Rahier, J. F., M. Moutschen, G. A. Van, R. M. Van, E. Louis, S. Segaert, P. Masson, and K. F. De. 2010. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology.(Oxford) 49:1815–1827. doi:keq183 [pii];10.1093/rheumatology/keq183 [doi]. 1308. Rahier, J. F., P. Papay, J. Salleron, S. Sebastian, M. Marzo, L. Peyrin-Biroulet, V. Garcia-Sanchez, W. Fries, D. P. van Asseldonk, K. Farkas, N. K. de Boer, T. Sipponen, P. Ellul, E. Louis, S. T. Peake, U. Kopylov, J. Maul, B. Makhoul, G. Fiorino, Y. Yazdanpanah, and M. Chaparro. 2011. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 60:456–462. doi:gut.2010.233981 [pii];10.1136/ gut.2010.233981 [doi]. 1309. Rahier, J. F., P. Papay, J. Salleron, S. Sebastian, P. Ellul, N. Teich, G. Fiorino, B. Blaha, V. Garcia- Sanchez, T. Haas, G. A. Van, V. Abitbol, Y. Yazdanpanah, and M. C. Chaparro. 2011. Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series. Aliment.Pharmacol.Ther. 33:499–500. doi:10.1111/j.1365-2036.2010.04558.x [doi]. 1310. Rambhia, K. J., M. Watson, T. K. Sell, R. Waldhorn, and E. Toner. 2010. Mass vaccination for the 2009 H1N1 pandemic: approaches, challenges, and recommendations. Biosecur.Bioterror. 8:321– 330. doi:10.1089/bsp.2010.0043 [doi]. 1311. Ramsey, M. A. and C. A. Marczinski. 2011. College students’ perceptions of H1N1 flu risk and attitudes toward vaccination. Vaccine 29:7599–7601. doi:S0264-410X(11)01180-7 [pii];10.1016/j. vaccine.2011.07.130 [doi]. 1312. Rao, S. S., W. P. Kong, C. J. Wei, H. N. van, J. P. Gorres, M. Nason, H. Andersen, T. M. Tumpey, and G. J. Nabel . 2010. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene- based vaccination against H5N1 influenza in mouse and ferret. PLoS.One. 5:e9812. doi:10.1371/ journal.pone.0009812 [doi]. 1313. Rappuoli, R. 2011. The challenge of developing universal vaccines. F1000.Med.Rep. 3:16. doi:10.3410/M3-16 [doi];16 [pii]. 1314. Rasoli, M., A. R. Omar, I. Aini, B. Jalilian, S. H. Syed Hassan, and M. Mohamed. 2010. Fusion of HSP70 gene of Mycobacterium tuberculosis to hemagglutinin (H5) gene of avian influenza virus in DNA vaccine enhances its potency. Acta Virol. 54:33–39.

152 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1315. Ratzan, S. C. 2010. All health is Local: the H1N1 vaccine. J.Health Commun. 15:1–2. doi:918960953 [pii];10.1080/10810730903489343 [doi]. 1316. Raude, J., A. L. Caille-Brillet, and M. Setbon. 2010. The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the vaccine and why? PLoS.Curr. 2:RRN1188. doi:10.1371/ currents.RRN1188 [doi];k/-/-/25dlajr91hxw3/1 [pii]. 1317. Rauw, F., V. Palya, B. S. Van, S. Welby, T. Tatar-Kis, Y. Gardin, K. M. Dorsey, M. M. Aly, M. K. Hassan, M. A. Soliman, B. Lambrecht, and T. van den Berg. 2011. Further evidence of and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains. Vaccine 29:2590–2600. doi:S0264- 410X(11)00087-9 [pii];10.1016/j.vaccine.2011.01.048 [doi]. 1318. Redelings, M. D., J. Piron, L. V. Smith, A. Chan, J. Heinzerling, K. M. Sanchez, D. Bedair, M. Ponce, and T. Kuo . 2011. Knowledge, attitudes, and beliefs about seasonal influenza and H1N1 vaccinations in a low-income, public health clinic population. Vaccine. doi:S0264-410X(11)01687-2 [pii];10.1016/j.vaccine.2011.10.050 [doi]. 1319. Redelman-Sidi, G. 2010. Influenza in patients with hematologic disease: an ounce of prevention is worth a pound of cure. Leuk.Lymphoma 51:1954–1956. doi:10.3109/10428194.2010.510226 [doi]. 1320. Rees, S., L. Stevens, J. Drayton, N. Engledow, and J. Sanders. 2011. Improving inpatient pneumococcal and influenza vaccination rates. J.Nurs.Care Qual. 26:358–363. doi:10.1097/ NCQ.0b013e31821fb6bb [doi]. 1321. Rehmani, R. and J. I. Memon. 2010. Knowledge, attitudes and beliefs regarding influenza vaccination among healthcare workers in a Saudi hospital. Vaccine 28:4283–4287. doi:S0264- 410X(10)00537-2 [pii];10.1016/j.vaccine.2010.04.031 [doi]. 1322. Reiber, C., E. C. Shattuck, S. Fiore, P. Alperin, V. Davis, and J. Moore. 2010. Change in human social behavior in response to a common vaccine. Ann.Epidemiol. 20:729–733. doi:S1047-2797(10)00165-1 [pii];10.1016/j.annepidem.2010.06.014 [doi]. 1323. Reilly, A., L. S. Kersun, K. McDonald, A. Weinberg, A. F. Jawad, and K. E. Sullivan. 2010. The efficacy of influenza vaccination in a pediatric oncology population. J.Pediatr.Hematol.Oncol. 32:e177–e181. doi:10.1097/MPH.0b013e3181d869f3 [doi]. 1324. Reiter, P. L., A. L. McRee, S. L. Gottlieb, L. E. Markowitz, and N. T. Brewer. 2011. Uptake of 2009 H1N1 vaccine among adolescent females. Hum.Vaccin. 7:191–196. doi:13847 [pii]. 1325. Ren, X. W., L. W. Ju, J. X. Yang, X. H. Lv, L. F. Jiang, N. Q. Zhao, and Q. W. Jiang. 2011. Antigenic and genetic variation in the hemagglutinins of H1N1 and H3N2 human influenza a viruses in the Shanghai area from 2005 to 2008. J.Med.Virol. 83:1113–1120. doi:10.1002/jmv.22078 [doi]. 1326. Reuss, A. M., D. Walter, M. Feig, L. Kappelmayer, U. Buchholz, T. Eckmanns, and G. Poggensee. 2010. Influenza vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: a secondary data analysis based on billing data of the German associations of statutory health insurance physicians. Dtsch.Arztebl.Int. 107:845–850. doi:10.3238/arztebl.2010.0845 [doi]. 1327. Reygrobellet, C., M. Viala-Danten, J. Meunier, F. Weber, and V. H. Nguyen. 2010. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Hum.Vaccin. 6:336–345. doi:10753 [pii]. 1328. Rhudy, L. M., S. J. Tucker, C. L. Ofstead, and G. A. Poland. 2010. Personal choice or evidence-based nursing intervention: nurses’ decision-making about influenza vaccination. Worldviews.Evid.Based. Nurs. 7:111–120. doi:WVN190 [pii];10.1111/j.1741-6787.2010.00190.x [doi]. 1329. Richard, S. A., C. Viboud, and M. A. Miller. 2010. Evaluation of Southern Hemisphere influenza vaccine recommendations. Vaccine 28:2693–2699. doi:S0264-410X(10)00118-0 [pii];10.1016/j. vaccine.2010.01.053 [doi].

153 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1330. Richardson, K. and A. Weinberg. 2011. Reduced immunogenicity of influenza vaccines in HIV-infected compared with uninfected pregnant women is associated with regulatory T cells. AIDS 25:595–602. doi:10.1097/QAD.0b013e32834411a8 [doi];00002030-201103130-00007 [pii]. 1331. Ricker, F. 2010. Influenza immunization policies and nursing concerns. Colo.Nurse 110:1, 5. 1332. Rimmelzwaan, G. F., R. Bodewes, and A. D. Osterhaus. 2011. Vaccination strategies to protect children against seasonal and pandemic influenza. Vaccine 29:7551–7553. doi:S0264- 410X(11)01223-0 [pii];10.1016/j.vaccine.2011.08.014 [doi]. 1333. Risi, G., L. Frenette, J. M. Langley, P. Li, D. Riff, E. Sheldon, D. W. Vaughn, and L. Fries. 2011. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine 29:6408–6418. doi:S0264- 410X(11)00617-7 [pii];10.1016/j.vaccine.2011.04.072 [doi]. 1334. Robertson, J. S. and O. G. Engelhardt. 2010. Developing vaccines to combat pandemic influenza. Viruses. 2:532–546. doi:10.3390/v2020532 [doi];viruses-02-00532 [pii]. 1335. Robertson, J. S. and S. C. Inglis. 2011. Prospects for controlling future pandemics of influenza. Virus Res. doi:S0168-1702(11)00377-7 [pii];10.1016/j.virusres.2011.09.024 [doi]. 1336. Robertson, J. S., C. Nicolson, R. Harvey, R. Johnson, D. Major, K. Guilfoyle, S. Roseby, R. Newman, R. Collin, C. Wallis, O. G. Engelhardt, J. M. Wood, J. Le, R. Manojkumar, B. A. Pokorny, J. Silverman, R. Devis, D. Bucher, E. Verity, C. Agius, S. Camuglia, C. Ong, S. Rockman, A. Curtis, P. Schoofs, O. Zoueva, H. Xie, X. Li, Z. Lin, Z. Ye, L. M. Chen, E. O’Neill, A. Balish, A. S. Lipatov, Z. Guo, I. Isakova, C. T. Davis, P. Rivailler, K. M. Gustin, J. A. Belser, T. R. Maines, T. M. Tumpey, X. Xu, J. M. Katz, A. Klimov, N. J. Cox, and R. O. Donis. 2011. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29:1836–1843. doi:S0264-410X(10)01817-7 [pii];10.1016/j. vaccine.2010.12.044 [doi]. 1337. Robien, M. A., A. R. Lifson, S. Duval, K. L. Nichol, and P. Ferrieri. 2011. Telephone survey assessment of household patterns of influenza vaccination, Twin Cities seven county metro area, 2008–2009. Vaccine 29:4033–4042. doi:S0264-410X(11)00413-0 [pii];10.1016/j.vaccine.2011.03.045 [doi]. 1338. Rockman, S. and L. Brown. 2010. Pre-pandemic and pandemic influenza vaccines. Hum.Vaccin. 6:792–801. doi:12915 [pii]. 1339. Rodriguez-Rieiro, C., M. D. Esteban-Vasallo, M. F. Dominguez-Berjon, J. Astray-Mochales, D. Iniesta- Fornies, D. Barranco-Ordonez, M. Cameno-Heras, and R. Jimenez-Garcia. 2011. Coverage and predictors of vaccination against 2009 pandemic H1N1 influenza in Madrid, Spain. Vaccine 29:1332– 1338. doi:S0264-410X(10)01562-8 [pii];10.1016/j.vaccine.2010.10.061 [doi]. 1340. Roggendorf, H., T. Sprave, S. Hertel, F. Morscheck, and M. Roggendorf. 2011. [Rate of influenza vaccination among medical staff working at a university hospital]. Dtsch.Med.Wochenschr. 136:1299–1304. doi:10.1055/s-0031-1280550 [doi]. 1341. Roldao, A., M. C. Mellado, L. R. Castilho, M. J. Carrondo, and P. M. Alves. 2010. Virus-like particles in vaccine development. Expert.Rev.Vaccines. 9:1149–1176. doi:10.1586/erv.10.115 [doi]. 1342. Rolfe, E. and L. A. Howard. 2010. Best practice model for immunization: one home care agency’s experience providing H1N1 and seasonal vaccine. Home.Healthc.Nurse 28:524–532. doi:10.1097/ NHH.0b013e3181f2f38c [doi];00004045-201010000-00003 [pii]. 1343. Rolland-Harris, E. and M. Tepper . 2011. Cost-effectiveness of Ontario’s pandemic vaccine program. Vaccine 29:3829–1. doi:S0264-410X(10)01271-5 [pii];10.1016/j.vaccine.2010.08.089 [doi]. 1344. Roman, F., F. Clement, W. Dewe, K. Walravens, C. Maes, J. Willekens, B. F. De, E. Hanon, and G. Leroux-Roels. 2011. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin.Vaccine Immunol. 18:835–843. doi:CVI.00480-10 [pii];10.1128/CVI.00480-10 [doi].

154 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1345. Roman, F., T. Vaman, B. Gerlach, A. Markendorf, P. Gillard, and J. M. Devaster. 2010. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28:1740–1745. doi:S0264-410X(09)01918-5 [pii];10.1016/j.vaccine.2009.12.014 [doi]. 1346. Roman, F., T. Vaman, F. Kafeja, E. Hanon, and D. P. Van. 2010. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin.Infect.Dis. 51:668–677. doi:10.1086/655830 [doi]. 1347. Romani, M. H., U. M. Musharrafieh, N. A. Lakkis, and G. N. Hamadeh. 2011. Family physicians beliefs and attitudes regarding adult pneumococcal and influenza immunization in Lebanon. Fam.Pract. doi:cmr038 [pii];10.1093/fampra/cmr038 [doi]. 1348. Romanowska, M., A. Banaszkiewicz, I. Nowak, A. Radzikowski, and L. B. Brydak. 2010. Immunization against influenza during the 2005/2006 epidemic season and the humoral response in children with diagnosed inflammatory bowel disease (IBD). Med.Sci.Monit. 16:CR433–CR439. doi:881131 [pii]. 1349. Rortveit, S., S. Hunskar, K. A. Wensaas, K. A. Simonsen, and G. Rortveit. 2011. [The influenza pandemic in a Norwegian municipality autumn 2009]. Tidsskr.Nor Laegeforen. 131:675–679. doi:2090054 [pii];10.4045/tidsskr.10.0858 [doi]. 1350. Rosenkrands, I., C. Vingsbo-Lundberg, T. J. Bundgaard, T. Lindenstrom, V. Enouf, S. van der Werf, P. Andersen, and E. M. Agger. 2011. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29:6283– 6291. doi:S0264-410X(11)00904-2 [pii];10.1016/j.vaccine.2011.06.040 [doi]. 1351. Rothan-Tondeur, M., Y. Filali-Zegzouti, J. Belmin, B. Lejeune, J. L. Golmard, W. B. De, F. Carrat, F. Piette, C. Mouala, and G. Gavazzi. 2010. Assessment of healthcare worker influenza vaccination program in French geriatric wards: a cluster-randomized controlled trial. Aging Clin.Exp.Res. 22:450– 455. doi:6708 [pii];10.3275/6708 [doi]. 1352. Rothan-Tondeur, M., Y. Filali-Zegzouti, J. L. Golmard, W. B. De, F. Piette, F. Carrat, B. Lejeune, and G. Gavazzi. 2011. Randomised active programs on healthcare workers’ flu vaccination in geriatric health care settings in France: the VESTA study. J.Nutr.Health Aging 15:126–132. 1353. Rothova, A., J. D. de Groot, and T. Mudrikova. 2011. Reactivation of acute retinal necrosis after flu H1N1 vaccination. Br.J.Ophthalmol. 95:291. doi:bjo.2010.185983 [pii];10.1136/bjo.2010.185983 [doi]. 1354. Rottinghaus, E. K., B. Vesosky, and J. Turner. 2010. TLR-2 independent recognition of Mycobacterium tuberculosis by CD11c+ pulmonary cells from old mice. Mech.Ageing Dev. 131:405–414. doi:S0047-6374(10)00111-9 [pii];10.1016/j.mad.2010.05.006 [doi]. 1355. Roukens, A. H., L. B. Gelinck, and L. G. Visser. 2012. Intradermal vaccination to protect against yellow Fever and influenza. Curr.Top.Microbiol.Immunol. 351:159–179. doi:10.1007/82_2011_124 [doi]. 1356. Rubin, G. J., H. W. Potts, and S. Michie. 2010. The impact of communications about swine flu (influenza A H1N1v) on public responses to the outbreak: results from 36 national telephone surveys in the UK. Health Technol.Assess. 14:183–266. doi:10.3310/hta14340-03 [doi]. 1357. Rubin, G. J., H. W. Potts, and S. Michie. 2011. Likely uptake of swine and seasonal flu vaccines among healthcare workers. A cross-sectional analysis of UK telephone survey data. Vaccine 29:2421–2428. doi:S0264-410X(11)00074-0 [pii];10.1016/j.vaccine.2011.01.035 [doi]. 1358. Rubin, J. L., L. J. McGarry, K. P. Klugman, D. R. Strutton, K. E. Gilmore, and M. C. Weinstein. 2010. Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC.Infect.Dis. 10:14. doi:1471-2334-10-14 [pii];10.1186/1471-2334-10-14 [doi].

155 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1359. Rubin, L. G. and B. Papsin. 2010. Cochlear implants in children: surgical site infections and prevention and treatment of acute otitis media and meningitis. Pediatrics 126:381–391. doi:peds.2010-1427 [pii];10.1542/peds.2010-1427 [doi]. 1360. Rubinstein, E., G. Predy, L. Sauve, G. W. Hammond, F. Aoki, C. Sikora, Y. Li, B. Law, S. Halperin, and D. Scheifele. 2011. The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. CMAJ. 183:E1033–E1037. doi:cmaj.110196 [pii];10.1503/cmaj.110196 [doi]. 1361. Rudenko, L., H. van den Bosch, I. Kiseleva, A. Mironov, A. Naikhin, N. Larionova, and D. Bushmenkov. 2011. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 29 Suppl 1:A40–A44. doi:S0264-410X(11)00688-8 [pii];10.1016/j.vaccine.2011.04.122 [doi]. a. Rudolf, M., M. Poppel, A. Frohlich, A. Breithaupt, J. Teifke, U. Blohm, T. Mettenleiter, M. Beer, and T. Harder. 2010. Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens. Vaccine 28:6832–6840. doi:S0264-410X(10)01183-7 [pii];10.1016/j.vaccine.2010.08.038 [doi]. 1362. Rudolph, W. and Y. T. Ben. 2011. A universal influenza vaccine: where are we in the pursuit of this “Holy Grail”? Hum.Vaccin. 7:10–11. doi:14925 [pii]. 1363. Ruiz, A. D., C. R. Frei, J. C. Barner, J. J. Carson, C. U. Oramasionwu, J. L. Ruiz, K. R. Daniels, J. F. Mohr, and M. E. Klepser. 2010. Influenza vaccination rates among pharmacists. J.Am.Pharm.Assoc. (2003.) 50:517–522. doi:R0M8546416712531 [pii];10.1331/JAPhA.2010.09146 [doi]. 1364. Rumyantsev, A. A., Z. X. Zhang, Q. S. Gao, N. Moretti, N. Brown, H. Kleanthous, S. Delagrave, F. Guirakhoo, M. S. Collett, and K. V. Pugachev. 2010. Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus. Virology 396:329–338. doi:S0042-6822(09)00657-6 [pii];10.1016/j.virol.2009.10.033 [doi]. 1365. Russell, C. J. 2011. Stalking influenza diversity with a universal antibody. N.Engl.J.Med. 365:1541– 1542. doi:10.1056/NEJMcibr1109447 [doi]. 1366. Russell, E. J., D. Roberts, and M. Lee. 2010. Pharmacist-driven seasonal influenza immunization program for health care workers. Am.J.Health Syst.Pharm. 67:1984–1985. doi:67/23/1984 [pii];10.2146/ajhp090610 [doi]. 1367. Ryan, K. J. and M. D. Rousculp. 2010. Opening and continuing the discussion on influenza vaccination timing. Am.J.Manag.Care 16:628–629. 1368. Saad, C. G., E. F. Borba, N. E. Aikawa, C. A. Silva, R. M. Pereira, A. L. Calich, J. C. Moraes, A. C. Ribeiro, V. S. Viana, S. G. Pasoto, J. F. Carvalho, I. L. Franca, L. K. Guedes, S. K. Shinjo, P. D. Sampaio-Barros, M. T. Caleiro, C. R. Goncalves, R. Fuller, M. Levy-Neto, M. C. Timenetsky, A. R. Precioso, and E. Bonfa. 2011. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/ H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann.Rheum.Dis. 70:1068–1073. doi:ard.2011.150250 [pii];10.1136/ard.2011.150250 [doi]. 1369. Sabarth, N., M. K. Howard, H. Savidis-Dacho, M. A. van, P. N. Barrett, and O. Kistner. 2010. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 28:650–656. doi:S0264-410X(09)01656-9 [pii];10.1016/j.vaccine.2009.10.105 [doi]. 1370. Sagawa, M., N. Kojimahara, N. Otsuka, M. Kimura, and N. Yamaguchi. 2011. Immune response to influenza vaccine in the elderly: association with nutritional and physical status. Geriatr.Gerontol.Int. 11:63–68. doi:GGI641 [pii];10.1111/j.1447-0594.2010.00641.x [doi]. 1371. Saha, R., S. Killian, and R. S. Donofrio. 2011. DNA vaccines: a mini review. Recent Pat DNA Gene Seq. 5:92–96. doi:BSP/DNAG/E-PUB 00026 [pii].

156 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1372. Sahini, L., A. Tempczyk-Russell, and R. Agarwal. 2010. Large-scale sequence analysis of hemagglutinin of influenza A virus identifies conserved regions suitable for targeting an anti-viral response. PLoS.One. 5:e9268. doi:10.1371/journal.pone.0009268 [doi]. 1373. Sakaguchi, S., B. Weitzner, N. Carey, P. Bozzo, K. Mirdamadi, N. Samuel, G. Koren, and A. Einarson. 2011. Pregnant women’s perception of risk with use of the H1N1 vaccine. J.Obstet.Gynaecol.Can. 33:460–467. 1374. Salathe, M. and J. H. Jones. 2010. Dynamics and control of diseases in networks with community structure. PLoS.Comput.Biol. 6:e1000736. doi:10.1371/journal.pcbi.1000736 [doi]. 1375. Salemi, S. and R. D’Amelio. 2010. Could autoimmunity be induced by vaccination? Int.Rev.Immunol. 29:247–269. doi:10.3109/08830181003746304 [doi]. 1376. Salemi, S., A. Picchianti-Diamanti, V. Germano, I. Donatelli, M. A. Di, M. Facchini, R. Nisini, R. Biselli, C. Ferlito, E. Podesta, A. Cappella, F. Milanetti, F. Rossi, R. Amodeo, F. Tabacco, R. R. Di, B. Lagana, and D. Amelio. 2010. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin.Immunol. 134:113–120. doi:S1521-6616(09)00839-0 [pii];10.1016/j.clim.2009.09.014 [doi]. 1377. Salles, M. J., Y. A. Sens, L. S. Boas, and C. M. Machado. 2010. Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs. Clin.Transplant. 24:E17–E23. doi:CTR1095 [pii];10.1111/j.1399-0012.2009.01095.x [doi]. 1378. Salmon, D. A., A. Akhtar, M. J. Mergler, K. S. Vannice, H. Izurieta, R. Ball, G. M. Lee, C. Vellozzi, P. Garman, F. Cunningham, B. Gellin, H. Koh, and N. Lurie. 2011. Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program. Pediatrics 127 Suppl 1:S78– S86. doi:peds.2010-1722L [pii];10.1542/peds.2010-1722L [doi]. 1379. Saluja, V., J. P. Amorij, J. C. Kapteyn, A. H. de Boer, H. W. Frijlink, and W. L. Hinrichs. 2010. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J.Control Release 144:127–133. doi:S0168-3659(10)00158-6 [pii];10.1016/j. jconrel.2010.02.025 [doi]. 1380. Saluja, V., J. P. Amorij, M. L. van Roosmalen, K. Leenhouts, A. Huckriede, W. L. Hinrichs, and H. W. Frijlink. 2010. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS.J. 12:109–116. doi:10.1208/s12248-009-9168-2 [doi]. 1381. Saluja, V., M. R. Visser, M. L. van Roosmalen, K. Leenhouts, A. Huckriede, W. L. Hinrichs, and H. W. Frijlink. 2010. Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles. Eur.J.Pharm.Biopharm. 76:470–474. doi:S0939-6411(10)00213-4 [pii];10.1016/j.ejpb.2010.08.003 [doi]. 1382. Saluja, V., M. R. Visser, V. W. ter, M. L. van Roosmalen, K. Leenhouts, W. L. Hinrichs, A. Huckriede, and H. W. Frijlink. 2010. Influenza antigen-sparing by immune stimulation with Gram- positive enhancer matrix (GEM) particles. Vaccine 28:7963–7969. doi:S0264-410X(10)01387-3 [pii];10.1016/j.vaccine.2010.09.066 [doi]. 1383. Saluja, V., W. L. Hinrichs, and H. W. Frijlink. 2010. Dried influenza vaccines: over the counter vaccines. Hum.Vaccin. 6:854–856. doi:12572 [pii];104161/hv.6.11.12572 [doi]. 1384. Samad, I., V. H. Chong, and S. S. Lim. 2011. Erythema multiforme secondary to H1N1 vaccine. South. Med.J. 104:73–74. doi:10.1097/SMJ.0b013e3181faf12e [doi]. 1385. Samayoa, L., F. Diaz-Mitoma, and A. Azizi. 2011. Characterization of a branched lipopeptide candidate vaccine against influenza A/Puerto Rico 8/34 which is recognized by human B and T-cell immune responses. Virol.J. 8:309. doi:1743-422X-8-309 [pii];10.1186/1743-422X-8-309 [doi]. 1386. Sambhara, S. and G. A. Poland. 2010. H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic. Annu.Rev.Med. 61:187–198. doi:10.1146/annurev.med.050908.132031 [doi].

157 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1387. Sambhara, V. 2011. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J.Infect.Dis. 203:1697–1698. doi:jir169 [pii];10.1093/infdis/jir169 [doi]. 1388. Samuel, D., L. Warrener, and K. Hoschler. 2011. Monoclonal antibodies to the haemagglutinin HA1 subunit of the pandemic influenza A/H1N1 2009 virus and potential application to serodiagnosis. J.Med.Virol. 83:559–567. doi:10.1002/jmv.21982 [doi]. 1389. Sanchez-Paya, J., I. Hernandez-Garcia, J. Barrenengoa-Sanudo, R. Camargo-Angeles, A. Rincon, and S. Romero-Candeira. 2010. [Frequency and factors associated with adverse reactions following the administration of influenza vaccine in personal health during the 2009–2010 Season]. Rev.Esp.Salud Publica 84:851–859. doi:S1135-57272010000600014 [pii]. 1390. Sanchez-Paya, J., I. Hernandez-Garcia, S. J. Barrenengoa, M. H. Rolando, A. R. Camargo, L. L. Cartagena, R. C. Villanueva, and H. M. Gonzalez. 2011. [Determinants of influenza vaccination in health staff: 2009–2010 season]. Gac.Sanit. 25:29–34. doi:S0213-9111(10)00292-X [pii];10.1016/j.gaceta.2010.09.018 [doi]. 1391. Santibanez, T. A., G. T. Mootrey, G. L. Euler, and A. P. Janssen. 2010. Behavior and beliefs about influenza vaccine among adults aged 50–64 years. Am.J.Health Behav. 34:77–89. doi:10.5555/ ajhb.2010.34.1.77 [pii]. 1392. Santos, C. D., R. B. Bristow, and J. V. Vorenkamp. 2010. Which health care workers were most affected during the spring 2009 H1N1 pandemic? Disaster.Med.Public Health Prep. 4:47–54. doi:01273293-201003000-00011 [pii]. 1393. Sarti, E., G. Manuell-Lee, J. L. Mosqueda, F. Gabilondo, A. de la Torre, V. Arreguin, G. Dominguez- Cheritt, A. E. Macias, and J. A. Cordova-Villalobos. 2010. [Influenza A H1N1 (2009): considerations at the time of declaring the end of the contingency in Mexico]. Rev.Invest Clin. 62:289–298. 1394. Sasaki, S., M. Sullivan, C. F. Narvaez, T. H. Holmes, D. Furman, N. Y. Zheng, M. Nishtala, J. Wrammert, K. Smith, J. A. James, C. L. Dekker, M. M. Davis, P. C. Wilson, H. B. Greenberg, and X. S. He. 2011. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J.Clin.Invest 121:3109–3119. doi:57834 [pii];10.1172/JCI57834 [doi]. 1395. Sasson, M., M. Mandelboim, and P. Shvartzman. 2011. Influenza vaccination for terminally ill cancer patients receiving palliative care: a preliminary report. J.Pain Symptom.Manage. 41:485–490. doi:S0885-3924(10)00694-9 [pii];10.1016/j.jpainsymman.2010.05.016 [doi]. 1396. Sato, K. and S. Itamura. 2010. [Trends and perspectives in development of influenza vaccines]. Nihon Rinsho 68:1697–1701. 1397. Sato, N. A., Y. Kano, and T. Shiohara. 2010. Lichen planus occurring after influenza vaccination: report of three cases and review of the literature. Dermatology 221:296–299. doi:000321191 [pii];10.1159/000321191 [doi]. 1398. Sato, N., K. Watanabe, K. Ohta, and H. Tanaka. 2011. Acute transverse myelitis and acute motor axonal neuropathy developed after vaccinations against seasonal and 2009 A/H1N1 influenza. Intern. Med. 50:503–507. doi:JST.JSTAGE/internalmedicine/50.4340 [pii]. 1399. Savard, C., A. Guerin, K. Drouin, M. Bolduc, M. E. Laliberte-Gagne, M. C. Dumas, N. Majeau, and D. Leclerc. 2011. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS. One. 6:e21522. doi:10.1371/journal.pone.0021522 [doi];PONE-D-11-05838 [pii]. 1400. Savas, E. and D. Tanriverdi. 2010. Knowledge, attitudes and anxiety towards influenza A/H1N1 vaccination of healthcare workers in Turkey. BMC.Infect.Dis. 10:281. doi:1471-2334-10-281 [pii];10.1186/1471-2334-10-281 [doi].

158 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1401. Savulescu, C., M. Valenciano, M. S. de, and A. Larrauri. 2010. Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network – pilot case-control studies using different control groups, 2008–2009 season, Spain. Vaccine 28:2903– 2907. doi:S0264-410X(10)00119-2 [pii];10.1016/j.vaccine.2010.01.054 [doi]. 1402. Savulescu, C., S. Jimenez-Jorge, M. S. de, J. Ledesma, F. Pozo, I. Casas, and A. Larrauri. 2011. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. Euro.Surveill 16. 1403. Schaefer, C., L. H. Butterfield, S. Lee, G. G. Kim, C. Visus, A. Albers, J. M. Kirkwood, and T. L. Whiteside. 2011. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multi-epitope peptide vaccine trial (ECOG 1696). Int.J.Cancer. doi:10.1002/ ijc.26481 [doi]. 1404. Schatz, M., C. D. Chambers, K. L. Jones, C. Louik, and A. A. Mitchell. 2011. Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System. Am.J.Obstet.Gynecol. 204:S64–S68. doi:S0002-9378(11)00086-X [pii];10.1016/j.ajog.2011.01.047 [doi]. 1405. Scheifele, D. W., B. J. Ward, M. Dionne, O. Vanderkooi, J. M. Langley, S. Dobson, Y. Li, B. Law, and S. A. Halperin. 2011. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr.Infect.Dis.J. 30:402–407. doi:10.1097/INF.0b013e3182068f33 [doi]. 1406. Scheifele, D. W., K. Marty, C. Lajeunesse, S. Y. Fan, G. Bjornson, J. M. Langley, and S. A. Halperin. 2011. Strategies for successful rapid trials of influenza vaccine. Clin.Trials. doi:1740774511419868 [pii];10.1177/1740774511419868 [doi]. 1407. Schijns, V. E. and E. C. Lavelle . 2011. Trends in vaccine adjuvants. Expert.Rev.Vaccines. 10:539– 550. doi:10.1586/erv.11.21 [doi]. 1408. Schmeisser, F., G. M. Vodeiko, V. Y. Lugovtsev, R. R. Stout, and J. P. Weir. 2010. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 28:2442–2449. doi:S0264-410X(10)00015-0 [pii];10.1016/j. vaccine.2009.12.079 [doi]. 1409. Schmidt, M. A., B. Crane, J. P. Mullooly, and A. L. Naleway. 2010. Frequency of medically attended events following rapid revaccination with trivalent inactivated influenza vaccine. Vaccine 28:7713– 7715. doi:S0264-410X(10)01353-8 [pii];10.1016/j.vaccine.2010.09.043 [doi]. 1410. Schmitt, H. J., J. P. Gregersen, H. Trusheim, and M. Broker. 2010. [Safety of cell culture-based influenza vaccines]. Med.Monatsschr.Pharm. 33:4–10. 1411. Schneider-Ohrum, K., B. M. Giles, H. K. Weirback, B. L. Williams, D. R. Dealmeida, and T. M. Ross. 2011. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine 29:9081–9092. doi:S0264-410X(11)01457-5 [pii];10.1016/j.vaccine.2011.09.051 [doi]. 1412. Schubert, C. 2010. New vaccine tailored to the weakened elderly . Nat.Med. 16:137. doi:nm0210-137a [pii];10.1038/nm0210-137a [doi]. 1413. Schuler, J. E., W. J. King, N. L. Dayneka, L. Rastelli, E. Marquis, Z. Chad, and C. Hui. 2011. Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/ H1N1 disease. Can.J.Public Health 102:196–199. 1414. Schultz-Cherry, S. and J. C. Jones. 2010. Influenza vaccines: the good, the bad, and the eggs. Adv. Virus Res. 77:63–84. doi:B978-0-12-385034-8.00003-X [pii];10.1016/B978-0-12-385034- 8.00003-X [doi].

159 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1415. Schuurmans, M. M., G. M. Tini, L. Dalar, G. Fretz, C. Benden, and A. Boehler. 2011. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J.Heart Lung Transplant. 30:685–690. doi:S1053-2498(11)00738-8 [pii];10.1016/j.healun.2011.01.707 [doi]. 1416. Schwartz, J. A., L. Buonocore, A. L. Suguitan, Jr., A. Silaghi, D. Kobasa, G. Kobinger, H. Feldmann, K. Subbarao, and J. K. Rose. 2010. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J.Virol. 84:4611–4618. doi:JVI.02637-09 [pii];10.1128/JVI.02637-09 [doi]. 1417. Schwartz, J. A., L. Buonocore, A. Suguitan, Jr., M. Hunter, P. A. Marx, K. Subbarao, and J. K. Rose. 2011. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J.Virol. 85:4602–4605. doi:JVI.02491-10 [pii];10.1128/ JVI.02491-10 [doi]. 1418. Schweon, S. J. 2010. Double jeopardy: pneumococcal pneumonia following seasonal influenza. Nursing. 40:60–61. doi:10.1097/01.NURSE.0000390682.88018.ef [doi];00152193-201012000- 00021 [pii]. 1419. Scott, K. 2010. Pandemic influenza H1N1 2009 – the Canadian experience. J.Popul.Ther.Clin. Pharmacol. 17:e358–e362. 1420. Seale, H., A. E. Heywood, M. L. McLaws, K. F. Ward, C. P. Lowbridge, D. Van, and C. R. MacIntyre. 2010. Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine. BMC.Infect.Dis. 10:99. doi:1471-2334-10-99 [pii];10.1186/1471-2334-10-99 [doi]. 1421. Seale, H., J. Leask, and C. R. MacIntyre. 2010. Attitudes amongst Australian hospital healthcare workers towards seasonal influenza and vaccination. Influenza.Other Respi.Viruses. 4:41–46. doi:IRV112 [pii];10.1111/j.1750-2659.2009.00112.x [doi]. 1422. Seale, H., K. F. Ward, N. Zwar, D. Van, J. Leask, and C. R. MacIntyre. 2010. Examining the knowledge of and attitudes to pandemic influenza among general practice staff. Med.J.Aust. 192:378–380. doi:sea10925_fm [pii]. 1423. Seale, H., Q. Wang, P. Yang, D. E. Dwyer, X. Wang, Y. Zhang, and C. R. Macintyre. 2010. Influenza vaccination amongst hospital health care workers in Beijing. Occup.Med.(Lond) 60:335–339. doi:kqq037 [pii];10.1093/occmed/kqq037 [doi]. 1424. Seale, H., R. Kaur, Q. Wang, P. Yang, Y. Zhang, X. Wang, X. Li, H. Zhang, Z. Zhang, and C. R. Macintyre. 2011. Acceptance of a vaccine against pandemic influenza A (H1N1) virus amongst healthcare workers in Beijing, China. Vaccine 29:1605–1610. doi:S0264-410X(10)01850-5 [pii];10.1016/j.vaccine.2010.12.077 [doi]. 1425. Seidman, J. C., S. A. Richard, C. Viboud, and M. A. Miller. 2011. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza.Other Respi.Viruses. doi:10.1111/ j.1750-2659.2011.00268.x [doi]. 1426. Sejvar, J. J., D. Pfeifer, and L. B. Schonberger. 2011. Guillain-barre syndrome following influenza vaccination: causal or coincidental? Curr.Infect.Dis.Rep. 13:387–398. doi:10.1007/s11908-011- 0194-8 [doi]. 1427. Sencer, D. J. 2011. Perspective: Swine-origin influenza: 1976 and 2009. Clin.Infect.Dis. 52 Suppl 1:S4–S7. doi:ciq006 [pii];10.1093/cid/ciq006 [doi]. 1428. Seo, K. Y., S. J. Han, H. R. Cha, S. U. Seo, J. H. Song, S. H. Chung, and M. N. Kweon. 2010. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. J.Immunol. 185:3610– 3619. doi:jimmunol.1000680 [pii];10.4049/jimmunol.1000680 [doi]. 1429. Seppelt, I. M., S. A. Webb, and R. Booy. 2010. All health professionals should receive the 2009 H1N1 influenza vaccine. Crit Care Resusc. 12:3–5.

160 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1430. Setbon, M. and J. Raude. 2010. Factors in vaccination intention against the pandemic influenza A/ H1N1. Eur.J.Public Health 20:490–494. doi:ckq054 [pii];10.1093/eurpub/ckq054 [doi]. 1431. Setse, R. W., G. L. Euler, A. G. Gonzalez-Feliciano, L. N. Bryan, C. Furlow, C. M. Weinbaum, and J. A. Singleton . 2011. Influenza vaccination coverage – United States, 2000–2010. MMWR Surveill Summ. 60 Suppl:38–41. doi:su6001a7 [pii]. 1432. Settembre, E. C., P. R. Dormitzer, and R. Rappuoli. 2011. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. J.Mol.Cell Biol. 3:144–146. doi:mjq046 [pii];10.1093/jmcb/mjq046 [doi]. 1433. Shahbic, H. E. and H. A. Said. 2010. Flu vaccine among health workers in Qatar. Saudi.Med.J. 31:1157–1160. doi:20102488’ [pii]. 1434. Shahgholi, E., M. A. Ehsani, P. Salamati, A. Maysamie, K. Sotoudeh, and T. Mokhtariazad. 2010. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr.Blood Cancer 54:716–720. doi:10.1002/pbc.22421 [doi]. 1435. Shahrabani, S. and U. Benzion. 2010. Workplace vaccination and other factors impacting influenza vaccination decision among employees in Israel. Int.J.Environ.Res.Public Health 7:853–869. doi:10.3390/ijerph7030853 [doi]. 1436. Shapshak, P., F. Chiappelli, C. Somboonwit, and J. Sinnott. 2011. The influenza pandemic of 2009: lessons and implications. Mol.Diagn.Ther. 15:63–81. doi:1 [pii];10.2165/11590660-000000000- 00000 [doi]. 1437. Shim, D. H., H. J. Ko, G. Volker, A. A. Potter, G. Mutwiri, L. A. Babiuk, and M. N. Kweon. 2010. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Vaccine 28:2311–2317. doi:S0264- 410X(10)00005-8 [pii];10.1016/j.vaccine.2009.12.069 [doi]. 1438. Shim, E. 2011. Prioritization of delayed vaccination for pandemic influenza. Math.Biosci.Eng 8:95– 112. 1439. Shim, E., L. A. Meyers, and A. P. Galvani. 2011. Optimal H1N1 vaccination strategies based on self-interest versus group interest. BMC.Public Health 11 Suppl 1:S4. doi:1471-2458-11-S1-S4 [pii];10.1186/1471-2458-11-S1-S4 [doi]. 1440. Shin, J. S., H. S. Do, H. S. Kim, S. W. Cho, and S. H. Seo. 2010. Protection of ferrets from infection by swine-origin 2009 A (H1N1) influenza virus by the inactivated vaccine. Viral Immunol. 23:395– 402. doi:10.1089/vim.2010.0022 [doi]. 1441. Shin, J. S., H. S. Kim, S. H. Cho, and S. H. Seo. 2010. IgG antibodies mediate protective immunity of inactivated vaccine for highly pathogenic H5N1 influenza viruses in ferrets. Viral Immunol. 23:321– 327. doi:10.1089/vim.2009.0093 [doi]. 1442. Shishkina, L. N., N. A. Mazurkova, V. A. Ternovoi, L. E. Bulychev, I. Tumanov, M. O. Skarnovich, A. S. Kabanov, N. N. Ryndiuk, V. I. Kuzubov, A. N. Mironov, E. A. Stavskii, and I. G. Drozdov. 2011. [Evaluation of immunogenicity and safety of 2 immunizations with allantoic intranasal live influenza vaccine Ultragrivac]. Zh.Mikrobiol.Epidemiol.Immunobiol.92–96. 1443. Shishkina, L. N., V. E. Nebol’sin, A. S. Kabanov, M. O. Skarnovich, N. A. Mazurkova, A. A. Sergeev, O. A. Serova, E. A. Stavskii, and I. G. Drozdov. 2011. [In vitro and in vivo efficacy of Ingavirin against strains of pandemic influenza virus A(H1N1/09)v]. Zh.Mikrobiol.Epidemiol.Immunobiol.93–96. 1444. Shoji, Y., C. E. Farrance, J. Bautista, H. Bi, K. Musiychuk, A. Horsey, H. Park, J. Jaje, B. J. Green, M. Shamloul, S. Sharma, J. A. Chichester, V. Mett, and V. Yusibov. 2011. A plant-based system for rapid production of influenza vaccine antigens. Influenza.Other Respi.Viruses. doi:10.1111/j.1750- 2659.2011.00295.x [doi].

161 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1445. Shoji, Y., J. A. Chichester, M. Jones, S. D. Manceva, E. Damon, V. Mett, K. Musiychuk, H. Bi, C. Farrance, M. Shamloul, N. Kushnir, S. Sharma, and V. Yusibov. 2011. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum.Vaccin. 7 Suppl:41–50. doi:14561 [pii]. 1446. Siegrist, C. A. 2010. [Vaccine update 2009: questions around the safety of the influenza A (H1N1) vaccine]. Rev.Med.Suisse 6:67–70. 1447. Silveira, M. B., D. A. Perez, A. Yamaguti, E. Z. Saraiva, M. G. Borges, and M. I. de Moraes-Pinto. 2011. Immunization status of residents in pediatrics at the Federal University of Sao Paulo, Brazil. Rev.Inst.Med.Trop.Sao Paulo 53:73–76. doi:S0036-46652011000200003 [pii]. 1448. Simpson, C. R., L. D. Ritchie, C. Robertson, A. Sheikh, and J. McMenamin. 2010. Vaccine effectiveness in pandemic influenza – primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol.Assess. 14:313–346. doi:10.3310/hta14340-05 [doi]. 1449. Singh, N., A. Pandey, and S. K. Mittal. 2010. Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert.Rev.Mol.Med. 12:e14. doi:S1462399410001432 [pii];10.1017/S1462399410001432 [doi]. 1450. Sintes, X., M. Nebot, C. Izquierdo, L. Ruiz, A. Dominguez, J. M. Bayas, I. Vera, J. Carratala, and D. Sousa. 2011. Factors associated with pneumococcal and influenza vaccination in hospitalized people aged >/=65 years. Epidemiol.Infect. 139:666–673. doi:S0950268810001846 [pii];10.1017/ S0950268810001846 [doi]. 1451. Sipo, I., M. Knauf, H. Fechner, W. Poller, O. Planz, R. Kurth, and S. Norley. 2011. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine 29:1690–1699. doi:S0264-410X(10)01810-4 [pii];10.1016/j.vaccine.2010.12.037 [doi]. 1452. Siret-Alatrista, A., F. Bouali, M. Demoly, P. J. Bousquet, and P. Demoly. 2011. The 2009–2010 H1N1 vaccination campaign for patients with egg allergy in a region of France. Allergy 66:298–299. doi:ALL2461 [pii];10.1111/j.1398-9995.2010.02461.x [doi]. 1453. Sirskyj, D., F. Diaz-Mitoma, A. Golshani, A. Kumar, and A. Azizi. 2011. Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses. Immunol.Cell Biol. 89:81–89. doi:icb201065 [pii];10.1038/icb.2010.65 [doi]. 1454. Sistigu, A., L. Bracci, M. Valentini, E. Proietti, R. Bona, D. R. Negri, A. R. Ciccaglione, E. Tritarelli, R. Nisini, M. Equestre, A. Costantino, C. Marcantonio, S. M. Santini, C. Lapenta, S. Donati, P. Tataseo, M. Miceli, A. Cara, and M. Federico. 2011. Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/ maturation of dendritic cells. Vaccine 29:3465–3475. doi:S0264-410X(11)00294-5 [pii];10.1016/j. vaccine.2011.02.059 [doi]. 1455. Siu, J. Y. 2011. The perceptions of and disincentives for receiving influenza A (H1N1) vaccines among chronic renal disease patients in Hong Kong. Health Soc.Care Community. doi:10.1111/j.1365- 2524.2011.01023.x [doi]. 1456. Skalli, S., E. Ferreira, J. F. Bussieres, and B. Allenet. 2010. [Influenza A/H1N1v 2009 during pregnancy and breastfeeding: which antiviral to choose?]. Ann.Pharm.Fr. 68:269–274. doi:S0003-4509(10)00067-2 [pii];10.1016/j.pharma.2010.04.005 [doi]. 1457. Skarlas, T., S. Zevgiti, K. Droebner, E. Panou-Pomonis, O. Planz, and M. Sakarellos-Daitsiotis. 2010. Influenza virus H5N1 hemagglutinin (HA) T-cell epitope conjugates: design, synthesis and immunogenicity. J.Pept.Sci. doi:10.1002/psc.1320 [doi].

162 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1458. Skiles, M. P., J. Cai, A. English, and C. A. Ford. 2011. Retail pharmacies and adolescent vaccination – an exploration of current issues. J.Adolesc.Health 48:630–632. doi:S1054-139X(10)00431-3 [pii];10.1016/j.jadohealth.2010.09.003 [doi]. 1459. Skountzou, I., M. P. Martin, B. Wang, L. Ye, D. Koutsonanos, W. Weldon, J. Jacob, and R. W. Compans. 2010. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28:4103–4112. doi:S0264-410X(09)01080-9 [pii];10.1016/j. vaccine.2009.07.058 [doi]. 1460. Skowronski, D. M., N. Z. Janjua, S. G. De, T. S. Hottes, J. A. Dickinson, N. Crowcroft, T. L. Kwindt, P. Tang, H. Charest, K. Fonseca, J. B. Gubbay, N. Bastien, Y. Li, and M. Petric. 2011. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 342:c7297. 1461. Skowronski, D. M., N. Z. Janjua, T. S. Hottes, and S. G. De. 2011. Mechanism for Seasonal Vaccine Effect on Pandemic H1N1 Risk Remains Uncertain. Clin.Infect.Dis. 52:831–832. doi:cir036 [pii];10.1093/cid/cir036 [doi]. 1462. Skowronski, D. M., S. G. De, N. S. Crowcroft, N. Z. Janjua, N. Boulianne, T. S. Hottes, L. C. Rosella, J. A. Dickinson, R. Gilca, P. Sethi, N. Ouhoummane, D. J. Willison, I. Rouleau, M. Petric, K. Fonseca, S. J. Drews, A. Rebbapragada, H. Charest, M. E. Hamelin, G. Boivin, J. L. Gardy, Y. Li, T. L. Kwindt, D. M. Patrick, and R. C. Brunham. 2010. Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during Spring–Summer 2009: four observational studies from Canada. PLoS.Med. 7:e1000258. doi:10.1371/journal.pmed.1000258 [doi]. 1463. Skowronski, D. M., T. S. Hottes, M. Chong, S. G. De, D. W. Scheifele, B. J. Ward, S. A. Halperin, N. Z. Janjua, T. Chan, S. Sabaiduc, and M. Petric. 2011. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics 128:e276–e289. doi:peds.2010-2777 [pii];10.1542/peds.2010-2777 [doi]. 1464. Smirnov, D., J. J. Schmidt, J. T. Capecchi, and P. D. Wightman. 2011. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29:5434–5442. doi:S0264-410X(11)00781-X [pii];10.1016/j.vaccine.2011.05.061 [doi]. 1465. Smith, J. H., P. Brooks, S. Johnson, S. M. Tompkins, K. M. Custer, D. L. Haas, R. Mair, M. Papania, and R. A. Tripp. 2011. Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice. Vaccine 29:2568–2575. doi:S0264-410X(11)00119-8 [pii];10.1016/j.vaccine.2011.01.059 [doi]. 1466. Smith, J., M. Lipsitch, and J. W. Almond. 2011. Vaccine production, distribution, access, and uptake. Lancet 378:428–438. doi:S0140-6736(11)60478-9 [pii];10.1016/S0140-6736(11)60478-9 [doi]. 1467. Smith, K. J., B. Y. Lee, M. P. Nowalk, M. Raymund, and R. K. Zimmerman. 2010. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine 28:7620–7625. doi:S0264-410X(10)01363-0 [pii];10.1016/j.vaccine.2010.09.053 [doi]. 1468. Smith, K. J., M. Raymund, M. P. Nowalk, M. S. Roberts, and R. K. Zimmerman. 2010. Cost- effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic. Am.J.Manag.Care 16:200–206. doi:12591 [pii]. 1469. Smith, L. R., M. K. Wloch, M. Ye, L. R. Reyes, S. Boutsaboualoy, C. E. Dunne, J. A. Chaplin, D. Rusalov, A. P. Rolland, C. L. Fisher, M. S. Al-Ibrahim, M. L. Kabongo, R. Steigbigel, R. B. Belshe, E. R. Kitt, A. H. Chu, and R. B. Moss. 2010. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 28:2565– 2572. doi:S0264-410X(10)00061-7 [pii];10.1016/j.vaccine.2010.01.029 [doi]. 1470. Smith, P. J. and J. A. Singleton. 2011. County-level trends in vaccination coverage among children aged 19–35 months – United States, 1995–2008. MMWR Surveill Summ. 60:1–86. doi:ss6004a1 [pii].

163 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1471. Smith, P. J., D. Wood, and P. M. Darden. 2011. Highlights of historical events leading to national surveillance of vaccination coverage in the United States. Public Health Rep. 126 Suppl 2:3–12. 1472. Smith-Norowitz, T. A., D. Wong, M. Kusonruksa, K. B. Norowitz, R. Joks, H. G. Durkin, and M. H. Bluth. 2011. Long term persistence of IgE anti-influenza virus antibodies in pediatric and adult serum post vaccination with influenza virus vaccine. Int.J.Med.Sci. 8:239–244. 1473. Smoljanovic, M., A. Smoljanovic, and M. Mlikotic. 2011. Predicting AH1N1 2009 influenza epidemic in Southeast Europe. Croat.Med.J. 52:115–125. 1474. Snelgrove, R. J., A. Godlee, and T. Hussell. 2011. Airway immune homeostasis and implications for influenza-induced inflammation. Trends Immunol. 32:328–334. doi:S1471-4906(11)00073-1 [pii];10.1016/j.it.2011.04.006 [doi]. 1475. Soboleski, M. R., J. D. Gabbard, G. E. Price, J. A. Misplon, C. Y. Lo, D. R. Perez, J. Ye, S. M. Tompkins, and S. L. Epstein. 2011. Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS.One. 6:e21937. doi:10.1371/journal.pone.0021937 [doi];PONE-D-11-05941 [pii]. 1476. Soboll, G., S. B. Hussey, J. M. Minke, G. A. Landolt, J. S. Hunter, S. Jagannatha, and D. P. Lunn. 2010. Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC) vaccination. Vet.Immunol.Immunopathol. 135:100–107. doi:S0165-2427(09)00396-1 [pii];10.1016/j.vetimm.2009.11.007 [doi]. 1477. Socan, M., K. Prosenc, and N. Tevz-Cizej. 2010. Influenza A(H1N1) outbreak in a long-term care facility for severely handicapped residents, Slovenia, March–April 2009. Euro.Surveill 15:19577. 1478. Solorzano, A., J. Ye, and D. R. Perez. 2010. Alternative live-attenuated influenza vaccines based on modifications in the polymerase genes protect against epidemic and pandemic flu. J.Virol. 84:4587– 4596. doi:JVI.00101-10 [pii];10.1128/JVI.00101-10 [doi]. 1479. Sommerfelt, M. A. 2011. T-cell-mediated and humoral approaches to universal influenza vaccines. Expert.Rev.Vaccines. 10:1359–1361. doi:10.1586/erv.11.127 [doi]. 1480. Song, H., V. Wittman, A. Byers, T. Tapia, B. Zhou, W. Warren, P. Heaton, and K. Connolly. 2010. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 28:5524–5532. doi:S0264-410X(10)00855-8 [pii];10.1016/j.vaccine.2010.06.044 [doi]. 1481. Song, J. M., B. Z. Wang, K. M. Park, R. N. Van, F. S. Quan, M. C. Kim, H. T. Jin, A. Pekosz, R. W. Compans, and S. M. Kang. 2011. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS.One. 6:e14538. doi:10.1371/journal.pone.0014538 [doi]. 1482. Song, J. M., J. Hossain, D. G. Yoo, A. S. Lipatov, C. T. Davis, F. S. Quan, L. M. Chen, R. J. Hogan, R. O. Donis, R. W. Compans, and S. M. Kang. 2010. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405:165–175. doi:S0042-6822(10)00378-8 [pii];10.1016/j.virol.2010.05.034 [doi]. 1483. Song, J. M., R. N. Van, J. Bozja, R. W. Compans, and S. M. Kang. 2011. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc.Natl.Acad. Sci.U.S.A 108:757–761. doi:1012199108 [pii];10.1073/pnas.1012199108 [doi]. 1484. Song, J. M., Y. C. Kim, A. S. Lipatov, M. Pearton, C. T. Davis, D. G. Yoo, K. M. Park, L. M. Chen, F. S. Quan, J. C. Birchall, R. O. Donis, M. R. Prausnitz, R. W. Compans, and S. M. Kang. 2010. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin.Vaccine Immunol. 17:1381–1389. doi:CVI.00100-10 [pii];10.1128/ CVI.00100-10 [doi].

164 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1485. Song, J. M., Y. C. Kim, P. G. Barlow, M. J. Hossain, K. M. Park, R. O. Donis, M. R. Prausnitz, R. W. Compans, and S. M. Kang. 2010. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res. 88:244–247. doi:S0166-3542(10)00705-9 [pii];10.1016/j.antiviral.2010.09.001 [doi]. 1486. Song, J. Y., H. J. Cheong, H. J. Woo, S. H. Wie, J. S. Lee, M. H. Chung, Y. R. Kim, S. I. Jung, K. H. Park, T. H. Kim, S. T. Uh, and W. J. Kim. 2011. Immunogenicity and safety of trivalent inactivated influenza vaccine: a randomized, double-blind, multi-center, phase 3 clinical trial in a vaccine-limited country. J.Korean Med.Sci. 26:191–195. doi:10.3346/jkms.2011.26.2.191 [doi]. 1487. Song, J. Y., H. J. Cheong, I. S. Hwang, W. S. Choi, Y. M. Jo, D. W. Park, G. J. Cho, T. G. Hwang, and W. J. Kim. 2010. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 28:3929–3935. doi:S0264-410X(10)00467-6 [pii];10.1016/j.vaccine.2010.03.067 [doi]. 1488. Song, J. Y., H. J. Cheong, J. Y. Heo, J. Y. Noh, W. S. Choi, D. W. Park, J. Lee, H. W. Jeong, S. Y. Kee, and W. J. Kim. 2011. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine 29:1395–1398. doi:S0264-410X(10)01823-2 [pii];10.1016/j.vaccine.2010.12.050 [doi]. 1489. Song, X., J. Chen, K. Sakwiwatkul, R. Li, and S. Hu. 2010. Enhancement of immune responses to influenza vaccine (H3N2) by ginsenoside Re. Int.Immunopharmacol. 10:351–356. doi:S1567-5769(09)00384-1 [pii];10.1016/j.intimp.2009.12.009 [doi]. 1490. Soonawala, D., G. F. Rimmelzwaan, L. B. Gelinck, L. G. Visser, and F. P. Kroon. 2011. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS.One. 6:e16496. doi:10.1371/journal.pone.0016496 [doi]. 1491. Soto, M. F., A. Olivarez, H. E. Jacobson, C. E. Hsu, and J. Miller. 2011. Risk communication and college students: the 2009 H1N1 pandemic influenza. Prev.Med. 52:473–474. doi:S0091-7435(11)00157-5 [pii];10.1016/j.ypmed.2011.04.004 [doi]. 1492. Souza, A. R., J. A. Braga, T. M. de Paiva, S. R. Loggetto, R. S. Azevedo, and L. Y. Weckx. 2010. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia. Vaccine 28:1117–1120. doi:S0264-410X(09)00759-2 [pii];10.1016/j.vaccine.2009.05.046 [doi]. 1493. Sow, S. O., B. J. Okoko, A. Diallo, S. Viviani, R. Borrow, G. Carlone, M. Tapia, A. K. Akinsola, P. Arduin, H. Findlow, C. Elie, F. C. Haidara, R. A. Adegbola, D. Diop, V. Parulekar, J. Chaumont, L. Martellet, F. Diallo, O. T. Idoko, Y. Tang, B. D. Plikaytis, P. S. Kulkarni, E. Marchetti, F. M. LaForce, and M. P. Preziosi. 2011. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N.Engl.J.Med. 364:2293–2304. doi:10.1056/NEJMoa1003812 [doi]. 1494. Soyer, O. U., S. Hudaverdiyev, E. Civelek, E. Isik, E. Karabulut, C. Kocabas, and B. E. Sekerel. 2011. Parental perspectives on influenza vaccination in children with asthma. Pediatr.Pulmonol. 46:139– 144. doi:10.1002/ppul.21332 [doi]. 1495. Stadtmauer, E. A., D. T. Vogl, P. E. Luning, J. Boyer, N. A. Aqui, A. P. Rapoport, K. R. McDonald, X. Hou, H. Murphy, R. Bhagat, P. A. Mangan, A. Chew, E. A. Veloso, B. L. Levine, R. H. Vonderheide, A. F. Jawad, C. H. June, and K. E. Sullivan. 2011. Transfer of influenza vaccine- primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 117:63–71. doi:blood-2010-07-296822 [pii];10.1182/blood-2010-07-296822 [doi]. 1496. Stanekova, Z. and E. Vareckova. 2010. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol.J. 7:351. doi:1743-422X-7-351 [pii];10.1186/1743-422X-7-351 [doi].

165 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1497. Stanekova, Z., J. Kiraly, A. Stropkovska, T. Mikuskova, V. Mucha, F. Kostolansky, and E. Vareckova. 2011. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Acta Virol. 55:61–67. 1498. Stark, C., E. Garman, J. McMenamin, D. McCormick, and K. Oates. 2010. Major incidents in rural areas: managing a pandemic A/H1N1/2009 cluster. Rural.Remote.Health 10:1413. doi:1413 [pii]. 1499. Stavroulopoulos, A., G. Stamogiannos, and V. Aresti. 2010. Pandemic 2009 influenza H1N1 virus vaccination: compliance and safety in a single hemodialysis center. Ren Fail. 32:1044–1048. doi:10. 3109/0886022X.2010.510232 [doi]. 1500. Stech, J., H. Garn, A. Herwig, O. Stech, B. Dauber, T. Wolff, T. C. Mettenleiter, and H. D. Klenk. 2011. Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine. J.Infect.Dis. 204:1483–1490. doi:jir613 [pii];10.1093/infdis/jir613 [doi]. 1501. Steel, J. 2011. New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges. BioDrugs. 25:285–298. doi:10.2165/11593870-000000000-00000 [doi]. 1502. Steel, J., A. C. Lowen, T. T. Wang, M. Yondola, Q. Gao, K. Haye, A. Garcia-Sastre, and P. Palese. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 1. doi:10.1128/mBio.00018-10 [doi]. 1503. Steelfisher, G. K., R. J. Blendon, M. M. Bekheit, E. W. Mitchell, J. Williams, K. Lubell, J. Peugh, and C. A. DiSogra. 2011. Novel pandemic A (H1N1) influenza vaccination among pregnant women: motivators and barriers. Am.J.Obstet.Gynecol. 204:S116–S123. doi:S0002-9378(11)00226-2 [pii];10.1016/j.ajog.2011.02.036 [doi]. 1504. Steens, A., E. G. Wijnans, J. P. Dieleman, M. C. Sturkenboom, M. A. van der Sande, and W. van der Hoek. 2011. Effectiveness of a MF-59-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study. BMC.Infect.Dis. 11:196. doi:1471-2334-11-196 [pii];10.1186/1471-2334-11-196 [doi]. 1505. Steffens, B., T. Kummerle, S. Koch, A. Birtel, C. Schwarze-Zander, J. Emmelkamp, W. V. Kern, C. Hertenstein, C. Wyen, C. Lehmann, O. A. Cornely, J. Rockstroh, and G. Fatkenheuer. 2011. Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne- Bonn cohort. Eur.J.Med.Res. 16:289–294. 1506. Steitz, J., P. G. Barlow, J. Hossain, E. Kim, K. Okada, T. Kenniston, S. Rea, R. O. Donis, and A. Gambotto. 2010. A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS.One. 5:e10492. doi:10.1371/journal.pone.0010492 [doi]. 1507. Stephenson, I., F. Hayden, A. Osterhaus, W. Howard, Y. Pervikov, L. Palkonyay, and M. P. Kieny. 2010. Report of the fourth meeting on ‘Influenza vaccines that induce broad spectrum and long- lasting immune responses’, World Health Organization and Wellcome Trust, London, United Kingdom, 9–10 November 2009. Vaccine 28:3875–3882. doi:S0264-410X(10)00474-3 [pii];10.1016/j. vaccine.2010.03.074 [doi]. 1508. Stittelaar, K. J., E. J. Veldhuis Kroeze, L. Rudenko, R. Dhere, S. Thirapakpoomanunt, M. P. Kieny, and A. D. Osterhaus. 2011. Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. Vaccine 29:9265–9270. doi:S0264-410X(11)01455-1 [pii];10.1016/j.vaccine.2011.09.049 [doi]. 1509. Stokes, S. and K. Ismail. 2011. Uptake of the H1N1 vaccine by maternity staff at a university hospital in the UK. Int.J.Gynaecol.Obstet. 112:247. doi:S0020-7292(10)00550-3 [pii];10.1016/j. ijgo.2010.10.009 [doi]. 1510. Stowe, J., N. Andrews, P. Bryan, S. Seabroke, and E. Miller. 2011. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: A database study. Vaccine. doi:S0264- 410X(11)01636-7 [pii];10.1016/j.vaccine.2011.10.029 [doi].

166 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1511. Stropkovska, A., J. Janulikova, and E. Vareckova. 2010. Trends in development of the influenza vaccine with broader cross-protection. Acta Virol. 54:7–19. 1512. Stroud, C., B. M. Altevogt, J. C. Butler, and J. S. Duchin. 2011. The Institute of Medicine’s Forum on Medical and Public Health Preparedness for Catastrophic Events: regional workshop series on the 2009 H1N1 influenza vaccination campaign. Disaster.Med.Public Health Prep. 5:81–86. doi:5/1/81 [pii];10.1001/dmp.2011.3 [doi]. 1513. Stuart, B., A. Davidoff, J. Lloyd, T. Shaffer, J. S. Shoemaker, and J. Kemner. 2010. Does influenza vaccination of older adult Medicare beneficiaries lower treatment costs for acute and chronic respiratory disease? Am.J.Geriatr.Pharmacother. 8:201–214. doi:S1543-5946(10)00039-5 [pii];10.1016/j.amjopharm.2010.05.003 [doi]. 1514. Suarez-Ramirez, J. E., T. Wu, Y. T. Lee, C. C. Aguila, K. R. Bouchard, and L. S. Cauley. 2011. Division of labor between subsets of lymph node dendritic cells determines the specificity of the CD8 T-cell recall response to influenza infection. Eur.J.Immunol. 41:2632–2641. doi:10.1002/eji.201141546 [doi]. 1515. Subbramanian, R. A., S. Basha, M. T. Shata, R. C. Brady, and D. I. Bernstein. 2010. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 28:8258–8267. doi:S0264-410X(10)01590-2 [pii];10.1016/j. vaccine.2010.10.077 [doi]. 1516. Suda, T., M. Kawano, Y. Nogi, N. Ohno, T. Akatsuka, and M. Matsui. 2011. The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus. Antiviral Res. 91:252–258. doi:S0166-3542(11)00350-0 [pii];10.1016/j.antiviral.2011.06.008 [doi]. 1517. Suguitan, A. L., Jr., X. Cheng, W. Wang, S. Wang, H. Jin, and S. Lu. 2011. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/ Vietnam/1203/2004 vaccine in ferrets. PLoS.One. 6:e21942. doi:10.1371/journal.pone.0021942 [doi];PONE-D-11-07053 [pii]. 1518. Suh, C., L. McQuillan, M. F. Daley, L. A. Crane, B. Beaty, J. Barrow, C. Babbel, L. M. Dickinson, and A. Kempe. 2010. Late-season influenza vaccination: a national survey of physician practice and barriers. Am.J.Prev.Med. 39:69–73. doi:S0749-3797(10)00261-8 [pii];10.1016/j. amepre.2010.03.010 [doi]. 1519. Suhardono, M., D. Ugiyadi, I. Nurnaeni, and I. Emelia. 2011. Establishment of pandemic influenza vaccine production capacity at Bio Farma, Indonesia. Vaccine 29 Suppl 1:A22–A25. doi:S0264- 410X(11)00689-X [pii];10.1016/j.vaccine.2011.04.123 [doi]. 1520. Sui, J., J. Sheehan, W. C. Hwang, L. A. Bankston, S. K. Burchett, C. Y. Huang, R. C. Liddington, J. H. Beigel, and W. A. Marasco. 2011. Wide prevalence of heterosubtypic broadly neutralizing human anti- influenza A antibodies. Clin.Infect.Dis. 52:1003–1009. doi:cir121 [pii];10.1093/cid/cir121 [doi]. 1521. Sui, Z., Q. Chen, F. Fang, M. Zheng, and Z. Chen. 2010. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28:7690–7698. doi:S0264-410X(10)01329-0 [pii];10.1016/j.vaccine.2010.09.019 [doi]. 1522. Sui, Z., Q. Chen, R. Wu, H. Zhang, M. Zheng, H. Wang, and Z. Chen. 2010. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch.Virol. 155:535–544. doi:10.1007/s00705-010-0621-4 [doi]. 1523. Sullivan, S. J., R. Jacobson, and G. A. Poland. 2010. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert.Rev.Vaccines. 9 :1127–1133. doi:10.1586/ erv.10.117 [doi].

167 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1524. Sullivan, S. J., R. M. Jacobson, W. R. Dowdle, and G. A. Poland. 2010. 2009 H1N1 influenza. Mayo Clin.Proc. 85:64–76. doi:mcp.2009.0588 [pii];10.4065/mcp.2009.0588 [doi]. 1525. Sullivan, S. M., J. Doukas, J. Hartikka, L. Smith, and A. Rolland. 2010. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert.Opin.Drug Deliv. 7:1433–1446. doi:10.1517/17 425247.2010.538047 [doi]. 1526. Sullivan, S. P., D. G. Koutsonanos, M. M. Del Pilar, J. W. Lee, V. Zarnitsyn, S. O. Choi, N. Murthy, R. W. Compans, I. Skountzou, and M. R. Prausnitz. 2010. Dissolving polymer microneedle patches for influenza vaccination. Nat.Med. 16:915–920. doi:nm.2182 [pii];10.1038/nm.2182 [doi]. 1527. Sun, K., J. Ye, D. R. Perez, and D. W. Metzger. 2011. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J.Immunol. 186:987–993. doi:jimmunol.1002664 [pii];10.4049/jimmunol.1002664 [doi]. 1528. Sun, S., Q. Wang, F. Zhao, W. Chen, and Z. Li. 2011. Glycosylation site alteration in the evolution of influenza A (H1N1) viruses. PLoS.One. 6:e22844. doi:10.1371/journal.pone.0022844 [doi];PONE-D-11-08948 [pii]. 1529. Sun, Y., C. Bian, K. Xu, W. Hu, T. Wang, J. Cui, H. Wu, Z. Ling, Y. Ji, G. Lin, L. Tian, Y. Zhou, B. Li, G. Hu, N. Yu, W. An, R. Pan, P. Zhou, Q. Leng, Z. Huang, X. Ma, and B. Sun. 2010. Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine. PLoS. One. 5:e14270. doi:10.1371/journal.pone.0014270 [doi]. 1530. Sunil, T. S. and L. K. Zottarelli. 2011. Student utilization of a university 2009 H1N1 vaccination clinic. Vaccine 29:4687–4689. doi:S0264-410X(11)00676-1 [pii];10.1016/j.vaccine.2011.04.110 [doi]. 1531. Suphaphiphat, P., M. Franti, A. Hekele, A. Lilja, T. Spencer, E. Settembre, G. Palmer, S. Crotta, A. B. Tuccino, B. Keiner, H. Trusheim, K. Balabanis, M. Sackal, M. Rothfeder, C. W. Mandl, P. R. Dormitzer, and P. W. Mason. 2010. Mutations at positions 186 and 194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve replication in cell culture and eggs. Virol.J. 7:157. doi:1743- 422X-7-157 [pii];10.1186/1743-422X-7-157 [doi]. 1532. Surichan, S., P. Wirachwong, W. Supachaturas, K. Utid, S. Theerasurakarn, P. Langsanam, P. Lakornrach, L. Nitisaporn, C. Chansikkakorn, W. Vangkanonta, R. Kaweepornpoj, K. Poopipatpol, S. Thirapakpoomanunt, S. Srichainak, W. Artavatkun, V. Chokevivat, and S. Wibulpolprasert. 2011. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic. Vaccine 29 Suppl 1:A29– A33. doi:S0264-410X(11)00686-4 [pii];10.1016/j.vaccine.2011.04.120 [doi]. 1533. Suspene, R., V. Petit, D. Puyraimond-Zemmour, M. M. Aynaud, M. Henry, D. Guetard, C. Rusniok, S. Wain-Hobson, and J. P. Vartanian. 2011. Double-stranded RNA adenosine deaminase ADAR-1- induced hypermutated genomes among inactivated seasonal influenza and live attenuated measles virus vaccines. J.Virol. 85:2458–2462. doi:JVI.02138-10 [pii];10.1128/JVI.02138-10 [doi]. 1534. Svindland, S. C., A. Jul-Larsen, R. Pathirana, S. Andersen, A. Madhun, E. Montomoli, I. Jabbal-Gill, and R. J. Cox. 2011. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza.Other Respi.Viruses. doi:10.1111/j.1750- 2659.2011.00271.x [doi]. 1535. Sy, L. S., I. L. Liu, Z. Solano, T. C. Cheetham, M. M. Lugg, S. K. Greene, E. S. Weintraub, and S. J. Jacobsen. 2010. Accuracy of influenza vaccination status in a computer-based immunization tracking system of a managed care organization. Vaccine 28:5254–5259. doi:S0264-410X(10)00782-6 [pii];10.1016/j.vaccine.2010.05.061 [doi]. 1536. Tabache, F., K. A. El, A. Naitlhou, H. Hassikou, A. Tarib, M. Baaj, and Y. Cherrah. 2011. Acute polyarthritis after influenza A (H1N1) immunization. Joint Bone Spine 78:321–322. doi:S1297- 319X(11)00022-4 [pii];10.1016/j.jbspin.2011.02.007 [doi].

168 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1537. Tacken, M. A., J. Mulder, R. A. Verheij, M. L. Heijnen, S. M. Campbell, and J. C. Braspenning. 2011. Seasonal flu vaccination in Dutch at-risk populations was not affected by A(H1N1) 2009 pandemic vaccination. Prev.Med. 52:184–185. doi:S0091-7435(10)00487-1 [pii];10.1016/j. ypmed.2010.12.004 [doi]. 1538. Tagajdid, R., A. H. El, T. Doblali, K. Sefiani, B. Belfquih, and S. Mrani. 2010. Healthcare worker acceptance of pandemic (H1N1) 2009 vaccination, Morocco. Emerg.Infect.Dis. 16:1638–1639. doi:10.3201/eid1610.100984 [doi]. 1539. Tai, W., L. Roberts, A. Seryshev, J. M. Gubatan, C. S. Bland, R. Zabriskie, S. Kulkarni, L. Soong, I. Mbawuike, B. Gilbert, F. Kheradmand, and D. B. Corry. 2011. Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic. Mucosal.Immunol. 4:197–207. doi:mi201050 [pii];10.1038/mi.2010.50 [doi]. 1540. Takada, A. 2010. [Immunity against influenza virus infection]. Nihon Rinsho 68:1625–1630. 1541. Talaat, K. R., M. E. Greenberg, M. H. Lai, G. F. Hartel, C. H. Wichems, S. Rockman, R. J. Jeanfreau, M. R. Ghosh, M. L. Kabongo, C. Gittleson, and R. A. Karron. 2010. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J.Infect.Dis. 202:1327–1337. doi:10.1086/656601 [doi]. 1542. Talaat, K. R., R. A. Karron, C. J. Luke, B. Thumar, B. A. McMahon, G. L. Chen, E. W. Lamirande, H. Jin, K. L. Coelingh, G. Kemble, and K. Subbarao. 2011. An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 29:3144–3148. doi:S0264- 410X(11)00278-7 [pii];10.1016/j.vaccine.2011.02.043 [doi]. 1543. Talbot, H. K., M. R. Griffin, Q. Chen, Y. Zhu, J. V. Williams, and K. M. Edwards. 2011. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J.Infect.Dis. 203:500–508. doi:jiq076 [pii];10.1093/infdis/jiq076 [doi]. 1544. Talbot, H. K., M. T. Rock, C. Johnson, L. Tussey, U. Kavita, A. Shanker, A. R. Shaw, and D. N. Taylor. 2010. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS.One. 5:e14442. doi:10.1371/journal. pone.0014442 [doi]. 1545. Talbot, T. R., H. Babcock, A. L. Caplan, D. Cotton, L. L. Maragakis, G. A. Poland, E. J. Septimus, M. L. Tapper, and D. J. Weber. 2010. Revised SHEA position paper: influenza vaccination of healthcare personnel. Infect.Control Hosp.Epidemiol. 31:987–995. doi:10.1086/656558 [doi]. 1546. Talbot, T. R., T. H. Dellit, J. Hebden, D. Sama, and J. Cuny. 2010. Factors associated with increased healthcare worker influenza vaccination rates: results from a national survey of university hospitals and medical centers. Infect.Control Hosp.Epidemiol. 31:456–462. doi:10.1086/651666 [doi]. 1547. Tamma, P. D., M. C. Steinhoff, and S. B. Omer. 2010. Influenza infection and vaccination in pregnant women. Expert.Rev.Respir.Med. 4:321–328. doi:10.1586/ers.10.26 [doi]. 1548. Tamura, S., H. Hasegawa, and T. Kurata. 2010. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn.J.Infect.Dis. 63:8–15. 1549. Tan, E. K., L. H. Lim, Y. L. Teoh, G. Ong, and H. L. Bock. 2010. Influenza and seasonal influenza vaccination among diabetics in Singapore: knowledge, attitudes and practices. Singapore Med.J. 51:623–630. 1550. Tan, L., H. Lu, D. Zhang, K. Wang, M. Tian, C. Liu, Y. Liu, B. Hu, and N. Jin. 2011. Efficacy of seasonal pandemic influenza hemagglutinin DNA vaccines delivered by electroporation against a seasonal H1N1 virus challenge in mice. Sci.China Life Sci. 54:293–299. doi:10.1007/s11427-011- 4150-5 [doi].

169 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1551. Tan, L., H. Lu, D. Zhang, M. Tian, B. Hu, Z. Wang, and N. Jin. 2010. Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/H1 subtype hemagglutinin combined with MHC class II-restricted epitopes. Virol.J. 7:363. doi:1743-422X-7-363 [pii];10.1186/1743-422X-7-363 [doi]. 1552. Tan, P. T., A. M. Khan, and J. T. August. 2011. Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability. Hum.Vaccin. 7:402–409. doi:13845 [pii]. 1553. Tan, P. T., A. T. Heiny, O. Miotto, J. Salmon, E. T. Marques, F. Lemonnier, and J. T. August. 2010. Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope- based vaccines. PLoS.One. 5:e8754. doi:10.1371/journal.pone.0008754 [doi]. 1554. Tan, T. Q., L. Bhattacharya, and M. V. Gerbie. 2011. Awareness, perceptions and knowledge of recommended adult vaccines among a nationwide sample of adult primary care providers. J.Reprod. Med. 56:301–307. 1555. Tang, X. C., H. R. Lu, and T. M. Ross. 2010. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Vaccine 28:6821–6831. doi:S0264-410X(10)01185-0 [pii];10.1016/j. vaccine.2010.08.040 [doi]. 1556. Tang, X. C., H. R. Lu, and T. M. Ross. 2011. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol. 24:311–319. doi:10.1089/vim.2011.0016 [doi]. 1557. Tanguy, M., C. Boyeau, S. Pean, E. Marijon, A. Delhumeau, and S. Fanello. 2011. Acceptance of seasonal and pandemic a (H1N1) 2009 influenza vaccination by healthcare workers in a french teaching hospital. Vaccine 29:4190–4194. doi:S0264-410X(11)00510-X [pii];10.1016/j. vaccine.2011.03.107 [doi]. 1558. Tao, L. N., H. Zhang, and S. H. Mao. 2010. [Research on the relationship between fever and H1N1 influenza vaccination in students]. Zhongguo Yi.Miao.He.Mian.Yi. 16:214–218. 1559. Tao, X. G., J. Giampino, D. A. Dooley, F. E. Humphrey, D. M. Baron, and E. J. Bernacki. 2010. Description of an influenza vaccination campaign and use of a randomized survey to determine participation rates. Infect.Control Hosp.Epidemiol. 31:151–157. doi:10.1086/649798 [doi]. 1560. Tavares, F., A. Delaigle, D. Slavin, V. Bauchau, L. Fries, and H. Seifert. 2011. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective. Vaccine 29:6402–6407. doi:S0264- 410X(11)00561-5 [pii];10.1016/j.vaccine.2011.04.026 [doi]. 1561. Taylor, C., A. Marathe, and R. Beckman. 2010. Same influenza vaccination strategies but different outcomes across US cities? Int.J.Infect.Dis. 14:e792–e795. doi:S1201-9712(10)02405-7 [pii];10.1016/j.ijid.2010.02.2267 [doi]. 1562. Taylor, D. N., J. J. Treanor, C. Strout, C. Johnson, T. Fitzgerald, U. Kavita, K. Ozer, L. Tussey, and A. Shaw. 2011. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29:4897–4902. doi:S0264-410X(11)00694-3 [pii];10.1016/j.vaccine.2011.05.001 [doi]. 1563. Tchuenche, J. M., S. A. Khamis, F. B. Agusto, and S. C. Mpeshe. 2011. Optimal control and sensitivity analysis of an influenza model with treatment and vaccination. Acta Biotheor. 59:1–28. doi:10.1007/ s10441-010-9095-8 [doi]. 1564. Tebas, P., I. Frank, M. Lewis, J. Quinn, L. Zifchak, A. Thomas, T. Kenney, R. Kappes, W. Wagner, K. Maffei, and K. Sullivan. 2010. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV- infected individuals. AIDS 24:2187–2192. doi:10.1097/QAD.0b013e32833c6d5c [doi].

170 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1565. Temiz, G., N. Kasifoglu, A. Kiris, S. Ozturk, G. Sahin, A. U. Yalcin, and T. Us. 2010. Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients. Ren Fail. 32:716– 720. doi:10.3109/0886022X.2010.486498 [doi]. 1566. Temte, J. L. and J. P. Prunuske. 2010. Seasonal influenza in primary care settings: review for primary care physicians. WMJ. 109:193–200. 1567. Tenbusch, M., T. Grunwald, T. Niezold, B. M. Storcksdieck Genannt, D. Hannaman, S. Norley, and K. Uberla. 2010. Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+) T-cell responses and immune effector mechanisms following DNA electroporation in mice. Vaccine 28:3273–3277. doi:S0264-410X(10)00282-3 [pii];10.1016/j.vaccine.2010.02.090 [doi]. 1568. Tennis, P., S. L. Toback, E. Andrews, L. J. McQuay, and C. S. Ambrose. 2011. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine 29:4947–4952. doi:S0264- 410X(11)00679-7 [pii];10.1016/j.vaccine.2011.04.113 [doi]. 1569. Thomas, R. E., T. Jefferson, and T. J. Lasserson. 2010. Influenza vaccination for healthcare workers who work with the elderly. Cochrane.Database.Syst.Rev.CD005187. doi:10.1002/14651858. CD005187.pub3 [doi]. 1570. Thomas, R. E., T. Jefferson, and T. J. Lasserson. 2010. Influenza vaccination for healthcare workers who work with the elderly: systematic review. Vaccine 29:344–356. doi:S0264-410X(10)01427-1 [pii];10.1016/j.vaccine.2010.09.085 [doi]. 1571. Thompson, M., J. Williams, A. Naleway, D. K. Li, S. Chu, S. Bozeman, H. A. Hill, J. Cragan, and D. K. Shay. 2011. The Pregnancy and Influenza Project: design of an observational case-cohort study to evaluate influenza burden and vaccine effectiveness among pregnant women and their infants. Am.J.Obstet.Gynecol. 204:S69–S76. doi:S0002-9378(11)00021-4 [pii];10.1016/j. ajog.2011.01.006 [doi]. 1572. Thongcharoen, P., P. Auewarakul, Y. Hutagalung, G. Ong, P. Gillard, M. Drame, and H. L. Bock. 2011. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population. J.Med.Assoc.Thai. 94:916–926. 1573. Thoon, K. C. and C. Y. Chong. 2010. Survey of healthcare workers’ attitudes, beliefs and willingness to receive the 2009 pandemic influenza A (H1N1) vaccine and the impact of educational campaigns. Ann.Acad.Med.Singapore 39:307–6. 1574. Thueng-in, K., S. Maneewatch, P. Srimanote, T. Songserm, P. Tapchaisri, N. Sookrung, P. Tongtawe, S. Channarong, and W. Chaicumpa. 2010. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines. Vaccine 28:6765–6777. doi:S0264- 410X(10)01076-5 [pii];10.1016/j.vaccine.2010.07.065 [doi]. 1575. Tingle, M. T. and M. S. Hayney. 2011. Choosing between live attenuated and trivalent inactivated influenza vaccines for healthy children. J.Am.Pharm.Assoc.(2003.) 51:776–777. doi:JVQ654168512546J [pii];10.1331/JAPhA.2011.11547 [doi]. 1576. Tiseo, M., B. Calatafimi, L. Ferri, A. Menardi, and A. Ardizzoni. 2010. Efficacy and safety of influenza vaccination during chemotherapy treatment. J.Support.Oncol. 8:271–272. 1577. Tissot, A. C., R. Renhofa, N. Schmitz, I. Cielens, E. Meijerink, V. Ose, G. T. Jennings, P. Saudan, P. Pumpens, and M. F. Bachmann. 2010. Versatile virus-like particle carrier for epitope based vaccines. PLoS.One. 5:e9809. doi:10.1371/journal.pone.0009809 [doi]. 1578. To, K. W., S. Lee, T. O. Chan, and S. S. Lee. 2010. Exploring determinants of acceptance of the pandemic influenza A (H1N1) 2009 vaccination in nurses. Am.J.Infect.Control 38:623–630. doi:S0196-6553(10)00542-0 [pii];10.1016/j.ajic.2010.05.015 [doi].

171 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1579. Toback, S. L., J. Herley, L. Edelman, and C. S. Ambrose. 2011. Trends in U.S. pediatric influenza vaccination from 2006 to 2010 among children with private insurance. Vaccine 29:4225–4229. doi:S0264-410X(11)00511-1 [pii];10.1016/j.vaccine.2011.03.108 [doi]. 1580. Torii, Y., H. Kimura, N. Ochi, K. Kaneko, H. Ando, T. Kiuchi, and Y. Ito. 2011. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients. Vaccine 29:4187– 4189. doi:S0264-410X(11)00522-6 [pii];10.1016/j.vaccine.2011.04.012 [doi]. 1581. Toronto, C. E. and S. M. Mullaney. 2010. Registered nurses and influenza vaccination. An integrative review. AAOHN.J. 58:463–471. doi:10.3928/08910162-20101027-01 [doi]. 1582. Torres-Ramirez, A. 2010. [Pandemic influenza caused by A(H1N1) in pregnant women]. Ginecol. Obstet.Mex. 78:121–127. 1583. Torrieri-Dramard, L., B. Lambrecht, H. L. Ferreira, T. van den Berg, D. Klatzmann, and B. Bellier. 2011. Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol.Ther. 19:602–611. doi:mt2010222 [pii];10.1038/mt.2010.222 [doi]. 1584. Torun, S. D. and F. Torun. 2010. Vaccination against pandemic influenza A/H1N1 among healthcare workers and reasons for refusing vaccination in Istanbul in last pandemic alert phase. Vaccine 28:5703–5710. doi:S0264-410X(10)00860-1 [pii];10.1016/j.vaccine.2010.06.049 [doi]. 1585. Torun, S. D., F. Torun, and B. Catak. 2010. Healthcare workers as parents: attitudes toward vaccinating their children against pandemic influenza A/H1N1. BMC.Public Health 10:596. doi:1471- 2458-10-596 [pii];10.1186/1471-2458-10-596 [doi]. 1586. Tosh, P. K., R. M. Jacobson, and G. A. Poland. 2010. Influenza vaccines: from surveillance through production to protection. Mayo Clin.Proc. 85:257–273. doi:mcp.2009.0615 [pii];10.4065/ mcp.2009.0615 [doi]. 1587. Toussaint, N. C., Y. Maman, O. Kohlbacher, and Y. Louzoun. 2011. Universal peptide vaccines – Optimal peptide vaccine design based on viral sequence conservation. Vaccine 29:8745–8753. doi:S0264-410X(11)01201-1 [pii];10.1016/j.vaccine.2011.07.132 [doi]. 1588. Tran, C. H., J. McElrath, P. Hughes, K. Ryan, J. Munden, J. B. Castleman, J. Johnson, R. Doty, D. R. McKay, J. Stringfellow, R. A. Holmes, P. D. Myers, P. A. Small, and J. G. Morris. 2010. Implementing a community-supported school-based influenza immunization program. Biosecur.Bioterror. 8:331– 341. doi:10.1089/bsp.2010.0029 [doi]. 1589. Treanor, J. J., D. N. Taylor, L. Tussey, C. Hay, C. Nolan, T. Fitzgerald, G. Liu, U. Kavita, L. Song, I. Dark, and A. Shaw. 2010. Safety and immunogenicity of a recombinant hemagglutinin influenza- flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28:8268–8274. doi:S0264- 410X(10)01469-6 [pii];10.1016/j.vaccine.2010.10.009 [doi]. 1590. Treanor, J. J., S. H. El, J. King, I. Graham, R. Izikson, R. Kohberger, P. Patriarca, and M. Cox. 2011. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 29:7733–7739. doi:S0264-410X(11)01178-9 [pii];10.1016/j.vaccine.2011.07.128 [doi]. 1591. Tremblay, C. L., D. Rouleau, C. Fortin, E. Toma, M. Sylla, L. Cyr, S. Cote, M. Baz, J. Sampalis, L. Trautman, R. P. Sekaly, and G. Boivin. 2011. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine 29:1359–1363. doi:S0264-410X(10)01761-5 [pii];10.1016/j.vaccine.2010.12.023 [doi]. 1592. Tremblay, M. E., A. Closon, G. D’Anjou, and J. F. Bussieres. 2010. Guillain-Barre syndrome following H1N1 immunization in a pediatric patient. Ann.Pharmacother. 44:1330–1333. doi:aph.1P078 [pii];10.1345/aph.1P078 [doi].

172 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1593. Trogdon, J. G., T. A. Nurmagambetov, and H. F. Thompson. 2010. The economic implications of influenza vaccination for adults with asthma. Am.J.Prev.Med. 39:403–410. doi:S0749-3797(10)00441-1 [pii];10.1016/j.amepre.2010.07.012 [doi]. 1594. Trtica-Majnaric, L., M. Zekic-Susac, N. Sarlija, and B. Vitale. 2010. Prediction of influenza vaccination outcome by neural networks and logistic regression. J.Biomed.Inform. 43:774–781. doi:S1532-0464(10)00058-4 [pii];10.1016/j.jbi.2010.04.011 [doi]. 1595. Tsai, T. F., A. Crucitti, P. Nacci, U. Nicolay, C. G. Della, J. Ferguson, and R. Clemens. 2011. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand.J.Infect.Dis. 43:702–706. doi:10.3109/0036554 8.2011.580777 [doi]. 1596. Tsai, T. F., P. L. Lim, S. F. von, and R. Clemens. 2011. The potential utility of adjuvanted seasonal influenza vaccine for travelers. J.Travel.Med. 18:231–232. doi:10.1111/j.1708-8305.2011.00527.x [doi]. 1597. Tsai, T. F., P. Pedotti, A. Hilbert, K. Lindert, M. Hohenboken, A. Borkowski, N. Groth, L. J. da Silva, and M. H. Kyaw. 2010. Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August–October 2009. Euro.Surveill 15. 1598. Tsai, T., M. H. Kyaw, D. Novicki, P. Nacci, S. Rai, and R. Clemens. 2010. Exposure to MF59- adjuvanted influenza vaccines during pregnancy – a retrospective analysis. Vaccine 28:1877–1880. doi:S0264-410X(09)01884-2 [pii];10.1016/j.vaccine.2009.11.077 [doi]. 1599. Tseng, Y. F., A. Y. Hu, M. L. Huang, W. Z. Yeh, T. C. Weng, Y. S. Chen, P. Chong, and M. S. Lee. 2011. Adaptation of High-Growth Influenza H5N1 Vaccine Virus in Vero Cells: Implications for Pandemic Preparedness. PLoS.One. 6:e24057. doi:10.1371/journal.pone.0024057 [doi];PONE-D-11-03637 [pii]. 1600. Tsou, T. P., C. H. Lin, Y. C. Lo, Y. S. Li, and C. H. Chiu. 2010. Outbreak of influenza in an overseas student travel group – Taiwan 2008. Scand.J.Infect.Dis. 42:375–378. doi:10.3109/00365540903499423 [doi]. 1601. Tsutsui, Y., U. Benzion, S. Shahrabani, and G. Y. Din. 2010. A policy to promote influenza vaccination: a behavioral economic approach. Health Policy 97:238–249. doi:S0168-8510(10)00132-6 [pii];10.1016/j.healthpol.2010.05.008 [doi]. 1602. Tu, W., H. Mao, J. Zheng, Y. Liu, S. S. Chiu, G. Qin, P. L. Chan, K. T. Lam, J. Guan, L. Zhang, Y. Guan, K. Y. Yuen, J. S. Peiris, and Y. L. Lau. 2010. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J.Virol. 84:6527–6535. doi:JVI.00519-10 [pii];10.1128/JVI.00519-10 [doi]. 1603. Tucker Edmonds, B. M., J. Coleman, K. Armstrong, and J. A. Shea. 2011. Risk Perceptions, Worry, or Distrust: What Drives Pregnant Women’s Decisions to Accept the H1N1 Vaccine? Matern.Child Health J. 15:1203–1209. doi:10.1007/s10995-010-0693-5 [doi]. 1604. Tuite, A. R., D. N. Fisman, J. C. Kwong, and A. L. Greer. 2010. Optimal pandemic influenza vaccine allocation strategies for the Canadian population. PLoS.One. 5:e10520. doi:10.1371/journal. pone.0010520 [doi]. 1605. Tuite, A., D. N. Fisman, J. C. Kwong, and A. Greer. 2010. Optimal pandemic influenza vaccine allocation strategies for the canadian population. PLoS.Curr. 2:RRN1144. doi:k/-/-/66mlsbkkz358/2 [pii]. 1606. Tuppin, P., S. Samson, A. Weill, P. Ricordeau, and H. Allemand. 2011. Seasonal influenza vaccination coverage in France during two influenza seasons (2007 and 2008) and during a context of pandemic influenza A(H1N1) in 2009. Vaccine 29:4632–4637. doi:S0264-410X(11)00609-8 [pii];10.1016/j. vaccine.2011.04.064 [doi].

173 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1607. Turner, N. 2011. We should give the influenza vaccine to elderly patients in rest homes who are suffering from severe dementia: No. J.Prim.Health Care 3:60–61. 1608. Turnour, C. E., S. J. Conaty, and M. A. Cretikos. 2010. An audit of pandemic (H1N1) 2009 influenza vaccine wastage in general practice. Med.J.Aust. 192:541. doi:letters_030510_fm-1 [pii]. 1609. Tutykhina, I. L., D. Y. Logunov, D. N. Shcherbinin, M. M. Shmarov, A. I. Tukhvatulin, B. S. Naroditsky, and A. L. Gintsburg. 2011. Development of adenoviral vector-based mucosal vaccine against influenza. J.Mol.Med.(Berl) 89:331–341. doi:10.1007/s00109-010-0696-0 [doi]. 1610. Uchida, T. 2011. Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine. Microbiol.Immunol. 55:19–27. doi:10.1111/j.1348-0421.2010.00273.x [doi]. 1611. Uhl, E. W., S. B. Harvey, F. Michel, Y. Perozo, J. Gabbard, S. M. Tompkins, and R. J. Hogan. 2010. Immunogenicity of avian H5N1 influenza virus recombinant vaccines in cats. Viral Immunol. 23:221– 226. doi:10.1089/vim.2009.0058 [doi]. 1612. Ujiie, M., S. Izumi, N. Takeshit, J. Takasaki, Y. Mizuno, Y. Kato, S. Kanagaw, and K. Kudo. 2010. [Household transmission of pneumococcal pneumonia associated with pandemic influenza (H1N1) 2009]. Nihon Kokyuki.Gakkai Zasshi 48:322–327. 1613. Ujike, M., K. Shimabukuro, K. Mochizuki, M. Obuchi, T. Kageyama, M. Shirakura, N. Kishida, K. Yamashita, H. Horikawa, Y. Kato, N. Fujita, M. Tashiro, and T. Odagiri. 2010. -resistant influenza viruses A (H1N1) during 2007–2009 influenza seasons, Japan. Emerg.Infect.Dis. 16:926– 935. doi:10.3201/eid1606.091623 [doi]. 1614. Ulvestad, E. 2010. [Meaningless mass vaccination]. Tidsskr.Nor Laegeforen. 130:2454. doi:2053127 [pii];10.4045/tidsskr.10.1143 [doi]. 1615. Umeda, Y., M. Morikawa, M. Anzai, Y. Sumida, M. Kadowaki, S. Ameshima, and T. Ishizaki. 2010. Acute exacerbation of idiopathic pulmonary fibrosis after pandemic influenza A (H1N1) vaccination. Intern.Med. 49:2333–2336. doi:JST.JSTAGE/internalmedicine/49.3890 [pii]. 1616. Urbanek, C., F. Palm, and A. J. Grau. 2010. Influenza and stroke risk: a key target not to be missed? Infect.Disord.Drug Targets. 10:122–131. doi:BSP/ID-DT/E-Pub/0017-10-2 [pii]. 1617. Urowitz, M. B., A. Anton, D. Ibanez, and D. D. Gladman. 2011. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. Arthritis Care Res.(Hoboken.) 63:1517–1520. doi:10.1002/acr.20599 [doi]. 1618. Uscher-Pines, L., J. Maurer, A. Kellerman, and K. M. Harris. 2010. Healthy young and middle age adults: what will it take to vaccinate them for influenza? Vaccine 28:7420–7422. doi:S0264- 410X(10)01277-6 [pii];10.1016/j.vaccine.2010.08.095 [doi]. 1619. Uscher-Pines, L., J. Maurer, and K. M. Harris. 2011. Racial and ethnic disparities in uptake and location of vaccination for 2009-H1N1 and seasonal influenza. Am.J.Public Health 101:1252–1255. doi:AJPH.2011.300133 [pii];10.2105/AJPH.2011.300133 [doi]. 1620. Vajo, Z. 2011. The seasonal influenza vaccine Agriflu((R)). Expert.Rev.Vaccines. 10:1513–1517. doi:10.1586/erv.11.133 [doi]. 1621. Vajo, Z., F. Tamas, L. Sinka, and I. Jankovics. 2010. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial. Lancet 375:49–55. doi:S0140-6736(09)62039-0 [pii];10.1016/S0140-6736(09)62039-0 [doi]. 1622. Vajo, Z., J. Wood, L. Kosa, I. Szilvasy, G. Paragh, Z. Pauliny, K. Bartha, I. Visontay, A. Kis, and I. Jankovics . 2010. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. J.Virol. 84:1237–1242. doi:JVI.01894-09 [pii];10.1128/JVI.01894-09 [doi].

174 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1623. Valenciano, M., E. Kissling, B. C. Ciancio, and A. Moren. 2010. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine 28:7381– 7388. doi:S0264-410X(10)01318-6 [pii];10.1016/j.vaccine.2010.09.010 [doi]. 1624. Valenciano, M., E. Kissling, J. M. Cohen, B. Oroszi, A. S. Barret, C. Rizzo, B. Nunes, D. Pitigoi, C. A. Larrauri, A. Mosnier, J. K. Horvath, J. O’Donnell, A. Bella, R. Guiomar, E. Lupulescu, C. Savulescu, B. C. Ciancio, P. Kramarz, and A. Moren. 2011. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS.Med. 8:e1000388. doi:10.1371/journal.pmed.1000388 [doi]. 1625. Valkenburg, S. A., S. Gras, C. Guillonneau, N. L. La Gruta, P. G. Thomas, A. W. Purcell, J. Rossjohn, P. C. Doherty, S. J. Turner, and K. Kedzierska. 2010. Protective efficacy of cross-reactive CD8+ T cells recognising mutant viral epitopes depends on peptide-MHC-I structural interactions and T cell activation threshold. PLoS.Pathog. 6:e1001039. doi:10.1371/journal.ppat.1001039 [doi]. 1626. Van Buynder, P. G., D. Carcione, V. Rettura, A. Daly, and E. Woods. 2011. Marketing paediatric influenza vaccination: results of a major metropolitan trial. Influenza.Other Respi.Viruses. 5:33–38. doi:10.1111/j.1750-2659.2010.00167.x [doi]. 1627. Van Buynder, P. G., J. K. Dhaliwal, J. L. Van Buynder, C. Couturier, M. Minville-Leblanc, R. Garceau, and F. W. Tremblay. 2010. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza.Other Respi.Viruses. 4:171–178. doi:IRV146 [pii];10.1111/j.1750- 2659.2010.00146.x [doi]. 1628. Van de Walle, G. R., M. A. May, S. T. Peters, S. M. Metzger, C. T. Rosas, and N. Osterrieder. 2010. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus. Vaccine 28:1048–1055. doi:S0264-410X(09)01674-0 [pii];10.1016/j.vaccine.2009.10.123 [doi]. 1629. van den Berg, J. H., K. Oosterhuis, W. E. Hennink, G. Storm, L. J. van der Aa, J. F. Engbersen, J. B. Haanen, J. H. Beijnen, T. N. Schumacher, and B. Nuijen. 2010. Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. J.Control Release 141:234–240. doi:S0168-3659(09)00621-X [pii];10.1016/j.jconrel.2009.09.005 [doi]. 1630. van den Berg, J. H., S. G. Quaak, J. H. Beijnen, W. E. Hennink, G. Storm, T. N. Schumacher, J. B. Haanen, and B. Nuijen. 2010. Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant? Int.J.Pharm. 390:32–36. doi:S0378-5173(09)00421-9 [pii];10.1016/j. ijpharm.2009.06.031 [doi]. 1631. van den Brand, J. M., J. H. Kreijtz, R. Bodewes, K. J. Stittelaar, A. G. van, T. Kuiken, J. Simon, R. A. Fouchier, G. G. Del, R. Rappuoli, G. F. Rimmelzwaan, and A. D. Osterhaus. 2011. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J.Virol. 85:2851–2858. doi:JVI.01939-10 [pii];10.1128/JVI.01939-10 [doi]. 1632. van Puijenbroek, E. P. and A. C. van Grootheest. 2011. Monitoring adverse events of vaccines against Mexican flu. Int.J.Risk Saf Med. 23:81–87. doi:3V37105T6U66M83J [pii];10.3233/JRS-2011-0525 [doi]. 1633. van Puijenbroek, E. P., N. Broos, and G. K. van. 2010. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands. Drug Saf 33 :1097–1108. doi:5 [pii];10.2165/11539270-000000000-00000 [doi]. 1634. van, A. S., A. Holvast, D. S. Telgt, C. A. Benne, H. A. de, J. Westra, C. G. Kallenberg, and M. Bijl. 2010. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. Clin.Immunol. 136:228–235. doi:S1521-6616(10)00530-9 [pii];10.1016/j.clim.2010.03.430 [doi].

175 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1635. Van, D. P., R. Arnou, F. Kafeja, A. Fiquet, P. Richard, S. Thomas, G. Meghlaoui, S. I. Samson, and E. Ledesma. 2010. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC.Infect.Dis. 10:134. doi:1471-2334-10-134 [pii];10.1186/1471-2334-10-134 [doi]. 1636. Van, D., M. L. McLaws, J. Crimmins, C. R. MacIntyre, and H. Seale. 2010. University life and pandemic influenza: attitudes and intended behaviour of staff and students towards pandemic (H1N1) 2009. BMC.Public Health 10:130. doi:1471-2458-10-130 [pii];10.1186/1471-2458-10-130 [doi]. 1637. Van, d., V, S. Pepin, M. Lambert, N. Fauchoux, Y. Donazzolo, M. Dupuy, C. Dakowski, and M. Denis. 2010. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine. Hum.Vaccin. 6:823–828. doi:13600 [pii]. 1638. van, M. A., N. Sabarth, H. S. Dacho, P. Bruhl, M. Schwendinger, B. A. Crowe, B. P. Noel, O. Kistner, and H. M. Keith. 2010. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. Vaccine 28:1778–1785. doi:S0264-410X(09)01912-4 [pii];10.1016/j.vaccine.2009.12.008 [doi]. 1639. van, W. R., M. M. Harmsen, D. E. Martens, B. P. Peeters, R. H. Wijffels, and R. J. Moormann. 2011. MDCK cell line with inducible allele B NS1 expression propagates delNS1 influenza virus to high titres. Vaccine 29:6976–6985. doi:S0264-410X(11)01069-3 [pii];10.1016/j.vaccine.2011.07.037 [doi]. 1640. Vance, M. A. 2011. Disease mongering and the fear of pandemic influenza. Int.J.Health Serv. 41:95–115. 1641. Vankerckhoven, V. and D. P. Van. 2010. Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. Expert.Opin.Drug Deliv. 7:1109–1125. doi:10.1517/174 25247.2010.507668 [doi]. 1642. van’t Land, B., M. Schijf, B. C. van Esch, B. J. van, J. Bastiaans, B. Schouten, L. Boon, and J. Garssen. 2010. Regulatory T-cells have a prominent role in the immune modulated vaccine response by specific oligosaccharides. Vaccine 28:5711–5717. doi:S0264-410X(10)00857-1 [pii];10.1016/j. vaccine.2010.06.046 [doi]. 1643. Vardavas, R., R. Breban, and S. Blower. 2010. A universal long-term flu vaccine may not prevent severe epidemics. BMC.Res.Notes 3:92. doi:1756-0500-3-92 [pii];10.1186/1756-0500-3-92 [doi]. 1644. Vardeny, O., J. J. Moran, N. K. Sweitzer, M. R. Johnson, and M. S. Hayney. 2010. Decreased T-cell responses to influenza vaccination in patients with heart failure. Pharmacotherapy 30:10–16. doi:10.1592/phco.30.1.10 [doi];10.1592/phco.30.1.10 [pii]. 1645. Vaux, S., D. Noel, L. Fonteneau, J. P. Guthmann, and D. Levy-Bruhl. 2010. Influenza vaccination coverage of healthcare workers and residents and their determinants in nursing homes for elderly people in France: a cross-sectional survey. BMC.Public Health 10:159. doi:1471-2458-10-159 [pii];10.1186/1471-2458-10-159 [doi]. 1646. Vazquez-Alvarez, M. C., C. Medrano-Lopez, and M. Camino-Lopez. 2010. H1N1 influenza vaccination and infection in pediatric heart transplants. J.Heart Lung Transplant. 29:1318. doi:S1053-2498(10)00452-3 [pii];10.1016/j.healun.2010.07.011 [doi]. 1647. Velan, B., G. Kaplan, A. Ziv, V. Boyko, and L. Lerner-Geva. 2011. Major motives in non-acceptance of A/H1N1 flu vaccination: the weight of rational assessment. Vaccine 29:1173–1179. doi:S0264- 410X(10)01744-5 [pii];10.1016/j.vaccine.2010.12.006 [doi]. 1648. Vellozzi, C., K. R. Broder, P. Haber, A. Guh, M. Nguyen, M. Cano, P. Lewis, M. M. McNeil, M. Bryant, J. Singleton, D. Martin, and F. Destefano. 2010. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010. Vaccine 28:7248–7255. doi:S0264-410X(10)01331-9 [pii];10.1016/j. vaccine.2010.09.021 [doi].

176 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1649. Vemula, S. V. and S. K. Mittal. 2010. Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert.Opin.Biol.Ther. 10:1469–1487. doi:10.1517/14712598.2010.51 9332 [doi]. 1650. Vesikari, T., A. Karvonen, S. Tilman, A. Borkowski, E. Montomoli, A. Banzhoff, and R. Clemens. 2010. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126:e762–e770. doi:peds.2009-2628 [pii];10.1542/peds.2009-2628 [doi]. 1651. Vesikari, T., M. Knuf, P. Wutzler, A. Karvonen, D. Kieninger-Baum, H. J. Schmitt, F. Baehner, A. Borkowski, T. F. Tsai, and R. Clemens. 2011. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N.Engl.J.Med. 365:1406–1416. doi:10.1056/NEJMoa1010331 [doi]. 1652. Viboud, C., M. Miller, D. Olson, M. Osterholm, and L. Simonsen. 2010. Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. PLoS.Curr.RRN1153. doi:k/-/-/35hpbywfdwl4n/8 [pii]. 1653. Vigano, A., V. Giacomet, E. Pariani, E. Giani, V. Manfredini, G. Bedogni, P. Erba, A. Amendola, A. Zanetti, and G. Zuccotti. 2011. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009–2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clin.Vaccine Immunol. 18:1503–1509. doi:CVI.05200-11 [pii];10.1128/ CVI.05200-11 [doi]. 1654. Vilarino, M. A., M. J. Lopes, A. L. Bueno, and M. R. Brito. 2010. [Influenza-vaccinated and non- vaccinated elderly: reported morbidity and sociodemographic aspects, Porto Alegre (RS, Brazil), 2004]. Cien.Saude Colet. 15:2879–2886. doi:S1413-81232010000600025 [pii]. 1655. Vilca Yengle, L. M., M. M. Campins, R. L. Cabero, J. A. Rodrigo Pendas, G. Martinez, X, P. E. Hermosilla, and R. J. Vaque. 2010. [Influenza vaccination in pregnant women. Coverage, practices and knowledge among obstetricians]. Med.Clin.(Barc.) 134:146–151. doi:S0025-7753(09)01400-6 [pii];10.1016/j.medcli.2009.10.004 [doi]. 1656. Villard, J. and C. A. Siegrist. 2011. Anti-HLA Antibody, Adjuvanted Vaccines and Efficacy of Influenza Immunization in Solid Organ Transplanted Recipients. Am.J.Transplant. 11:2539–2540. doi:10.1111/ j.1600-6143.2011.03746.x [doi]. 1657. Vincent, A. L., J. R. Ciacci-Zanella, A. Lorusso, P. C. Gauger, E. L. Zanella, M. E. Kehrli, Jr., B. H. Janke, and K. M. Lager. 2010. Efficacy of inactivated swine influenza virus vaccines against the 2009 A/H1N1 influenza virus in pigs. Vaccine 28 :2782–2787. doi:S0264-410X(10)00103-9 [pii];10.1016/j.vaccine.2010.01.049 [doi]. 1658. Virseda, S., M. A. Restrepo, E. Arranz, P. Magan-Tapia, M. Fernandez-Ruiz, A. G. de la Camara, J. M. Aguado, and F. Lopez-Medrano. 2010. Seasonal and Pandemic A (H1N1) 2009 influenza vaccination coverage and attitudes among health-care workers in a Spanish University Hospital. Vaccine 28:4751–4757. doi:S0264-410X(10)00639-0 [pii];10.1016/j.vaccine.2010.04.101 [doi]. 1659. Vitek, W. S., A. Akers, L. A. Meyn, G. E. Switzer, B. Y. Lee, and R. H. Beigi. 2011. Vaccine eligibility and acceptance among ambulatory obstetric and gynecologic patients. Vaccine 29:2024–2028. doi:S0264-410X(11)00054-5 [pii];10.1016/j.vaccine.2011.01.026 [doi]. 1660. Vivancos, R., D. Showell, B. Keeble, S. Goh, M. Kroese, A. Lipp, and J. Battersby. 2011. Vaccination of poultry workers: delivery and uptake of seasonal influenza immunization. Zoonoses.Public Health 58:126–130. doi:JVB1315 [pii];10.1111/j.1863-2378.2009.01315.x [doi]. 1661. Vivancos, R., M. Reacher, and P. Cosford. 2011. Programme to vaccinate poultry workers against seasonal influenza: options for delivery in the East of England. Zoonoses.Public Health 58:60–68. doi:JVB1294 [pii];10.1111/j.1863-2378.2009.01294.x [doi].

177 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1662. Vodeiko, G. M. and J. P. Weir. 2011. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza. Influenza.Other Respi.Viruses. doi:10.1111/j.1750- 2659.2011.00285.x [doi]. 1663. Voeten, J. T., I. V. Kiseleva, H. L. Glansbeek, S. M. Basten, Drieszen-van der Cruijsen SK, L. G. Rudenko, H. van den Bosch, and J. G. Heldens. 2010. Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model. Arch.Virol. 155:1391–1399. doi:10.1007/ s00705-010-0719-8 [doi]. 1664. Vujanic, A., J. L. Wee, K. J. Snibson, S. Edwards, M. Pearse, C. Quinn, M. Moloney, S. Taylor, J. P. Scheerlinck, and P. Sutton. 2010. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens. Vaccine 28:2593–2597. doi:S0264- 410X(10)00049-6 [pii];10.1016/j.vaccine.2010.01.018 [doi]. 1665. Wacheck, V., A. Egorov, F. Groiss, A. Pfeiffer, T. Fuereder, D. Hoeflmayer, M. Kundi, T. Popow- Kraupp, M. Redlberger-Fritz, C. A. Mueller, J. Cinatl, M. Michaelis, J. Geiler, M. Bergmann, J. Romanova, E. Roethl, A. Morokutti, M. Wolschek, B. Ferko, J. Seipelt, R. Dick-Gudenus, and T. Muster. 2010. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J.Infect.Dis. 201:354–362. doi:10.1086/649428 [doi]. 1666. Waddington, C. S., W. T. Walker, C. Oeser, A. Reiner, T. John, S. Wilkins, M. Casey, P. E. Eccleston, R. J. Allen, I. Okike, S. Ladhani, E. Sheasby, K. Hoschler, N. Andrews, P. Waight, A. C. Collinson, P. T. Heath, A. Finn, S. N. Faust, M. D. Snape, E. Miller, and A. J. Pollard. 2010. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months–12 years: open label, randomised, parallel group, multicentre study. BMJ 340:c2649. 1667. Waddington, C., N. Andrews, K. Hoschler, W. Walker, C. Oeser, A. Reiner, T. John, S. Wilkins, M. Casey, P. Eccleston, R. Allen, I. Okike, S. Ladhani, E. Sheasby, P. Waight, A. Collinson, P. Heath, A. Finn, S. Faust, M. Snape, E. Miller, and A. Pollard. 2010. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. Health Technol.Assess. 14:1–130. doi:10.3310/ hta14460-01 [doi]. 1668. Waffarn, E. E. and N. Baumgarth . 2011. Protective B cell responses to flu – no fluke! J.Immunol. 186:3823–3829. doi:186/7/3823 [pii];10.4049/jimmunol.1002090 [doi]. 1669. Wahlen, M. K., R. R. Bessette, M. E. Bernard, D. J. Springer, and C. A. Benson. 2010. Improving influenza vaccine distribution in preparation for an H1N1 influenza pandemic: lessons from the field. J.Med.Pract.Manage. 26:182–187. 1670. Walker, A. M. 2010. Signal detection for vaccine side effects that have not been specified in advance. Pharmacoepidemiol.Drug Saf 19:311–317. doi:10.1002/pds.1889 [doi]. 1671. Walker, D. W., S. S. Sloan, and J. D. Kozlica. 2011. Public health worker attitudes and beliefs concerning 2009 H1N1 and seasonal influenza vaccines. Am.J.Infect.Control. doi:S0196-6553(11)00832-7 [pii];10.1016/j.ajic.2011.05.010 [doi]. 1672. Walker, K. O., N. Steers, L. J. Liang, L. S. Morales, N. Forge, L. Jones, and A. F. Brown. 2010. The vulnerability of middle-aged and older adults in a multiethnic, low-income area: contributions of age, ethnicity, and health insurance. J.Am.Geriatr.Soc. 58:2416–2422. doi:10.1111/j.1532- 5415.2010.03189.x [doi]. 1673. Walker, W. T. and S. N. Faust. 2010. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert.Rev.Vaccines. 9:1385–1398. doi:10.1586/erv.10.141 [doi].

178 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1674. Walter, D., M. M. Bohmer, M. Heiden, S. Reiter, G. Krause, and O. Wichmann. 2011. Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10 – results from thirteen consecutive cross-sectional surveys. Vaccine 29:4008–4012. doi:S0264-410X(11)00451-8 [pii];10.1016/j.vaccine.2011.03.069 [doi]. 1675. Walter, E. B., N. J. Allred, G. K. Swamy, A. S. Hellkamp, and R. J. Dolor. 2010. Influenza vaccination of household contacts of newborns: a hospital-based strategy to increase vaccination rates. Infect. Control Hosp.Epidemiol. 31:1070–1073. doi:10.1086/656563 [doi]. 1676. Walter, E. B., S. Rajagopal, Y. Zhu, K. M. Neuzil, M. P. Fairchok, and J. A. Englund. 2010. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine 28:4376–4383. doi:S0264-410X(10)00582-7 [pii];10.1016/j.vaccine.2010.04.058 [doi]. 1677. Wang, B. Z., R. Xu, F. S. Quan, S. M. Kang, L. Wang, and R. W. Compans. 2010. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS.One. 5:e13972. doi:10.1371/journal.pone.0013972 [doi]. 1678. Wang, D. J., D. A. Boltz, J. McElhaney, J. A. McCullers, R. J. Webby, and R. G. Webster. 2011. No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies. Influenza.Other Respi.Viruses. doi:10.1111/j.1750-2659.2011.00294.x [doi]. 1679. Wang, T. T., G. S. Tan, R. Hai, N. Pica, L. Ngai, D. C. Ekiert, I. A. Wilson, A. Garcia-Sastre, T. M. Moran, and P. Palese. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc.Natl.Acad.Sci.U.S.A 107:18979–18984. doi:1013387107 [pii];10.1073/pnas.1013387107 [doi]. 1680. Wang, W., C. M. Anderson, C. J. De Feo, M. Zhuang, H. Yang, R. Vassell, H. Xie, Z. Ye, D. Scott, and C. D. Weiss. 2011. Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. PLoS.Pathog. 7:e1002081. doi:10.1371/journal.ppat.1002081 [doi];PPATHOGENS-D-11-00117 [pii]. 1681. Wang, W., H. Chen, W. J. Tan, Y. Deng, M. Wang, Y. Liu, X. Yin, K. Zhang, J. Guan, J. F. Zhou, Y. L. Shu, and L. Ruan. 2010. [DNA vaccination via in vivo electroporation can elicit specific immune response against highly pathogenic H5N1 influenza viral structural antigens in mice]. Bing.Du Xue. Bao. 26:170–175. 1682. Wang, W., H. Xie, Z. Ye, R. Vassell, and C. D. Weiss. 2010. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J.Virol.Methods 165:305–310. doi:S0166-0934(10)00036-4 [pii];10.1016/j.jviromet.2010.02.009 [doi]. 1683. Wang, Y., Z. Xiao, and W. Wang. 2010. Awareness of the background rate of sudden cardiac death during mass immunization with pandemic H1N1 influenza vaccines increases the intended vaccination rate. Prev.Med. 51:445–446. doi:S0091-7435(10)00358-0 [pii];10.1016/j.ypmed.2010.08.019 [doi]. 1684. Wanitchang, A., J. Kramyu, and A. Jongkaewwattana. 2010. Enhancement of reverse genetics- derived swine-origin H1N1 influenza virus seed vaccine growth by inclusion of indigenous polymerase PB1 protein. Virus Res. 147:145–148. doi:S0168-1702(09)00380-3 [pii];10.1016/j. virusres.2009.10.010 [doi]. 1685. Ward, K., H. Seale, N. Zwar, J. Leask, and C. R. Macintyre. 2011. Annual influenza vaccination: coverage and attitudes of primary care staff in Australia. Influenza.Other Respi.Viruses. 5:135–141. doi:10.1111/j.1750-2659.2010.00158.x [doi]. 1686. Warncke, M., M. Buchner, G. Thaller, A. Dodero, A. Bulashevska, D. Pfeifer, J. Timmer, and H. Veelken. 2011. Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells. Cancer Immunol.Immunother. 60:49–60. doi:10.1007/s00262-010-0918-x [doi].

179 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1687. Wasilenko, J. L., L. Sarmento, S. Spatz, and M. Pantin-Jackwood. 2010. Cell surface display of highly pathogenic avian influenza virus hemagglutinin on the surface of Pichia pastoris cells using alpha- agglutinin for production of oral vaccines. Biotechnol.Prog. 26:542–547. doi:10.1002/btpr.343 [doi]. 1688. Watanabe, T. 2011. Henoch-Schonlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1). Pediatr.Nephrol. 26:795–798. doi:10.1007/s00467-010-1722-8 [doi]. 1689. Watson, J. M. and R. G. Pebody. 2011. Pandemic influenza vaccines. BMJ 342:d545. 1690. Watts, G. 2011. New findings on H1N1 vaccine prompt revised prescribing advice. BMJ 342 :d2524. 1691. Weaver, E. A., A. M. Rubrum, R. J. Webby, and M. A. Barry. 2011. Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS.One. 6:e18314. doi:10.1371/ journal.pone.0018314 [doi]. 1692. Webb, L., M. Petersen, S. Boden, V. LaBelle, J. A. Bird, D. Howell, A. W. Burks, and S. Laubach. 2011. Single-dose influenza vaccination of patients with egg allergy in a multicenter study. J.Allergy Clin.Immunol. 128:218–219. doi:S0091-6749(11)00275-2 [pii];10.1016/j.jaci.2011.02.013 [doi]. 1693. Weeramanthri, T. S., A. G. Robertson, G. K. Dowse, P. V. Effler, M. G. Leclercq, J. D. Burtenshaw, S. J. Oldham, D. W. Smith, K. J. Gatti, and H. M. Gladstones. 2010. Response to pandemic (H1N1) 2009 influenza in Australia – lessons from a State health department perspective. Aust.Health Rev. 34:477–486. doi:AH10901 [pii];10.1071/AH10901 [doi]. 1694. Wei, C. J., J. C. Boyington, K. Dai, K. V. Houser, M. B. Pearce, W. P. Kong, Z. Y. Yang, T. M. Tumpey, and G. J. Nabel. 2010. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci.Transl.Med. 2:24ra21. doi:2/24/24ra21 [pii];10.1126/ scitranslmed.3000799 [doi]. 1695. Wei, C. J., J. C. Boyington, P. M. McTamney, W. P. Kong, M. B. Pearce, L. Xu, H. Andersen, S. Rao, T. M. Tumpey, Z. Y. Yang, and G. J. Nabel. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060–1064. doi:science.1192517 [pii];10.1126/ science.1192517 [doi]. 1696. Wei, H. J., W. Chang, S. C. Lin, W. C. Liu, D. K. Chang, P. Chong, and S. C. Wu. 2011. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine 29:7163–7172. doi:S0264-410X(11)00824-3 [pii];10.1016/j.vaccine.2011.05.077 [doi]. 1697. Wei, J., J. Waithman, R. Lata, N. A. Mifsud, J. Cebon, T. Kay, M. J. Smyth, A. J. Sadler, and W. Chen. 2010. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a. J.Immunol. 185:6013–6022. doi:jimmunol.1002129 [pii];10.4049/jimmunol.1002129 [doi]. 1698. Weil-Olivier, C. 2010. [First season of pandemic influenza A/H1N1]. Rev.Prat. 60:1388. 1699. Weil-Olivier, C. 2010. [Influenza live attenuated intra-nasal vaccines]. Arch.Pediatr. 17:904–905. doi:S0929-693X(10)70171-8 [pii];10.1016/S0929-693X(10)70171-8 [doi]. 1700. Weil-Olivier, C. and B. Lina. 2011. Vaccination coverage with seasonal and pandemic influenza vaccines in children in France, 2009–2010 season. Vaccine 29:7075–7079. doi:S0264- 410X(11)01039-5 [pii];10.1016/j.vaccine.2011.07.018 [doi]. 1701. Weinberg, A., L. Y. Song, R. Walker, M. Allende, T. Fenton, J. Patterson-Bartlett, S. Nachman, G. Kemble, T. T. Yi, P. Defechereux, D. Wara, J. S. Read, and M. Levin. 2010. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J.Acquir.Immune.Defic.Syndr. 55:189–196. doi:10.1097/ QAI.0b013e3181e46308 [doi].

180 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1702. Weinberg, A., L. Y. Song, T. Fenton, S. A. Nachman, J. S. Read, J. Patterson-Bartlett, and M. J. Levin. 2010. T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines. AIDS Res.Hum.Retroviruses 26:51–59. doi:10.1089/aid.2009.0163 [doi]. 1703. Weinke, T., B. Gartner, M. Knuf, P. Sandow, and P. Wutzler. 2011. [Consensus report. Recommendations for the upcoming influenza vaccination season]. MMW.Fortschr.Med. 153:46–47. 1704. Weisser, M. 2011. [Vaccination under immunosuppressive therapy of chronic inflammatory diseases]. Internist (Berl) 52:277–282. doi:10.1007/s00108-010-2680-8 [doi]. 1705. Weldon, W. C., B. Z. Wang, M. P. Martin, D. G. Koutsonanos, I. Skountzou, and R. W. Compans. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS.One. 5. doi:10.1371/journal.pone.0012466 [doi]. 1706. Weldon, W. C., M. P. Martin, V. Zarnitsyn, B. Wang, D. Koutsonanos, I. Skountzou, M. R. Prausnitz, and R. W. Compans. 2011. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin.Vaccine Immunol. 18:647–654. doi:CVI.00435-10 [pii];10.1128/CVI.00435-10 [doi]. 1707. White, S. W., R. W. Petersen, and J. A. Quinlivan. 2010. Pandemic (H1N1) 2009 influenza vaccine uptake in pregnant women entering the 2010 influenza season in Western Australia. Med.J.Aust. 193:405–407. doi:whi10200_fm [pii]. 1708. Wichmann, O., P. Stocker, G. Poggensee, D. Altmann, D. Walter, W. Hellenbrand, G. Krause, and T. Eckmanns. 2010. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro.Surveill 15. 1709. Wicker, S., H. F. Rabenau, H. Bias, D. A. Groneberg, and R. Gottschalk. 2010. Influenza A (H1N1) 2009: Impact on Frankfurt in due consideration of health care and public health. J.Occup.Med. Toxicol. 5:10. doi:1745-6673-5-10 [pii];10.1186/1745-6673-5-10 [doi]. 1710. Wicker, S., H. F. Rabenau, R. Gottschalk, G. Krause, and S. McLennan. 2010. [Low influenza vaccination rates among healthcare workers. Time to take a different approach]. Bundesgesundheitsblatt.Gesundheitsforschung.Gesundheitsschutz. 53:1298–1303. doi:10.1007/ s00103-010-1176-y [doi]. 1711. Wiesener, N., T. Schutze, S. Lapp, M. Lehmann, N. Jarasch-Althof, P. Wutzler, and A. Henke. 2011. Analysis of different DNA vaccines for protection of experimental influenza A virus infection. Viral Immunol. 24:321–330. doi:10.1089/vim.2011.0001 [doi]. 1712. Wiesik-Szewczyk, E., M. Romanowska, P. Mielnik, H. Chwalinska-Sadowska, L. B. Brydak, M. Olesinska, and J. Zabek . 2010. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin.Rheumatol. 29:605–613. doi:10.1007/s10067-010-1373-y [doi]. 1713. Wijnans, L., B. S. de, J. Dieleman, J. Bonhoeffer, and M. Sturkenboom. 2011. Safety of pandemic H1N1 vaccines in children and adolescents. Vaccine 29:7559–7571. doi:S0264-410X(11)01225-4 [pii];10.1016/j.vaccine.2011.08.016 [doi]. 1714. Win, M. K., A. Chow, M. Chen, Y. F. Lau, E. E. Ooi, and Y. S. Leo. 2010. Influenza B outbreak among influenza-vaccinated welfare home residents in Singapore. Ann.Acad.Med.Singapore 39:448–452. 1715. Wiwanitkit, V. 2011. Health care workers and swine flu. Disaster.Med.Public Health Prep. 5:9. doi:5/1/9 [pii];10.1001/dmp.2011.4 [doi]. 1716. Wolf, Y. I., A. Nikolskaya, J. L. Cherry, C. Viboud, E. Koonin, and D. J. Lipman. 2010. Projection of seasonal influenza severity from sequence and serological data. PLoS.Curr. 2:RRN1200. doi:10.1371/ currents.RRN1200 [doi];k/-/-/agr0htar1u6r/22 [pii].

181 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1717. Wolfson, W. 2010. FDA balks on MedImmune’s cell-grown flu vaccine. Nat.Biotechnol. 28:115. doi:nbt0210-115b [pii];10.1038/nbt0210-115b [doi]. 1718. Wong, C. A., Z. Berkowitz, C. G. Dorell, R. A. Price, J. Lee, and M. Saraiya. 2011. Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National health interview survey, 2008. Cancer. doi:10.1002/cncr.26246 [doi]. 1719. Wong, L. P. and I. C. Sam. 2010. Factors influencing the uptake of 2009 H1N1 influenza vaccine in a multiethnic Asian population. Vaccine 28:4499–4505. doi:S0264-410X(10)00549-9 [pii];10.1016/j. vaccine.2010.04.043 [doi]. 1720. Wong, L. P. and I. C. Sam. 2011. Knowledge and attitudes in regard to pandemic influenza A(H1N1) in a multiethnic community of Malaysia. Int.J.Behav.Med. 18:112–121. doi:10.1007/s12529-010-9114- 9 [doi]. 1721. Wong, S. Y., E. L. Wong, J. Chor, K. Kung, P. K. Chan, C. Wong, and S. M. Griffiths. 2010. Willingness to accept H1N1 pandemic influenza vaccine: a cross-sectional study of Hong Kong community nurses. BMC.Infect.Dis. 10:316. doi:1471-2334-10-316 [pii];10.1186/1471-2334-10-316 [doi]. 1722. Woo, T. M. 2010. 2009 H1N1 influenza pandemic. J.Pediatr.Health Care 24:258–266. doi:S0891-5245(10)00113-6 [pii];10.1016/j.pedhc.2010.05.001 [doi]. 1723. Wood, J. M., E. Montomoli, R. W. Newman, A. Daas, K. H. Buchheit, and E. Terao. 2011. Collaborative study on influenza vaccine clinical trial serology – part 2: reproducibility study. Pharmeur.Bio Sci.Notes 2011:36–54. 1724. Wood, J. M., R. W. Newman, A. Daas, E. Terao, and K. H. Buchheit. 2011. Collaborative study on influenza vaccine clinical trial serology – part 1: CHMP compliance study. Pharmeur.Bio Sci.Notes 2011:27–35. 1725. Wood, N. and C. A. Siegrist. 2011. Neonatal immunization: where do we stand? Curr.Opin.Infect.Dis. 24:190–195. doi:10.1097/QCO.0b013e328345d563 [doi]. 1726. Wood, N. J. 2010. The role of the Immunisation Adverse Events Clinic at The Children’s Hospital at Westmead. N.S.W.Public Health Bull. 21:234–236. doi:NB10041 [pii];10.1071/NB10041 [doi]. 1727. Wu, B., F. Fu, and L. Wang. 2011. Imperfect vaccine aggravates the long-standing dilemma of voluntary vaccination. PLoS.One. 6:e20577. doi:10.1371/journal.pone.0020577 [doi];PONE-D-11-06246 [pii]. 1728. Wu, C. Y., Y. C. Yeh, Y. C. Yang, C. Chou, M. T. Liu, H. S. Wu, J. T. Chan, and P. W. Hsiao. 2010. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS. One. 5:e9784. doi:10.1371/journal.pone.0009784 [doi]. 1729. Wu, J., F. Wang, F. Fang, W. Zhang, H. Chang, L. Zheng, and Z. Chen. 2011. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. Arch.Virol. 156:387–395. doi:10.1007/s00705-010-0860-4 [doi]. 1730. Wu, J., F. Xu, L. Lu, M. Lu, L. Miao, T. Gao, W. Ji, L. Suo, D. Liu, R. Ma, R. Yu, J. Zhangzhu, W. Liu, Y. Zeng, X. Li, X. Zhang, X. Pang, and Y. Deng. 2010. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N.Engl.J.Med. 363:2416–2423. doi:10.1056/NEJMoa1006736 [doi]. 1731. Wu, J., S. Z. Liu, S. S. Dong, X. P. Dong, W. L. Zhang, M. Lu, C. G. Li, J. C. Zhou, H. H. Fang, Y. Liu, L. Y. Liu, Y. Z. Qiu, Q. Gao, X. M. Zhang, J. T. Chen, X. Zhong, W. D. Yin, and Z. J. Feng. 2010. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Vaccine 28:6221–6227. doi:S0264- 410X(10)00991-6 [pii];10.1016/j.vaccine.2010.07.008 [doi].

182 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1732. Wu, J., X. Zhong, C. K. Li, J. F. Zhou, M. Lu, K. Y. Huang, M. Dong, Y. Liu, F. J. Luo, N. Du, C. Chui, L. Q. Liu, N. M. Smith, B. Li, N. M. Shi, L. F. Song, Y. Gao, D. Y. Wang, X. Wang, W. F. Zhu, Y. Yan, Z. Li, J. T. Chen, A. J. McMichael, W. D. Yin, X. N. Xu, and Y. Shu. 2011. Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine 29:1009–1016. doi:S0264-410X(10)01692-0 [pii];10.1016/j.vaccine.2010.11.058 [doi]. 1733. Wu, Q., S. Xiao, H. Fan, Y. Li, J. Xu, Z. Li, W. Lu, X. Su, W. Zou, M. Jin, H. Chen, and L. Fang. 2011. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine. Antiviral Res. doi:S0166-3542(11)00451-7 [pii];10.1016/j.antiviral.2011.10.001 [doi]. 1734. Wu, R., Y. Guan, Z. Yang, J. Chen, H. Wang, Q. Chen, Z. Sui, F. Fang, and Z. Chen. 2010. A live bivalent influenza vaccine based on a H9N2 virus strain. Vaccine 28:673–680. doi:S0264- 410X(09)01651-X [pii];10.1016/j.vaccine.2009.10.102 [doi]. 1735. Wu, Z. Q., J. Ji, K. J. Zuo, Q. M. Xie, H. M. Li, J. Liu, F. Chen, C. Y. Xue, J. Y. Ma, and Y. Z. Bi. 2010. Cloning and phylogenetic analysis of hemagglutinin gene of H9N2 subtype avian influenza virus from different isolates in China during 2002 to 2009. Poult.Sci. 89:1136–1143. doi:89/6/1136 [pii];10.3382/ps.2010-00695 [doi]. 1736. Wunderink, R. G. 2010. Influenza and bacterial pneumonia – constant companions. Crit Care 14:150. doi:cc8974 [pii];10.1186/cc8974 [doi]. 1737. Xie, H., C. Doneanu, W. Chen, J. Rininger, and J. R. Mazzeo. 2011. Characterization of a Recombinant Influenza Vaccine Candidate Using Complementary LC-MS Methods. Curr.Pharm.Biotechnol. doi:BSP/ CPB/E-Pub/000215-12-15 [pii]. 1738. Xie, H., X. Jing, X. Li, Z. Lin, E. Plant, O. Zoueva, H. Yang, and Z. Ye. 2011. Immunogenicity and cross-reactivity of 2009–2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS. One. 6:e16650. doi:10.1371/journal.pone.0016650 [doi]. 1739. Xu, C., T. Bai, A. D. Iuliano, M. Wang, L. Yang, L. Wen, Y. Zeng, X. Li, T. Chen, W. Wang, Y. Hu, L. Yang, Z. Li, S. Zou, D. Li, S. Wang, Z. Feng, Y. Zhang, H. Yu, W. Yang, Y. Wang, M. A. Widdowson, and Y. Shu. 2011. The seroprevalence of pandemic influenza H1N1 (2009) virus in China. PLoS.One. 6:e17919. doi:10.1371/journal.pone.0017919 [doi]. 1740. Xu, K., Z. Y. Ling, L. Sun, Y. Xu, C. Bian, Y. He, W. Lu, Z. Chen, and B. Sun. 2011. Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol. 24:45–56. doi:10.1089/vim.2010.0056 [doi]. 1741. Xu, Q., W. Wang, X. Cheng, J. Zengel, and H. Jin. 2010. Influenza H1N1 A/Solomon Island/3/06 virus receptor binding specificity correlates with virus pathogenicity, antigenicity, and immunogenicity in ferrets. J.Virol. 84:4936–4945. doi:JVI.02489-09 [pii];10.1128/JVI.02489-09 [doi]. 1742. Xu, W., L. Han, and Z. Lin. 2011. Screening of random peptide library of hemagglutinin from pandemic 2009 A(H1N1) influenza virus reveals unexpected antigenically important regions. PLoS. One. 6:e18016. doi:10.1371/journal.pone.0018016 [doi]. 1743. Xu, Y., L. H. Yao, A. J. Chen, J. Q. Guo, X. Y. Liu, H. Bo, L. Q. Liu, Y. L. Shu, and Z. Q. Zhang. 2010. [Construction, expression and immunogenicity analysis of a fusion protein containing M2e of influenza A virus fused to a modified Pseudomonas aeruginosa exotoxin A]. Bing.Du Xue.Bao. 26:189–194. 1744. Xu, Z., R. Zhou, M. Jin, and H. Chen. 2010. Selection pressure on the hemagglutinin gene of influenza A (H1N1) virus: adaptation to human and swine hosts in Asia. Acta Virol. 54:113–118. 1745. Yadav, R. K. 2010. Seasonal flu vaccine. Indian Pediatr. 47:722. 1746. Yaesoubi, R. and T. Cohen. 2011. Dynamic health policies for controlling the spread of emerging infections: influenza as an example. PLoS.One. 6:e24043. doi:10.1371/journal.pone.0024043 [doi];PONE-D-11-06214 [pii].

183 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1747. Yalcin, S. S., M. Kondolot, N. Albayrak, A. B. Altas, Y. Karacan, B. Kuskonmaz, S. Aksu, M. Cetin, H. Goker, K. Yurdakok, and D. Uckan. 2010. Serological response to influenza vaccine after hematopoetic stem cell transplantation. Ann.Hematol. 89:913–918. doi:10.1007/s00277-009-0897- 1 [doi]. 1748. Yamaguchi, K., M. Hisano, M. Horiya, N. Watanabe, T. Kubo, T. Kato, and A. Murashima. 2010. [Influenza vaccination safety during pregnancy]. Kansenshogaku Zasshi 84:449–453. 1749. Yamaguchi, S., S. Ohfuji, and Y. Hirota. 2010. Influenza vaccine effectiveness in primary school children in Japan: a prospective cohort study using rapid diagnostic test results. J.Infect.Chemother. 16:407–413. doi:10.1007/s10156-010-0070-8 [doi]. 1750. Yamashita, A., N. Kawashita, R. Kubota-Koketsu, Y. Inoue, Y. Watanabe, M. S. Ibrahim, S. Ideno, M. Yunoki, Y. Okuno, T. Takagi, T. Yasunaga, and K. Ikuta. 2010. Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition. Biochem.Biophys.Res.Commun. 393:614–618. doi:S0006- 291X(10)00242-1 [pii];10.1016/j.bbrc.2010.02.031 [doi]. 1751. Yamazaki, T., M. Nagashima, D. Ninomiya, Y. Arai, Y. Teshima, A. Fujimoto, A. Ainai, H. Hasegawa, and J. Chiba. 2011. Passive immune-prophylaxis against influenza virus infection by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from plasmids. Jpn.J.Infect.Dis. 64:40–49. 1752. Yang, C. F., R. B. Belshe, G. Kemble, E. Song, D. Ye, B. Liang, T. Yi, C. S. Ambrose, K. Coelingh, and R. E. Walker. 2010. Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. Vaccine 28:5128–5134. doi:S0264-410X(10)00658-4 [pii];10.1016/j.vaccine.2010.02.109 [doi]. 1753. Yang, P., C. Tang, D. Luo, Z. Zhan, L. Xing, Y. Duan, W. Jia, D. Peng, X. Liu, and X. Wang. 2010. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine. Vet.Microbiol. 146:17–23. doi:S0378-1135(10)00155-0 [pii];10.1016/j.vetmic.2010.03.024 [doi]. 1754. Yang, P., Y. Duan, C. Wang, L. Xing, X. Gao, C. Tang, D. Luo, Z. Zhao, W. Jia, D. Peng, X. Liu, and X. Wang. 2011. Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets. Vaccine 29 :698–705. doi:S0264-410X(10)01635-X [pii];10.1016/j.vaccine.2010.11.026 [doi]. 1755. Yang, S. G., J. E. Wo, M. W. Li, F. F. Mi, C. B. Yu, G. L. Lv, H. C. Cao, H. F. Lu, B. H. Wang, H. Zhu, and L. J. Li. 2010. Expression of H5N1 influenza virus hemagglutinin protein fused with protein transduction domain in an alphavirus replicon system. J.Virol.Methods 163:31–39. doi:S0166-0934(09)00338-3 [pii];10.1016/j.jviromet.2009.07.012 [doi]. 1756. Yanni, E. A., N. Marano, P. Han, P. J. Edelson, S. Blumensaadt, M. Becker, S. Dwyer, K. Crocker, T. Daley, X. Davis, N. Gallagher, V. Balaban, M. McCarron, A. Mounts, H. Lipman, C. Brown, and P. Kozarsky. 2010. Knowledge, attitudes, and practices of US travelers to Asia regarding seasonal influenza and H5N1 avian influenza prevention measures. J.Travel.Med. 17:374–381. doi:10.1111/ j.1708-8305.2010.00458.x [doi]. 1757. Yao, Q., K. P. Fischer, L. Li, B. Agrawal, Y. Berhane, D. L. Tyrrell, K. S. Gutfreund, and J. Pasick. 2010. Immunogenicity and protective efficacy of a DNA vaccine encoding a chimeric protein of avian influenza hemagglutinin subtype H5 fused to CD154 (CD40L) in Pekin ducks. Vaccine 28:8147– 8156. doi:S0264-410X(10)01423-4 [pii];10.1016/j.vaccine.2010.09.081 [doi]. 1758. Yassi, A., K. Lockhart, J. A. Buxton, and I. McDonald. 2010. Vaccination of health care workers for influenza: promote safety culture, not coercion. Can.J.Public Health 101 Suppl 1:S41–S45.

184 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1759. Yasuda, Y., R. Komatsu, K. Matsushita, T. Minami, Y. Suehiro, H. Sawata, N. Nakura, R. K. Jaeger, and M. Lattanzi. 2010. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv.Ther. 27:444–457. doi:10.1007/s12325-010-0043-4 [doi]. 1760. Yates, L., M. Pierce, S. Stephens, A. C. Mill, P. Spark, J. J. Kurinczuk, M. Valappil, P. Brocklehurst, S. H. Thomas, and M. Knight. 2010. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. Health Technol.Assess. 14:109–182. doi:10.3310/hta14340-02 [doi]. 1761. Yewdell, J. W. 2011. Viva la Revolucion: Rethinking Influenza A Virus Antigenic Drift. Curr.Opin.Virol. 1:177–183. doi:10.1016/j.coviro.2011.05.005 [doi]. 1762. Yi, S., D. Nonaka, M. Nomoto, J. Kobayashi, and T. Mizoue. 2011. Predictors of the uptake of A (H1N1) influenza vaccine: findings from a population-based longitudinal study in Tokyo. PLoS.One. 6:e18893. doi:10.1371/journal.pone.0018893 [doi]. 1763. Yin, J. K., G. Khandaker, H. Rashid, L. Heron, I. Ridda, and R. Booy. 2011. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza.Other Respi.Viruses. 5:299–305. doi:10.1111/j.1750-2659.2011.00229.x [doi]. 1764. Yin, J. K., H. Wang, S. R. Skinner, G. Salkeld, and R. Booy. 2011. Assessing seasonal vaccine- related cross-protection from 2009 pandemic H1N1 influenza through teacher absenteeism. Aust.N.Z.J.Public Health 35:393–394. doi:10.1111/j.1753-6405.2011.00748.x [doi]. 1765. Yoo, B. K., A. Berry, M. Kasajima, and P. G. Szilagyi. 2010. Association between Medicaid reimbursement and child influenza vaccination rates. Pediatrics 126:e998–1010. doi:peds.2009-3514 [pii];10.1542/peds.2009-3514 [doi]. 1766. Yoo, B. K., M. Kasajima, C. E. Phelps, K. Fiscella, N. M. Bennett, and P. G. Szilagyi. 2011. Influenza vaccine supply and racial/ethnic disparities in vaccination among the elderly. Am.J.Prev.Med. 40:1–10. doi:S0749-3797(10)00553-2 [pii];10.1016/j.amepre.2010.09.028 [doi]. 1767. Yoo, B. K., M. L. Holland, J. Bhattacharya, C. E. Phelps, and P. G. Szilagyi. 2010. Effects of mass media coverage on timing and annual receipt of influenza vaccination among Medicare elderly. Health Serv.Res. 45:1287–1309. doi:HESR1127 [pii];10.1111/j.1475-6773.2010.01127.x [doi]. 1768. Yoo, J. K., D. P. Baker, and E. N. Fish. 2010. Interferon-beta modulates type 1 immunity during influenza virus infection. Antiviral Res. 88:64–71. doi:S0166-3542(10)00671-6 [pii];10.1016/j. antiviral.2010.07.006 [doi]. 1769. Yoshida, T., R. Yoshida, B. Y. Ma, S. Mikolajczak, D. J. Kelvin, and A. Ochi. 2010. A novel mitogen fusion protein against CD40+ cells with potent vaccine adjuvant properties. Vaccine 28:3688–3695. doi:S0264-410X(10)00350-6 [pii];10.1016/j.vaccine.2010.03.014 [doi]. 1770. Young, F. and F. Marra. 2011. A systematic review of intradermal influenza vaccines. Vaccine 29:8788–8801. doi:S0264-410X(11)01496-4 [pii];10.1016/j.vaccine.2011.09.077 [doi]. 1771. Yri, O. E., D. Torfoss, O. Hungnes, A. Tierens, K. Waalen, T. Nordoy, S. Dudman, A. Kilander, K. F. Wader, B. Ostenstad, R. Ekanger, P. Meyer, and A. Kolstad. 2011. Rituximab blocks protective serological response to influenza A(H1N1) 2009 vaccination in lymphoma patients during or within six months after treatment. Blood. doi:blood-2011-08-372649 [pii];10.1182/blood-2011-08-372649 [doi]. 1772. Yu, D. S., H. Y. Li, and X. M. Gao. 2010. [Analysis of influenza type A(H1N1) antibody levels in different population in Gansu province]. Zhongguo Yi.Miao.He.Mian.Yi. 16:219–21, 260. 1773. Yudin, M. H., M. Salaripour, and M. D. Sgro. 2010. Acceptability and feasibility of seasonal influenza vaccine administration in an antenatal clinic setting. J.Obstet.Gynaecol.Can. 32:745–748.

185 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1774. Yudin, M. H., M. Salripour, and M. D. Sgro. 2010. Impact of patient education on knowledge of influenza and vaccine recommendations among pregnant women. J.Obstet.Gynaecol.Can. 32:232– 237. 1775. Yusibov, V., S. J. Streatfield, and N. Kushnir. 2011. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum.Vaccin. 7:313–321. doi:14207 [pii]. 1776. Zaharatos, G. J., J. Yu, C. Pace, Y. Song, S. Vasan, D. D. Ho, and Y. Huang. 2011. HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice. Vaccine. doi:S0264-410X(11)01693-8 [pii];10.1016/j.vaccine.2011.10.056 [doi]. 1777. Zakay-Rones, Z. 2010. Human influenza vaccines and assessment of immunogenicity. Expert.Rev. Vaccines. 9:1423–1439. doi:10.1586/erv.10.144 [doi]. 1778. Zamparo, E. and D. Little. 2011. Immunogenicity and effectiveness of virosomal adjuvanted vaccines against influenza: a brief review of their utility in the elderly population. J.Prev.Med.Hyg. 52:116–119. 1779. Zanvit, P., A. Tichopad, M. Havlickova, O. Novotna, M. Jirkovska, K. Kolostova, D. Cechova, J. Julak, I. Sterzl, and L. Prokesova. 2010. Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A. Immunol.Lett. 134:26–34. doi:S0165-2478(10)00200-2 [pii];10.1016/j.imlet.2010.08.006 [doi]. 1780. Zarocostas, J. 2011. WHO backs further probes into possible link between H1N1 vaccine and narcolepsy in children. BMJ 342:d909. 1781. Zarubaev, V. V., A. V. Garshinina, N. A. Kalinina, A. A. Shtro, S. V. Beliaevskaia, V. E. Nebol’sin, and O. I. Kiselev. 2010. [Protective activity of Ingavirin in experimental lethal influenza due to pandemic influenza virus A (H1N1)v in albino mice]. Antibiot.Khimioter. 55:24–31. 1782. Zeng, W., K. J. Horrocks, G. Robevska, C. Y. Wong, K. Azzopardi, M. Tauschek, R. M. Robins-Browne, and D. C. Jackson. 2011. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J.Biol.Chem. 286:12944–12951. doi:M111.227744 [pii];10.1074/jbc.M111.227744 [doi]. 1783. Zhan, Y., Z. Yang, L. Li, D. Ye, H. Wu, R. Fu, S. Zhao, Y. Wang, R. Zhou, and R. Chen. 2011. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China. Jpn.J.Infect.Dis. 64:190–194. 1784. Zhang, J., A. E. While, and I. J. Norman. 2010. Knowledge and attitudes regarding influenza vaccination among nurses: a research review. Vaccine 28:7207–7214. doi:S0264-410X(10)01222-3 [pii];10.1016/j.vaccine.2010.08.065 [doi]. 1785. Zhang, J., E. B. Tarbet, H. Toro, and D. C. Tang. 2011. Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases. Expert.Rev.Vaccines. 10:1539–1552. doi:10.1586/erv.11.141 [doi]. 1786. Zhang, L. X., Z. J. Yu, J. F. Zhou, and Y. L. Shu. 2011. [The development of influenza virus-like particle vaccines]. Bing.Du Xue.Bao. 27:402–408. 1787. Zhang, Q., Z. Guo, and N. E. MacDonald. 2011. Vaccine preventable community-acquired pneumonia in hospitalized children in Northwest China. Pediatr.Infect.Dis.J. 30:7–10. doi:10.1097/ INF.0b013e3181ec6245 [doi]. 1788. Zhang, Q., Z. Wang, Y. Yuan, Z. Xue, G. Zhai, W. Zuo, S. Zhu, G. Zhu, and X. Xu. 2011. Immunoadjuvant effects of hemagglutinating virus of Japan envelope (HVJ-E) on the inactivated H9 subtype avian influenza virus vaccine. Vet.Immunol.Immunopathol. 141:116–123. doi:S0165-2427(11)00080-8 [pii];10.1016/j.vetimm.2011.02.021 [doi].

186 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011

1789. Zhang, W. W., L. Li, and F. C. Zhu. 2010. [Research progress of influenza type A(H1N1) vaccine and monitoring adverse reaction]. Zhongguo Yi.Miao.He.Mian.Yi. 16:275–278. 1790. Zhang, W., T. Xue, X. Wu, P. Zhang, G. Zhao, D. Peng, S. Hu, X. Wang, X. Liu, W. Liu, and X. Liu. 2011. Increase in viral yield in eggs and MDCK cells of reassortant H5N1 vaccine candidate viruses caused by insertion of 38 amino acids into the NA stalk. Vaccine 29:8032–8041. doi:S0264- 410X(11)01295-3 [pii];10.1016/j.vaccine.2011.08.054 [doi]. 1791. Zhang, X., M. Liu, C. Liu, J. Du, W. Shi, E. Sun, H. Li, J. Li, and Y. Zhang. 2011. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens. Intervirology 54:290–299. doi:000319440 [pii];10.1159/000319440 [doi]. 1792. Zhang, X., Y. Zhao, and A. U. Neumann. 2010. Partial immunity and vaccination for influenza. J.Comput.Biol. 17:1689–1696. doi:10.1089/cmb.2009.0003 [doi]. 1793. Zhang, Z., Y. Li, S. Xu, F. Chen, L. Zhang, B. Jiang, and X. Chen. 2010. Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus. Virol.J. 7:89. doi:1743- 422X-7-89 [pii];10.1186/1743-422X-7-89 [doi]. 1794. Zhao, G., L. Du, W. Xiao, S. Sun, Y. Lin, M. Chen, Z. Kou, Y. He, S. Lustigman, S. Jiang, B. J. Zheng, and Y. Zhou. 2010. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 28:7233–7240. doi:S0264-410X(10)01194-1 [pii];10.1016/j. vaccine.2010.08.049 [doi]. 1795. Zhao, G., S. Sun, L. Du, W. Xiao, Z. Ru, Z. Kou, Y. Guo, H. Yu, S. Jiang, Y. Lone, B. J. Zheng, and Y. Zhou. 2010. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol.J. 7:151. doi:1743-422X-7-151 [pii];10.1186/1743-422X-7-151 [doi]. 1796. Zhao, G., Y. Lin, L. Du, J. Guan, S. Sun, H. Sui, Z. Kou, C. C. Chan, Y. Guo, S. Jiang, B. J. Zheng, and Y. Zhou . 2010. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol.J. 7:9. doi:1743-422X-7-9 [pii];10.1186/1743-422X-7-9 [doi]. 1797. Zhao, K., G. X. Li, Y. Y. Jin, H. X. Wei, Q. S. Sun, T. T. Huang, Y. F. Wang, and G. Z. Tong. 2010. Preparation and immunological effectiveness of a Swine influenza DNA vaccine encapsulated in PLGA microspheres. J.Microencapsul. 27:178–186. doi:10.3109/02652040903059239 [doi]. 1798. Zhao, K., X. Shi, Y. Zhao, H. Wei, Q. Sun, T. Huang, X. Zhang, and Y. Wang. 2011. Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 29:8549–8556. doi:S0264-410X(11)01435-6 [pii];10.1016/j. vaccine.2011.09.029 [doi]. 1799. Zheng, Z., W. Luo, H. Song, Y. Chen, J. Xiong, Y. Chen, Y. Gu, H. Chen, J. W. Shih, J. Zhang, and N. Xia. 2010. Antibody reactivity of conformational peptide mimics of a conserved H5N1 neutralization site in different fusion proteins. Arch.Virol. 155:19–26. doi:10.1007/s00705-009-0542-2 [doi]. 1800. Zhou, B., Y. Li, J. A. Belser, M. B. Pearce, M. Schmolke, A. X. Subba, Z. Shi, S. R. Zaki, D. M. Blau, A. Garcia-Sastre, T. M. Tumpey, and D. E. Wentworth. 2010. NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine 28:8015–8025. doi:S0264-410X(10)01324-1 [pii];10.1016/j.vaccine.2010.08.106 [doi]. 1801. Zhou, D., T. L. Wu, M. O. Lasaro, B. P. Latimer, E. M. Parzych, A. Bian, Y. Li, H. Li, J. Erikson, Z. Xiang, and H. C. Ertl. 2010. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol.Ther. 18:2182–2189. doi:mt2010202 [pii];10.1038/mt.2010.202 [doi].

187 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA

1802. Zhou, J. J., J. Tian, D. Y. Fang, Y. Liang, H. J. Yan, J. M. Zhou, H. L. Gao, C. Y. Fu, Y. Liu, H. Z. Ni, C. W. Ke, and L. F. Jiang. 2011. Analysis of antigen epitopes and molecular pathogenic characteristics of the 2009 H1N1 pandemic influenza A virus in China. Acta Virol. 55:195–202. 1803. Zhou, X. and J. E. McElhaney. 2011. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine 29 :2169–2177. doi:S0264- 410X(10)01781-0 [pii];10.1016/j.vaccine.2010.12.029 [doi]. 1804. Zhu, W., B. W. Higgs, C. Morehouse, K. Streicher, C. S. Ambrose, J. Woo, G. W. Kemble, B. Jallal, and Y. Yao. 2010. A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine 28:2865–2876. doi:S0264-410X(10)00136-2 [pii];10.1016/j.vaccine.2010.01.060 [doi]. 1805. Zimmerman, R. K., D. S. Lauderdale, S. M. Tan, and D. K. Wagener. 2010. Prevalence of high- risk indications for influenza vaccine varies by age, race, and income. Vaccine 28:6470–6477. doi:S0264-410X(10)01032-7 [pii];10.1016/j.vaccine.2010.07.037 [doi]. 1806. Zimmerman, R. K., S. M. Albert, M. P. Nowalk, M. A. Yonas, and F. Ahmed. 2011. Use of standing orders for adult influenza vaccination a national survey of primary care physicians. Am.J.Prev.Med. 40:144–148. doi:S0749-3797(10)00637-9 [pii];10.1016/j.amepre.2010.10.027 [doi]. 1807. Zuccotti, G. V. and V. Fabiano. 2011. Influvac, a trivalent inactivated subunit influenza vaccine. Expert. Opin.Biol.Ther. 11:89–98. doi:10.1517/14712598.2011.541436 [doi]. 1808. Zuccotti, G. V. and V. Fabiano. 2011. Strategies for preventing influenza: future perspectives in influenza vaccine technology. Expert.Opin.Biol.Ther. 11:1–4. doi:10.1517/14712598.2010.539047 [doi]. 1809. Zuccotti, G. V., E. Pariani, A. Scaramuzza, L. Santoro, E. Giani, M. Macedoni, A. Gazzarri, G. Anselmi, A. Amendola, and A. Zanetti. 2011. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009–2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus. Diabet.Med. doi:10.1111/j.1464- 5491.2011.03449.x [doi]. 1810. Zuccotti, G., L. Pogliani, E. Pariani, A. Amendola, and A. Zanetti. 2010. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF59-adjuvanted vaccine. JAMA 304:2360–2361. doi:304/21/2360 [pii];10.1001/jama.2010.1729 [doi]. 1811. Zverev, V. V., M. P. Kostinov, N. A. Mikhailova, S. N. Zhirova, A. N. Mironov, O. A. Terkacheva, A. A. Romanova, and A. P. Cherdantsev. 2011. [Immunogenicity of inactivated subunit adsorbed monovalent vaccine against influenza A/California/7/2009 (H1N1) strain]. Vopr.Virusol. 56:20–23.

188